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Exploring the Plasmodium falciparum Transcriptome Using Hypergeometric Analysis of Time 
Series (HATS) 
Daniel Scanfeld 
Malaria poses a significant public health and economic threat in many regions of the world, 
disproportionately affecting children in sub-Saharan Africa under the age of five.  Though 
success has been celebrated in lowering infection rates, it remains a serious challenge, causing at 
least 200 million infections and 655,000 deaths per year, with deleterious effects on economic 
growth and development.   
Investigation of the malaria parasite Plasmodium falciparum has entered the post-genomics age, 
with several strains sequenced and many microarray gene expression studies performed.  Gene 
expression studies allow a full sampling of the genomic repertoire of a parasite, and their detailed 
analysis will prove invaluable in deciphering novel parasite biology as well as the modes of 
action of antimalarial drug resistance. 
We have developed a computational pipeline that converts a series of fluorescence readings from 
a DNA microarray into a meaningful set of biological hypotheses based on the comparison of 
two lines, generally one that is drug sensitive and one that is drug resistant.  Each step of the 
computational pipeline is described in detail in this thesis, beginning with data normalization and 
alignment, followed by visualization through dimensionality reduction, and finally a direct 
analysis of the differences and similarities between the two lines.  Comparisons and analyses 





An important component of the analytical methods we have developed is a suite of visualization 
tools that help to easily identify outliers and experimental flaws, measure the significance of 
predictions, show how lines relate and how well they can be aligned, and demonstrate the results 
of an analysis.  These visualization tools should be used as a starting point for further biological 
study to test the resulting hypotheses. 
We also developed a software tool, Gene Attribute and Set Enrichment Ranking (GASER), 
which combines a wealth of genomic data from the TDR Targets web site along with expression 
data from a variety of sources, and allows researchers to create sophisticated weighted queries to 
undercover potential drug targets.  Queries in our system can be updated in real time, along with 
their accompanying gene and gene set lists. 
We analyzed all possible pair-wise combinations of 11 parasite lines to create baseline 
distributions for gene and gene set enrichment.  Using the baseline as a comparison, we 
identified and discarded spurious results and recognized stochastic genes and gene sets. 
We analyzed three major sets of parasite lines: those involving manipulation of the multidrug 
resistance-1 (PfMDR1) transporter, a key resistance determinant; those involving manipulation 
of the P. falciparum chloroquine resistance transporter (PfCRT), another important resistance 
determinant; and finally a set of parasites that had varying sensitivity to artemisinins.   
This analysis resulted in a rich library of high scoring genes that may merit further exploration as 
potential modes of action of resistance.  More specifically, we found that manipulation of pfcrt 
expression resulted in an up-regulation of tRNA synthetases, which might serve to increase 
protein production in response to reduced amino acid availability from degraded hemoglobin.  





metabolism and up-regulation of a number of ABC transporters.  Finally, when comparing 
artemisinin sensitive to artemisinin tolerant lines, we found an increased abundance of redox 
metabolites and the transcripts involved in redox regulation, and significant reduction in 
transcription and altered expression of transcripts encoding for core histone proteins.  These 
alterations could help confer an increased tolerance to drug induced redox perturbation by 
lowering endogenous redox stress. 
We also offer a robust computational tool, Hypergeometric Analysis of Time Series (HATS), to 
handle challenging biological questions related to comparison of time series experiments.  Our 
pipeline provides a rigorous method for aligning expression experiments and then determining 
which genes and gene sets differ most between them.  The changes in gene expression level 
between drug-sensitive and drug-resistant lines offer important clues in our quest for 
understanding mechanisms of resistance and identifying new drug targets.  
Our pipeline allows for comparison of future lines with our base set and holds potential for other 
organisms, especially those similar to Plasmodium with a strong time-dependent component.  
The full excel files of all the analyses performed in this thesis can be found at: 
(http://www.fidock.org/dan).
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Chapter 1 - Introduction 
OVERVIEW 
People have suffered from malaria for hundreds of millennia, as evidenced by references to 
periodic fevers in texts dating back to 2700 B.C. in China, 2000 B.C. in Mesopotamia, 1570 B.C. 
in Egypt, and Hindu cuneiform texts from Nineveh in the sixth century B.C. [1-3].  As early as 
550 B.C., Empedocles of Agrigentum performed one of the first engineering efforts to reduce 
marshes and swamps by altering the course of several rivers to avoid stagnant water forming in 
Selinus [4].  Hippocrates wrote about malaria around 400 B.C. describing the malaria chills, 
fevers, and sweats, and the periodicity of infection and the relationship between stagnant water 
and enlarged spleens [4, 5]. 
The term malaria originates from Italian “mala aria,” which translates to “bad air.”  In England, 
the disease was called “marsh fever” due to its association with swamps [6].  Human 
understanding of malaria evolved from these vague associations to a more rigorous scientific 
inquiry in the late 19th century, when the germ theory of disease came of age [1].  This new 
perception of microorganisms as a cause of disease opened the door for a number of key malaria-
related discoveries. 
In 1880, Charles Louis Alphonse Laveran, a French doctor working in a military hospital in 
Algeria, discovered the cause of malaria when he observed a motile parasite in the blood of a 
patient who had just died of the disease.  His discovery was recognized with the Nobel Prize in 
1907 [7, 8].  At around the same time, a Cuban doctor named Juan Carlos Finlay y Barres began 





In 1886, Camillo Golgi of Italy established that there were at least two forms of malaria, one 
with tertian periodicity (48 hour lifecycle, P. falciparum, P. vivax) and one with quartan 
periodicity (72-hour lifecycle, P. malariae), which produced differing numbers of merezoites 
upon maturity [10].  He also noted that fever coincided with the rupture and release of 
merozoites into the blood stream [11]. 
In 1897, a British officer in the Indian Medical Service named Ronald Ross demonstrated that 
malaria parasites could be transmitted from infected patients to mosquitoes [12].  He performed a 
series of experiments where he fed mosquitoes on malaria infected patients and then found 
oocysts in the mosquitoes’ stomachs after four or five days [13, 14].  Moving to avian malaria, 
he showed in 1897 that culicine mosquitoes transmitted Plasmodium relictum from bird-to-bird 
[1, 15, 16].  Ross’s mosquito work earned him a Nobel Prize in 1902 [17]. 
Two Italian researchers, Amico Bignami and Giambattista Grassi, proved that malaria could be 
passed from patient to mosquito and back through Anopheles claviger while working with 
malaria near Rome [18].  They went on to prove that only the female mosquito can transmit 







THE BURDEN OF MALARIA 
Geographical distribution 
In the history of the world, few microorganisms have played a larger role than malaria, in its 
overall impact on human morbidity and mortality as well as on historical events, economics, and 
modern medicine.  Over the last century, an estimated 150 to 300 million people succumbed to 
malaria, totaling 2-5% of all deaths [19, 20]. 
As illustrated in Figure 1.1, malaria is centered in the tropics with reach into subtropical regions 
in five continents.  The disease is endemic in 100 countries inhabited by 3.3 billion people, 
causing 200-500 million cases per year and between 655,000 and 1.24 million deaths [21-23], 
making malaria one of the three most deadly communicable diseases.  Africa accounts for 90% 
of malaria mortality, with children under five years of age accounting for 86% of malaria deaths 
globally; malaria kills 1 child in 20 before the age of 5 in Africa [21, 22].   
The global distribution of the disease is largely affected by climatic patterns [24].  Attempts to 
control malaria have been successful in temperate zones with strong seasonality and cold 
winters.  This has largely been due to a considerably lower base case reproduction rate of malaria 
in temperate regions, facilitating the successful vector control efforts that led to eradication.  
Rainfall, humidity, and seasonality influence transmission rates, as well as gametocyte carriage, 
the sexual form of the parasite, which is affected by immune competence, increased 
urbanization, and other factors [25].  The map below shows how the disease burden has 






Figure 1.1.  The global distribution of malaria. 
The changing distribution of malaria risk from 1946 to 1994 reproduced from Sachs and 
Malaney [26].  Vast malaria endemic areas in North and South America, Europe, and 
Asia in 1946 and 1966 are now malaria free, with the disease burden increasingly being 
confined to tropical regions. 
Symptoms 
The majority of patients experience fever, chills, sweating, and headaches, often in combination 
with dizziness, myalgia, abdominal pain, nausea, vomiting, mild diarrhea, and dry cough [27].  
Children with severe malaria frequently develop one or more of the following symptoms: severe 
anemia, respiratory distress in relation to metabolic acidosis, acute renal failure, or cerebral 
malaria.  In malaria endemic areas, it is possible to develop partial immunity, allowing for 
asymptomatic infections to occur [27, 28]. 
For non-immune individuals infected with P. falciparum, the first symptoms of malaria usually 
appear within 10 days, while the incubation period for P. vivax and P. ovale is approximately 15-





dormant liver forms known as hypnozoites, which are not present in P. falciparum 
and P.malariae [28]. 
Economic implications 
The economic impact of malaria has been shown to be deep and long lasting.  There is a striking 
correlation between malaria and poverty when analyzing per-capita gross domestic product, and 
malaria-endemic countries have demonstrated lower rates of economic growth [26].   
Studies of the economic burden of malaria traditionally calculate direct public and private 
medical costs, as well as foregone income as a result of mortality and morbidity from malaria.  
These analyses demonstrate a significant impact, averaging approximately 1% of gross domestic 
product (GDP) [26]. However, the true effect of malaria on long-term economic growth and 
development is likely to be much higher, given its adverse effects on education, worker 
productivity, and investment.   
These indirect determinants have costly consequences.  For instance, high infant and child 
mortality rates are closely linked to high fertility rates as families seek to achieve a set number of 
surviving children.  High fertility rates, in turn, are likely to lead to reduced investments in 
education per child, a cycle detrimental to economic growth [29].  Malaria takes a further toll on 
human capital in affected regions by contributing significantly to absenteeism in school, again 
limiting prospects for future growth [30].  Perhaps most costly in terms of economic 
development is the disease’s isolating effect with regard to trade and foreign direct investment, 
with industries like tourism especially impacted [31].  The aggregate loss in economic growth 





A public health challenge 
Early malaria-control efforts 
In the 1910s, there were estimates of up to four million cases of malaria per year in the United 
States [32], and parasite rates nearing 50% in children were not uncommon [33].  Figure 1.2 
shows the prevalence of malaria in the United States in the 1930s, with the bulk of the mortality 
in the southern states.  Interestingly, malaria also affected the northern states, including New 
York, with a significant malaria zone in the Finger Lakes region [34].  Even New York City was 
impacted; on Oct. 13, 1877, The Real Estate Record and Guide wrote that malaria in Central 
Park was “becoming more palpably widespread and painful,” reporting “chills and fevers and 
other malarious disorders” [35].  Malaria remained a problem among drug addicts using 






Figure 1.2.  Ten-year average malaria mortality for the U.S. by county 1929-1938. 
This map shows the ten-year average malaria mortality for the United States by county 
for the period 1929-1938 [34].  Solid black counties have 50 or more deaths per 100,000 
people.  Dark gray counties have 25-50 deaths per 100,000 people.  Light gray counties 
have less than 25 deaths per 100,000 people.  White counties have no reported deaths. 
In 1914, the U.S. Public Health Service (USPHS) received funds from Congress to control 
malaria [37], and a range of initiatives were implemented over the next 30 years to study and 
reduce the number of cases of malaria.  The USPHS especially focused on controlling malaria on 
military bases in malarious regions in the south to ensure soldiers could train year-round.  The 
U.S. Tennessee Valley Authority (TVA) was created in 1933, enabling the development of an 
organized malaria control program in the Tennessee River valley, where 30% of the population 
was affected by malaria.  By 1947, the program had significantly reduced the problem of malaria 
in the U.S. [38]. 
The National Malaria Eradication Program, a partnership among state and local health agencies 
of 13 southeastern states and the Centers for Disease Control and Prevention (CDC), began 
operations in 1947 [39].  The program consisted mainly of the application of the insecticide 
dichlorodiphenyltrichloroethane (DDT) to the interiors of rural homes, as well as drainage and 
removal of mosquito breeding sites, and spraying of insecticides.  The program successfully 
removed malaria as a public health concern in the U.S. by 1949 [40].  The precipitous drop in 






Figure 1.3.  Malaria morbidity and mortality rates from 1920-1946. 
This chart from the USPHS shows the rapid decrease in malaria morbidity and mortality 







Figure 1.4. Malaria eradication stamps 
More than 90 nations issued malaria eradication stamps in the early 1960s, most with the 
motto, “The world united against malaria.”  Reproduced from Hundley et al. [41]. 
Encouraged by these successes against malaria, the World Health Organization (WHO) launched 
the Global Malaria Eradication Programme (GMEP) in 1955 [42], focusing on a two-pronged 
attack consisting of DDT for vector control and the inexpensive and highly effective antimalarial 
drug chloroquine for treatment and prevention [43].  During this time malaria was successfully 
removed from many regions of the world, including most of Europe.  Unfortunately, many 
factors contributed to the discontinuation of the program after 14 years, including resistance to 
DDT, emerging resistance to chloroquine, high rates of parasite transmission, logistical 





The public health landscape today: policy coordination  
In 1998, the WHO, United Nations Children's Fund (UNICEF), United Nations Development 
Programme (UNDP), and the World Bank launched the Roll Back Malaria (RBM) Partnership to 
provide a coordinated global response to the disease [45].  The RBM Partnership is comprised of 
more than 500 partners, including malaria endemic countries, their bilateral and multilateral 
development partners, the private sector, nongovernmental and community-based organizations, 
foundations, and research and academic institutions [46].  In 2008, world leaders and the global 
malaria community gathered to endorse the Global Malaria Action Plan (GMAP), which outlines 
the RBM Partnership’s vision for reducing the burden of malaria and its eventual eradication 
[47]. 
The public health landscape today: financing  
The Global Fund to Fight AIDS, Tuberculosis and Malaria was launched in 2002 as an 
international financing organization to address the three diseases [48].  By December 2010, the 
Global Fund had funded the distribution of a cumulative 160 million insecticide-treated bednets 
(ITNs) and provided indoor residual spraying in dwellings 31 million times [49, 50].  The Global 
Fund had also financed treatment for 170 million cases of malaria by the end of 2010.  Donors 
include more than 40 countries, foundations such as the Bill and Melinda Gates Foundation, 
corporations, religious groups, and others, with disbursements exceeding $3 billion in 2010 [51]. 
The President’s Malaria Initiative (PMI), launched in 2005 by President George W. Bush, 
pledged to increase U.S. funding of malaria prevention and treatment in sub-Saharan Africa by 
more than $1.2 billion over five years (FY2006-FY2010) [52].  Today, the PMI is part of the 
President’s Global Health Initiative, which outlines an expanded strategy to halve the burden of 





for International Development and implemented with the CDC [53].  Between 2006 and 2010, 
PMI provided $1.265 billion in funding, with expenditures reaching around $500 million in 2010 
[54]. 
The public health landscape today: interventions 
The WHO recommends (1) vector control through insecticide-treated bednets (ITNs), indoor 
residual spraying (IRS), and larval control in specific settings; (2) chemoprevention for the most 
vulnerable populations, specifically pregnant women and children; (3) confirmation of malaria 
diagnosis through microscopy or rapid diagnostic tests (RDTs); and (4) timely treatment with 
appropriate medicines [55]. 
Vector control 
According to the WHO, the percentage of households owning at least one ITN in sub-Saharan 
Africa is estimated to have increased from 3% in 2000 to 50% in 2011.  Since 96% of people 
with access to an ITN use it [56], the main barrier to universal coverage is access to bednets.  
Indoor residual spraying (IRS) with WHO-approved chemicals is another key intervention for 
reducing malaria transmission through vector control.  A total of 185 million people were 
protected by IRS in 2010, representing 6% of the global population at risk [55]. 
These are important public health achievements, but the task of covering the remaining 
households with bednets and replacing those that have already been distributed every three years 
remain significant challenges.  In addition, all ITNs and 77% IRS use a single class of 
insecticides, the pyrethroids, increasing the risk that mosquitoes will develop resistance to it.  






Malaria poses serious risks for pregnant women.  It increases maternal anemia, which is the 
cause of 10,000 maternal deaths each year in Africa [58].  Malaria infection in the mother also 
increases risk of abortion, stillbirth, congenital infection, intrauterine growth retardation, and low 
birth weight.  Given these grave risks, the WHO recommends that pregnant women receive 
intermittent preventive treatment (IPTp) [59].  By the end of 2010, 35 countries in sub-Saharan 
Africa had adopted IPTp as a national policy, with the goal of treating pregnant women with at 
least two doses of sulfadoxine-pyrimethamine (SP) [55]. 
IPT also holds great potential for infants (IPTi), and is recommended by the WHO in countries 
with moderate to high malaria transmission and low resistance to SP [55].  In Tanzania, two 
studies showed that IPTi reduced malaria and anemia for children under the age of one by up to 
60% [60]. 
Seasonal malaria chemoprevention (SMC), or intermittent treatment during the malaria season, is 
recommended for children in areas where at least 60% of malaria cases take place within four 
months.  In a review of the efficacy of SMC for children between the ages of three and five, the 
treatment prevented 78% of clinical malaria episodes and 61% of severe malaria episodes [61]. 
Diagnosis 
It is an ongoing challenge to clinically diagnose malaria, given the non-specific nature of many 
of its symptoms.  The failure of clinical algorithms in diagnosing malaria elucidates this 
challenge; one study that tested clinical algorithms found they would have sent home 16% of 






Given the difficulty of diagnosing malaria clinically and the importance of treating the disease 
promptly, RDTs and microscopy offer important tools in ensuring proper treatment.  This is 
especially vital in the face of mounting drug resistance [64, 65], and the WHO recommends that 
everyone with a suspected case of malaria be tested by RDT or microscopy [55].  Giemsa 
microscopy uses a mixture of methylene blue and eosin stains introduced by Gustave Giemsa in 
1904 to enable diagnosis [66].  These tests are reliable and inexpensive and allow for 
quantification of parasites and differentiation of species; however, they require trained 
microscopists, which are not always available in remote malarious regions.  Rapid diagnostic 
tests (RDTs) function by detecting proteins produced by malaria parasites present in the blood of 
an infected individual [67].  Currently, over 80 RDTs are on the market, detecting histidine-rich 






THE MALARIA PARASITE 
The Plasmodia genus of parasitic protists 
Malaria is an ancient disease, with hundreds or thousands of species infecting many different 
organisms, including mammals, birds, and reptiles [69, 70].  P. falciparum evolved eons ago, 
potentially during the separation of hominoid lineages, including early humans and the great 
apes.  It has been estimated with 95% confidence that P. falciparum first infected the ancestors 
of modern humans as recently as 112,000 years ago or up to 1 million years ago [71].   
Malaria is transmitted by female mosquitoes of the genus Anopheles.  Humans are mainly 
infected by four species of Plasmodium: P. falciparum, P. vivax, P. ovale, and P. malariae, with 
the majority of cases caused by P. falciparum and P. vivax.  P. falciparum is the most virulent 
and causes nearly all malaria related deaths [43].  Human infections with the monkey malaria 
parasite, P. knowlesi have also been reported recently in Borneo [72]. 
The lifecycle of malaria infection 
Beginning with the bite of an infected Anopheles mosquito, sporozoites invade the liver and over 
the course of ~one week proliferate asymptomatically, eventually releasing thousands of 
merozoites into the bloodstream to infect red blood cells (RBCs) [43].  Within the RBC, the 
parasite undergoes a series of morphological transitions over the course of 48 hours known as the 
intraerythrocytic developmental cycle (IDC), resulting in a new generation of merozoites that 
rupture the RBCs and reinitiate the cycle [73].  The clinical signs and symptoms of malaria are a 







Figure 1.5.  The lifecycle of P. falciparum. 
This figure from Greenwood et al. [43] depicts the lifecycle of the malaria parasite as it 





The majority of the malaria parasites invading the RBCs are haploid asexual forms; however a 
small percentage commit to gametocytogenesis, and become the diploid, sexual forms of the 
parasite, that are ingested by the mosquito in the next blood meal [43].  The male and female 
gametocytes complete their sexual development into gametes in the mosquito midgut, then fuse 
to form an oocyte, which passes through the midgut lining and lodges in the basal lamina where 
it transitions into an oocyst that divides into many sporozoites [74].  The sporozoites invade the 








From the first century AD until the turn of the 20th century, one of the most popular methods for 
treating high fevers was bloodletting, a practice popularized by the Greek physician Galen [75, 
76].  Unfortunately for those who received this treatment, it only served to exacerbate the anemia 
caused by malaria and often made the patient worse. 
 
Figure 1.6. Advertisement for a folk remedy. 
Image from Century Illustrated Monthly May 1885.  An example of a folk remedy that 
claims to offer “a positive, radical, and permanent cure” for malaria. 
Beyond bloodletting, a number of folk remedies emerged.  In 1750, for example, it was 
recommended to wear a fish otolith around the neck to relieve malaria.  In The Mirror of Stones, 





certain Fish, and is beneficial to the Life of Man.  For being hung about the Neck, or otherwise 
carried, it drives off and takes away the Miseries of Quartan Ague [malaria]” [77]. 
 
Figure 1.7.  The Mirror of Stones. 
A book that gives insight into medical treatments in the 1750s, including amulets offering 
protection from malaria. 
In Calabria, Italy, an area severely affected by malaria, folk treatments included fasting and 
purging, along with ingesting a variety of unpalatable items, such as the urine of a healthy 
woman, earthworms, the head of a viper, and goat dung.  Calabrian people also turned to magic 
remedies.  They wore amulets with walnut shells, spiders, and the skeletons and fangs of snakes 






It is told that in 1630, the Countess of Chinchón Lima, Peru fell ill of tertian fever.  After the 
rumor of her illness spread throughout the city, a Spaniard offered up a miracle drug derived 
from the bark of a tree, which she took and was cured [78].  Though the story is likely untrue, the 
miracle tree was named the cinchona tree after the Countess.  Quinine was brought to Europe by 
the Jesuits, who learned about the bark during their missionary work in Peru [79]. 
 
Figure 1.8.  Cinchona succirubra. 
Image from the Nueva Quinolgia (1862), based on the botanical expedition of Ruiz and 
Pavón [79].  Quinine is derived from the bark of the Cinchona tree. 
Given the difficulty of maintaining quality control in the powdered bark, two French chemists, 
Pierre Joseph Pelletier and Jean Bienaime Caventou, set out to isolate the drug responsible for its 
curative properties.  In 1820, they identified an alkaloid which they named quinine, a word 
derived from the Quechua word, quinaquina, meaning “bark of barks” [80].  Quinine became the 





cinchona trees in South America and increasing global demand, it was at times difficult to obtain 
quinine.  After German soldiers suffered from malaria during World War I, German chemists 
were commissioned during the 1920s to find a synthetic alternative.  By 1932, they had produced 
mepacrine, a simplified version of quinine [79]. 
Chloroquine 
During World War II, German-American trade ceased and the Japanese cut off stores of quinine 
in Java, leaving American soldiers without access.  American scientists quickly began to 
manufacture mepacrine, which was used both as a prophylactic and treatment for soldiers.  The 
Japanese, however broadcasted that mepacrine would make your skin yellow (which it did) and 
make you sterile (which it did not).  This caused many U.S. soldiers to throw away their 
mepacrine pills, leaving them vulnerable to malaria.  America responded by synthesizing 
variants of sontoquine, another antimalarial drug developed by German chemists.  In 1934, they 
found one that was more effective than mepacrine and sontoquine, easier to manufacture, and did 
not appear to have adverse side effects.  The drug was called chloroquine [79].  By 1946, the 
U.S. had explored more than 15,000 compounds and found several antimalarials, including 
amodiaquine and primaquine [82]. 
Chloroquine was used extensively throughout the world alongside DDT to great success, 
unfortunately signs of resistance appeared in 1957 along the Thai/Cambodian border [83], in 
1960 in South America [84], and 1978 in Africa [85].  In 1973, Thailand became the first country 
to replace chloroquine as a first-line drug as a matter of national policy.  Over the next 20 years, 





Emergence of resistance 
Efforts to combat malaria have repeatedly been stymied by the development and spread of drug-
resistant parasites [87].  Figure 1.9 summarizes a recurring theme in antimalarial drug 
development where a novel antimalarial is introduced and effectively treats the disease until 
resistant strains arise and spread to lessen the efficacy of the drug.  Quinine was first used as an 
antimarial in the 17th century, and was effective for centuries, until resistance was first 
documented in 1910 [88], then slowly resistance spread across the globe, making it ineffective in 
most areas today.  Chloroquine was used extensively in Africa, because it was the cheapest drug 
on the market, highly effective, and had low toxicity in humans, however resistance developed in 
1978 in East Africa and soon spread to all endemic regions [89, 90].  A similar narrative exists 
for many of the drugs in Figure 1.9: amodiaquine, sulfadoxine / pyrimethamine, mefloquine, 
halofantrine, and atovoquone / proguanil [91].  The treatment regime that remains the most 
effective are the artemisinin-based combination therapies (ACTs), the current first line 






Figure 1.9.  Emergence of resistance to the principal antimalarials. 
Each row represents an antimalarial drug.  The two dates to the left of each row indicate 
the date of first use and the date of first reported instance of resistance.  The heavy color 
in the bar represents time periods where the drug was highly effective, and as the color 
becomes lighter, the degree of resistance to the drug in the field increases.  Each oval on 
the timeline represents the date when resistance first appeared to a given drug in a 
specific area.  This figure is reproduced from Ekland and Fidock [91]. 
Artemisinin and ACTs 
 
Figure 1.10. A depiction of the Artemisia annua plant. 
In the 1960’s, China was fighting a war in malaria-ridden North Vietnam.  Worried by growing 
signs of chloroquine resistance, the Chinese government established a large, secret research 
program to find a replacement.  Named Project 523, more than 500 scientists from more than 60 
institutions were recruited to examine plants used in Chinese herbal medicine as a treatment in 
1967.  Artemisia annua, or sweet wormwood was frequently mentioned as a cure for intermittent 
fever in Chinese resources, leading the scientists to focus on it as a potential treatment.  In the 
early 1970’s, they extracted qinghaosu, or artemisinin, and soon confirmed its effectiveness.  





2,000 years of being used as an herbal remedy, China began to manufacture and distribute it as a 
treatment for malaria [79].   
The west, however, took much longer to accept artemisinin and subsequently distribute it 
throughout the developing world.  The original discoveries were published in Chinese, and 
western scientists were skeptical when they finally saw the results.  Even after the efficacy of the 
drug was confirmed, western countries demanded lengthy toxicology testing and lacked 
financing to distribute this expensive drug in impoverished countries [79]. 
Artemisinin is potent against CQ- and SP-resistant P. falciparum, with more rapid parasite 
clearance and fever resolution times than any other licensed antimalarial [93, 94].  Also, 
artemisinin kills gametocytes, which decreases transmission [43, 95].  Artemesinin is a vital 
component of any malaria program, and widespread resistance to it would be devastating; 
unfortunately, there is already evidence of resistance emerging in Southeast Asia [96-101]. 
To counteract this, public health agencies have rejected the use of monotherapies and instead 
recommend using artemisinin in combination with other antimalarial drugs.  The WHO has 
declared that all grants for malaria treatment specify ACTs, and the major pharmaceutical 






Figure 1.11.  The adoption of artemisinin. 
This maps shows the official first-line antimalarial policy in Africa in 2003 and 2007, 
demonstrating the dramatic shift from a diversity of first-line antimalarials (typically 
chloroquine or sulphadoxine–pyrimethamine) towards the adoption of artemisinin-based 
combination therapies.  Reproduced from Eastman and Fidock [44]. 
ACTs combine artemisinin derivatives with a longer-lasting partner drug, which then eliminates 
parasites that have acquired artemisinin resistance.  Artemisinin derivatives attack both asexual 
blood stage parasites and gametocytes, meaning it alleviates symptoms while also decreasing 
parasite transmission [43].  Key partner drugs include mefloquine, lumefantrine, amodiaquine, 
and piperaquine [44].  
Sites of action of antimalarial drugs 
Although scientific understanding of parasite biology remains limited, a number of processes 





degradation and heme detoxification, folate biosynthesis, and protein synthesis in the apicoplast 
[102].  The liver or sexual stage parasites are poorly understood, largely because of the technical 
challenges inherent in their study [43], and therefore modes of action of drugs that target these 
stages are ill-defined. 
Figure 1.12 summarizes the known antimalarials and their putative sites of action in the parasite.  
Sulphadoxine-pyrimethamine and possibly the artemisinins and mefloquine localize to the 
cytosol.  The rest of the antimalarials, including chloroquine, amodiaquine, mefloquine, 
lumefantrine, piperaquine, pyronaridine, and the artemisinins, are thought to act at least in part in 






Figure 1.12. Site of action of antimalarial drugs. 
This figure depicts an intraerythrocytic P. falciparum parasite with its major features and 
the proposed sites of action of many of the antimalarials.  The figure is reproduced from 









The first genome to be sequenced was the bacteriophage fX174, using the Sanger method in 
1978 [103-105].  Since the early 1990s, the bulk of all sequencing has been performed using a 
capillary based, semi-automated implementation of the Sanger method [106].  In shotgun 
sequencing, genomic DNA is randomly fragmented into segments of various sizes, then cloned 
to a high-copy number plasmid vector that is used to transform E. coli [107].  The process results 
in an amplified template that exists in many clonal copies of a single plasmid insert located in a 
bacterial colony that is spatially isolated and can be picked.  An alternative to this process, for 
targeted resequencing, is to carry out polymerase chain reaction (PCR) sequencing using primers 
that flank the sequence of interest [108].  The PCR amplicons can be used as material for the 
sequencing processing in a similar method to that used for the bacterial colonies. 
The sequencing process proceeds in a series of cycles, in which the template is denatured, then 
primers are annealed and extended [109].  Primers must be used that are complementary to the 
sequence immediately flanking the region of interest [110].  A key feature of the Sanger 
sequencing method is the random incorporation of fluorescently labeled dideoxynucleotides 
(ddNTPs), which terminate the primer extension process [111].  The series of cycles result in a 
set of end-labeled extension products of every possible length for the sequence in question.  
These products are heat denatured, and the single stranded, end-labeled extension products are 





size where their fluorescent end tags are excited by a laser to detect the nucleotide.  The resulting 
trace is translated into DNA sequence via software tools, with accompanying error probabilities 
for each base that is called by the software [113, 114].  This process can be done in parallel in 96 
or 384 independent capillaries. 
The sequencing of the P. falciparum genome was accomplished using Sanger sequencing over 
six years, from 1996-2002.  Sanger sequencing technologies can currently produce sequence 
fragment read-lengths of around 1,000 basepairs (a kilobase), with a per-base raw accuracy of 
99.999%.  When utilized in high-throughput shotgun sequencing, the cost is around $0.50 per 
kilobase of DNA sequence [106]. 
Illumina Solexa sequencing 
The Illumina Genome Analyzer, commonly known as Solexa, was built out of work by Turcatti 
et al. and the merging of Solexa, Lynx Therapeutics, Manteia Predictive Medicine, and Illumina 
[115, 116].  In Solexa sequencing, clonally amplified sequence features are generated directly on 
the surface of an array using bridge PCR.  The sequencing cycle begins with the incorporation of 
four modified deoxynucleotide species that have both a fluorescent label and a reversibly 
terminating moiety in the 3’ position.  A modified DNA polymerase drives extension of the 
primers, and then all four channels are imaged.  Next, the fluorescent labels and terminating 
moiety are removed and the cycle begins again.  The modified deoxynucleotide species are 3’-
OH unprotected cleavable fluorescent 2’-deoxynucleotides [115].  These species are reversible 
terminators, which means that only a single base incorporation can happen each cycle, because 
of a chemically cleavable moiety at the 3’ hydroxyl position.  The species also contain one of 





There are eight independent lanes on a single-flow cell, and currently read lengths range from 36 
to around 100 base pairs; as the length is extended the confidence in each base call is reduced.  
There are several factors limiting the possible sequence lengths, the two main factors being 
incomplete fluorescent cleavage, and incomplete terminating moiety cleavage.  The former 
would add noise to the measurement, while the latter would weaken the signal as fewer 
sequences would be expandable each run.  The average raw error rate is around 1.5%, which can 
be reduced to 0.1% through the use of quality metrics.  Mate-paired reads, derived from the 
opposite end of each fragment, are possible through a modification to the system, allowing for 
two sequence reads that are several hundred base pairs apart [117]. 
The sequencing of the P. falciparum reference genome 
The first malaria parasite sequencing began in 1996 and was reported in Nature in 2002 [118].  
The genome sequenced was the 3D7 P. falciparum clone, an isolate from an airport worker in the 
Netherlands that is sensitive to chloroquine, but resistant to sulfadoxine [73].  The genome 
consists of 23 megabases spread over 14 chromosomes, equal to 23 million basepairs, or just 
under one percent of the size of the human genome, which is 3,200 megabases, or 3.2 billion 
basepairs.  The genome encodes roughly 5,500 genes and has a very high concentration of As 
and Ts relative to Cs and Gs.  This skewed nucleotide distribution makes sequencing 
Plasmodium more difficult.  Since P. falciparum is a parasite, it has a high proportion of genes 
devoted to immune evasion and host-parasite interactions and encodes fewer genes for enzymes 
and transporters relative to other organisms. 
The genome was sequenced using whole chromosome shotgun sequencing.  Whole genome 





effective at that time.  In addition, high quality, large insert libraries of A+T rich P. falciparum 
DNA have never been constructed in E. coli, making transfection difficult. 
The P. falciparum genome is the most A+T-rich genome coded to date, with 80.6% of the base 
pairs A+T, rising to around 90% in introns and intergenic regions [118].  In the original paper, 
5,300 protein-encoding genes were identified, which has since been increased to around 5,500.  
Fifty percent of the genes were predicted to contain introns, an amount that is similar to S. 
pombe, and much greater than organisms such as S. cervisiae with 5% introns.  Forty nine 
percent of the genes overlapped with expressed sequence tags (ESTs), which increases their 
prediction confidence, as a gene product had been discovered with a matching sequence. 
Transcriptional profiling 
The invention of the microarray 
In 1995, Schena et al. first described a high-capacity system developed to monitor the expression 
of many genes in parallel, termed a complementary DNA microarray [119].  It measured the 
differential expression of 45 Arabidopsis genes using a two-color fluorescence hybridization.  
The next year, a 1,161 DNA element microarray was used to elaborate the transcriptional profile 
of human tumor cells [120, 121].  In 1998, time was incorporated into microarray studies with a 
set of yeast time series microarray experiments that sampled 6,220 Saccharomyces cerevisiae 
genes across the cell cycle [122, 123].  This work demonstrated that regulatory network 
information could be inferred from gene expression measurements taken across the cell cycle, 
and illustrated the dynamic nature of gene expression, with some genes expressed in individual 





The first P. falciparum microarrays 
The first P. falciparum microarray was created in 2000, based on 3,648 random inserts from a P. 
falciparum mung bean nuclease genome library [124].  The study found significant gene 
expression differences between the trophozoite stage and the sexual stage gametocyte.  A five 
sample time series of P. falciparum the next year looked at ~15% of the genome and revealed a 
coordinated program of gene expression, with up-regulated genes at each time point clustering 
into functional groups [125].  Upon completion of the P. falciparum genome in 2002, the malaria 
research community had the necessary genomic data to construct microarrays of the full genome 
and could begin full transcriptional profiling studies [118]. 
The first two full genome microarrays were produced in 2003, allowing for the transcriptional 
profiling of all the putative genes in the P. falciparum genome [126-128].  The Winzeler lab 
created a high-density oligonucleotide array composed of nearly 500,000 features, which they 
used to measure the expression levels of all the genes in the genome at nine different stages that 
encompassed the human and mosquito lifecycles [128].  They found that genes with correlated 
levels of expression were often involved in similar functions and cellular processes. 
The full 48-hour IDC was first measured by Bozdech and Llinas in the DeRisi lab in HB3 in 
2003, and then repeated in Dd2 and 3D7 in 2006 [73, 129].  These data are striking in their 
uniformity and the cyclic nature of the expression of many of the genes.  Heat maps of the gene 
expression cycle reveal that most genes peak only once over the 48 hours and follow a wave of 
expression that repeats over the next 48 hours, correlating with the waves of fever the patient 
experiences Figure 1.13.  The similarity of expression levels between all three strains is also 





genes are expressed at different stages, these expression studies are very helpful in identifying 






Figure 1.13.  P. falciparum IDC transcriptome 
a. Heatmap of the IDC transcriptome in which 2,712 genes have been sorted by phase of 
expression along the y-axis.  The characteristic morphological stages appear to the left at 
their corresponding phase of peak gene expression (b-m).  Biochemical processes that 
match up to the timing of the heatmap appear to the right.  Each graph represents the 
average expression of the set and the mean peak-to-trough amplitude is shown in 
parentheses.  Bozdech et al. [129]. 
Transcriptional profiling studies of P. falciparum 
An analysis of 3D7 parasites that produce gametocytes and F12, a derivate clone of 3D7 not 
capable of producing gametocytes, uncovered 117 genes that were differentially expressed 
during hours 30 and 40, around when gametocytogenesis would begin [130].  Up-regulation of 
the mRNAs for two early gametocyte markers, Pfs16 and Pfg27, was strong in 3D7, and their 
expression levels were used as a reference to find highly correlated genes, which were then 
confirmed by Northern blot analysis. 
In a large study using 123 microarray hybridizations, many of which were duplicates, 
perturbations of P. falciparum by antifolate drugs demonstrated a genetically hard-wired 
metabolic transcriptome that failed to mount a protective response [131].  The parasites were 
treated with WR99210 for 24 hours and showed little transcriptional changes, even while dying 
from the treatment.  The study suggests that parasites cannot mount protective immune responses 
in real time upon sudden exposure to drug, but can adjust their transcriptional regulation after 
long-term exposure to drug. 
P. falciparum erythrocyte membrane protein 1 (PfEMP1) proteins are antigens that provide an 
integral component to the P. falciparum infected red blood cell’s ability to evade the host 
immune system [132].  The var gene family that encodes PfEMP1 proteins is regulated by a 





were selected to express different var genes demonstrated that mutually exclusive expression 
was governed by transcriptional silencing [133]. 
Histone deacetylase (HDAC) inhibitors present a promising potential treatment for P. falciparum 
infection, as they are potential inhibitors of growth [134].  Transcriptional profiling was 
performed on parasites exposed to 20 different antimalarials [135], including several HDAC 
inhibitors, and the parasites exposed to the HDAC inhibitors exhibited a general deregulation of 
the typical expression cascade, while the other drugs did not cause nearly as profound an effect 
on gene regulation [136]. 
MacKinnon et al. demonstrated techniques to culture-adapt field isolates and then profile their 
transcription [137].  They compared the expression profiles of field isolates to parasites that had 
been propagated in laboratories for long periods of time and found several differentially 
regulated gene sets, including export proteins and sexual stage proteins. 
Recent reports of reduced in vivo susceptibility to ACTs on the Thai-Cambodian border have 
necessitated study of the mechanisms mediating artemisinin tolerance and resistance [96].  Mok 
et al. profiled three field isolates that exhibited slow clearance times and eight field isolates with 
normal parasite clearance times [138].  Their ex-vivo profiling included a time series profile of 
each sample that uncovered reduced expression in the ring and trophozoite stages in the parasites 
with slow clearance times. 
Foth et al. performed a full time series of the IDC at two hour resolution using microarrays to 
measure gene expression levels, while simultaneously measuring protein levels using 2D-DIGE 





mRNAs, with the abundance of most proteins peaked a median 11 hours after the corresponding 
peak in mRNA levels. 
High-density genomic tiling arrays 
Microarrays also allow for sampling the DNA sequence of an organism, a process first 
completed in 2006 in yeast with a whole-genome DNA microarray that could detect all single-
nucleotide differences between two genomes [140].  Dharia et al. produced a tiling-array for P. 
falciparum in 2009, and they demonstrated the ability to detect most single-nucleotide 
polymorphism (SNPs), small insertions, and all known copy number variations (CNV) between 
three laboratory isolates [141].  They also found that in vitro fosmidomycin resistance was based 
on a copy number change of the pfdxr gene, allowing the parasite to overcome the inhibition of 
isoprenoid biosynthesis. 
Tiling arrays were used to characterize 14 P. falciparum genomes from patient isolates from the 
Peruvian Amazon [142].  A limited number of genotypes were observed in the population with a 
low frequency of recombination; however, evidence for clindamycin resistance was uncovered in 
a subset of the samples with point mutations in the apicoplast genome near known clindamycin 
resistance conferring locations. 
Tiling arrays were also used to map the position and enrichment of nucleosomes across the P. 
falciparum genome for three time points in the IDC [143].  The fluctuations of nucleosome 
coverage for most of the genome was very small, however certain gene families demonstrated 
large changes in chromatin structure, including the var and rif gene families, and some 





Eastman et al. used tiling arrays to discover that piperaquine resistance is associated with a copy 
number variation on a segment of chromosome 5 of P. falciparum [94].  Transgene expression 
studies will be necessary to uncover the contribution of each gene in the implicated section to the 
drug resistance phenotype. 
Gene Set Enrichment Analysis (GSEA) 
In the past, analysis of transcriptional profiling data involved filtering and normalizing gene 
expression levels and then ranking genes by their up-regulation in a comparison [144].  Though 
such an analysis is important, looking at individual genes tends to over-emphasize genes that are 
already known by the researcher.  Also, a major challenge in microarray analysis is dissociating 
the actual biological signal from the experimental noise, thus lowering the confidence a 
researcher can have in any one probe’s signal [145]. 
Rather than focusing on individual genes, GSEA looks for up and down-regulation at the level of 
the gene set by determining whether members of a gene set tend to occur more toward the top or 
the bottom of a ranked gene list [146].  GSEA determines the significance of a gene sets by 
calculating an enrichment score by walking down a ranked list of genes, increasing a score when 
a gene is in the set, and decreasing the score when it is not in the set [147].  GSEA has been used 
to analyze many different types of expression data, including SNP data from genome-wide 
association studies [148], lung cancer [149], leukemia [150], and resistance to chemotherapy 
[151].  We use GSEA extensively in our analysis of malaria parasite gene expression. 
Metabolomics 
Metabolomics is the study of the entire repertoire of metabolites in a biological system, including 





metabolomic information to knowledge of genome sequence and gene expression studies helps 
to solidify our understanding of the underlying biology of an organism, and how that biology 
changes between organisms. 
Teng et al. performed a metabolomic analysis of trophozoite-stage P. falcipaum parasites that 
had been isolated from the red blood cell using saponin-permeabilisation, and estimated the 
intracellular concentrations of 41 compounds [153].  This study demonstrated that metabolites 
could be measured in P. falcipaum, and opened the door for analysis of metabolomic differences 
between parasite strains and across the IDC. 
Olszewski et al. profiled the metabolome of the malaria parasite at six time points along the full 
IDC, and many of the metabolites varied in phase as seen in gene expression studies [154].  
Uninfected red blood cells were also profiled to examine the differential metabolite levels, and 
some of the metabolites exhibited differential levels across the time series, including arginine, 
which was converted to ornithine by the malaria parasite.  Further metabolomic studies using 13C 
labeled compounds revealed distinct differences in tricarboxylic acid (TCA) metabolism 
compared to most other organisms [155].  TCA metabolism and glycolysis in P. falciparum were 
found to not be connected in the standard cyclic way, instead working off of a branched structure 
with glutamate and glutamine acting as the major carbon sources. 
In silico metabolic analysis has also been performed on P. falciparum, in the form of 
reconstruction and flux-balance analysis of the P. falciparum metabolic network.  Plata et al. 
reconstructed a metabolic network with 1001 reactions and 616 metabolites, with enzyme-gene 
associations between 366 genes and 75% of the enzymatic reactions [156].  40 genes were 







i - In the face of such a virulent disease and diminishing treatment options, we seek to understand 
the genetic mechanisms of antimalarial drug resistance in hopes of driving research in drug 
targeting. 
We have developed a software tool, Gene Attribute and Set Enrichment Ranking (GASER), 
which allows researchers to find meaningful patterns within a wide range of data types to drive 
the drug discovery process.  Queries can be visualized and updated in real time. 
ii -  The P. falciparum chloroquine resistance transporter (PfCRT) and the multidrug resistance-1 
(PfMDR1) transporter have been identified as determinants of decreased in vitro susceptibility to 
several antimalarial drugs. 
We have developed a computational pipeline to explore similarities and differences among genes 
and gene sets in both resistant and tolerant lines.  We analyzed the transcriptional differences 
between parasite lines with altered PfCRT or PfMDR1 expression or sequence. 
iii - ACTs have become the first-line antimalarial in many endemic countries, and has been 
highly effective even in areas of chloroquine and sulfadoxine-pyrimethamine resistance, though 
recent reports of reduced parasite susceptibility to ACTs have spurred investigation into the 
mechanisms that modulate drug response.   
We utilized the HATS pipeline to analyze expression data from a lab-selected artemisinin-
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Drug resistance is a daunting problem in malaria chemotherapy, and a dwindling group of 
effective drugs threatens to leave millions of people vulnerable in the coming years [157].  A 
paucity of research leads and relatively few drug targets create a challenging environment for 
drug discovery and development, which is already a time-consuming and expensive venture 
[158].  Computational methods that prioritize drug targets hold great promise for improving the 
drug development pipeline. 
The sequencing of the P. falciparum genome and the emergence of several high throughput 
technologies for assaying gene function have created an unprecedented amount of genomic data 
that needs to be harnessed for antimalarial drug target detection.  This need is filled by the open 
access TDR Targets database, which is developed through an extensive public and private 
partnership and finds meaningful patterns within a wide range of data types to drive the drug 
discovery process for tropical diseases [159-161]. 
We present a software tool, Gene Attribute and Set Enrichment Ranking (GASER), which builds 
on TDR Targets by providing an interface that can update and visualize queries in real time.  A 
key component of the tool is our gene expression analysis algorithm, Hypergeometric Analysis 
of Time Series (HATS), which augments current techniques by incorporating gene set 
enrichment into the analysis. 
With a background pool of 11 parasite lines, we computed the baseline expression levels for each 





invariant gene sets and provides a measure of confidence for any enrichment result. We used 
GASER to create a prioritized list of drug targets, and compare it to a list of known drug targets. 
As more genomic data becomes available, we hope that our tool can help leverage existing 
knowledge by updating queries based on new data and offering researchers novel leads as they 








Over the past 40 years, the cost of collecting, storing, and distributing information has declined 
dramatically, creating rich databases in every field, ranging from climate information to 
shopping preferences to genomics.  As the cost of storing data approaches zero and processing 
speed continues to increase, we can now search and sort quantities of data that would have 
seemed impossible even five years ago.  The advent of cloud computing has only served to 
amplify these effects.   
Across these fields, tools have emerged to facilitate the capture, storage, search, analysis, and 
visualizations that can drive decision-making.  Today it is commonplace to search for movie 
rentals on Netflix, choose a restaurant after reviewing Yelp, and explore real estate options on 
Zillow – all of which help to make a seemingly infinite amount of information understandable 
and actionable.  The average person is now able to make data-driven decisions in everyday life, 
rather than depending on limited information collected by a small sample of friends or experts.   
The same trend is taking place in science with a range of available databases.  Information is 
being collected more quickly than ever; today a single DNA sequencer can generate in a day 
what it took 10 years to collect for the Human Genome Project [162].  The development of high-
throughput screening platforms has reduced the cost of assays almost 100-fold in the last few 
years, and the throughput has gone up by two orders of magnitude [163].  Biological databases 
span data types, including nucleotide sequences [164], protein sequences [165], protein 





genomic databases, such as PlasmoDB [172], offer a resource for data analysis and visualization 
focused on Plasmodium.  This data repository contains several broad categories of data, 
including annotated genomes, evidence of transcription, proteomics, protein function, population 
biology and evolution.  Researchers can query these data and then combine results to facilitate 
analysis. 
 
Figure 2.1.  Screenshot of PlasmoDB,  a database used to interrogate features of 
Plasmodium biology.  
This screenshot of PlasmoDB depicts the major features of the web site.  On the top bar, 
a user can search by gene ID or gene description, while the panels below allow for the 
exploration of many data types as well as links to popular genomic search tools. 
TDR Targets 
The focus of our work is on TDR (“Tropical Diseases Research”) Targets, a database and 





pathogens [161].  In the past, a major bottleneck in identifying drug targets has been the 
difficulty of capturing the relevant data from the sea of genomic information in an easily 
accessible format [160]. 
Computational efforts to understand the biology of the human malarial parasite, P. falciparum, 
generally incorporate an analysis of both attributes and gene sets.  Attributes can be measured for 
each gene and then ranked to drive biological interpretations.  Common genomic attributes 
include gene expression levels [73, 129], predictions of locality [173], transmembrane domains 
[174], and druggability [175].  Gene sets, also called “sets,” are any grouping of genes under a 
common description.  While attributes are measured on a continuum from 0 to 1, sets are binary: 
a gene is either a member of the set or not.  Some examples of sets are GO categories [176], 
protein domains [177] and metabolic pathways [178, 179].   
TDR Targets allows a user to create a weighted search query in order to create a ranked list of 
genes that prioritizes a set of attributes thought to be indicative of a gene’s promise as a drug 
target [159-161].  The web site combines a large amount of data in a simple format that allows 
researchers to easily post queries and share them with the research community, along with the 






Figure 2.2.  TDR Targets screen shot demonstrating gene filtration and specification. 
This figure from Aguero et al. [161] depicts a search for P. falciparum drug targets using 
TDR Targets, demonstrating target filtration and specification for a number of categories, 





Development of the GASER software for Plasmodium falciparum database mining 
Our software, termed GASER, expands the use of TDR Targets beyond drug target identification 
to include ranked prioritization of genes and gene sets in other focus areas.  We also incorporate 
additional data, such as time series microarray gene expression data, and offer a real-time 
method with which to alter queries.  GASER allows a researcher to explore a genome by 
weighing attributes and filtering by sets to reveal a ranked list of genes.  Once a ranked list of 
genes has been determined, it can be used to sort a list of gene sets by their enrichment toward 
the top of the gene list.  The attribute list and the set list can then be sorted according to 
correlation to the gene list.   
GASER offers a number of enhancements to TDR Targets that build a more global view of the 
types of data used in a query, helping a researcher to identify which data types are 
interchangeable and which produce the maximum differential information.  This helps both in 
streamlining queries and in promoting a better understanding of the effect each data type has on 
the query.  Our core improvements are described below.  
• Offers a more generalizable tool.  While TDR Targets focuses only on drug target 
prioritization, GASER can search through genomic information to answer a wide variety 
of potential questions.  For example, a user can query the genes and gene sets that are 
differentially expressed between any sets of experiments in our database, looking at 
individual stages of the parasite lifecycle or the entire lifecycle.  A user can then use this 
information to form hypotheses around the biological differences between the 





• Expands analysis to include gene sets.  Whereas TDR Targets outputs only genes, 
GASER adds a layer of analysis by also showing gene sets that score highly in our ranked 
list and using this information to filter for genes that are both high scoring and involved 
in gene sets that are also high scoring. 
• Uses a more robust data pool.  GASER adds a great deal of information to the queries 
in the form of microarray gene expression data from a variety of parasite lines, whereas 
TDR Targets includes limited gene expression information in the form of quintiles for 
each stage of the intraerythrocytic developmental cycle (IDC). 
• Offers an interactive user interface.  GASER’s interactive user interface shows the list 
of genes and gene sets updating dynamically as a researcher alters a query.  This 
visualization feature helps the researcher to quickly hone in on the appropriate weighting 
of different variables to create the most useful output. 
• Ranks attributes by sets.  Given a gene set of interest, GASER produces a ranked list of 
all the attributes ordered on how enriched the gene set is in that attribute.  For example, if 
a gene set was enriched in a comparison between two lines, GASER can also return other 
comparisons of lines in which the set scores highly, allowing the user to discover other 
situations where the same biology is important. 
• Ranks sets by attributes.  Given an attribute of interest, GASER produces a ranked list 
of sets based on their enrichment in the attribute.  GASER uses the following process: (1) 
creates a ranked list of genes based a given query, (2) uses the ranked list as a new 
attribute, and (3) creates a ranked list of sets enriched in that attribute. 
• Identifies correlations.  For any attribute, GASER can create a ranked list of attributes 





useful to incorporate in the query, and which attributes are uncorrelated, and therefore 
potentially valuable additions to the query. 
•  Identifies similar sets.  As with attributes, GASER can create a ranked list of sets based 
on correlation to a given set.  This provides a useful exploration tool for identifying 
similar sets and determining how much they overlap.  
Drug target identification 
A history of resistance 
The affordable and widely used antimalarials chloroquine and sulfadoxine-pyrimethamine, the 
mainstays of malaria control for several decades, are now ineffective in most malaria-endemic 
areas [44, 180].  Fortunately, in recent years, artemisinin-based combination therapies have filled 
the void created by resistance.  One hundred million children per year are now treated with fixed 
dose artemisinin-based combination therapies that cost as low as forty cents per child and are 
over 95% effective [181].  However, recent reports of the emergence of artemisinin tolerance in 
Southeast Asia have raised concerns of resistance developing, and a possible loss of the linchpin 
of malaria treatment today [96, 97, 101]. 
Urgent need for new drugs 
The need for new antimalarial drugs is clear, and treatments with independent modes of action 
would increase the arsenal of available drug combinations, delaying the emergence of resistance 
to the individual components [180, 182].  However, drug discovery is a high-risk, lengthy, and 
expensive process lasting at least 12 years and costing nearly $500 million per drug to complete 
the pipeline [183].  Computational methods to gather genomic data and aid in the drug target 





Known drug targets 
Recent publications list seven genes in the P. falciparum genome as validated drug targets: 
PF10_0084 (tubulin beta chain), PF10_0289 (adenosine deaminase), PFD0830w (bifunctional 
dihydrofolate reductase-thymidylate synthase), PFE0520c (topoisomerase I), PFF0160c 
(dihydroorotate dehydrogenase), PF10_0334 (flavoprotein subunit of succinate dehydrogenase) 
and PFI1020c (inosine-50-monophosphate dehydrogenase) [184, 185].  Presumably, many others 
await identification. 
Computational prediction of drug targets 
Using GASER, we bring together a wealth of genomics data and tailor a search query that 
maximizes for the seven aforementioned drug targets.  In the results, we discuss the genes that 








This section describes the data sources we compiled for our analyses and then introduces the 
computational pipeline used to create and analyze queries. 
Data from TDR Targets  
GASER draws most of its data from TDR Targets, all of which is publicly accessible from the 
TDR Targets web site (http://tdrtargets.org/).  The data is divided into the following 11 
categories.  
Basic genome annotation data 
Genome annotation identifies the biologically significant features of the genome [186].  Basic 
annotation data includes gene ID, gene name, gene product name, exon count, length of gene, 
length of protein, molecular weight of protein, isoelectric point of protein, hydrophobicity of 
proteins, number of transmembrane domains and presence of signal peptide.  TDR Targets 
obtains its data from the following genome databases: GenBank [187], GeneDB [188], 
PlasmoDB [172], ToxoDB, Leproma, and TubercuList. 
Functional annotation data 
Functional annotation links the genome to biological processes [186].  Functional annotations 
include Gene Ontology (GO) terms, protein domain information from Pfam or InterPro, and 





Structural data  
As many drugs bind to discrete binding sites, the identification of the atomic structure of a 
protein can be a very helpful component of rational drug design [189].  When available, TDR 
Targets incorporates crystal structure and molecular modeling of either part or the whole protein 
based on a template structure, retrieved from the Protein Data Bank (PDB) [190]. 
Expression data 
The pattern by which a gene is expressed provides clues to its biological role [119].  TDR 
Targets provides expression experiments from a number of sources [73, 128, 129], with genes 
divided into 5 bins according to the percentile of their expression (from least expressed to most 
expressed): 0-20%, 20-40%, 40-60%, 60-80%, and 80-100%.  This format allows users to add 
expression data into their queries, for example filtering by genes in the top quintile of the ring 
stage. 
Antigenicity data 
Plasmodium has the ability to vary surface protein expression, altering the antigen repertoire that 
is exposed to the immune system and in turn the virulence of the disease, linking antigenic 
variation to pathogenicity [191].  TDR Targets incorporates an antigenicity score developed by 
Kolaskar and Tongaonkar.  Their method predicts antigenic determinants by calculating the 
number of hydrophobic residues on the surface of a protein [192].  Each predicted epitope is 
scored based on physicochemical properties of the amino acid residues.  The cumulative 
antigenicity score is the sum of all the scores of the predicted epitopes, and is then normalized by 





Phylogenetic distribution data 
Linking a gene to its orthologs in other organisms helps us to transfer functional information for 
a gene from a reference species to the parasite species of interest.  There are several fully 
sequenced Plasmodium species from which we can build up a set of orthologous genes [193].  
Paralogs and orthologs for each gene were obtained from the OrthoMCL database [194], which 
provides a scalable method for constructing orthologous groups across multiple eukaryotic taxa.  
It uses a Markov clustering algorithm to group putative orthologs and paralogs.   
Essentiality data  
Gene essentiality is determined by exploring orthologous genes in other species where 
knockdown or knockout experiments have been performed.  Data were obtained from the 
Saccharomyces Genome Database (SGD) [195], Profiling of E. coli Chromosome (PEC) [196], 
the Keio Collection [197], National Microbial Pathogen Data Resource (NMPDR) [198], and 
WormBase [199], and in silico essentiality data from a flux-balance analysis metabolic network 
reconstruction [156]. 
Curated data on gene validation  
Curated data consists of genetic and biochemical data from functional studies of genes from the 
literature.  It is represented in a structured ontology format that includes the type of validation. 
Druggability data  
The druggability index (Dindex) is an important metric in the TDR Targets database that 
measures the likelihood that a protein is a drug target.  It is a composite score of a set of 
druggability prediction methods, resulting in a score from 0 (not druggable at all) to 1 (highly 





Local Alignment Search Tool (BLAST) against a database of known targets from Inpharmatica 
SAR literature database (StARlite) to compute the Dindex [200]. 
Assayability 
An assayability assessment is a key component for the later screening program for lead 
compounds, therefore biochemical and/or cellular assays for binding and function of a target 
need to be available.  In TDR Targets, a target is considered assayable if it has an enzyme 
included in Sigma Aldrich’s collection of assays, or if it can be determined it has been assayed 
via the Braunschweig Enzyme Database (BRENDA) database [201]. 
Bibliographic references  
Bibliographic references were mined from PubMed, and can be used as a proxy for the amount 






Gene set data sources 
PlasmoDB provides a wealth of gene set information, which we have parsed and incorporated 
into GASER based on version 8.2 of PlasmoDB.  6,372 genes were included in the current 
version [202, 203].  We downloaded four major sources of gene sets from PlasmoDB, GO 
categories, InterPro signatures, metabolic pathway information and EC numbers.  We also 
included a set of miscellaneous sets from a variety of sources, including custom gene sets of 
interest. 
GO 
The GO Consortium produces a standardized vocabulary that can be applied to all eukaryotes 
even as knowledge of gene and protein roles continue to develop and expand [176].  PlasmoDB 
contains a record of a mapping of the GO categories onto P. falciparum, providing an extensive 
knowledge base of the function of many of the genes in the genome.  1,664 GO categories 
involving 4,415 genes are included, spanning a huge range of biological functions.  On average, 
genes had 3.85 categories per gene.  Each GO category had an average of 10.2 genes.  There 
were 16,997 GO category labels applied in total, covering 69.3% of the genome. 
InterPro 
InterPro is a database of predictive protein signatures, integrating data from diverse source 
repositories, including Pfam [166], PRINTS [204], PROSITE [205], SMART [206], ProDom 
[207], PIRSF [208], SUPERFAMILY [209], PANTHER [210], CATHGene3D [211], 
TIGRFAMs [212], and HAMAP [177, 213].  Each of these sources has its own focus and 
methodology of signature production, and InterPro integrates them into a single database.  





occurrence of functional domains, repeats, and other important sites.  3,369 InterPro signatures 
were included in PlasmoDB with an average of 3.56 genes each.  3,888 genes were labeled with 
an InterPro signature, averaging 3.09 labels per gene.  There were 11,997 InterPro labels applied 
in total, covering 61.0% of the genome. 
Metabolic pathways 
PlasmoDB has an extensive array of metabolic pathway information culled from the malaria 
Metabolic Pathways database, which was developed and curated by Hagai Ginsburg [178, 179].  
The metabolic pathways of Plasmodium were extracted from the Kyoto University Encyclopedia 
of Genes and Genomes site (KEGG), which provides a knowledge base for the systematic 
analysis of gene function [167, 214].  The malaria Metabolic Pathways database trimmed KEGG 
data to remove irrelevant entries and then annotated it with current knowledge within the malaria 
research community.  182 metabolic pathways were detailed, averaging 36.7 genes, with 
pathways ranging from 2 genes to 342 genes.  2,938 genes were part of at least one pathway, 
averaging 2.3 pathways per gene.  There were 6,671 metabolic pathway assignments applied in 
total, covering 46.1% of the genome.  In many respects, the metabolic pathway assignment data 
is the most useful in our gene set enrichment analysis, as enrichment in a pathway is 
straightforward to interpret as a recognizable biological process. 
EC 
The hierarchical EC numbering system is the standard resource for classifying enzymatic 
chemical reactions [176].  The sixth edition was published by the International Union of 
Biochemistry and Molecular Biology in 1992 and contains 3,196 different enzymes.  625 EC 
numbers were detailed, averaging 9.4 genes each.  1,100 genes were labeled as an enzyme, with 





Each EC number has 4 digits, each of which can be removed to more generally define the type of 
enzyme in question.  For example, any gene that is a member of 3.6.4.8, the EC number for 
proteasome ATPase, will also be a member of 3.6.4.- (acting on ATP; involved in cellular and 
subcellular movement), 3.6.-.- (acting on acid anhydrides), 3.-.-.- (hydrolase nomenclature),  and 
-.-.-.- (all enzymes).  The most general category (-.-.-.-) contained 1,100 genes, all the genes that 
were labeled as an enzyme.  There were 5,860 EC numbers applied in total, covering 17.3% of 
the genome. 
Gene sets from miscellaneous sources 
While the majority of the gene sets was taken directly from PlasmoDB, we also compiled 587 
additional gene sets from a variety of sources, with an average of 10.5 genes in each gene set.  
2,754 genes were included in 2.2 sets on average, covering 43.2% of the genome.  The total 
number of gene/set pairs was 6,177. 
Genome coverage 
After applying all the gene set labels from PlasmoDB as well as the set of labels we incorporated 
from other sources, 47,682 total labels were applied, assigning 5,184 genes to 6,427 gene sets.  
This accounts for 81.4% of the genome, each gene being a member on average of 9.2 sets, with 
the most labeled gene being represented in 45 sets. 
Overlap of gene set data sources 
We analyzed the overlap between the datasets, and found the GO categories overlapped well 
with the other categories.  76.3% of genes given a GO category were also assigned an InterPro 
signature, 57.3% were assigned to a metabolic pathway, 23.9% had an EC number, and 53.4% 





InterPro had an even larger overlap with the rest of the datasets, with much more overlap in 
metabolic pathways.  86.6% of genes given an InterPro signature were also assigned a GO 
category, 69.4% assigned to a metabolic pathway, 28.1% given an EC number, and 58.6% 
represented in the miscellaneous gene sets. 
Genes that mapped to a metabolic pathway were well annotated in the other datasets, especially 
in InterPro protein structure assignments.  86.2% of metabolic pathway genes were present in 
GO categories, 91.8% in InterPro sets, 37.3% had EC numbers, and 73.4% were represented in 
the miscellaneous sets. 
Genes with EC numbers were heavily represented in the other families of gene sets, with 95.7% 
of genes with an EC number also being assigned to a GO category, 99.3% to an InterPro 
signature, 99.6% to a metabolic pathway, and 80.6% to the miscellaneous sets.  Nearly every 
gene labeled as an enzyme was also attached to a metabolic pathway. 
Finally, genes from the miscellaneous sets were also well represented in the other types, with 
85.7% of genes in a miscellaneous set also appearing in a GO category, 82.8% assigned an 







We attempted to include all publicly available gene expression data in our analysis.  A summary 
of the strains in our data set is available below. 
HB3 
The first IDC transcriptome of P. falciparum consisted of hourly samples through the entire 48-
hour cycle [129].  The transcriptome of HB3, along with that of 3D7 and Dd2 are the most 
complete transcriptomes elaborated to date, and therefore constitutes a rich dataset to help align 
sparser time series.  HB3 and Dd2 were used for a genetic cross to show that chloroquine 
resistance is not linked to mdr-like genes and HB3 was used as the chloroquine-sensitive parent 
of the cross [215].  HB3 was also used as the pyrimethamine-resistant parent in a cross with 3D7 
to show that pyrimethamine resistance results from point mutations in the gene encoding 
dihydrofolate reductase-thymidylate synthase [216].  The Hondo-1 strain was isolated in 1983 
from a patient treated during an outbreak of urban malaria in Choluteca, Honduras in January 
1980 and was determined to be pyrimethamine-sensitive [217].  HB3 was derived from Hondo-1 
by microscopic selection and is as sensitive to pyrimethamine as the original line [218]. 
Dd2 
Dd2 was used as the chloroquine resistant (CQR) parent of the HB3 and Dd2 cross [215].  Dd2 is 
a clone from the W2-MEF line of the Indochina III isolate W2 [219].  W2-MEF was created by 
maintaining the W2 strain in continuous culture in increasing concentrations of mefloquine 
hydrochloride for 96 weeks and is four to six times more resistant to mefloquine than the 
parental clone W2 [219].  Dd2 is also pyrimethamine resistant.  The full transcriptome of Dd2 






In 2002, the full genome of the 3D7 clone was completed [118].  As the only fully sequenced 
human malaria parasite it serves a vital role in genomic studies, and among many other uses it 
was the model all the microarray experiments referred to in this paper.  Therefore the DeRisi lab 
ran a full transcriptome on 3D7 to confirm the major findings of the HB3 transcriptome [73].  
3D7 was derived from the isolate NF54 from the Netherlands by limiting dilution [220].  NF54 
was derived from a patient living near Schipol Airport, Amsterdam, who had never left the 
Netherlands [221].  3D7 was used as the pyrimethamine-sensitive parent in a cross with HB3 
[220]. 
FCB 
FCB has gene sequence polymorphisms, pfmdr1 amplicons, and DNA fingerprints characteristic 
of an Asian origin [222, 223].  FCB is believed to have descended from the same laboratory 
strain as FCR3 and ItG2, two other commonly used strains [224].  FCB contains two copies of 
pfmdr1 and carries the Asian/African pfcrt allele that confers chloroquine (CQ) resistance as well 
as the pfmdr1 N86Y mutation that has been associated with resistance to CQ and reduced 
mefloquine (MFQ) inhibitory concentration (IC)50 values [225].  
FCB_3’KD 
FCB_3’KD was generated in the Fidock laboratory from the multi-drug resistant parasite line 
FCB by disrupting 1 of the 2 copies of pfmdr1 [225].  The knockdown line demonstrated a 3-fold 






106/1 and FCB are both non-recombinant parasite lines that appear highly related genetically by 
microsatellite studies.  Each has the same pfcrt haplotype other than residue 76, with 106/1 
harboring the wildtype K76 responsible for chloroquine susceptibility.  Both lines have identical 
pfmdr1 haplotypes.  106/1 was one of 20 clones of P. falciparum isolated from patients attending 
a village clinic in Sudan during 10 days in October and November in 1989 [226].   
7G8 
IMTM22 was isolated from a clinical patient in Manaus, Brazil in 1980, and then later cloned by 
the limiting dilution method to produce 7G8 [227].  7G8 is chloroquine and pyrimethamine 
resistant.   
7G8_CTRL 
7G8_CTRL was generated in the Fidock laboratory from 7G8 by allelic exchange via single 
crossover recombination targeting codon 76 of the mutant pfcrt allele [228].  In 7G8_T76K, this 
residue is back mutated to K and results in a drug-sensitive parasite, while 7G8_CTRL 
incorporated a plasmid with no mutation, serving as a control for the genetic manipulation.   
7G8_T76K 
7G8_T76K was generated in the Fidock laboratory from 7G8 by allelic exchange via single 
crossover recombination targeting codon 76 of the mutant pfcrt allele for back mutation from T 
to K [228].  
Dd2-REG 
Dd2-REG is a clone of the Dd2 line created in the Fidock lab to investigate dihydroartemisinin 






The Dd2-EXO samples were created by treating the Dd2-REG samples with terminator 
exonuclease.  This treatment degrades any ribonucleic acid (RNA) that does not have a 5’-
triphosphate, 5’-cap, or 5’hydroxyl group, and helps to identify altered mRNA processing 
between two lines. 
3b1-REG 
To investigate genetic determinants mediating reduced susceptibility to DHA, increasing drug-
selection pressure was place on Dd2-REG, starting at 2.8 nM, and then increased over the course 
of 200 days to 28 nM.   
3b1-EXO 
As with Dd2-REG and Dd2-EXO, 3b1-REG was treated with terminator exonuclease to create 
3b1-EXO. 
Statement of contribution.  Dr. Sophie Adjalley performed an eight time-point study of the 
transcriptome of the parasite lines (FCB, FCB 3’KD, 106/1, 7G8, 7G8_CTRL, 7G8_T76K), in 
the Llinas laboratory in 2009.  Dr. Richard Eastman performed a six-time point study of the 






User interface components 
Our work on GASER focused on developing a web site that enables a researcher to instantly see 
the effect of altering variables and to more quickly access the information needed to adjust a 
query.  This is accomplished largely through a modular user interface, which couples “lists” and 
“panels” for genes, gene sets, and queries.  The lists allow for sorting and filtering to narrow a 
search, while the panel components provide the researcher with additional information and links 
about the gene, gene set, or query they are examining. 
 





GASER has four main sections.  The “genes” section in blue in the upper left lists the 
current gene ordering.  The “sets” section in green in the upper right lists the current gene 
set ordering.  The “attributes” section in red in the lower left lists the available attributes.  
The “tags” section in yellow in the lower right lists the current tag ordering.  Clicking on 
a gene in the tag list filters the set list to only the sets for which the gene is a member.  
Clicking on a set in the sets list filters the gene list to only show the corresponding 
member genes of the set. 
Gene list 
The gene list provides the current list of genes based on the selected attribute.  It can be sorted 
and/or filtered in real time.  A search box allows for zeroing in on a specific subset of the genes.  
The gene list can be sorted by any attribute in the system, which includes all attributes pulled 
from TDR Targets or PlasmoDB, as well as any queries created by the user or shared by the user.  
The list can be filtered by any set in the system or set of sets, or it can be filtered by any attribute 
and a cutoff.  For example, the list of genes could be filtered by genes that are at least two-fold 
different between strain A and strain B at time point 36. 
Gene panel 
The individual gene panel provides all the relevant gene information as well as links to more 
data.  This includes the attribute and the score for the gene for that attribute.  It also includes any 
gene sets to which the gene belongs.  The full set of gene expression information for that gene is 
available to examine in tabular form 
Gene set list 
The gene set list functions in a similar way to the gene list.  Here the list of gene sets is sorted by 
their enrichment in the current gene list.  We locked the gene set list to the gene list to ensure 
that a change in sorting of the gene list automatically updates the gene set list.  This novel 





the genes and the gene sets.  The list can be filtered by the database from which the set 
originated, by a specific enrichment score, or by an average expression level. 
Gene set panel 
The gene set panel is similar to the gene panel, but it offers aggregate data based on all the genes 
in the gene set.  We implemented custom visualizations of the gene set enrichment over time for 
each of the time series (Figure 2.4), which enables the researcher to see where the expression 
peaks over time, the correlation of the gene set’s expression, and for which windows of the time 
series the set is enriched to be up or down. 
 
Figure 2.4. An enrichment plot of the transporter gene set FCB vs. 106/1. 
A gene set plot of the transporter gene set in FCB vs. 106/1.  The gray lines represent the 
log fold changes of each gene in the gene set across the time series.  The genes are 
ordered from darkest to lightest according to the time point that has the lowest false 
discovery rate.  The black line is an average of these genes, while the red line is the 
normalized enrichment score of the gene sets across the time series.  Any significantly up 






The query list displays all the queries that have been created.  When a query is selected it is 
loaded in the query window, and then the gene and gene set lists are updated accordingly.  This 
makes it easy to peruse all the current queries and compare their results.  It is also possible to sort 
the queries according to similarity to a given query based on the similarity of their gene and gene 
sets results. 
Query panel 
This panel allows the user to dynamically update a query, by presenting all the possible attributes 
and helping the user to build a weighted combination of attributes, along with any desired 
filtering.  Any weighting or variable can be changed here and in real time the gene and gene set 






Enrichment ranking using the HATS computational pipeline 
Description
 
Figure 2.5. HATS computational pipeline. 
The HATS computational pipeline involves six steps that carry the data from creation to 
final analysis and is the foundation for a large portion of our analyses. 
We developed a computational pipeline, called HATS (Figure 2.5), that measures the fold 
change for each gene between two parasite lines by aligning each time series and then comparing 
at an individual time point or across a range of time points that could encompass a stage or the 
complete development cycle.  Gene set enrichment is also measured over the same time periods.  
HATS fits into the GASER tool by aligning all the disparate expression data in GASER and 
computing gene fold change and gene set enrichment for any parasite line comparison a 
researcher would analyze in GASER. 













The HATS pipeline has several major steps: data creation, normalization and filtering, 
alignment, dimensionality reduction, individual gene analysis, and gene set analysis.  An 
overview of this process is described below and then in more specific detail in the subsequent 
chapters as it is applied to different use cases.  
Data creation 
Each of our data sets is a time series measurement of the transcriptome of a given parasite.  The 
experiments are performed over multiple time points, because the majority of the genes in P. 
falciparum fluctuate over the 48-hour IDC in a cyclic fashion [73, 129].  If we were to compare 
two solitary time points between two lines, the expression differences would likely reflect 
differences in timing of the genes, not in the actual biological signal of the comparison.  
Therefore we sample at six or eight time points and then impute and align the curves to make 
comparisons. 
Each transcriptome was measured on a two channel microarray, such that each cDNA sample 
corresponding to an individual parasite line and time point was coupled to the Cy5 functional 
dye, while a common reference pool made up of samples from all time points of the 3D7 
reference strain were couple to the Cy3 functional dye.  Data were acquired using a GenePix 
4000B scanner and analyzed using the GenePix Pro 4 software (Axon Instruments, Union City, 
CA, USA).  A representative section of one of the microarrays appears in Figure 2.6. 
The result of the data creation face is fluorescence information for each channel for possibly 
multiple probes for each gene.  The next step is to normalize, filter, and combine this data to 






Figure 2.6.  An example of a P. falciparum microarray hybridization. 
This figure is an image from one of our microarray image files.  A subsection of the array 
shows the red channel, the green channel, and then both channels overlayed. 
Normalization and filtering 
To measure the relative abundance of mRNAs throughout the IDC, the total RNA at each 
time point in one channel was compared to a reference pool of total RNA from all time 
points of 3D7 in a standard two-color competitive hybridization [229].  Each channel has its 
own fluorescence distribution and must first be normalized in order to have a proper inter-





and the median background intensity of probes with at least 200 expression units and a 
regression correlation coefficient greater than or equal to 0.75 was used as a normalizing 
factor.  Each difference was divided by this mean to alleviate any intensity shifts between the 
two channels. 
Figure 2.6 is a cartoon representation of part of a microarray, providing an example for the 
various expression levels a probe can have.  Probes with low signal intensity or that did not 
cover an adequate portion of the circle were removed when more than 50% of the pixels were 
within two standard deviations of the background in either channel.  Each file was also hand-






Figure 2.7.  Filtering the expression values of a microarray. 
a. The fluorescence from the red channel.  b. The fluorescence from the green channel.  c. 
A representation of what both channels would look like combined.  Areas in red are high 
in the red channel, areas in green are high in the green channel, areas in yellow have 
equal amounts red and green.  d. In this step, any bad probes are removed, including 
probes with low signal or not full coverage of the probe.  e. Shows only the probes that 
are up in the red channel.  f. Shows only the probes that are up in the green channel.  g.  
Shows only the probes that are not significantly up in either channel. 
Any probe that had less than 80% coverage in the time series was filtered out.  Any missing 





all time points.  Probe similarity was measured using Pearson correlation, which is a measure of 
the correlation between two variables, resulting in a value between +1 and -1.  Most probes have 
reliably close correlates due to the cyclic nature of Plasmodium gene expression.   
The microarrays contained roughly one probe per kilobase of sequence per gene [129].  For each 
gene that had more than one probe, it was necessary to combine the expression values at each 
probe into one expression value to facilitate comparisons with other strains.  Expression values 
were combined by finding the median value of all probe values that were not filtered out in the 
above steps. 
Interpolation and Alignment 
The fast Fourier transform (FFT) maps time series data into frequency data, and locates 
frequencies that have intrinsic periodicity [129].  To properly align the lines, we used FFT to 
calculate the strength of the signal at the 48 hour frequency and impute expression levels at 
unassayed time points, creating a smooth sine curve over the 48-hour lifecycle.  This allowed us 
to extrapolate the expression level and rank of each gene at any time point in the lifecycle.  By 
focusing on the main frequency of the data, much of the noise is removed, and strains are 
automatically aligned to each other, as variations in speed through different stages of the 
lifecycle are reduced. 
Dimensionality reduction 
We utilized dimensionality reduction techniques to validate the alignment of the time points and 
characterize differences between lines.  Principal component analysis (PCA) of the all lines 





We compiled a background pool of lines that were previously described: FCB, FCB_3’KD, 
106/1, 7G8, 7G8_CTRL, 7G8_T76K, 3D7, Dd2, HB3, Dd2-REG, 3B1-REG.  To reach coverage 
of eight time points per hour, we imputed any missing time points and then aligned to 3D7.  All 
genes that were represented in all 11 strains were used to create a matrix of values that we 
reduced to a three-dimensional projection using PCA.  Our interpretation of the PCA analysis 
appears in the Results section. 
Single gene analysis 
We used two methods to determine which genes were significantly up or down-regulated 
between lines, area under the curve (AUC) and orthogonal projections to latent structures 
discriminant analysis (OPLS-DA), which are fully described in Chapter 3.  These methods result 
in a ranked ordering of genes based on how significantly up or down they were in a comparison.  
For each gene, we computed the fold change for each possible pair of comparisons from the 11 
background lines.  We found the rank of each gene in each comparison and then recorded the 
mean and standard deviation of the distribution of the rankings.  Then we compared our original 
gene ranking to the distribution to calculate a normalized fold change where +1 signifies one 
standard deviation above the mean fold change rank. 
Gene set analysis 
The biological analysis of a microarray study focusing on the gene level is fraught with 
difficulties, including dealing with the random noise associated with the experiment and devising 
a method with which to expand observations on the gene level to something more systemic.  A 
full description of our gene set analysis methods appear in Chapter 3.  Briefly, the method takes 
as input a ranked list of genes, and returns a ranked list of gene sets by their enrichment in the 





the one used in the single gene analysis.  Example gene set enrichments are depicted in Figure 
2.8. 
 
Figure 2.8.  Example gene set enrichments. 
Each panel represents an example gene set.  The vertical bar represents all the genes in 
the genome sorted by expression.  Genes in red are up-regulated, while genes in blue are 
down-regulated.  The location of each gene in the gene set is marked by a line to the right 
of the color bar, indicating the distribution of the gene set in the ranked list.  a. An 
example of a gene set that is enriched to be up in A.  b. An example of a gene set that is 







Our analysis focuses on three critical questions the GASER toolkit helps to address, ranging 
from specific questions about drug target prediction to more general questions that help to better 
describe the data we are interrogating.  The first is the creation of a potential drug target list and 
the comparison of that list to known drug targets.  The second is a PCA analysis of all the 
parasite lines for which we have expression data.  The third is an analysis of the enrichment 
scores for the background pool to find the most variant and most invariant genes and gene sets. 
Potential drug target list 
As a proof of principle for our tool, we attempted to build a query that would make the seven 
verified drug targets score highly.  As you update a query in GASER, you can immediately see 
the effect on the gene ranking, so we incrementally updated our equation until many of the 
verified drug targets scored highly.  Our analysis was ad hoc, in that expert knowledge was used 
to determine which variables to use, and the values were tweaked to build a query that tried to 
maximize the ranking of the verified drug targets.  Figure 2.9 displays the final version of the 
query, which is a weighted sum of 14 variables.  Some of the variables we weighted heavily 
included: whether the gene was an enzyme, availability of reagents and assays, the druggability 
index score, number of transmembrane domains, number of references, and the existence of a 
known structure. 
Our analysis was limited by the fact that it required expert knowledge and manual tweaking of 
values.  Currently, we are developing a search algorithm that systematically explores the space of 
all available variables to determine a global solution that maximizes the ranking for a set of 





set of targets and then compare that to existing knowledge to attempt to understand why a set of 
variables worked well. 
 
Figure 2.9.  P. falciparum drug target search query. 
A screenshot from GASER of the query builder for a sample drug target search query.  
The column on the left names the attributes used in our sum query.  The right column 
contains the weightings used to produce the score.  Each gene has a value between 0.0 
and 1.0 for each attribute.  Each weighting can be any value, for our query, we kept the 
weightings between 0.0 and 10.0.  The score for each gene is a weighted sum of these 






Figure 2.10.  The top 20 scoring genes from drug target search 1. 
The top 20 genes from our first drug target search.  Many of the top scoring genes were 





The top twenty genes in our search query are displayed in Figure 2.10.  The highest scoring gene 
was PFC0525c, a putative glycogen synthase kinase that codes for PfGSK-3.  Phosphorylation 
by protein kinases is integral to many signal transduction pathways in eukaryotes, and P. 
falciparum kinases are highly divergent from those in humans, and therefore attractive drug 
targets [230].  A homology model of the protein has been developed, and it is currently being 
studied as an antimalarial drug target [231, 232]. 
The second highest gene was PF10_0289, a putative adenosine deaminase that is in the list of 
seven verified drug targets.  P. falciparum parasites treated with cyclohexylamine, a spermidine 
synthase inhibitor, had their development arrest in the trophozoite stage and differentially 
expressed the polyamine biosynthesis, including adenosine deaminase [233].  This finding 
verified the polyamine biosynthesis pathway as an antimalarial drug target. 
The third gene was also a verified drug target, PFD0830w, bifunctional dihydrofolate reductase-
thymidylate synthase.  Dihydrofolate reductase (DHFR) is a target of the DHFR inhibitors 
pyrimethamine and proguanil, and observed amino acid changes in DHFR confer resistance to 
the two drugs [234, 235]. 
The fourth gene was a putative methionine aminopeptidase, PF10_0150/PfMetAP1b, which 
functions in a process that is essential for proper protein folding and the initial steps of 
catabolism of hemoglobin [236].  Aminopeptidases are recent targets for chemotherapy [237], 
and inhibitors of PfMetAP1a have been shown to possess antimalarial activity [238].  The sixth 
gene in the ranked list, PF14_0327 was also a putative methionine aminopeptidase of type II. 
The fifth gene was PFI1170c, thioredoxin reductase, which catalyzes the NADPH-dependent 





when comparing P. falciparum to humans [239].  Specific inhibitors of thioredoxin reductase 
have been discovered and could function as potential antimalarial agents [240]. 
The seventh gene was PFE1050w, an adenosylhomocysteinase known as SAHH, is necessary for 
the active methylation of different biomolecules [241].  Interestingly, SAHH, was over-
expressed in in-vitro selected artemisinin-resistant progeny with artelinic acid compared to the 
parental [242], while it was down-regulated after treatment with artemether [243]. 
The eighth gene, PF10_0053, a putative tRNA ligase, and the ninth gene, PFI1105w, a 
phosphoglycerate kinase, were the first two genes that were not referenced extensively in the 
literature.  These genes have all the attributes we believe comprise potential drug targets; the fact 
that they have not yet been researched extensively may provide an opportunity for future 
experimentation. 
The tenth gene, PF14_0127, N-myristoyltransferase, is known as PfNMT, and is currently being 
researched as a potential drug target.  Molecules incorporating a benzothiazole core 
scaffold have been shown to inhibit PfNMT [244]. 
As is evident from a review of the first ten genes in the list, many are either validated targets or 
heavily researched as potential drug targets.  The seven verified targets were at positions 2, 3, 19, 
21, 34, 50, and 293 out of a list of 5,590 genes.  The likelihood this would have happened at 
random is 2.6e-12. 
Upon completion of our search, we explored the results, using the sets and tags sections to gain a 
better understanding of the biology behind these gene choices.  Figure 2.11 shows a screenshot 





highly.  A user of the system can jump between sets and genes to find out more about the 
biological processes involved in their data. 
 
Figure 2.11.  The folate biosynthesis pathway. 
A screenshot from GASER showing the folate biosynthesis pathway selected in the sets 
list.  Only genes from the pathway are visible in the genes list, with their ranking 
appearing to the left of their name.   
PCA of all parasite lines (reference pool) 
Transcriptional profiling data from 11 lines were used in our GASER database.  Each was 
aligned to the 3D7 transcriptome [73], making them easily comparable.  To visualize the 
similarities and differences of the lines, we created a PCA plot of the data in a reduced 
dimensional space, which appears in Figure 2.12.  The following analysis describes the genes 





We ran our gene set enrichment methods on each of the principal components for the reference 
pool.  The PCA analysis converted a gene expression space of ~3,000 genes into a five-
dimensional principal component space, from which we produced five ranked lists of genes.  For 
each principal component, the accompanying gene list began with genes that had the highest 
values in the principal component down to genes that had the lowest. 
In our gene set analyses, we deemed any set with a false discovery rate (FDR) less than or equal 
to 0.25 to be significant.  The significance ratio (SR) is the ratio of the number of sets that are 
significant in either direction over the total number of sets.  This ratio helps describe the 
biological relevance of a ranked gene list.  As the number of significant sets in a comparison 
rises, the SR rises accordingly.  The first five principal components had SRs of 0.211, 0.189, 0.0, 
0.011, 0.062 respectively.  This clearly shows that the first two principal components have a 
much stronger biological signal than the other three.  This is most likely because the first two 
principal components capture the signal of the time series, while the other three components 






Figure 2.12.  Reference pool principal components analysis (PCA), showing a view of 
components 1, 2, and 3. 
a. PCA of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD (red), (c.) 106/1 
(yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K (green), (g.) 3D7 
(violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG (maroon), (k.) 3b1-REG 
(tan). This orientation focuses on the first 2 principal components.  While the time points 
match well, 3D7, Dd2, and HB3 have fuller signals than the other lines, and stretch 





Figure 2.13.  Reference pool principal component 1. 
Principal component 1 of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD (red), 
(c.) 106/1 (yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K (green), 
(g.) 3D7 (violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG (maroon), (k.) 
3b1-REG (tan).  There were 103 enriched sets up, including many RNA sets, and 97 
enriched sets down, including the centriole, centrosome, and cell cycle sets. 
The first principal component had 103 enriched sets up and 97 enriched sets down out of 947 for 
a significance ratio (SR) of 200/947=0.211.  This is a very strong biological signal, as was 
evidenced by the plot of the component, with each line matching up to the others, it was a strong 
signal that peaked in the ring stage.  The proteasome is heavily down in principal component 1, 
which makes sense as it is supposed to be most expressed during the trophozoite stage, where it 
is involved with hemoglobin metabolism [245].  The centriole, centrosome, and cell cycle gene 





schizont stages when the parasite is rapidly dividing.  A number of RNA sets are enriched to be 
up in principal component 1, including RNA modification, RNA polymerase III, RNA splicing, 
and the RNA recognition motif domain. 
Figure 2.14.  Reference pool principal component 2. 
Principal component 2 of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD (red), 
(c.) 106/1 (yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K (green), 
(g.) 3D7 (violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG (maroon), (k.) 
3b1-REG (tan).  Oxidoreductase activity is up, and utilization of phospholipids is down. 
Principal component 2 peaks in the trophozoite stage, which matches well with the 
oxidoreductase activity set that is enriched up, as oxygen radicals are released during the 
proteolysis of hemoglobin [245].  Also, the centrosome proteins that were down in the ring stage 





The second principal component had 106 enriched sets up and 73 enriched sets down out of 947 
for an SR of 179/947=0.189.  The utilization of phospholipids set is down, signifying that the 
second principal component is focusing on the time period after the phospholipids have been 
utilized for invasion.  
Figure 2.15.  Reference pool principal component 3. 
Principal component 3 of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD (red), 
(c.) 106/1 (yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K (green), 
(g.) 3D7 (violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG (maroon), (k.) 
3b1-REG (tan).  No gene sets were enriched up or down, indicating that the component is 
mostly focused on differences in experiment. 
The third principal component had 0 enriched sets up and 0 enriched sets down out of 947 for an 





appears from visual inspection that this component is mostly focused on differences in 
experiment.  The lines are clearly segregated based on the time and location of the parasite, with 
the pfcrt and pfmdr1 strains distinct from the 3D7, HB3, Dd2, 3b1-REG, and Dd2-REG strains.  
This emphasizes the utility of the SR for discriminating whether a ranked gene list has biological 
significance or is merely encompassing outside noise influencing the experiments. 
Figure 2.16.  Reference pool principal component 4. 
Principal component 4 of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD (red), 
(c.) 106/1 (yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K (green), 
(g.) 3D7 (violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG (maroon), (k.) 
3b1-REG (tan).  There are very few gene sets up or down in this component, however 





The myosin complex is one of only two significant gene sets up in component 4.  Apicomplexan 
parasites use an actomyosin motor to drive invasion of host cells, therefore significance in this 
gene set suggests increased invasion in the time points contributing most to the signal [246]. 
The fourth principal component had two enriched sets up and eight enriched sets down out of 
947 for an SR of 10/947=0.011.  In general there is very little biological signal coming from this 
component. 
Figure 2.17.  Reference pool principal component 5. 
a. Principal component 5 of all 11 lines in the pool: (a.) FCB (blue), (b.) FCB_3’KD 
(red), (c.) 106/1 (yellow), (d.) 7G8 (purple), (e.) 7G8_CTRL (brown), (f.) 7G8_T76K 
(green), (g.) 3D7 (violet), (h.) Dd2 (orange), (i.) HB3 (light green), (j.) Dd2-REG 
(maroon), (k.) 3b1-REG (tan).  There were 34 sets up and 25 down, including proteasome 





The fifth principal component had 34 enriched sets up and 25 enriched sets down out of 947 for 
an SR of 59/947=0.062.  Proteasome and redox regulation are both down, correlating with the 
smaller influence of the trophozoite stage in the fifth component.  The dynein heavy chain 
contains a large motor domain along the microtubule, both of which are up in principal 
component 5. 
After examining the enrichment results for the five principal components, it is clear that some 
components were much more amenable to biological interpretation.  This demonstrates that 
dimensionality reduction can sometimes recover clear interpretations of the signal around the 
reduction, while at other times, though there is a strong mathematical component to the 
reduction, there isn’t a clear biological correlate, making it less useful for analysis. 
Variant gene sets 
Since malaria parasites have to survive while facing a fully functioning human immune system, 
they have evolved sophisticated strategies for immune evasion [247].  One such strategy is to 
undergo clonal antigenic variation, encoding multicopy, nonallelic gene families for surface 
molecules that are important targets of the immune response [247].  Antigenic variation involves 
repertoires of contingency genes that are expressed differentially and usually are subtelomeric 
[248].  
One major finding of our pooled analysis was that we could sort the genes and gene sets 
according to their average ranking, allowing us to create a list of the most variant and most 
invariant genes and gene sets.  For each gene, we examined 55 comparisons between 11 lines 
and calculated the rank of the gene in each comparison.  For example if a gene had a higher fold 





would be 0.75.  If a gene ranked less than 0.5 in a comparison between A and B, then instead we 
used the ranking in the comparison between B and A, which would be above 0.5.  These 
rankings create a distribution for the normal fold change that a gene experiences between two 
lines.  From that distribution we can calculate a mean, which signifies the fold change that a gene 
will demonstrate between two randomly selected lines on average.  We also calculated the 
standard deviation of the distribution.  Now if we sort all genes by their mean fold change, we 
have a list of genes where the genes at the top of the list are highly variant, meaning they change 
their expression a great deal from line to line.  At the bottom of the list are the highly invariant 
genes, which should be the house keeping genes that are integral to the function of the parasite 
and must maintain a steady expression level and do not change at all from line to line. 
We calculated similar statistics for the gene sets based on the enrichment score of the gene set, 
creating a ranked list of gene sets where gene sets at the top are highly variant, and gene sets at 
the bottom are highly invariant.  We filtered out any gene set that appeared in less than half of 
the 55 possible comparisons, leaving 1,319 gene sets, of which the top 50 are listed in Table 2.1, 
with antigenic variant gene sets in bold.  We found these by taking the mean rank of a gene set in 
all pair-wise comparisons and sorting by highest mean.  This maximizes for gene sets that have 
the most variation between lines.  Our original hypothesis that the antigenic variant gene sets 
would be the most variant was confirmed. 
Set Description Size Mean StDev 
Hagai Ginsburg ... 
Functional annotation of merozoite 
invasion related proteins 63 0.99 0.02 
Merozoiteproteins 
Functional annotation of merozoite 
invasion-related proteins 65 0.99 0.02 
Hagai Ginsburg ... 
Subcellular localization of proteins 
involved in invasion 56 0.99 0.02 
proteinsLocalizpath 
Subcellular localization of proteins 





Hagai Ginsburg ... 
Established and putative Maurer s clefts 
proteins 89 0.99 0.02 
MCprot 
Established and putative Maurers clefts 
proteins 97 0.99 0.02 
GO:0020003 symbiont-containing vacuole 7 0.98 0.04 
AV:phist phist gene family 73 0.98 0.03 
Resetting 
Rosette formation between normal and 
infected RBC 315 0.97 0.06 
GO:0030260 entry into host cell 15 0.97 0.08 
PF09716 
Malarial early transcribed membrane 
protein (ETRAMP) 14 0.96 0.06 
TIGR01495 
ETRAMP: early transcribed membrane 
protein (ETRAMP) family 14 0.96 0.06 
KE:PFA03010.RIBOSOME  -  72 0.96 0.09 
Hagai Ginsburg ... Ribosomal structure 134 0.96 0.08 
ribosomeStruct Ribosomal structure 135 0.96 0.08 
GO:0003735 structural constituent of ribosome 150 0.96 0.09 
 PF07133 Merozoite surface protein (SPAM) 6 0.95 0.06 
GO:0005840 ribosome 140 0.95 0.08 
DomSurfaceProt Domains of merozoite surface proteins 14 0.95 0.10 
GO:0006412 translation 251 0.95 0.08 
PF09687 
Protein of unknown function 
(P_fal_TIGR01639) 32 0.94 0.09 
TIGR01639 
P_fal_TIGR01639: Plasmodium 
falciparum uncharacterized domain 
TIGR01639 48 0.94 0.08 
GPI_prots 
Genes coding for GPI-anchored 
membrane proteins 30 0.94 0.07 
cytoadherencescheme 
interactions between modified host cell 
membrane and endothelial cell 113 0.94 0.08 
SSF47592 SWIB/MDM2 domain 5 0.94 0.10 
GO:0033643 host cell part 5 0.94 0.11 
GO:0020033 antigenic variation 182 0.94 0.09 
HJ:up in 106176I and 
106176I352K 
Genes significantly up-regulated in 
106/176I and 106/176I-352K parasites 
from Jiang et al PLOS One 2008 33 0.94 0.11 
PD936484 
POLYPROTEIN GLYCOPROTEIN M G2 
TRANSMEMBRANE NONSTRUCTURAL 
MEMBRANE CONTAINS: PRECURSOR 
SIGNAL 48 0.94 0.09 
GO:0005622 intracellular 336 0.94 0.09 
AP2_PF14_0633_1 Matching set 1 for AP2 - PF14_0633 261 0.94 0.07 
Hagai Ginsburg ... 
Genes coding for GPI anchored 
membrane proteins 25 0.94 0.06 
AV:hyp hyp gene family 51 0.94 0.09 
GO:0020009 microneme 11 0.93 0.10 





PTEX Translocon of exported proteins (PTEX) 7 0.93 0.08 
GO:0016255 attachment of GPI anchor to protein 28 0.93 0.09 
GO:0022625 cytosolic large ribosomal subunit 30 0.93 0.11 
GO:0022627 cytosolic small ribosomal subunit 27 0.93 0.11 
AP2_PFD0985w_D1_1 Matching set 1 for AP2 - PFD0985w_D1 973 0.93 0.09 
AP2_PF14_0633_2 Matching set 2 for AP2 - PF14_0633 343 0.93 0.08 
Transporters Genes coding for transport proteins 114 0.93 0.12 
TIGR01478 
STEVOR: variant surface antigen, 
stevor family 36 0.93 0.08 
GO:0020002 host cell plasma membrane 190 0.93 0.10 
GO:0020008 Rhoptry 14 0.93 0.11 
GO:0003774 motor activity 103 0.93 0.11 
GO:0050776 regulation of immune response 9 0.93 0.11 
GO:0005634 nucleus 452 0.92 0.06 
SSF46966 Spectrin repeat 9 0.92 0.11 
GO:0042000 
translocation of peptides or proteins into 
host 11 0.92 0.11 
Hagai Ginsburg ... 
Functional annotation of merozoite 
invasion related proteins 63 0.99 0.02 
Merozoiteproteins 
Functional annotation of merozoite 
invasion-related proteins 65 0.99 0.02 
Hagai Ginsburg ... 
Subcellular localization of proteins 
involved in invasion 56 0.99 0.02 
proteinsLocalizpath 
Subcellular localization of proteins 
involved in invasion 70 0.99 0.03 
Hagai Ginsburg ... 
Established and putative Maurer s clefts 
proteins 89 0.99 0.02 
MCprot 
Established and putative Maurers clefts 
proteins 97 0.99 0.02 
GO:0020003 symbiont-containing vacuole 7 0.98 0.04 
AV:phist phist gene family 73 0.98 0.03 
Resetting 
Rosette formation between normal and 
infected RBC 315 0.97 0.06 
GO:0030260 entry into host cell 15 0.97 0.08 
Table 2.1.  50 most variant gene sets by mean enrichment rank in the pool. 
Of the 20 amplified gene families described in Templeton et al., 10 families had at least 5 genes 
present in the microarray experiments and had enrichment measured in at least half of the 
pairwise comparisons [249].  Eight of the ten families were ranked 184 or higher out of 1319 
gene sets, for a p-value of 8.3e-8.  The families appearing in the top 50 are in bold in Table 2.1.  





early transcribed membrane protein (ETRAMP) (14 genes, ranked 11), Hyp (51 genes, ranked 
31), stevor (36 genes, ranked 43), Pfmc-2TM (12 genes, ranked 56), rifin (175 genes, ranked 63), 
var (57 genes, ranked 87), Fatty acyl CoA synthetase (10 genes, ranked 112), Plasmodium 
falciparum domain of unknown function (CPW_WPC) (9 genes, ranked 507), and 
Lysophospholipase (11 genes, ranked 605).  This result serves as an excellent proof of principal 
that tracking the mean enrichment of a pool will cull out the highly variant gene sets, of which 
antigenic variant sets are prime examples. 
A 65-gene merozoite invasion-related set ranked highest on the list, and upon further 
examination it becomes clear that a preponderance of surface molecules contribute to the rank, 
including 13 merozoite surface proteins, six merozoite surface protein like proteins, four 
erythrocyte binding antigens, five reticulocyte binding proteins.  There were also two 6-cysteine 
proteins that are part of an amplified gene family [249].  The rhoptries are specialized secretory 
organelles at the apical end of the invasive form of the parasite that contribute to host cell 
invasion and modification [250].  Nine rhoptry-associated proteins belong to the invasion gene 
set as well as five proteins from the multi-gene Clag family [251]. 
Maurer’s clefts are membranous structures used by the parasite to sort and export proteins, 
including virulence and other proteins used to remodel the erythrocyte [252].  The set of genes 
associated with the Maurer’s cleft is the second highest scoring one, due in part to the large 
number of surface proteins trafficked through the Maurer’s cleft. 
The most invariant gene sets that contain at least five genes and appear in at least half of the 





pair-wise comparisons and sorting by lowest mean.  This maximizes for gene sets that have the 
least variation between lines. 
Set Description Size Mean StDev 
SM00248 Ankyrin repeat 14 0.62 0.09 
PF00023 Ankyrin repeat 15 0.63 0.09 
SSF50156 PDZ domain-like 6 0.63 0.10 
PS50297 Ankyrin repeat region circular profile 16 0.63 0.08 
SSF57586 TNF receptor-like 7 0.63 0.11 
SSF48403 Ankyrin repeat 16 0.63 0.08 
PR00153 
Cyclophilin peptidyl-prolyl cis-trans 
isomerase signature 9 0.64 0.10 
GO:0004826 phenylalanine-tRNA ligase activity 5 0.64 0.10 
SSF47954 Cyclin-like 10 0.64 0.11 
GO:0006520 cellular amino acid metabolic process 5 0.65 0.09 
PF00169 PH domain 5 0.65 0.11 
Hagai Ginsburg ... Utilization of phospholipids 10 0.65 0.10 
3.6.1.3 Adenosinetriphosphatase 6 0.65 0.11 
GO:0051726 regulation of cell cycle 14 0.65 0.10 
GO:0008283 cell proliferation 5 0.65 0.11 
PS50072 
Cyclophilin-type peptidyl-prolyl cis-trans 
isomerase domain profile 10 0.65 0.10 
PF00160 
Cyclophilin type peptidyl-prolyl cis-trans 
isomerase/CLD 10 0.65 0.10 
SSF50891 Cyclophilin-like 10 0.65 0.10 
Hagai Ginsburg ... Fatty acid synthesis in the apicoplast 10 0.65 0.12 
SSF54736 ClpS-like 5 0.65 0.11 
GO:0006410 transcription, RNA-dependent 6 0.66 0.11 
SM00332 Protein phosphatase 2C-like 11 0.66 0.10 
Glyoxylate Glyoxylate metabolism 6 0.66 0.11 
GO:0006415 translational termination 6 0.66 0.12 
SM00386 RNA-processing protein, HAT helix 5 0.66 0.11 
SSF51156 Insect cysteine-rich antifreeze protein 5 0.66 0.09 
GO:0004003 ATP-dependent DNA helicase activity 10 0.66 0.11 
Hagai Ginsburg ... Leucine Isoleucine and Valine Metabolism 6 0.66 0.10 
GO:0000049 tRNA binding 6 0.66 0.12 
GO:0032259 Methylation 6 0.66 0.11 
GO:0051287 NAD or NADH binding 7 0.66 0.11 
GO:0016018 cyclosporin A binding 8 0.66 0.12 
SSF47769 SAM/Pointed domain 6 0.66 0.10 
SSF81324 Voltage-gated potassium channels 19 0.66 0.11 






Activating enzymes of the ubiquitin-like 
proteins 8 0.67 0.11 
GO:0003747 translation release factor activity 5 0.67 0.11 
GO:0006470 protein amino acid dephosphorylation 18 0.67 0.09 
PF00481 Protein phosphatase 2C 9 0.67 0.11 
SSF55856 
Cytochrome b5-like heme/steroid binding 
domain 5 0.67 0.12 
Hagai Ginsburg ... 
Calcium calmodulin activation of protein 
kinases 8 0.67 0.12 
Hagai Ginsburg ... Molecular model of vesicle exocytosis 6 0.67 0.12 
GO:0016301 kinase activity 5 0.67 0.11 
GO:0003729 mRNA binding 5 0.67 0.12 
GO:0004239 methionyl aminopeptidase activity 5 0.67 0.12 
PF04055 Radical SAM superfamily 5 0.67 0.11 
SSF102114 Radical SAM enzymes 5 0.67 0.11 
6.3.2.19 Ubiquitin--protein ligase 10 0.67 0.11 
SSF54585 Cdc48 domain 2-like 5 0.67 0.12 
SSF57184 Growth factor receptor domain 6 0.67 0.13 
SM00248 Ankyrin repeat 14 0.62 0.09 
PF00023 Ankyrin repeat 15 0.63 0.09 
SSF50156 PDZ domain-like 6 0.63 0.10 
PS50297 Ankyrin repeat region circular profile 16 0.63 0.08 
SSF57586 TNF receptor-like 7 0.63 0.11 
SSF48403 Ankyrin repeat 16 0.63 0.08 
PR00153 
Cyclophilin peptidyl-prolyl cis-trans 
isomerase signature 9 0.64 0.10 
GO:0004826 phenylalanine-tRNA ligase activity 5 0.64 0.10 
SSF47954 Cyclin-like 10 0.64 0.11 
GO:0006520 cellular amino acid metabolic process 5 0.65 0.09 
Table 2.2.  50 most invariant gene sets by mean enrichment rank in the pool. 
Gene sets involved in metabolic processes stand out in this list, including cellular amino acid 
metabolic process, glyoxylate metabolism, leucine, isoleucine, and valine metabolism, and 
cellular metabolic process.  Identification of invariant gene sets can help focus the interpretation 
of future analyses, because invariant gene sets that have significant differences between two 
parasite lines should be valued more highly than the same difference in a variant set. 
We also looked at the most variant genes.  We filtered out any gene that appeared in less than 





Gene Description Mean StDev 
PF14_0767 Stevor 0.97 0.07 
PF08_0003 tryptophan/threonine-rich antigen 0.95 0.08 
PF10_0343 S-antigen 0.94 0.12 
PFA0340w 
2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase, 
putative 0.94 0.09 
PF13_0198 reticulocyte binding protein 2 homologue a 0.94 0.13 
PF10_0348 duffy binding-like merozoite surface protein 0.94 0.09 
PF13_0011 gamete antigen 27/25 0.94 0.11 
PF10_0350 probable protein, unknown function 0.94 0.09 
PFL0035c acyl-CoA synthetase, PfACS7 0.93 0.11 
PF14_0183 signal recognition particle, RNP, putative 0.93 0.12 
MAL13P1.176 reticulocyte binding protein 2 homologue b 0.93 0.11 
PF07_0004 Plasmodium exported protein, unknown function 0.93 0.09 
PF10_0351 probable protein, unknown function 0.93 0.12 
PFB0100c knob-associated histidine-rich protein 0.93 0.13 
PF10_0345 merozoite surface protein 3 0.93 0.11 
PFD0110w 
normocyte binding protein 1,reticulocyte binding protein 
homologue 1 0.93 0.12 
PF11_0033 probable protein, unknown function 0.93 0.12 
MAL7P1.81 
eukaryotic translation initiation factor 3 37.28 kDa subunit, 
putative 0.93 0.11 
MAL13P1.268 conserved Plasmodium protein, unknown function 0.93 0.11 
PFA0110w ring-infected erythrocyte surface antigen 0.93 0.11 
PFD0090c Plasmodium exported protein (PHISTa), unknown function 0.92 0.14 
PF14_0734 serine/threonine protein kinase, FIKK family 0.92 0.11 
PFB0105c Plasmodium exported protein (PHISTc), unknown function 0.92 0.13 
PF14_0337 conserved Plasmodium protein, unknown function 0.92 0.12 
PFL2520w reticulocyte binding protein homologue 3, pseudogene 0.92 0.11 
PF11_0503 Plasmodium exported protein (PHISTc), unknown function 0.92 0.11 
MAL8P1.161 Plasmodium exported protein (hyp7), unknown function 0.92 0.13 
MAL13P1.49 conserved Plasmodium protein, unknown function 0.92 0.12 
PF14_0076 plasmepsin I 0.92 0.13 
MAL8P1.88 conserved Plasmodium protein, unknown function 0.91 0.12 
PF14_0730 Plasmodium exported protein (PHISTb), unknown function 0.91 0.12 
PFI1780w Plasmodium exported protein (PHISTc), unknown function 0.91 0.12 
MAL7P1.208 rhoptry-associated membrane antigen 0.91 0.12 
PFL2550w DnaJ protein, putative 0.91 0.13 
PF14_0067 LCCL domain-containing protein 0.91 0.13 
PFB0106c Plasmodium exported protein, unknown function 0.91 0.13 
PF11_0514 Plasmodium exported protein (PHISTa), unknown function 0.91 0.14 
PFI0675w conserved Plasmodium protein, unknown function 0.91 0.11 
PF10_0344 glutamate-rich protein 0.91 0.12 





PFB0300c merozoite surface protein 2 0.91 0.13 
PF14_0758 Plasmodium exported protein (hyp17), unknown function 0.91 0.13 
PFI1475w merozoite surface protein 1 0.91 0.12 
PF08_0008 GPI-anchored micronemal antigen 0.91 0.12 
PF10_0346 merozoite surface protein 6 0.91 0.11 
PF14_0733 serine/threonine protein kinase, FIKK family 0.91 0.14 
PFL1140w integral membrane protein, putative 0.91 0.13 
PFF1535w Plasmodium exported protein (hyp5), unknown function 0.91 0.11 
PF13_0058 conserved Plasmodium protein, unknown function 0.90 0.13 
PFL1945c early transcribed membrane protein 12 0.90 0.13 
Table 2.3.  50 most variant genes by mean fold change rank in the pool. 
The most variant gene in the genome is a member of the antigenic variant set of stevors, and 
three of the top seven are labeled as antigens.  Genes that top this list are predominantly involved 
in parasite antigenicity, as were the most variant gene sets. 
If we reverse the highly variant gene list, then we get the most invariant genes. 
Gene Description Mean StDev 
PF13_0348 rhoptry protein 0.58 0.06 
MAL7P1.152 conserved Plasmodium protein, unknown function 0.58 0.05 
PFB0875c chromatin-binding protein, putative 0.58 0.06 
PFF1400w RAP protein, putative 0.58 0.06 
PF08_0084 RNA-binding protein (U1 snRNP-like), putative 0.59 0.07 
PF10_0149 cysteinyl-tRNA synthetase, putative 0.59 0.08 
PFL0630w iron-sulfur subunit of succinate dehydrogenase 0.59 0.07 
PF13_0117 TBC domain protein, putative 0.59 0.07 
PF10_0293 transcription factor, putative 0.59 0.07 
MAL7P1.113 DEAD/DEAH box ATP-dependent RNA helicase, putative 0.59 0.06 
PF14_0313 conserved Plasmodium protein, unknown function 0.60 0.08 
PF14_0277 coatamer beta subunit, putative 0.60 0.07 
PF08_0070 RAP protein, putative 0.60 0.08 
MAL8P1.103 conserved Plasmodium protein, unknown function 0.60 0.07 
PFE0970w 
cytochrome c oxidase assembly protein (heme A: 
farnesyltransferase), putative 0.60 0.08 
PFL2160c conserved Plasmodium protein, unknown function 0.60 0.07 
PF13_0204 nuclear movement protein, putative 0.60 0.08 
PF14_0381 delta-aminolevulinic acid dehydratase 0.60 0.08 





PFL1635w Ulp1 protease, putative 0.61 0.07 
PFD0440w peptidase, M22 family, putative 0.61 0.08 
PF14_0661 small subunit rRNA processing KH domain protein, putative 0.61 0.07 
PFD0780w glutamyl-tRNA(Gln) amidotransferase subunit A, putative 0.61 0.07 
MAL7P1.68 zinc finger protein, putative 0.61 0.06 
PFF0150c conserved Plasmodium protein, unknown function 0.61 0.08 
PF07_0086 conserved Plasmodium membrane protein, unknown function 0.61 0.07 
PF11_0210 metal ion channel - Mg2 , Co2  and Ni2  0.61 0.09 
PFL0265w conserved Plasmodium protein, unknown function 0.61 0.07 
PFL1495w conserved Plasmodium protein, unknown function 0.61 0.07 
MAL8P1.9 u6 snRNA-associated Sm-like protein, putative 0.61 0.07 
PFL2555w Plasmodium exported protein (PHISTa), unknown function 0.61 0.11 
PFL0135w conserved Plasmodium protein, unknown function 0.61 0.07 
PFC0715c conserved Plasmodium protein, unknown function 0.61 0.10 
PF13_0150 DNA-directed RNA polymerase 3 largest subunit 0.61 0.07 
PF08_0112 conserved Plasmodium protein, unknown function 0.61 0.07 
PFL0295c conserved protein, unknown function 0.62 0.06 
PFL1100w conserved Plasmodium protein, unknown function 0.62 0.09 
PFI1585c mitochondrial ribosomal protein S6 precursor, putative 0.62 0.09 
PF14_0273 rRNA (adenosine-2'-O-)-methyltransferase, putative 0.62 0.08 
PF13_0077 DEAD box helicase, putative 0.62 0.09 
MAL13P1.256 phosphatidylinositol transfer protein, putative 0.62 0.06 
PFF0445w conserved Plasmodium protein, unknown function 0.62 0.07 
PF10_0278 nucleolar preribosomal assembly protein, putative 0.62 0.07 
PFI1085w ubiquitin-like protein, putative 0.62 0.09 
PF14_0665 conserved Plasmodium protein, unknown function 0.62 0.11 
PF14_0695 DNA-directed RNA polymerase, alpha subunit, putative 0.62 0.08 
PFL0615w tetratricopeptide repeat family protein, putative 0.62 0.08 
PF08_0043 conserved Plasmodium protein, unknown function 0.62 0.09 
MAL8P1.207 erythrocyte membrane protein 1, PfEMP1 0.62 0.07 
MAL13P1.316 conserved Plasmodium protein, unknown function 0.62 0.09 
Table 2.4.  50 most invariant genes by mean fold change rank in the pool. 
One highly invariant gene, MAL8P1.207, was paradoxically a var gene, which are usually highly 
variant.  In this case, the gene was most likely not expressed by any of the lines, and therefore 
maintained a steady signal.  The 3rd gene on the list is PFB0875c, a chromatin-binding protein, 
could be invariant because it interacts with chromatin, and slight changes in expression could 





the iron-sulfur subunit of succinate dehydrogenase and part of the branched TCA cycle [253].  
The 15th gene on this list is cytochrome c oxidase assembly protein (heme A: 
farnesyltransferase), putative, which presumably is so invariant because it is involved in the 
processing of heme, one of the most important actions of the parasite.  Also on the list, 
PF14_0381, delta-aminolevulinic acid dehydratase is involved with heme processing, catalyzing 







Now that the study of P. falciparum has firmly entered the genomics age, new data is becoming 
available an unprecedented rate.  Tools that place this data at the fingertips of researchers in 
inventive and compelling ways will bridge the current technical divide between bench 
researchers and computational biologists.  TDR Targets is one such tool, placing a huge amount 
of data in the public domain and facilitating collaboration on queries [161].   
We built upon this powerful tool for prioritizing drug targets in parasites by including methods to 
analyze gene sets and enabling real-time queries.  Incorporating gene sets recovers a more 
biologically relevant explanation of the data, based on categorizations including metabolic 
pathways, gene ontology sets, and protein domains.  Meanwhile, updating queries in real-time 
enables a researcher to immediately understand the impact of a change and then further improve 
the query.  This dynamic, interactive format fosters exploration. 
Developing a background pool 
Using the HATS algorithm, we compiled, aligned, normalized, and imputed the full time-series 
for 11 diverse P. falciparum lines.  Three of the lines were full transcriptome experiments during 
which the parasites were sampled every hour across the full 48-hour lifecycle [73, 129].  These 
datasets gave a rich, full sampling of the time series that proved that most genes follow a single 
wave of expression across the 48 hours with one peak and one valley.  Their work showed how 
well each time point compared to the one before and after it, and opened the door for more cost-
effective experiments that only needed to sample the space periodically.  The first line analyzed 





sensitive fully sequenced line 3D7.  When comparing these three full transcriptomes, the highly 
streamlined gene cascade was remarkably conserved [73]. 
The remaining eight lines in our pool come from microarray studies performed in the lab that can 
be grouped into three sets, the pfmdr1 set, the pfcrt set, and the DHA-tolerant set.  The pfmdr1 
set includes the multi-drug resistant parental FCB with two copies of pfmdr1, the FCB_3’KD 
line that has only one functional copy of pfmdr1 and increased mefloquine sensitivity, and finally 
106/1, a line that is highly related to FCB and has two copies of pfmdr1 but only expresses one 
copy [225].  The pfcrt set includes the chloroquine and pyrimethamine-resistant parental 7G8, 
the drug-sensitive 7G8_CTRL that has a plasmid in pfcrt but no sequence change, and 
7G8_T76K, that contains the back mutation at T76K that confers wildtype drug sensitivity [228].  
These two sets of strains were sampled at eight time points six hours apart.  The final set 
involves Dd2-REG a clone of the Dd2 line and 3b1-REG a DHA-tolerant line that resulted from 
increasing drug-selection pressure on Dd2-REG.  Both these lines were sampled six times eight 
hours apart (Eastman et al., in preparation). 
The importance of a background pool 
All lines were aligned to 3D7 and then missing time points were imputed using FFT.  For each 
time point and each pair of lines A vs. B, a fold change was calculated for each gene in order to 
build a ranked gene list.  As there were 11 lines in the background pool, there were 55 possible 
pairings of lines.  This created a distribution for each gene of 55 fold changes that is used to 
normalize any fold change measured on that gene.  This enables us to filter genes based on 
whether they are up or down-regulated compared to the distribution of the gene in question.  This 
is very important, because the variation in line-to-line gene expression differences is quite large 





depending on the line.  Meanwhile, there are genes that rarely change between lines, where even 
a 20% change might be very meaningful. 
As we had the mean ranking of each gene, we sorted all genes by that ranking to recover a list of 
variant and invariant genes.  Highly variant genes had different expression values in all the lines 
sampled, and we were able to filter out what otherwise might have seemed like large fold 
changes.  Highly invariant genes changed minimally between lines, and even the slightest change 
in expression might be meaningful.  As a proof of principle, the genes that were most variant 
included many of the genes from the known antigenic variant families.  The genes that were the 
most invariant included genes that played roles in integral functions of the parasite, including the 
processing of heme. 
Each ranked gene list in the background pool comparison was measured for gene set enrichment, 
creating a ranked gene set list for every comparison.  Distributions were measured for each set, 
and a similar list of highly variant and highly invariant gene sets was produced. 
The list of highly variant and invariant genes and gene sets should be used in future studies as a 
reference to gauge whether the genes and gene sets that are changing are actually interesting or 
prone to stochastic variation.  Also, this process highlights invariant genes and gene sets that 
might be interesting even though they not have changed significantly. 
PCA 
To further analyze the gene expression in the background pool, we reduced the dimensionality of 
the space to five principal components.  We found that the two strongest components nearly 





counterclockwise path through the space, indicating that by far the strongest signal in any 
comparison will be the time dependent component.  This means that aligning parasite lines 
properly is of the utmost importance in order to draw meaningful information from the 
comparison. 
The first two principal components also demonstrated that our alignment algorithm worked quite 
well, samples were clustered closely by time point on the plot.  Time point 1 from each of the 11 
lines clustered neatly together, as did the rest of the time points in the time series. 
The third principal component split the data roughly into two groups based on time and location 
of the experiment.  This indicated that the next strongest signal was not biological, but 
experimental, meaning that either the experimental bias is very strong, or the biological signals 
are relatively weak.  Such an analysis could be useful in the future for removing experimental 
noise from the system.  If the experimental noise could be accurately depicted in a component, 
that component could then be removed from the data, reducing the experimental noise and 
boosting the rest of the signals in the data, which are hopefully more relevant to the biological 
question being posed. 
The development of GASER and future directions 
We developed GASER as a means to explore the results of our transcriptional studies in an 
intuitive and powerful way.  We then realized it would work quite well with other types of data, 
so we incorporated the data from TDR Targets.  Grouping all data into sets and attributes helped 
to organize the disparate sources we included and lent itself to a user interface that could easily 





Once we finalize the first version of GASER, we will make it available online, where we hope 
scientists will use the tool to develop and share queries that harness the unprecedented levels of 
data available to guide their work.  Our hope is that other researchers will add their gene 
expression data and other sources of data to our site to improve the experience for all.  As the 
number of microarray experiments on the site increases, the probability that a user will find 
meaningful information from their queries will increase.  The background pool will also get 







Chapter 3 - Defining gene set expression differences between paired 
Plasmodium falciparum cell lines using Hypergeometric Analysis of 
Time Series (HATS) 
 
Daniel Scanfelda, Sophie H. Adjalleyb†, Michael Muhlec, Elyse Kozlowskid, Manuel Llinásd, 
David Fidockb 
a Center for Computational Biology and Bioinformatics, Columbia University College of 
Physicians and Surgeons, New York, NY 10032, USA; bDepartment of Microbiology and 
Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University 
Medical Center, New York, NY 10032, USA; cExxon Mobil Chemical Company, Baytown, TX, 
USA; dDepartment of Molecular Biology & Lewis-Sigler Institute for Integrative Genomics, 
Princeton University, Princeton, NJ 08544, USA; eThe Malaria Research Institute, W. Harry 
Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins 
Bloomberg School of Public Health, Baltimore, MD 21205, USA. 
 
† Current address: Genome Biology Unit, European Molecular Biology Laboratory, 69117, 
Heidelberg, Germany. 
 
The word presented in this chapter is part of a manuscript in preparation.  Author contributions: 
SHA, ML and DF designed the experiments. SHA performed the experiments. DS and MM 
developed analytic tools for microarray data processing. EK helped with the microarray 







The study of transcriptional differences in cell lines that have been genetically modified or 
perturbed to identify compensatory expression changes has been a fertile area of research in 
many organisms [255, 256].  Previous transcriptomic analyses of Plasmodium falciparum have 
focused on average expression across a set of time points [73, 129, 138], which is sufficient to 
identify genes with substantial differences in fold changes between lines. However, the power of 
such analyses is restricted by possible differences in cell cycle duration as a result of the 
perturbation being examined. 
We introduce Hypergeometric Analysis of Time Series (HATS), a method that combines fast 
Fourier transforms (FFT) with gene set enrichment analysis (GSEA) to align time series 
microarray data and identify significant gene set expression differences between paired cell lines. 
We analyze the effects associated with copy number variations and alterations in the 
Plasmodium falciparum antimalarial drug resistance determinants pfmdr1 and pfcrt [257, 258]. 
HATS is particularly useful in comparing lines growing at non-uniform rates and could facilitate 
analysis of differences between strains in a number of organisms. 
The spread of antimalarial resistance across the globe has compromised disease treatment.  Our 
work aims to advance an understanding of the transcriptional changes that accompany alterations 
of two genes that play an important role in drug resistance, pfmdr1 and pfcrt, by comparing 
isogenic parental and mutant lines [44].  The P. falciparum chloroquine resistance transporter 
(PfCRT) and the multidrug resistance-1 (PfMDR1) transporter have been identified as 





chloroquine, mefloquine, quinine, halofantrine, artemisinin and lumefantrine [259, 260].  In 
particular the PfCRT K76T mutation, which is ubiquitous to chloroquine-resistant (CQR) 
parasites across all endemic regions, has been identified as a highly sensitive marker of 
chloroquine (CQ) treatment failure in vivo, and in vitro this mutation has been found to be 
critical for resistance to this drug [228, 261].  Amplification of pfmdr1 is also associated with a 
significantly increased risk of treatment failure in P. falciparum-infected patients receiving 
mefloquine monotherapy or artesunate-mefloquine combination therapy [262].  Both proteins 
localize to the membrane of the digestive vacuole, an acidic compartment that is the site of 
hemoglobin degradation and the target of several antimalarial compounds [263]. 
Our HATS analysis returned an extensive set of significantly changing genes and gene sets.  
Interestingly, we found that manipulation of pfcrt expression resulted in an up-regulation of 
tRNA synthetases, which might serve to increase protein production in response to reduced 
amino acid availability from degraded hemoglobin.  Our investigation into the effect of pfmdr1 
copy number changes found that an increase in glycerophospholipid metabolism and up-
regulation of a number of ABC transporters accompany parasite lines with more than one copy 
of pfmdr1.  
In addition, we performed a combined analysis of many strain pairs to evaluate the 
transcriptional differences between CQR and CQS parasites as well as multi-copy pfmdr1 and 








We sought to compare the transcriptional profiles of a set of P. falciparum lines and discover 
candidate genes and gene sets that were significantly up or down-regulated across lines.  To 
circumvent the experimental challenges of conducting a 48-hour time series, we imputed the full 
48-hour intraerythrocytic developmental cycle (IDC) from eight time points sampled every six 
hours.  Using FFT, we demonstrate the utility of aligning time points throughout the full 48 
hours, not simply at the starting position, and why this is vital for analysis of expression at the 
individual time point. 
Biological overview of P. falciparum and determinants of resistance 
IDC 
P. falciparum’s haploid, 23-Mb genome contains nearly 5,500 genes, 60% of which are 
unannotated [118].  Beginning with the bite of an infected Anopheles mosquito, sporozoites 
invade the liver and over the course of ~one week proliferate asymptomatically, eventually 
releasing thousands of merozoites that infect red blood cells (RBC) [43].  Within the RBC, the 
parasite undergoes a series of morphological transitions over the course of 48 hours, resulting in 
a new generation of merozoites that reinitiate the IDC [73].  Transcriptional profiling of the IDC 
revealed a unique eukaryotic transcriptome distinguished by a wave of gene expression that 
typically reaches a single maximum and minimum during the 48-hour cycle [73, 128, 129].  
Notably, the gene peaks cascade across the time series, with gene expression highest as genes are 






In our transcriptional studies, we focus individually on the ring, trophozoite, and schizont stages 
of the IDC.  Peaking in hours 12-16 of the IDC, the ring stage sees the parasite flatten into a ring 
form that begins to feed on the surrounding RBC through the cytostome, a small dense ring at the 
surface of the parasite [264].  During the very active trophozoite stage, peaking in hours 24-28 of 
the IDC, most of the RBC cytoplasm is consumed [245].  The trophozoite stage includes the 
growth of the acidic, oxygen-rich, lysosome-like digestive vacuole and the bulk of the 
haemoglobin degradation [265].  Finally, during the schizont stage, peaking in hours 32-36, four 
to five rounds of binary division prepare the merozoites for reinvasion [245]. 
Digestive vacuole 
Our work focuses on the digestive vacuole, which is important to understanding resistance, 
because many of the antimalarial resistance determinants localize to its membrane.  The malaria 
parasite is highly adapted to cope with oxidative stress, a major source being the metabolism of 
hemoglobin, which forms reactive oxygen species and the release of toxic ferriprotoporphyrin IX 
[266].  The digestive vacuole is the site of hemoglobin digestion and heme detoxification [267].  
Hemoglobin makes up 95% of the cytosolic protein of the RBC, and during the IDC as the 
cytoplasm is consumed, 60-80% of the hemoglobin is degraded [245].  The uptake of host 
cytoplasm begins in the middle of the ring stage, with cytoplasm being internalized through 
cytostome-derived invaginations into several compartments [267].  As the parasite enters the 
tropohozoite stage, the compartments coalesce to form the digestive vacuole and the hemoglobin 
digestion and hemozoin formation occur in the vesicles feeding the vacuole [267].  Hemoglobin 
proteolysis transforms the hemoglobin into amino acids for use by the parasite and hemozoin, 






Mutations in pfcrt are associated with resistance to chloroquine, as well as other drugs used to 
prevent malaria.  Believed to be a transport protein, PfCRT is thought to expel drugs that would 
eliminate the malaria parasite, thereby curtailing their effectiveness. 
Chloroquine resistance maps as a Mendelian trait to a 36kb segment of chromosome 7 in a 
genetic cross between a chloroquine-sensitive (CQS) strain and a CQR strain of P. falciparum 
[223].  A 13-exon gene, pfcrt, located within this segment associated completely with Asian, 
African, and South American parasite lines that were also CQR [268].   
PfCRT encodes a 49 kDa putative transporter, PfCRT, that spans ten predicted transmembrane 
domains and localizes to the membrane of the digestive vacuole [163].  Bioinformatic analyses 
focusing on similarity searches within specific regions of the protein have confirmed that PfCRT 
is a member of the drug/metabolite transporter superfamily [269].  Figure 3.1 presents a 
predicted structure for PfCRT that shows the ten predicted transmembrane domains and 
mutations identified in CQR strains as well as a table of the pfcrt allelic variants identified in 
both field isolates and laboratory-adapted lines [270].   
Allelic exchange experiments involving CQS strains have shown that the replacement of the 
wild-type allele with mutant pfcrt alleles can confer CQ resistance [271].  There is great 
sequence diversity among the mutations from the resistant lines, which segregate by geographic 
origin, but the one mutation in common is K76T.  This mutation has been shown to be essential 
for CQR through the use of allelic exchange.  Removal of the K76T mutation from the resistant 







Figure 3.1.  Predicted structure and haplotypes of PfCRT. 
a. This figure from Valderramos et al. [270] depicts the ten predicted transmembrane 
domains of PfCRT.  Each black circle represents a mutation identified in a CQR line, 
while the red circle is the K76T mutation that is common to all CQR lines and the yellow 
circle is the S163R mutation common to amantadine- and halofantrine-resistant lines.  b. 






Allelic exchange studies that diminished the expression of pfcrt resulted in a parasite line that 
was less resistant to chloroquine, suggesting that modulation of the expression levels of pfcrt can 
affect the degree of chloroquine resistance [272].  Expression studies of PfCRT at the surface of 
Xenopus laevis oocytes have shown that resistant forms of PfCRT can transport chloroquine, 
while the wild-type PfCRT does not; therefore, one form of chloroquine resistance is due to 
efflux of chloroquine from the digestive vacuole by mutant PfCRT [273]. 
PfMDR1 
Another important resistance determinant is P. falciparum multidrug resistance protein 1, 
pfmdr1, which encodes PfMDR1, an adenosine-5'-triphosphate (ATP)-binding cassette 
transporter [274, 275].  Similar to PfCRT, PfMDR1 is resident in the digestive vacuole 
membrane [270].  Mutations in this gene are thought to influx malarial drugs into the digestive 
vacuole, thereby enabling altered susceptibility to drug.  It is therefore an important area of study 
for malaria.   
PfMDR1, also known as Pgh1, is orthologous to a plasma membrane glycoprotein that mediates 
multidrug resistance in mammalian tumor cell lines [276]. In a heterologous yeast system, 
pfmdr1 complemented the function of a defective STE6 transporter, suggesting that PfMDR1 
functions as a transporter, and that this transport ability is altered by mutations that impact 
antimalarial susceptibility [277].  Figure 3.2 demonstrates the structure of the 160 kDa PfMDR1, 
based on two domains that consist of six predicted transmembrane segments each joined together 






A range of experiments has demonstrated that pfmdr1 plays an important role in the parasite’s 
response to a number of drugs.  Stepwise selection for increased mefloquine resistance resulted 
in amplification and over-expression of pfmdr1, and demonstrated cross-resistance to 
halofantrine and quinine [274, 276, 278].  It was also shown that disruption of one of two copies 
of pfmdr1 in the mefloquine-resistant parasite strain FCB resulted in a line that manifested a 
three-fold decrease in mefloquine resistance [225]. 
An examination of field isolates from Thailand showed that increased pfmdr1 copy number 
associated with an increase in resistance to mefloquine, halofantrine, quinine, dihydroartemisinin 
and artesunate, and at times a decrease in resistance to chloroquine [262, 279, 280].  
Investigations via allelic exchange of the pfmdr1 3’ coding region found the N1042D mutation 
contributing to quinine resistance in vivo, and the triple mutation S1034C / N1042D / D1246Y 






Figure 3.2.  Predicted structure and haplotypes of PfMDR1. 
a. This figure from Valderramos et al [41] depicts the two homologous halves of 
PfMDR1, each having six transmembrane domains.  b. This table from Valderramos et al. 





Data collection and computational analysis 
Transcriptional profiling 
The first microarray was created in 1995, ushering in the era of high-throughput gene expression 
studies [119].  This technological advance reduced the money and time needed to retrieve 
massive amounts of genetic data, creating an exciting opportunity for computational analysis. 
Expression profiling of human samples was achieved in 1996 [120, 121], followed shortly 
thereafter by an influential set of yeast time series microarray experiments that sampled 6,220 S. 
cerevisiae genes across the cell cycle [122, 123]. 
The completion of the P. falciparum genome in 2002 provided the genomic data necessary to 
begin transcriptional profiling studies [118].  Even before the full sequence was elaborated, 
shotgun DNA microarrays were run in 2000 using random inserts from a genomic library to 
demonstrate stage-specific gene expression [124].  A five sample time series of P. falciparum 
revealed a coordinated program of gene expression looking at ~15% of the genome [125].  The 
first two full genome microarrays were created in 2003, the first being used to analyze the 
expression levels of the genome at 9 different stages, encompassing the human and mosquito 
lifecycle [126-128].   
The first three full P. falciparum transcriptomes were completed in 2003 [129] and 2006 [73], 
each sampling every hour.  The transcriptome of the sexual stage was elaborated by examining 
purified gametocytes [282].  An analysis of parasites that produce gametocytes and parasites not 
capable of producing gametocytes revealed 117 genes that were differentially expressed during 
hours 30 and 40, as gametocytogenesis would begin [130].  Perturbations of P. falciparum by 





mount a protective response [131].  In a transcriptional profiling study of the var gene family, it 
was found that transcriptional silencing governs the mutual exclusive expression of var genes 
[133].  Transcriptional profiling was performed on parasites exposed to 20 different 
antimalarials, and those parasites exposed to HDAC inhibitors exhibited a general deregulation 
of expression [135].  MacKinnon et al. developed a technique to culture-adapt field isolates and 
perform transcriptional profiling across the time series [137]. 
HATS 
Previous transcriptional analyses have focused on average expression [73, 129] or a stage of the 
parasite lifecycle [138], and look at gene set enrichment over that same period of time.  As 
described in chapter 2, our HATS algorithm improves on these analyses by (1) aligning strains 
that grow at non-uniform rates in a manner that reduces experimental noise, (2) identifying 
significant changes at the gene and gene set level, and (3) ascertaining the window of peak 
enrichment.  This allows for analysis at individual time points and enables identification of 
smaller and subtler gene expression changes.   
Two complementary methods were used to determine significantly up or down-regulated genes:  
a comparison of the fold change of each gene, and Orthogonal Projections to Latent Structures 
Least Squares Discriminant Analysis (OPLS-DA).  Through a modified GSEA algorithm, we 
identified significant gene sets at each time point in the lifecycle, allowing us to analyze how this 
enrichment changes between lines over time.  We also analyzed a reference pool of 11 lines to 
create a baseline for gene and gene set enrichment, helping us remove spurious hits from our 








Figure 3.3.  HATS computational pipeline.  
The HATS computational pipeline involves six steps that carry the data from creation to 
final analysis and is the foundation for a large portion of our analyses.  
Data creation 
The philosophy behind GSEA is that analyzing data using gene sets helps to reduce a large 
degree of the noise inherent in microarray data [146].  For our analysis, we assembled gene sets 
from gene ontology (GO) categories, metabolic pathway identification, pfam domains, yeast two 
hybrid screens, and literature searches.  To minimize bias in our search, we developed as 
complete a list as possible.  The resulting 6,472 gene sets included 81.4% of the genome.  A 
significant portion of the genome is not represented in these gene sets, including the genes that 













have no functional annotation ascribed to them.  As more data regarding biological processes of 
P. falciparum becomes available, we can rerun our analyses to obtain more complete coverage. 
Normalization and filtering 
The Cy5 and Cy3 channels were separately normalized by the mean difference between the 
median foreground intensity and the median background intensity of a set of representative 
probes.  The representative probes contained more than 50% of the pixels above 2 standard 
deviations of the background in both channels, had at least 200 expression units, and a regression 
correlation coefficient greater than or equal to 0.75 [73].  This normalization helped to alleviate 
any intensity shifts between the two channels. 
We explored the transcriptomes of our lines by compiling pair-wise datasets (A vs. B), which 
maximized the number of genes available for analysis.  The analysis began at the probe level 
with a dataset of 10,114 probes over 8 time points.  At each time point, probes were removed 
that did not contain more than 50% of the pixels above 2 standard deviations of the background 
in both channels, had fewer than 200 expression units, or were flagged manually by the curator 
or automatically by the GenePix software.  For each gene and each time point, the probes were 
combined into one value by taking the median value of the probes. 
Any gene with more than two missing values (less than 6 of 8 time points) for either line A or B 
was filtered from the dataset.  Missing values were recovered through comparison to the gene 
with a full set of expression values that had maximal Pearson correlation to the gene with 





Interpolation and alignment 
Rationale 
An important property of biological processes is that a single process may unfold at different and 
possibly non-uniform rates in different lines, making it insufficient to simply pair points taken at 
equal time intervals [283].  This is especially true of gene expression in malaria parasites, which 
follows a 48-hour IDC characterized by distinct transcriptional activity correlating with 
morphological and metabolic changes over time [129].  Our analysis of a set of P. falciparum 
lines, described below, revealed differences in IDC length and the speed at which a line proceeds 
through each morphological stage.  Any analysis of the unaligned data would have been 
corrupted by differences in position in the IDC.  The cyclical nature of gene expression in P. 
falciparum would have augmented this disparity, because any misalignment would focus on the 
slight shifts in the wave of expression due to differences in timing, not biology [139].  To 
address these issues, we developed methods that better align time series microarray data, and that 
subsequently identify significant transcriptional differences at individual time points by gene set 
enrichment. 
Strains analyzed 
Microarray experiments were performed on custom chips containing roughly 1 probe per 
kilobase (KB) of each gene.  Six lines (Table 1) were analyzed at 8 time points (6, 12, 18, 24, 30, 
36, 42, and 48 hours post-invasion) on 2 channels, 1 for a synchronized line, and a second 
control channel that represented the expression levels of a set of pooled and unsynchronized 





106/1 and FCB are both non-recombinant parasite lines that appear highly related genetically by 
microsatellite studies [284].  Each has the same PfCRT haplotype other than residue 76, with 
106/1 harboring the wildtype K76 responsible for chloroquine susceptibility [228].  Both lines 
have identical PfMDR1 haplotypes.  FCB_3’KD was generated in the Fidock laboratory from the 
multi-drug resistant parasite line FCB by disrupting 1 of the 2 copies of pfmdr1 [225].  
7G8_CTRL and 7G8_T76K lines were previously generated in the Fidock laboratory from the 
CQR parasite strain 7G8 by allelic exchange via single crossover recombination targeting codon 
76 of the mutant pfcrt allele [228].  In 7G8_T76K, this residue is back mutated to K and results 
in a drug-sensitive parasite, while 7G8_CTRL incorporated a plasmid with no mutation, serving 
as a control for the genetic manipulation. 
Fast Fourier Transform (FFT) 
To properly align the lines, we used FFT to impute expression levels at 376 unassayed time 
points and then the median values of all probes for each gene were selected to create a smooth 
sine curve over the 48-hour lifecycle (Figure 3.4 and Figure 3.5).  This allowed us to extrapolate 
the expression level and rank of each gene at any time point in the lifecycle.  Much of the 
experimental noise is removed by focusing on the main frequency of the data, and variations in 
speed through different stages of the lifecycle are reduced, automatically aligning the strains.  
We used dynamic time warping to align two series of 384 points by first finding the Pearson 
correlation between each pair of points, and then calculating the optimal straight path through the 






Figure 3.4.  Point imputation of FCB from eight time points to the full time series. 
a. A plot of the expression levels calculated at each of eight time-points in the FCB line.  
Genes have been sorted by phase calculated on the full curves using a FFT.  The 
distinctive cascade of expression shows most genes peaking only once during the cycle, 
with sets of genes peaking at each time point.  b. A plot of the imputed time points for the 
FCB line (384 points – 8 per hour). The cascade of expression is still evident and has 






Figure 3.5.  Point imputation of FCB_3’KD ordered by phase in FCB. 
a. A plot of the expression levels calculated at each of eight time-points in the 
FCB_3’KD line ordered by phase in FCB.  b. A plot of the imputed time points for the 
FCB_3’KD line ordered by phase in FCB. 
We investigated 6 pairs of lines in our study, but we will focus mostly on the FCB vs. 
FCB_3’KD comparison as an illustration.  Each line was aligned to 3D7 by calculating the 
Pearson correlation of each pair of imputed time points (1 from FCB and 1 from 3D7) and the 
optimal start point was inferred using dynamic programming (Figure 3.6).  The original time 
points were also aligned to 3D7 to reveal the differences in growth rate between the two lines.  
These differences in parasite growth rate could represent important phenotypic differences, 
including fitness costs associated with slower progression through developmental stages. 
 
Figure 3.6.  Alignment of time course data of FCB and FCB_3’KD to 3D7. 
a. Pearson Correlation of FCB to 3D7.  The heat map displays the point-to-point 
correlation between FCB and 3D7, with each cell representing the Pearson correlation 
between two time points.  Regions of correlation are in red and anti-correlation in blue.  





diagonal to a given time point indicates the measure of correlation that time point has 
with its neighbors.  A thicker area of correlation indicates less change is happening 
between time points, while a thinner area indicates a larger amount of change between 
time points.  b. Pearson Correlation of FCB_3’KD to 3D7. 
 
Figure 3.7.  Alignment of the original time points of all lines to 3D7. 
a. Alignment of the original time points for FCB (blue), FCB_3’KD (red), and 106/1 
(yellow) to 3D7 reveals differences in speed of each line.  At the first time point, each 
line corresponds very well, while by the final time point 106/1 is eight hours further 
along than FCB_3’KD, with FCB in between.  b. Alignment of all the original time 
points for FCB (blue), FCB_3’KD (red), 106/1 (yellow), 7G8 (purple), 7G8_CTRL 
(brown), 7G8_T76K (green), 3D7 (violet), Dd2 (orange), HB3 (light green), Dd2-REG 
(maroon), 3B1-REG (tan) to 3D7 reveals differences in speed of each line. 
Dimensionality reduction 
We utilized dimensionality reduction techniques to validate the alignment of the time points and 
characterize differences between lines.  Principal component analysis (PCA) of the pfmdr1 lines 
rendered an informative reduction of the approximately 3,000 dimensions of expression data 
(Figure 3.8).  The first two principal components accurately recover the progression of the lines 





each line in close proximity.  Each successive principal component focuses on differences 
between the lines, with components 3-5 highlighting differences between FCB and the 
FCB_3’KD and 106/1 lines.  
 
Figure 3.8.  PCA of the pfmdr1 lines: FCB, FCB_3’KD, 106/1. 
Components 1, 2, and 3 of a PCA of the three pfmdr1 lines: (a.) FCB (blue), (b.) 
FCB_3’KD (red), and (c.) 106/1 (yellow). This orientation focuses on components 1 and 





PCA of the pfcrt lines created an equally interesting reduction of the gene expression space 
(Figure 3.9).  The first two principal components accurately recover the progression of the lines 
through the 48-hour lifecycle, running counterclockwise around the plot with time points from 
each line in close proximity.  Each successive principal component focuses on differences 
between the three lines, with each line having a unique position in principal component 3, 
principal component 4 splits 7G8_T76K from the other two lines, and principal component 5 






Figure 3.9.  PCA of the pfcrt lines: 7G8, 7G8_CTRL, 7G8_T76K. 
Components 1, 2, and 3 of a PCA of the three pfcrt lines: (d.) 7G8 (purple), (e.) 
7G8_CTRL (brown), (f.) 7G8_T76K (green).  This orientation focuses on components 1 
and 2.  The time points match each other well and proceed in a counterclockwise fashion.  
7G8_T76K aligns perpendicular to the other 2 lines in the third principal component, 





Individual gene analysis 
We used 2 methods to determine which genes were significantly up or down-regulated between 
lines: area under the curve (AUC) and OPLS-DA. 
 
Figure 3.10.  Alignment of pfmdr1 expression in FCB. 
a. The alignment of pfmdr1 expression in FCB (blue) to FCB_3’KD (red), 106/1 
(yellow).  Though there are amplitude differences, the main peak and valley of the gene 
is remarkably well conserved across all 3 lines.  b. The alignment of pfmdr1 expression in 






Figure 3.11.  Area under the curve (AUC) plots for pfmdr1 in FCB, FCB_3’KD, and 106/1. 
a. AUC plot for pfmdr1 in FCB (blue) and FCB_3’KD (red).  b. AUC plot for pfmdr1 in 
FCB (blue) and 106/1 (yellow).  c. AUC plot for pfmdr1 in FCB_3’KD (red) and 106/1 
(yellow). 
Area under the curve 
When comparing line A to line B, we calculated the fold change of each gene in A vs. B by 
computing the area under the imputed, aligned expression curve for A and then dividing by the 
area for B.  AUC of the absolute expression data focuses on the time points of maximal 
expression for a given gene, because the areas of minimal expression are much noisier and of 
less interest biologically.  We then ranked the genes by fold change and carefully examined any 
gene that had a fold change above 2.0, reducing the number of candidate genes by more than a 





Line A Line B Stage Genes Up Down Sets Up Down 
FCB FCB_3’KD All 3171 235 328 2377 74 32 
FCB FCB_3’KD Ring 3171 725 532 2377 38 0 
FCB FCB_3’KD Trophozoite 3171 582 597 2377 19 14 
FCB FCB_3’KD Schizont 3171 477 781 2377 35 17 
Table 3.1.  Summary of the area under the curve (AUC) analysis. 
Shows the number of genes and gene sets that are significant in each comparison.  The 
number of genes available for this analysis, 3171, was less than the total number of genes 
in the genome, because there was not adequate coverage for some genes.  Any probe that 
had valid measurements for less than 6 of the 8 time points was excluded. 
Using the absolute expression gene plot we created, we measured the AUC for each of the lines, 
reflecting the total amount of gene expression across the lifecycle.  The fold change was 
calculated by dividing the area of 1 line by the area of another line.  This method is similar to the 
averaging method used by Bozdech [73, 129] to compute fold change and would be identical if 
the time points were equally spaced.  Since the time points are not equally spaced after alignment 
and imputation, the results are slightly different. 
OPLS-DA 
We utilized OPLS-DA to create disjoint PCA models for each of our lines, remove the variation 
orthogonal to the classes, and compute the effect of each gene on each model.  For each of the 11 
parasite lines we prepared models, and then given a pair-wise comparison between two lines, 
OPLS-DA created a confidence value for each gene for its differential expression.  Combining 
these calculations resulted in a list of genes ranked by the confidence we had in their expression 
in 1 model compared to another. 
We used OPLS-DA to confirm our findings from the AUC method and identify genes off in 





expression changes and ignores where that expression happens in the time series.  OPLS-DA 
helps to separate predictive variation from orthogonal, or non-predictive, variation [285].  This 
allows for an examination of the actual differences between lines, while ignoring the orthogonal 
variation that captures much of the noise inherent to the system. 
The two methods result in similar rankings, with an average Spearman Correlation of 0.89.  A 
comparison of the two ranked lists using gene set analysis yield an average Spearman 
Correlation of 0.81.  A complete comparison of the two methods can be found in Table 3.2. 
Line A Line B Gene Correlation Gene Set Correlation 
FCB FCB_3’KD 0.88 0.79 
FCB 106/1 0.88 0.81 
FCB_3’KD 106/1 0.89 0.83 
Table 3.2.  Comparison between AUC and OPLS-DA. 
The gene and gene set correlation between the two methods in each comparison. 
Comparison 
Though the AUC and OPLS-DA methods were well correlated, a subset of the genes examined 
were scored differently by each (Figure 3.12).  The AUC method was better at recognizing 
changes in expression restricted to a small number of time points, while the OPLS-DA method 
focused on more global differences and was better at recognizing genes that were out of phase.  







Figure 3.12.  Example of genes to compare gene ranking techniques. 
a. AUC plot for PFE1085w, a putative DEAD/DEAH box ATP-dependent RNA helicase, 
in FCB (blue) and FCB_3’KD (red).  This gene scored highly in both methods, because 
the fold change is evident at all time points.  b. AUC plot for PFI0720w, a putative 
transporter, in FCB and FCB_3’KD.  In this gene the difference in expression was much 
more noticeable in the AUC method, because the peak of expression is isolated to a small 
number of hours.  c. AUC plot for PFL0295c, a conserved protein of unknown function, 
in FCB and FCB_3’KD. This gene is out of phase between the two lines and picked up 
by OPLS-DA, but not the AUC method.  
Gene set analysis 
While in the AUC and OPLS-DA methods there are significant genes that would be missed, our 
time series GSEA method presents an alternative that identifies genes that peak only at a small 





point, we retrieve a great deal more information than the more global efforts of AUC and OPLS-
DA. 
Analyzing microarray data at the gene set level helps to remove the noise inherent in the 
experimental system.  By focusing on gene sets, random fluctuations in gene expression and 
probes that produce faulty measurements are discounted, because the algorithm focuses on the 
“leading edge” of a gene set, or the genes that contribute most to the enrichment score.  Gene set 
analysis also eases the work of the researcher, because instead of perusing a ranked list of genes 
and relying on expert knowledge of the biological systems in question, one can substitute a 
ranked list of gene sets with biologically relevant descriptions. 
Hypergeometric enrichment analysis (HEA) 
We explored the lines at the gene set level using HEA, an algorithm we developed based on the 
popular GSEA method.  GSEA is a computational method that identifies sets of genes that 
display statistically significant, concordant differences between two biological states [146].   
Given a gene set, HEA calculates the probability that each gene would appear so high or low on 
the ranked list of genes using the hypergeometric distribution.  We randomly permute the data 
1,000 times, and on each of these permutations, calculate the probabilities for each gene set.  We 
average all these values per gene set and use that as a scaling factor to create a normalized 
enrichment score using log 10 probabilities.  Next, we create normalized enrichment scores for 
all the gene sets in all the permutations.  We average a ratio where the numerator is the number 
of sets in a permutation scoring higher than the actual gene set score and the denominator is the 





determine the false discovery rate (FDR).  Since the FDR is a bit noisy at the tails, we enforce all 
values to be monotonically decreasing at the tails. 
We compared our results to a background set of 11 lines.  We performed GSEA on each pair to 
find the mean and standard deviation of the enrichment score for each gene set.  We used this to 
calculate a normalized enrichment score to remove gene sets that were stochastically expressed 
and thus very high in all comparisons.  We normalized our gene fold change results in the same 
way. 
To more generally characterize our results, we compiled a set of larger GO categories that 
subsume the GO categories in our analysis.  Using the hypergeometric distribution, we measured 
the probability that the GO categories in these larger sets would appear at the top of the list. 
 
Figure 3.13. Gene set enrichment plots. 
a. A gene set plot of the transporter gene set in FCB vs. FCB_3’KD.  The gray lines 
represent the log fold changes of each gene in the gene set across the time series.  The 
genes are ordered from darkest to lightest according to the time point that has the lowest 
false discovery rate.  The black line is an average of these genes, while the red line is the 
normalized enrichment score of the gene sets across the time series.  Any significantly up 





translation gene set in FCB vs. FCB_3’KD.  Many of the genes were under-expressed 
and the gene set is significantly down-regulated in FCB.  
Hypergeometric analysis of time series (HATS) 
Ranked list 
For our initial gene set analysis, described in the HEA section above, we used a ranked list of 
genes using a process similar to GSEA.  This analysis, however, misses the genes that change 
phase between lines.  Our method, HATS, addresses this issue by not just reporting the 
enrichment of a gene set, but also allowing the user to examine the time points for which the 
gene sets are most enriched.  For each time point, the fold change of each gene is calculated and 
converted into a ranked list and hypergeometric enrichment analysis is performed on each of 
these ranked lists.  A proper line alignment is vital to the success of our time series algorithm. 
Enrichment calculation 
The enrichment calculation for each gene set identifies the subset of the gene set that scores most 
highly, known as the leading edge.  The plots in Figure 3.13 represent all the genes in two gene 
sets when comparing FCB to FCB_3’KD and succinctly summarize the activity of that gene set 
across the time series.  Genes that contribute most to the leading edges at each time point are 
darker. 
False discovery score (FDS) 
The FDS measures the extent to which a gene set is up or down enriched across the time series.  
It is calculated by multiplying the FDRs calculated for a a gene set at each time point, and then 
taking the negative log of that P-value.  We filtered the results by choosing only gene sets that 
had an FDS >=77.06.  A gene set could reach that threshold in many ways, such as getting an 






We examined six parasite lines in our study, and we focus on six comparisons in the following 
results section: FCB vs. FCB_3’KD, FCB vs. 106/1, FCB_3’KD vs. 106/1, 7G8 vs. 7G8_T76K, 
7G8 vs 7G8_CTRL, 7G8_T76K vs 7G8_CTRL.  For each comparison, we examine the 
transcriptional changes that occur in the ring stage, the trophozoite stage, the schizont stage, and 
from the lifecycle as a whole.  In each case we calculate the fold change of a gene using the 
AUC technique limited to the section of the time series being examined.  The significant changes 
we find provide hypotheses as to the compensatory mutations surrounding the acquisition of 
drug resistance via mutations or changes in copy number in pfmdr1 and pfcrt. 
An important feature of our results is that the findings of significance have been compared to a 
background set of parasite lines.  For each of the 55 possible pair-wise comparisons of parasite 
lines, each gene and gene set is ranked by up-regulation.  This creates a background distribution, 
which is used to normalize any gene or gene set ranking.  Given a gene set ranking between line 
A and line B, a background distribution is formed excluding A and B for each gene and gene set.  
Then the actual gene and gene set rankings are compared to the distribution, creating a 
normalized score that equals the number of standard deviations above or below the mean ranking 
of gene or gene set. 
Significant sets are reported in tables using the following five columns: set, description, size, 
norm, and P-val.  Set is the identifier used for the set.  Description is a text description of the 
genes in the set.  Size is the number of genes in the set that had valid gene expression 
measurements in the two lines being compared.  For each set, we calculate its rank in every 





many standard deviations above or below the mean the current gene set ranking is.  P-val is the 
original enrichment score for the set using the hyper geometric distribution. 
The criteria for inclusion in our gene set results tables was that at least five genes from the set 
had to have a valid measurement in the comparison, an FDR less than or equal to 0.25, and a 
normalized score greater than or equal to 1.0, which indicates the enrichment score for that gene 
set was at least one standard deviation above the average enrichment score for that gene set. 
We also examine genes that were enriched in each comparison.  We do not include any genes of 
unknown function in our result tables.  We include genes that have a normalized fold change 
greater than 3.0, indicating that the fold change for the gene in the comparison was three 
standard deviations above average for that gene. 
Significant genes are reported in tables using the following four columns: gene, description, 
norm, and fold.  Gene is the identifier used for the gene.  Description is a text description of the 
genes in the set.  For each gene, we calculate its rank in every background pair of lines and use 
this distribution to produce a norm score that calculates how many standard deviations above or 
below the mean the current gene ranking is.  Fold is the fold change between the two lines being 
compared. 
The full excel files of all the analyses performed in this thesis can be found at: 
(http://www.fidock.org/dan).  On the web site there are excel files for every comparison that 
contain the full time series data for each gene, the enrichment scores for each set, and a detailed 






FCB vs. FCB_3’KD 
The first comparison of the pfmdr1 set is the multi-drug resistant FCB with two copies of pfmdr1 
vs. the sensitive FCB_3’KD with one functional copy of pfmdr1.  We examine gene sets and 
genes that are up or down-regulated in this comparison, as they may hint at compensatory 
transcriptional changes due to the change in copy number of pfmdr1. 
Set Description Size Norm P-val 
AP2_PFF0670w_D1_1 Matching set 1 for AP2 - PFF0670w_D1 105 2.3 7.87 
KE:PFA00620 PYRUVATE.METABOLISM  11 1.98 4.18 
AP2_PFF0670w_D1_2 Matching set 2 for AP2 - PFF0670w_D1 211 1.97 6.13 
GO:0000175 3'-5'-exoribonuclease activity 6 1.37 4.77 
GO:0016337 cell-cell adhesion 48 1.35 6.57 
KE:PFA00240 PYRIMIDINE.METABOLISM 41 1.27 6.16 
PfEMP1 PfEMP1 domain architectures 42 1.06 7.15 
GO:0009405 Pathogenesis 70 1.04 6.09 
Table 3.3.  8 enriched sets up in FCB vs. FCB_3’KD. 
Eight gene sets were significantly up in FCB compared to FCB_3’KD.  The AP2 genes are a 
known family of transcription factors in P. falciparum [286-288].  The AP2 set for PF0670w_D1 
was up in FCB, and is linked to gene expression and translation [287].  Pyruvate and pyrimidine 
metabolism are both up in the multi-drug resistant parasite.  PfEMP1 is an antigenic variant set, 
demonstrating that they are not completely culled from the results using the normalized score, 
but the majority of the antigenic variant sets have been removed. 
Gene Description Fold Norm 
PFF0945c acyl-CoA synthetase, PfACS12 4.3 4.3 
PF14_0097 cytidine diphosphate-diacylglycerol synthase 2.01 3.49 
PF14_0174 pseudouridine synthase, putative 1.34 3.46 
PFB0140w zinc finger protein, putative 1.69 3.39 





PF10_0057 regulator of nonsense transcripts, putative 1.81 3.16 
PF11_0331 TCP-1/cpn60 chaperonin family, putative 1.79 3.13 
PF10_0214 RNA binding protein, putative 1.52 3 
Table 3.4.  8 enriched genes up in FCB vs. FCB_3’KD. 
Eight genes were significantly up in FCB compared to FCB_3’KD.  PF14_0097, Cytidine 
diphosphate-DAG synthase, is an enzyme in the phospholipid biosynthesis pipeline [289].  
PFF0945c is an acyl-Coa synethetase, PfACS12, which is an interesting gene family in P. 
falciparum because it is subject to histone modifications and epigenetic gene regulation [290, 
291]. 
Set Description Size Norm P-val 
SM00717 SANT domain, DNA binding 5 1.31 5.07 
PF00249 Myb-like DNA-binding domain 5 1.31 5.07 
Table 3.5. 2 enriched sets down in FCB vs. FCB_3’KD. 
2 gene sets were significantly down in FCB compared to FCB_3’KD, both a set of five genes 
with the same Myb-like binding domain, the SANT domain. 
Gene Description Fold Norm 
PF11_0090 pescadillo-like protein 1.47 9.99 
PF14_0711 DNA repair metallo-beta-lactamase protein, putative 1.6 5.91 
PFE0195w cation transporting P-ATPase 1.83 4.43 
PF14_0360 eukaryotic translation initiation factor eIF2A, putative 1.52 4.41 
PF14_0661 small subunit rRNA processing KH domain protein, putative 1.3 4.01 
PF14_0081 DNA-repair helicase, putative 1.47 3.2 
PF10_0275 protoporphyrinogen oxidase 1.64 3.03 
Table 3.6.  8 enriched genes down in FCB vs. FCB_3’KD. 
Eight genes were significantly down in FCB compared to FCB_3’KD.  PF10_0275, 





in the heme biosynthesis pathway and has been reported to be inhibited by atovoquone, a 
mitochondrial inhibitor that may secondarily affect heme synthesis [292]. 
Set Description Size Norm P-val 
KE:PFA00564 GLYCEROPHOSPHOLIPID.METABOLISM 15 2.37 4.48 
PF07690 Major Facilitator Superfamily 12 2.2 6.24 
SSF56300 Metallo-dependent phosphatases 12 2 4.95 
GO:0006810 Transport 94 1.93 5.54 
ERGolgiVacuole 
Transporters of the ER/Golgi and digestive 
vacuole membranes 23 1.48 5.88 
SSF103473 MFS general substrate transporter 32 1.47 6.59 
GO:0005215 transporter activity 18 1.46 5.06 
Hagai Ginsburg ... Genes coding for transport proteins 83 1.35 10.25 
AP2_MAL8P1.153_1 Matching set 1 for AP2 - MAL8P1.153 327 1.2 7.16 
Maurer 
Exported parasite proteins associated with 
Maurers clefts 6 1.09 3.98 
Transporters Genes coding for transport proteins 93 1.08 11.55 
PM: 
confirmed and currently testing genes in the 
digestive vacuole 32 1.04 6.5 
Table 3.7. 12 enriched sets up in FCB vs. FCB_3’KD in the ring stage. 
Twelve gene sets were significantly up in FCB compared to FCB_3’KD in the ring stage.  
Several transport gene sets were up, interesting because pfmdr1 is a transport protein, and a 
change in copy number could cause compensatory transcriptional shifts in other transporters.  
The gene set for the digestive vacuole was also significant.  pfmdr1 localizes to the plasma 
membrane of the digestive vacuole, and therefore changes in expression could cause changes to 
the expression levels of the genes that localize to the digestive vacuole.  Glycerophospholipid 
metabolism was the most significant gene set in the ring stage.  Glycerophospholipids constitute 
around 80% of the total phospholipids in the parasite, and are essential components of the 
parasite membranes [293]. 
Gene Description Fold Norm 
PFE1085w DEAD/DEAH box ATP-dependent RNA helicase, putative 3.59 3.94 





PF13_0023 DNA-directed RNA polymerase 2, putative 2.03 3.83 
PF14_0529 gamma-adaptin, putative 2.14 3.37 
PFI0470w FHA domain protein, putative 1.71 3.27 
PF13_0102 secretory complex protein 63 2.73 3.05 
MAL13P1.327 mitochondrial ribosomal protein S17 precursor, putative 2.02 3.01 
Table 3.8.  8 enriched genes up in FCB vs. FCB_3’KD in the ring stage. 
Eight genes were significantly up in FCB compared to FCB_3’KD in the ring stage. PFE1085w 
was up and is strongly associated with sporozoite-induced protective immunity [294].  In 
artesunate treated cells PFI0470w, a putative zinc finger bearing protein, was over-expressed 
[295]. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.9. 0 enriched sets down in FCB vs. FCB_3’KD in the ring stage. 
No gene sets were significantly down in FCB compared to FCB_3’KD in the ring stage. 
Gene Description Fold Norm 
PFI1060w tetratricopeptide repeat family protein, putative 2.52 7.63 
PFF0945c acyl-CoA synthetase, PfACS12 3.48 5.07 
PFL2405c osmiophilic body protein 2.67 4.05 
PFC0375c U2 snRNP spliceosome subunit, putative 1.95 3.93 
PFL0705c adrenodoxin-type ferredoxin, putative 6.33 3.68 
MAL13P1.122 SET domain protein, putative 2.28 3.61 
PFD0505c protein phosphatase, putative 2.15 3.59 
PF08_0095 dihydropteroate synthetase 1.97 3.32 
MAL7P1.201 RNA helicase, putative 2.07 3.32 
PF14_0364 cleavage and polyadenylation specifity factor, putative 1.97 3.27 
PF10_0114 DNA repair protein RAD23, putative 1.63 3.17 
MAL13P1.227 ubiquitin conjugating enzyme 1.74 3.04 
Table 3.10.  12 enriched genes down in FCB vs. FCB_3’KD in the ring stage. 
12 genes were significantly down in FCB compared to FCB_3’KD in the ring stage.  PFL2405c 





H3K36 methyltransferase and was shown to target histone 3 in vitro [297, 298].  PF08_0095 
encodes deoxyhypusine synthase (DHPS), which is a target of some antifolates [299]. 
Set Description Size Norm P-val 
GO:0000226 microtubule cytoskeleton organization 6 2.94 4.33 
AP2_PFF0670w_D1_2 Matching set 2 for AP2 - PFF0670w_D1 211 2.66 6.13 
AP2_PFF0670w_D1_1 Matching set 1 for AP2 - PFF0670w_D1 105 2.2 9.19 
EQ:C5M2895 C5M28 95 77 1.41 6.28 
GO:0016337 cell-cell adhesion 48 1.05 7.19 
Table 3.11. 5 enriched sets up in FCB vs. FCB_3’KD in the trophozoite stage. 
Five gene sets were significantly up in FCB compared to FCB_3’KD in the trophozoite stage.  
Microtubule cytoskeleton organization and the AP2 set linked to gene expression and translation 
were both up [286]. 
Gene Description Fold Norm 
MAL8P1.67 nucleolar preribosomal assembly protein, putative 3.31 6.49 
PFE1085w DEAD/DEAH box ATP-dependent RNA helicase, putative 3.07 5.67 
PF14_0244 ABC transporter, (EPP family), putative 1.57 3.48 
PFB0795w ATP synthase F1, alpha subunit, putative 1.82 3.44 
PFI0135c serine repeat antigen 9 3.73 3.22 
PF14_0681 diacylglycerol kinase, putative 2.42 3.15 
PFI0240c Cu2  -transporting ATPase, putative 1.85 3.09 
Table 3.12.  7 enriched genes up in FCB vs. FCB_3’KD in the trophozoite stage. 
Seven genes were significantly up in FCB compared to FCB_3’KD in the trophozoite stage.  
PF14_0244 encodes an ABC transporter that is possibly homologous to Pdr5p, the yeast 
multidrug resistance pump, which shows up-regulation in yeast cells under artesunate pressure 
[300].  PFE1085w and PFI0240c were both up and are strongly associated with sporozoite-
induced protective immunity [294]. 
Set Description Size Norm P-val 





SM00717 SANT domain, DNA binding 5 1.17 5.31 
PF00249 Myb-like DNA-binding domain 5 1.17 5.31 
GO:0015935 small ribosomal subunit 12 1.09 5.5 
Table 3.13.  4 enriched sets down in FCB vs. FCB_3’KD in the trophozoite stage. 
Four gene sets were significantly down in FCB compared to FCB_3’KD in the trophozoite stage. 
Gene Description Fold Norm 
PFF0945c acyl-CoA synthetase, PfACS12 8.1 5.54 
PF11_0201 ubiquitin-protein ligase, putative 1.98 4.12 
PFD0455w 40S ribosomal processing protein, putative 1.71 4.11 
PF13_0302 phosphatase 2A regulatory subunit-related protein, putative 2.06 3.78 
PF13_0309 U3 snoRNA-associated small subunit rRNA processing protein, putative 2.14 3.71 
PF13_0340 exosome complex exonuclease, putative 3.29 3.53 
PFA0530c adenylate kinase, putative 3.08 3.5 
PF13_0182 ubiquitin-activating enzyme 2.03 3.08 
PF11_0331 TCP-1/cpn60 chaperonin family, putative 3.75 3.07 
PF14_0063 ATP-dependent Clp protease, putative 2.32 3.02 
Table 3.14.  10 enriched genes down in FCB vs. FCB_3’KD in the trophozoite stage. 
10 genes were significantly down in FCB compared to FCB_3’KD in the trophozoite stage.  
PFF0945c is an acyl-Coa synethetase, PfACS12, which was significantly up over the entire 
lifecycle, but is significantly down in the trophozoite stage.  This signifies that the expression of 
this gene is much more variable in FCB than in FCB_3’KD, in that the peaks of expression are 
much higher, but the valleys of expression are also much lower.  PfACS12 is a member of a 
subteolmeric gene family [290]. 
Set Description Size Norm P-val 
SSF52518 
Thiamin diphosphate-binding fold (THDP-
binding) 7 3 3.72 
AP2_PFF0670w_D1_2 Matching set 2 for AP2 - PFF0670w_D1 211 2.25 9.02 
GO:0005488 Binding 137 2.11 8.63 
SSF48371 ARM repeat 92 1.95 6.71 
AP2_PFF0670w_D1_1 Matching set 1 for AP2 - PFF0670w_D1 105 1.93 11.08 





GO:0046789 host cell surface receptor binding 19 1.26 4.54 
GO:0019867 outer membrane 6 1.23 4.3 
PF05658 Hep_Hag 6 1.17 4.3 
Table 3.15.  9 enriched sets up in FCB vs. FCB_3’KD in the schizont stage. 
Nine gene sets were significantly up in FCB compared to FCB_3’KD in the schizont stage.  The 
highest scoring set was thiamine diphosphate-binding fold (THDP-binding), which consists of 
seven enzymes for which THDP is essential [301].  In fact, the metabolic pathway to produce 
thiamine has been proposed as a drug target [301].  The Hep_Hag and outer membrane sets 
consist entirely of var genes that are antigenic variants. 
Gene Description Fold Norm 
PFL0255c UGA suppressor tRNA-associated antigenic protein, putative 2.62 7.94 
PFL2180w mitochondrial ribosomal protein L3 precursor, putative 2.38 6.11 
PFI0475w small nuclear ribonucleoprotein (snRNP), putative 2.38 4.64 
PF07_0077 actin-like protein, putative 1.43 4.08 
PFD0265w pre-mRNA splicing factor, putative 1.53 4.07 
PFI0260c dynein heavy chain, putative 1.68 3.7 
PF14_0664 biotin carboxylase subunit of acetyl CoA carboxylase, putative 2.89 3.64 
PF07_0035 Cg1 protein 1.59 3.63 
PFF1150w ribonuclease HII, putative 2.3 3.55 
PFE1240w tRNA-YW synthesizing protein, putative 1.88 3.44 
MAL8P1.67 nucleolar preribosomal assembly protein, putative 4.01 3.44 
PF10_0362 DNA polymerase zeta catalytic subunit, putative 1.31 3.4 
MAL7P1.187 erythrocyte membrane protein 1, PfEMP1 3.49 3.29 
PFI0550w cysteine repeat modular protein 1 1.89 3.21 
PFL0805w perforin like protein 2 1.83 3.01 
Table 3.16.  15 enriched genes up in FCB vs. FCB_3’KD in the schizont stage. 
15 genes were significantly up in FCB compared to FCB_3’KD in the schizont stage.  In 
artesunate-treated cells PF14_0664, a putative biotin carboxylase subunit of acetyl CoA 
carboxylase, was over-expressed, as was PFI0470w, a putative zinc finger bearing protein, in the 





conserved predicted surface proteins that possess an mTM domain that suggests a role in 
intracellular signaling or transport [302].  Interestingly, P. berghei mutants lacking expression of 
PCRMP1 showed that it is essential for transmission from the mosquito to the mouse [303]. 
Set Description Size Norm P-val 
SSF55315 L30e-like 8 1.35 4.53 
Table 3.17.  1 enriched sets down in FCB vs. FCB_3’KD in the schizont stage. 
One gene set, the ribosomal protein L30-e like domain, was significantly down in FCB compared 
to FCB_3’KD in the schizont stage. 
Gene Description Fold Norm 
PFE0165w actin-depolymerizing factor 2.28 6.42 
PFI1005w ADP-ribosylation factor, putative 3.31 5.41 
MAL8P1.58 phosphatidylglycerophosphate synthase 2.65 4.78 
PF14_0489 transcriptional regulatory protein sir2b 1.65 4.67 
PFE0195w cation transporting P-ATPase 2.82 3.24 
PF14_0576 ubiquitin carboxyl-terminal hydrolase isozyme L3 3.81 3.21 
PFL2150c cytoplasmic translation machinery associated protein, putative 2.36 3.19 
PF14_0141 60S ribosomal protein L10, putative 3.54 3.03 
Table 3.18.  8 enriched genes down in FCB vs. FCB_3’KD in the schizont stage. 
8 genes were significantly down in FCB compared to FCB_3’KD in the schizont stage.  
Phospholipid synthesis was enriched up in the ring stage, while MAL8P1.58, 
phosphatidylglycerophosphate synthase was down in the schizont stage.  PF14_0489 codes for 
PfSir2B, and has been shown to be required for silencing for a specific subset of var genes [304].  
PF14_0576 is involved in post-translational modification, having been found to possess both 






FCB vs. 106/1 
The second comparison of the pfmdr1 set is the multi-drug resistant FCB with two copies of 
pfmdr1 vs. the sensitive 106/1 with two copies of pfmdr1, but expression of only one.  This 
comparison is a useful companion to the FCB vs. FCB_3’KD comparison in that FCB_3’KD and 
106/1 both express only one copy of pfmdr1, and therefore any significant genes and gene sets 
that are common to both FCB vs FCB_3’KD and FCB vs. 106/1 are more likely to be valid.  To 
that end, we have indicated with an asterisk which genes and gene sets also came up as 
significant in the FCB vs. FCB_3’KD comparison. 
Set Description Size Norm P-val 
*AP2_PFF0670w_D1_1 Matching set 1 for AP2 - PFF0670w_D1 103 1.99 6.73 
*AP2_PFF0670w_D1_2 Matching set 2 for AP2 - PFF0670w_D1 209 1.89 7.1 
Table 3.19. 2 enriched sets up in FCB vs. 106/1. 
Two gene sets were significantly up in FCB compared to 106/1, both subsets of the genes 
putatively controlled by the AP2 transcription factor PFF0670w.  These gene sets were also 
significantly up in FCB vs. FCB_3’KD. 
Gene Description Fold Norm 
*PFB0140w zinc finger protein, putative 1.8 4.43 
*PFF0945c acyl-CoA synthetase, PfACS12 4.32 4.29 
PFL0495c ABC transporter, (TAP family), putative 1.58 4.09 
PFI0910w DNA helicase, putative 1.72 3.57 
*PF14_0174 pseudouridine synthase, putative 1.3 3.4 
*PF10_0214 RNA binding protein, putative 1.58 3.36 
PFF0520w calcium-dependent protein kinase 1.45 3.21 
PF08_0021 SPRY domain, putative 1.7 3.15 
PF11_0294 6-phosphofructokinase 1.42 3.06 
PFF1125c RNA-binding protein mei2 homologue, putative 1.8 3.02 





10 genes were significantly up in FCB compared to 106/1.  The ABC transporter, PFL0495, was 
up.  PF11_0294 is a phosphofructokinase that is over-expressed in gametocytes, while its partner 
PFI0755c, also a phosphofructokinase is expressed in the blood stages [306].  This would 
suggest a larger gametocyte component in FCB compared to 106/1.  In artesunate-treated cells 
PFF1125c, a putative RNA binding protein, was over-expressed [295]. 
Set Description Size Norm P-val 
SSF46689 Homeodomain-like 11 1.49 4.69 
GO:0015935 small ribosomal subunit 10 1.27 6.38 
SSF54236 Ubiquitin-like 19 1.24 5.18 
Table 3.21. 3 enriched sets down in FCB vs. 106/1. 
Three gene sets were significantly down in FCB compared to 106/1. 
Gene Description Fold Norm 
*PF11_0090 pescadillo-like protein 1.4 5.22 
*PF14_0360 eukaryotic translation initiation factor eIF2A, putative 1.58 4.57 
*PF10_0275 protoporphyrinogen oxidase 1.76 3.16 
*PF14_0711 DNA repair metallo-beta-lactamase protein, putative 1.48 3.16 
PF07_0091 cell cycle control protein cwf15, putative 2.13 3.09 
Table 3.22. 5 enriched genes down in FCB vs. 106/1. 
Five genes were significantly down in FCB compared to 106/1.  PF10_0275 is involved in heme 
synthesis, and was also down in FCB compared to FCB_3’KD. 
Set Description Size Norm P-val 
Hagai 
Ginsburg ... 
Transporters of the mitochondrial and apicoplast 
membranes 6 2.09 4.57 
mitochonApico 
Transporters of the mitochondrial and apicoplast 
membranes 14 1.95 4.93 
*SSF103473 MFS general substrate transporter 32 1.66 8.21 
GO:0005887 integral to plasma membrane 14 1.65 5.49 
*Hagai 
Ginsburg ... Genes coding for transport proteins 87 1.26 10.95 
*Transporters Genes coding for transport proteins 95 1.17 13.3 






Table 3.23.  7 enriched sets up in FCB vs. 106/1 in the ring stage. 
Seven gene sets were significantly up in FCB compared to 106/1 in the ring stage, many 
involving transport.  The digestive vacuole gene set was significantly up in FCB vs. 106/1, as it 
was in FCB vs FCB_3’KD, implying that two functional copies of pfmdr1 increases the 
expression of genes localized to the digestive vacuole. 
Gene Description Fold Norm 
PF14_0061 PPR repeat protein 2.05 4.11 
PFI0085c Plasmodium exported protein (hyp5), unknown function 5.52 3.94 
PF13_0118 type I signal peptidase 2.1 3.35 
*PFI0470w FHA domain protein, putative 1.73 3.31 
*MAL13P1.327 mitochondrial ribosomal protein S17 precursor, putative 2.09 3.3 
PF13_0242 isocitrate dehydrogenase (NADP), mitochondrial precursor 1.63 3.05 
PF10_0316 
N-acetylglucosaminyl-phosphatidylinositol biosynthetic protein, 
putative 1.82 3.02 
PFI0150c 
retrieval receptor for endoplasmic reticulum membrane proteins, 
putative 2.48 3 
Table 3.24.  8 enriched genes up in FCB vs. 106/1 in the ring stage. 
Eight genes were significantly up in FCB compared to 106/1 in the ring stage.  PF13_0118 is a 
signal peptidase that is significantly up.  MAL13P1.167 is another signal peptidase, not 
significant in this comparison, whose altered transcription profile in artesunate treated cells 
suggested an alteration in intracellular trafficking [295]. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.25. 0 enriched sets down in FCB vs. 106/1 in the ring stage. 
No gene sets were significantly down in FCB compared to 106/1 in the ring stage. 
Gene Description Fold Norm 





*PFF0945c acyl-CoA synthetase, PfACS12 2.95 4.25 
PF11_0461 Rab GTPase 6 2.55 4.11 
*PFI1060w tetratricopeptide repeat family protein, putative 2.1 3.59 
PFC0980c RNA triphosphatase 1.58 3.53 
*PF14_0364 cleavage and polyadenylation specifity factor, putative 2.69 3.53 
PF14_0524 protein phosphatase, putative 2.92 3.47 
*MAL7P1.201 RNA helicase, putative 2.06 3.4 
*PFD0505c protein phosphatase, putative 2.09 3.36 
MAL13P1.395 krox-like protein. Putative 2.52 3.15 
PFI0700c met-10  like protein, putative 1.89 3.12 
PFL0255c UGA suppressor tRNA-associated antigenic protein, putative 1.94 3 
Table 3.26.  12 enriched genes down in FCB vs. 106/1 in the ring stage. 
Twelve genes were significantly down in FCB compared to 106/1 in the ring stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.27.  0 enriched sets up in FCB vs. 106/1 in the trophozoite stage. 
No gene sets were significantly up in FCB compared to 106/1 in the trophozoite stage. 
Gene Description Fold Norm 
*PFE1085w DEAD/DEAH box ATP-dependent RNA helicase, putative 2.16 3.7 
PFI0970c TLD domain containing protein 6.27 3.63 
MAL13P1.134 DEAD box helicase, putative 2.05 3.57 
*PFB0795w ATP synthase F1, alpha subunit, putative 1.67 3.29 
PFC0170c dihydrolipoamide acyltransferase, putative 1.61 3.24 
MAL8P1.203 serine/threonine protein kinase, FIKK family 1.45 3.12 
MAL13P1.196 serine/threonine protein kinase, putative 2 3.06 
MAL13P1.96 chromosome segregation protein, putative 2.5 3 
Table 3.28.  8 enriched genes up in FCB vs. 106/1 in the trophozoite stage. 
Eight genes were significantly up in FCB compared to 106/1 in the trophozoite stage. 
Set Description Size Norm P-val 
PS50053 Ubiquitin domain profile 14 2.49 5.05 





Hagai Ginsburg ... 
Genes coding for chaperones and their 
regulators 78 1.23 6.72 
*GO:0015935 small ribosomal subunit 10 1.11 7.11 
Table 3.29. 4 enriched sets down in FCB vs. 106/1 in the trophozoite stage. 
Four gene sets were significantly down in FCB compared to 106/1 in the trophozoite stage. 
Gene Description Fold Norm 
*PFF0945c acyl-CoA synthetase, PfACS12 7.79 5.91 
PF14_0174 pseudouridine synthase, putative 1.82 4.22 
*PF11_0201 ubiquitin-protein ligase, putative 2.06 4.22 
PF13_0158 nonsense-mediated mRNA decay protein Upf3, putative 1.95 3.75 
*PF13_0340 exosome complex exonuclease, putative 3.49 3.61 
*PFD0455w 40S ribosomal processing protein, putative 1.68 3.49 
PF08_0121 peptidyl-prolyl cis-trans isomerase precursor 2.06 3.47 
*PF13_0309 
U3 snoRNA-associated small subunit rRNA processing protein, 
putative 2.05 3.43 
PF14_0027 40S ribosomal protein S31/UBI, putative 3.31 3.33 
*PFA0530c adenylate kinase, putative 3 3.2 
*PF11_0331 TCP-1/cpn60 chaperonin family, putative 3.69 3.11 
PF14_0360 eukaryotic translation initiation factor eIF2A, putative 2.52 3.01 
Table 3.30.  12 enriched genes down in FCB vs. 106/1 in the trophozoite stage. 
Twelve genes were significantly down in FCB compared to 106/1 in the trophozoite stage. 
Set Description Size Norm P-val 
*AP2_PFF0670w_D1_2 Matching set 2 for AP2 - PFF0670w_D1 209 2.24 7.95 
*AP2_PFF0670w_D1_1 Matching set 1 for AP2 - PFF0670w_D1 103 1.89 10.49 
*GO:0019867 outer membrane 7 1.44 4.72 
*AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 508 1.42 6.15 
*PF05658 Hep_Hag 6 1.4 5.04 
*GO:0046789 host cell surface receptor binding 18 1.29 6.57 
Table 3.31.  6 enriched sets up in FCB vs. 106/1 in the schizont stage. 
Six gene sets were significantly up in FCB compared to 106/1 in the schizont stage. 
Gene Description Fo ld Norm 
*PFL0255c UGA suppressor tRNA-associated antigenic protein, putative 2.89 7.54 





*PFD0265w pre-mRNA splicing factor, putative 1.87 5.1 
*PFI0475w small nuclear ribonucleoprotein (snRNP), putative 2.04 4.8 
PF13_0278 Ran-binding protein, putative 2.1 4.1 
PF11_0078 dna2/nam7 helicase family member, putative 1.8 3.62 
*PFL0805w perforin like protein 2 2.02 3.43 
*PFE1240w tRNA-YW synthesizing protein, putative 1.95 3.31 
MAL13P1.281 glutamate--tRNA ligase, putative 1.56 3.28 
PFE0750c RNA recognition motif, putative 1.69 3.16 
PFE1085w DEAD/DEAH box ATP-dependent RNA helicase, putative 3.36 3.13 
*PFI0260c dynein heavy chain, putative 1.49 3.07 
PFF1095w leucyl tRNA synthase 1.89 3.06 
PF10_0362 DNA polymerase zeta catalytic subunit, putative 1.59 3.06 
Table 3.32.  14 enriched genes up in FCB vs. 106/1 in the schizont stage. 
Fourteen genes were significantly up in FCB compared to 106/1 in the schizont stage. 
Set Description Size Norm P-val 
GO:0006913 nucleocytoplasmic transport 10 1.94 4.77 
SM00176 Ran GTPase 9 1.81 4.18 
GO:0007264 small GTPase mediated signal transduction 16 1.63 4.72 
GO:0015935 small ribosomal subunit 10 1.56 5.48 
GO:0015986 ATP synthesis coupled proton transport 13 1.24 4.43 
KE:PFA00193 ATP.SYNTHESIS 12 1.18 4.49 
Table 3.33.  6 enriched sets down in FCB vs. 106/1 in the schizont stage. 
Six gene sets were significantly down in FCB compared to 106/1 in the schizont stage. 
Gene Description Fold Norm 
*MAL8P1.58 phosphatidylglycerophosphate synthase 2.91 4.84 
*PF14_0489 transcriptional regulatory protein sir2b 1.73 4.73 
*PF14_0141 60S ribosomal protein L10, putative 4.66 3.97 
*PFE0165w actin-depolymerizing factor 1.91 3.47 
PF10_0203 ADP-ribosylation factor 1.91 3.39 
PF11_0447 translation initiation factor eIF-1A, putative 1.93 3.38 
PF13_0182 ubiquitin-activating enzyme 4.39 3.36 
PF11_0172 folate/biopterin transporter, putative 3.32 3.3 
PF14_0240 60S ribosomal protein L21e, putative 6.63 3.28 





*PF14_0576 ubiquitin carboxyl-terminal hydrolase isozyme L3 3.68 3.11 
PFF1415c DnaJ protein, putative 2.12 3.1 
PFC0290w 40S ribosomal protein S23, putative 3.78 3.03 
Table 3.34.  13 enriched genes down in FCB vs. 106/1 in the schizont stage. 
Thirteen genes were significantly down in FCB compared to 106/1 in the schizont stage.  
PF11_0172 was over-expressed in late time points in a lumefantrine-tolerant line [307].  
PF11_0301, spermidine synthase, was significantly down in FCB and is a component of the 
polyamine biosynthetic pathway which is currently under investigation as an antimalarial target 
[233].  Spermidine synthase inhibition using cyclohexylamine has caused development to 
completely arrest at the early trophozoite stage [233].  PF14_0576 is involved in post-








FCB_3’KD vs. 106/1 
The third comparison of the pfmdr1 set is the sensitive FCB_3’KD with one functional copy of 
pfmdr1 vs. the sensitive 106/1 with two copies of pfmdr1, but expression of only one. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.35.  0 enriched sets up in FCB_3’KD vs. 106/1. 
No gene sets were significantly up in FCB_3’KD compared to 106/1. 
Gene Description Fo ld Norm 
PFE0195w cation transporting P-ATPase 1.84 4.99 
PF13_0327 cytochrome c oxidase subunit 2, putative 1.28 4.88 
PF11_0074 exonuclease, putative 1.36 4.81 
PFF1225c DNA polymerase 1, putative 1.36 4.15 
PFD0440w peptidase, M22 family, putative 1.19 4.08 
PF14_0132 40S ribosomal protein S9A, putative 1.25 3.96 
PFL0310c eukaryotic translation initiation factor 3 subunit 8, putative 1.51 3.89 
PFF1500c DEAD/DEAH box ATP-dependent RNA helicase 3.22 3.78 
PF13_0080 telomerase reverse transcriptase, putative 1.96 3.66 
PFE1140c G10 protein, putative 2.46 3.49 
PF14_0211 Ctr copper transporter domain containing protein, putative 4.04 3.35 
PF13_0204 nuclear movement protein, putative 1.14 3.35 
PFL0495c ABC transporter, (TAP family), putative 1.38 3.17 
PFI1700c sec-1 family protein 1.22 3.11 
PF14_0277 coatamer beta subunit, putative 1.13 3.09 
PF14_0548 ATPase Vps4, putative 1.58 3.06 
Table 3.36.  16 enriched genes up in FCB_3’KD vs. 106/1. 
16 genes were significantly up in FCB_3’KD compared to 106/1.  The ABC transporter, 
PFL0495, was up in FCB_3’KD, and was also significantly up in FCB vs. 106/1. 
Set Description Size Norm P-val 





PF00501 AMP-binding enzyme 12 1.38 4.78 
PR00154 AMP-binding signature 11 1.17 4.95 
PF00227 Proteasome A-type and B-type 13 1.15 4.7 
GO:0051603 proteolysis involved in cellular protein catabolic process 13 1.15 4.7 
GO:0005839 proteasome core complex 13 1.15 4.7 
GO:0004298 threonine-type endopeptidase activity 13 1.15 4.7 
Table 3.37.  7 enriched sets down in FCB_3’KD vs. 106/1. 
Seven gene sets were significantly down in FCB_3’KD compared to 106/1. 
Gene Description Fold Norm 
PF14_0519 mitochondrial ribosomal protein S11 precursor, putative 1.41 4.26 
PFL2295w nucleolar rRNA processing protein, putative 1.25 3.95 
PFF1595c erythrocyte membrane protein 1, PfEMP1 2.04 3.06 
Table 3.38.  3 enriched genes down in FCB_3’KD vs. 106/1. 
Three genes were significantly up in FCB_3’KD compared to 106/1. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.39.  0 enriched sets up in FCB_3’KD vs. 106/1 in the ring stage. 
No gene sets were significantly up in FCB_3’KD compared to 106/1 in the ring stage. 
Gene Description Fold Norm 
PFF0105w MYND finger protein, putative 2.98 6.76 
PF14_0028 pre-mRNA splicing factor, putative 1.3 4.69 
PFF1335c 4-methyl-5(B-hydroxyethyl)-thiazol monophosphate biosynthesis enzyme 6.57 4.11 
PFL0310c eukaryotic translation initiation factor 3 subunit 8, putative 2.04 3.58 
PFE1140c G10 protein, putative 2.26 3.56 
PFF1500c DEAD/DEAH box ATP-dependent RNA helicase 3.31 3.4 
PFE0930w WD-repeat protein, putative 1.59 3.27 
PFB0330c serine repeat antigen 7 2.42 3.26 
PFL0495c ABC transporter, (TAP family), putative 1.8 3.21 
PF14_0061 PPR repeat protein 1.47 3.06 
PF11_0524 lsm4 homologue, putative 1.68 3.03 
PF13_0264 ubiquitin-activating enzyme e1, putative 1.57 3.01 





Table 3.40.  13 enriched up in FCB_3’KD vs. 106/1 in the ring stage. 
Thirteen genes were significantly up in FCB_3’KD compared to 106/1 in the ring stage.  
PF08_0095 encodes DHPS, which is a target of some antifolates [299]. 
Set Description Size Norm P-val 
HJ: 
Genes significantly up-regulated in 106/176I and 
106/176I-352K parasites with CQ treatment from 
Jiang et al PLOS One 2008 6 1.22 5.49 
Hagai Ginsburg ... Actin and filaments 9 1.19 4.61 
AP2_MAL8P1.153_1 Matching set 1 for AP2 - MAL8P1.153 338 1.09 7.37 
Table 3.41.  3 enriched sets down in FCB_3’KD vs. 106/1 in the ring stage. 
Three gene sets were significantly down in FCB_3’KD compared to 106/1 in the ring stage. 
Gene Description Fold Norm 
PF14_0518 nifU protein, putative 1.33 5.17 
PF10_0369 DNA repair helicase rad25, putative 1.58 3.44 
PF10_0162 Plasmodium exported protein (PHISTc), unknown function 1.88 3.14 
Table 3.42.  3 enriched genes down in FCB_3’KD vs. 106/1 in the ring stage. 
Three genes were significantly up in FCB_3’KD compared to 106/1 in the ring stage. 
Set Description Size Norm P-val 
PD936484 
POLYPROTEIN GLYCOPROTEIN M G2 
TRANSMEMBRANE NONSTRUCTURAL 
MEMBRANE CONTAINS: PRECURSOR SIGNAL 29 1.23 7.13 
Table 3.43.  1 enriched set up in FCB_3’KD vs. 106/1 in the trophozoite stage. 
One gene set was significantly up in FCB_3’KD compared to 106/1 in the trophozoite stage. 
Gene Description Fold Norm 
PFC0170c dihydrolipoamide acyltransferase, putative 1.55 4.26 
PFF0105w MYND finger protein, putative 1.51 3.69 
PFE0905w RAP protein, putative 3.09 3.61 
MAL8P1.113 peptidase family C50, putative 1.34 3.48 





PF14_0042 U3 small nucleolar ribonucleoprotein, U3 snoRNP, putative 1.33 3.39 
MAL13P1.196 serine/threonine protein kinase, putative 1.65 3.2 
PFE0930w WD-repeat protein, putative 2.41 3.07 
MAL13P1.42 recombinase, putative 1.86 3.03 
PFA0225w 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 2.54 3.03 
Table 3.44.  10 enriched genes in FCB_3’KD vs. 106/1 in the trophozoite stage. 
10 genes were significantly up in FCB_3’KD compared to 106/1 in the trophozoite stage. 
Set Description Size Norm P-val 
PF07422 Sexual stage antigen s48/45 domain 6 2.27 3.96 
GO:0060627 regulation of vesicle-mediated transport 8 2.03 3.76 
SM00176 Ran GTPase 7 1.93 4.39 
GO:0006913 nucleocytoplasmic transport 8 1.92 4.81 
SM00174 Small GTPase, Rho type 9 1.9 4.23 
SM00173 Ras small GTPase, Ras type 9 1.9 4.23 
PF00071 Ras family 9 1.81 4.23 
GO:0004175 endopeptidase activity 24 1.81 5.06 
GO:0030131 clathrin adaptor complex 11 1.76 4.45 
KE:PFA00193 ATP.SYNTHESIS 12 1.73 4.77 
SM00175 Ras small GTPase, Rab type 9 1.68 4.23 
PR00449 Transforming protein P21 ras signature 9 1.68 4.23 
3.4.25.1 Proteasome endopeptidase complex 17 1.55 6.37 
GO:0007264 small GTPase mediated signal transduction 13 1.48 4.02 
GO:0005783 endoplasmic reticulum 45 1.48 6.04 
GO:0046961 
proton-transporting ATPase activity, rotational 
mechanism 13 1.46 4.1 
GO:0015986 ATP synthesis coupled proton transport 14 1.38 4.56 
SK3: 
PHOSPHOLIPIDS.SYNTHESIS.PE.PS.PC.METABOL
ISM 16 1.34 4.16 
SK2: 
PHOSPHOLIPIDS.SYNTHESIS.PE.PS.PC.METABOL
ISM 16 1.34 4.16 
GO:0008565 protein transporter activity 24 1.34 5.28 
PF00227 Proteasome A-type and B-type 13 1.29 6.04 
GO:0051603 
proteolysis involved in cellular protein catabolic 
process 13 1.29 6.04 
GO:0005839 proteasome core complex 13 1.29 6.04 
GO:0004298 threonine-type endopeptidase activity 13 1.29 6.04 
GO:0006886 intracellular protein transport 60 1.28 6.27 
KE:PFA03050 PROTEASOME 28 1.17 5.69 
ERGolgiVacuol
e 
Transporters of the ER/Golgi and digestive vacuole 
membranes 23 1.15 6.53 





106/176I-352K parasites with CQ treatment from 
Jiang et al PLOS One 2008 
GO:0015078 hydrogen ion transmembrane transporter activity 7 1.02 3.8 
Table 3.45.  29 enriched sets down in FCB_3’KD vs. 106/1 in the trophozoite stage. 
29 gene sets were significantly down in FCB_3’KD compared to 106/1 in the trophozoite stage. 
Gene Description Fold Norm 
MAL13P1.271 V-type ATPase, putative 2.61 4.49 
PFF1500c DEAD/DEAH box ATP-dependent RNA helicase 1.7 4.42 
MAL8P1.67 nucleolar preribosomal assembly protein, putative 2.97 4.38 
PFL1345c histone S-adenosyl methyltransferase, putative 1.51 3.69 
PF13_0227 vacuolar ATP synthase subunit d, putative 1.86 3.2 
PFD0355c peptidyl-tRNA hydrolase PTH2, putative 1.32 3.1 
PFF0370w 
para-hydroxybenzoate--polyprenyltransferase (4- hydroxybenzoate 
octaprenyltransferase), putative 1.66 3.05 
PF14_0746 Plasmodium exported protein (PHISTb), unknown function 2.53 3.05 
Table 3.46.  8 enriched genes down in FCB_3’KD vs. 106/1 in the trophozoite stage. 
Eight genes were significantly down in FCB_3’KD compared to 106/1 in the trophozoite stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.47.  0 enriched sets up in FCB_3’KD vs. 106/1 in the schizont stage. 
No gene sets were significantly up in FCB_3’KD compared to 106/1 in the schizont stage. 
Gene Description Fold Norm 
PFB0265c DNA repair endonuclease, putative 1.96 3.65 
PFL2395c apicoplast dimethyladenosine synthase, putative 2.64 3.54 
PFE0195w cation transporting P-ATPase 2.35 3.38 
MAL13P1.118 3',5'-cyclic nucleotide phosphodiesterase, putative 1.47 3.31 
PF11_0305 RNA methyltransferase, putative 3.91 3.26 
PF13_0196 MSP7-like protein 2.23 3.26 
PFF0500c step II splicing factor, putative 1.53 3.14 
MAL13P1.42 recombinase, putative 1.69 3.02 





Eight genes were significantly down in FCB_3’KD compared to 106/1 in the schizont stage. 
Set Description Size Norm P-val 
Hagai 
Ginsburg ... Peptidases and proteases 86 1.95 5.52 
GO:0015992 proton transport 6 1.9 3.75 
SM00176 Ran GTPase 7 1.66 4.33 
GO:0007035 vacuolar acidification 6 1.53 3.88 
3.6.3.14 H(+)-transporting two-sector ATPase 11 1.52 5.36 
GO:0008565 protein transporter activity 24 1.47 4.82 
KE:PFA00193 ATP.SYNTHESIS 12 1.3 5.38 
GO:0015986 ATP synthesis coupled proton transport 14 1.28 6.21 
GO:0046961 
proton-transporting ATPase activity, rotational 
mechanism 13 1.27 5.77 
PF00501 AMP-binding enzyme 12 1.16 4.36 
PR00154 AMP-binding signature 11 1.14 4.53 
GO:0006886 intracellular protein transport 60 1.09 5.55 
6.2.1.3 Long-chain-fatty-acid--CoA ligase 12 1.07 4.36 
Table 3.49.  12 enriched sets down in FCB_3’KD vs. 106/1 in the schizont stage. 
12 gene sets were significantly down in FCB_3’KD compared to 106/1 in the schizont stage. 
Gene Description Fold Norm 
MAL13P1.271 V-type ATPase, putative 1.92 4.5 
PF11_0414 P-loop containing nucleoside triphosphate hydrolase, putative 1.72 4.45 
PF11_0524 lsm4 homologue, putative 1.51 4.28 
PF07_0035 Cg1 protein 1.64 4.16 
PFD0830w bifunctional dihydrofolate reductase-thymidylate synthase 2.13 3.88 
PF13_0227 vacuolar ATP synthase subunit d, putative 1.6 3.52 
PF10_0379 phospholipase, putative 2.43 3.25 
MAL8P1.40 RNA binding protein, putative 1.58 3.16 
PF11_0447 translation initiation factor eIF-1A, putative 1.39 3.15 
PFD0367w mitochondrial carrier protein, putative 2.03 3.06 
Table 3.50.  10 enriched genes down in FCB_3’KD vs. 106/1 in the schizont stage. 
10 genes were significantly down in FCB_3’KD compared to 106/1 in the schizont stage.  






7G8 vs. 7G8_T76K 
The first comparison of the pfcrt set is the CQR parental line 7G8 vs. the CQS 7G8_T76K line.  
Any genes or gene sets that significantly up or down-regulated in this comparison, may shed 
light on the compensatory transcriptional changes accompanying the acquisition of chloroquine 
sensitivity via the T76K point mutation. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.51.  0 enriched sets up in 7G8 vs. 7G8_T76K. 
No gene sets were significantly up in 7G8 compared to 7G8_T76K.  
Gene Description Fold Norm 
PF14_0200 pantothenate kinase, putative 1.57 3.79 
PFL0540w GPI mannosyltransferase I 1.39 3.58 
PF14_0722 cysteine repeat modular protein 4 1.63 3.58 
PF14_0690 histone deacetylase, putative 1.97 3.39 
PF14_0494 small subunit rRNA processing factor, putative 1.25 3.28 
PFE0505w cyclophilin, putative 1.31 3.18 
PFE0675c 
deoxyribodipyrimidine photolyase (photoreactivating enzyme, DNA 
photolyase), putative 1.31 3.12 
PFE1310c nucleolar Jumonji domain interacting protein, putative 1.21 3.11 
PFF1305w mitochondrial ribosomal protein L46 precursor, putative 1.3 3.05 
Table 3.52.  9 enriched genes up in 7G8 vs 7G8_T76K. 
9 genes were significantly up in 7G8 compared to 7G8_T76K.  One gene had a very high 
normalized fold change (4.68) PF10_0334, a flavoprotein subunit of succinate dehydrogenase, 
but was only analyzed in 40% of the comparisons, and therefore was not in the list [309].  This 
was very interesting, as PF10_0334 is only one of seven verified drug targets [184].  PF14_0722 





shown to be expressed in sporozoites [302].  PF14_0690 is a putative histone deacetylase, which 
could play a role in transcriptional regulation [136]. 
Set Description Size Norm P-val 
ProteasomeMeditated 
Proteasome-mediated degradation of non-
native ER proteins 31 2.17 5.83 
rabCycle Rab cycle 28 1.67 5.66 
SSF54001 Cysteine proteinases 30 1.59 5.57 
GO:0008234 cysteine-type peptidase activity 20 1.46 6.51 
3.4.22.- Cysteine endopeptidases. 14 1.45 7.38 
SM00645 Peptidase C1A, papain C-terminal 13 1.2 7.57 
PF00112 Papain family cysteine protease 13 1.2 7.57 
Table 3.53.  8 enriched sets down in 7G8 vs. 7G8_T76K. 
Eight gene sets were significantly down in 7G8 compared to 7G8_T76K, meaning that these 
gene sets were expressed less in the resistant line compared to sensitive.  It has been shown that 
CQ treatment gives rise to programmed cell death including activation of cysteine proteases 
[310], therefore the down-regulation of the cysteine protease gene set in the CQR line suggests 
an enhanced ability for the resistant line to handle an increase in cysteine protease activity in the 
presence of CQ.  There is longstanding evidence that immunoglobulin G (IgG) has a protective 
role in P. falciparum infection [311].  Immunoglobulin production was down-regulated in the 
resistant strain. 
Gene Description Fold Norm 
PF11_0177 deubiquinating/deneddylating enzyme 1.35 3.78 
PFB0260w proteasome 26S regulatory subunit, putative 1.67 3.27 
PF08_0120 GTPase activator, putative 1.17 3.21 
Table 3.54.  3 enriched genes down in 7G8 vs. 7G8_T76K. 
Three genes were significantly down in 7G8 compared to 7G8_T76K.  PF11_0177 is a 
deubiquinating/deneddylating enzyme, which reverses a post translational modification that is 





Set Description Size Norm P-val 
No significant sets.     
Table 3.55.  0 enriched sets up in 7G8 vs. 7G8_T76K in the ring stage. 
No gene sets were significantly up in 7G8 compared to 7G8_T76K in the ring stage. 
Gene Description Fold Norm 
PFL0330c DNA-directed RNA polymerase III subunit, putative 1.63 5.75 
MAL13P1.225 thioredoxin 2 1.87 3.6 
PF07_0123 mRNA (N6-adenosine)-methyltransferase, putative 1.6 3.59 
MAL7P1.28 rRNA/tRNA ribonuclease MRP/P subunit, putative 1.4 3.49 
PFL0670c bifunctional aminoacyl-tRNA synthetase, putative 1.36 3.45 
PFF1430c amino acid transporter, putative 1.77 3.32 
PF14_0690 histone deacetylase, putative 2.01 3.28 
PF11_0067 translocon component PTEX88 1.65 3.25 
PF14_0156 small subunit rRNA dimethylase, putative 1.38 3.14 
Table 3.56.  9 enriched genes up in 7G8 vs. 7G8_T76K in the ring stage. 
Nine genes were significantly up in 7G8 compared to 7G8_T76K in the ring stage.  A protein 
export machine, PTEX, is a translocon of exported proteins, including PTEX88 (PF11_0067) 
and thioredoxin 2 (MAL13P1.225), which functions as a common portal for numerous crucial 
processes [312].  A putative amino acid transporter aat1 in P. chabaudi has been implicated as a 
determinant of CQ-R by the A173E mutation in P. chabaudi [313].  The orthologue of aat1 in P. 
falciparum is PFF1430c, which is significantly up in the ring stage in 7G8. 
Set Description Size Norm P-val 
PR01415 Ankyrin repeat signature 8 2.39 3.85 
PS50088 Ankyrin repeat profile 9 2.24 4.47 
Chromatin 
Structure and organization of centromeric 
chromatin 9 1.94 4.94 
PR00503 Bromodomain signature 5 1.67 3.63 
SM00297 Bromodomain 7 1.4 3.59 
PS50014 Bromodomain profile 7 1.4 3.59 
PF00439 Bromodomain 7 1.4 3.59 





DomSurfaceProt Domains of merozoite surface proteins 11 1.12 6.94 
PF01529 DHHC zinc finger domain 8 1.08 5.26 
PS50216 Zinc finger DHHC-type profile 8 1.08 5.26 
AP2_PFF0200c_DLD_1 Matching set 1 for AP2 - PFF0200c_DLD 260 1.06 5.87 
AP2_PF10_0075_D3_1 Matching set 1 for AP2 - PF10_0075_D3 260 1.06 5.87 
AP2_PFF0200c_DLD_2 Matching set 2 for AP2 - PFF0200c_DLD 313 1.01 5.79 
AP2_PF10_0075_D3_2 Matching set 2 for AP2 - PF10_0075_D3 313 1.01 5.79 
Table 3.57.  15 enriched sets down in 7G8 vs. 7G8_T76K in the ring stage. 
15 gene sets were significantly down in 7G8 compared to 7G8_T76K in the ring stage.  Four of 
these gene sets involved AP2 motifs, focusing on two AP2s, PFF0200c and PF10_0075_D3.  
PFF0200c (PFSIP2) does not appear to act as a transcriptional regulator in the blood stage, 
however it is involved in var gene silencing in the early stages of gametocytogenesis [286, 287].  
PFF0200c was shown to be involved in heterochromatin as a DNA tethering protein [314], 
which is interesting as the structure and organization of centromeric chromatin gene set is also 
significantly down.  Two sets involving merozoite proteins were enriched, the domains of 
merozoite surface proteins set, and the sequence element bound by PF10_0075_D3 is enriched in 
the upstream sequences of merozoite development and invasion genes [287]. 
Gene Description Fold Norm 
PF13_0131 acetyltransferase, GNAT family, putative 1.88 6.53 
PF13_0257 glutamate--tRNA ligase, putative 1.91 3.68 
PFI0680c arginyl-tRNA synthetase, putative 1.63 3.54 
PFI1645c histidyl-tRNA synthetase, putative 1.85 3.48 
PFD0980w holo-(acyl-carrier protein) synthase, putative 5.29 3.38 
PFC0800w band 7-related protein 2.23 3.33 
PFC0250c AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative 1.33 3.19 
PF10_0328 bromodomain protein, putative 1.38 3.13 
Table 3.58.  8 enriched genes down in 7G8 vs. 7G8_T76K in the ring stage. 
Eight genes were significantly down in 7G8 compared to 7G8_T76K in the ring stage.  The gene 





acetyltransferase.  The next three highest genes were a putative glutamate-tRNA ligase, a 
putative arginyl-tRNA synthetase, and a putative histidyl-tRNA synthetase. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.59.  0 enriched sets up in 7G8 vs. 7G8_T76K in the trophozoite stage. 
No gene sets were significantly up in 7G8 compared to 7G8_T76K in the trophozoite stage. 
Gene Description Fold Norm 
PF14_0451 mitochondrial ribosomal protein S14 precursor, putative 1.34 4.96 
PF11_0255 ribonucleoprotein, putative 1.57 4.36 
PF11_0116 tRNA m5C-methyltransferase, putative 1.33 4.16 
PFI0425w transporter, putative 1.44 3.45 
PF11_0066 centrin-4 1.2 3.31 
MAL13P1.165 GPI transamidase subunit PIG-U, putative 1.3 3.29 
PF14_0028 pre-mRNA splicing factor, putative 1.13 3.15 
PF10_0123 GMP synthetase 1.42 3.09 
Table 3.60.  8 enriched genes down in 7G8 vs. 7G8_T76K in the trophozoite stage. 
Eight genes were significantly up in 7G8 compared to 7G8_T76K in the trophozoite stage.  
PFI0425w, a putative transporter, was significantly up. 
Set Description Size Norm P-val 
PF01529 DHHC zinc finger domain 8 1.46 4.72 
PS50216 Zinc finger DHHC-type profile 8 1.46 4.72 
GO:0050776 regulation of immune response 8 1.21 5.49 
HJ: 
Genes significantly up-regulated in 106/176I and 
106/176I-352K parasites with CQ treatment from Jiang 
et al PLOS One 2008 6 1.16 4.81 
GO:0020007 apical complex 5 1.15 4.36 
Hagai 
Ginsburg ... Genes coding for GPI anchored membrane proteins 20 1.09 5.03 
Table 3.61.  7 enriched sets down in 7G8 vs. 7G8_T76K in the trophozoite stage. 
Seven gene sets were significantly down in 7G8 compared to 7G8_T76K in the trophozoite 





was significantly down in the CQR line, meaning that the CQS line up-regulated the same genes 
as parasites under CQ treatment.  The regulation of the immune response and immunoglobulin 
production is down in the resistant line. 
Gene Description Fold Norm 
PFE0560c MORN repeat protein, putative 1.33 3.56 
PF13_0131 acetyltransferase, GNAT family, putative 1.57 3.55 
PF11_0177 deubiquinating/deneddylating enzyme 1.68 3.2 
Table 3.62.  3 enriched genes down in 7G8 vs. 7G8_T76K in the trophozoite stage. 
Three genes were significantly down in 7G8 compared to 7G8_T76K in the trophozoite stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.63.  0 enriched sets up in in 7G8 vs. 7G8_T76K in the schizont stage. 
No gene sets were significantly up in 7G8 compared to 7G8_T76K in the schizont stage. 
Gene Description Fold Norm 
PF14_0200 pantothenate kinase, putative 1.63 4.1 
PF11_0225 ABC transporter GCN20 1.42 3.88 
PFE0505w cyclophilin, putative 1.58 3.78 
PF10_0123 GMP synthetase 1.67 3.13 
PFL2280w serine/threonine protein kinase, putative 1.45 3.11 
PFL0970w pre-mRNA splicing factor, putative 1.8 3.03 
Table 3.64.  6 enriched genes up in 7G8 vs. 7G8_T76K in the schizont stage. 
Six genes were significantly up in 7G8 compared to 7G8_T76K in the schizont stage.  
PF11_0225 is a homolog of yeast Gcn20 protein which has been shown to be involved in 
translation initiation [316]. 
Set Description Size Norm P-val 
3.4.22.- Cysteine endopeptidases. 14 1.66 5.78 





PF00112 Papain family cysteine protease 13 1.62 5.97 
SM00645 Peptidase C1A, papain C-terminal 13 1.62 5.97 
Table 3.65.  4 enriched sets down in 7G8 vs. 7G8_T76K in the schizont stage. 
Four gene sets were significantly down in 7G8 compared to 7G8_T76K in the schizont stage.  It 
was found that plant homologs of pfcrt play a significant role in regulating the redox potentional 
of the cytosol [317].  The cell redox homeostasis gene set is significantly down in the resistant 
line, possibly because pfcrt is regulating the redox potential better in the resistant than the 
sensitive line. 
Gene Description Fold Norm 
PFD0965w phosphatidylinositol 4-kinase, putative 1.44 7.75 
PFB0480w syntaxin, Qa-SNARE family 3.29 3.07 
Table 3.66.  2 enriched genes down in 7G8 vs. 7G8_T76K in the schizont stage. 
Two genes were significantly down in 7G8 compared to 7G8_T76K in the schizont stage.  
PFD0965w, a putative phosphatidylinositol 4-kinase, had the highest normalized fold change 
(7.75), which is a central enzyme in the formation of phosphoinositides, which are a group of 
essential phospholipids that have been shown to trigger exflagellation, affect hemoglobin 






7G8 vs. 7G8_CTRL 
The second comparison of the pfcrt set is the CQR parental line 7G8 vs. the low-level CQR 
7G8_CTRL line.  The expression of pfcrt was altered in both 7G8_CTRL and 7G8_T76K, in that 
the addition of a plasmid, dropped the transcription of pfcrt compared to the parental 7G8.  
Transcriptional changes between 7G8 and 7G8_CTRL may have to do with compensatory 
expression changes as a result of altered pfcrt expression. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.67. 0 enriched sets up in 7G8 vs. 7G8_CTRL. 
No gene sets were significantly up in 7G8 compared to 7G8_CTRL. 
Gene Description Fold Norm 
PFL0970w pre-mRNA splicing factor, putative 1.31 3.68 
PF14_0200 pantothenate kinase, putative 1.41 3.59 
PFL0540w GPI mannosyltransferase I 1.5 3.53 
PF14_0690 histone deacetylase, putative 1.76 3.5 
PF07_0115 cation transporting ATPase, putative 1.39 3.29 
Table 3.68.  5 enriched genes up in 7G8 vs. 7G8_CTRL. 
Five genes were significantly up in 7G8 compared to 7G8_CTRL. 
Set Description Size Norm P-val 
chapfold Chaperone-assisted protein folding 65 1.6 5.4 
SSF56235 
N-terminal nucleophile aminohydrolases (Ntn 
hydrolases) 17 1.42 4.59 
Hagai Ginsburg 
... Peptidases and proteases 92 1.32 6.44 
proteases Peptidases and proteases 92 1.3 5.96 
PF00227 Proteasome A-type and B-type 14 1.25 5.3 
GO:0051603 
proteolysis involved in cellular protein catabolic 





GO:0005839 proteasome core complex 14 1.25 5.3 
GO:0004298 threonine-type endopeptidase activity 14 1.25 5.3 
3.4.25.1 Proteasome endopeptidase complex 18 1.25 5.88 
Hagai Ginsburg 
... 
Genes coding for components of the proteasome 
degradation machinery their timed transcription 74 1.18 7.78 
GO:0004175 endopeptidase activity 24 1.14 4.62 
proteaUbiqpath 
Proteasome-mediated proteolysis of ubiquinated 
proteins 66 1.14 6.29 
proteasome_new 
Genes coding for the components of the proteasome 
degradation machinery and their timed transcription 73 1.13 6.56 
HJ: 
Genes significantly up-regulated in 106/176I and 
106/176I-352K parasites with CQ treatment from 
Jiang et al PLOS One 2008 6 1.01 5.36 
Table 3.69.  14 enriched sets down in 7G8 vs. 7G8_CTRL. 
Fourteen gene sets were significantly down in 7G8 compared to 7G8_CTRL.  The bulk of these 
gene sets involve the proteasome.  The set of genes that was significantly up-regulated in 
parasites with CQ treatment [315] was significantly down in the CQR line, meaning that the low 
level CQR line up-regulated the same genes as parasites under CQ treatment.  This signal was 
also apparent in 7G8 vs 7G8_T76K. 
Gene Description Fold Norm 
PF14_0601 replication factor C3 2.31 4.63 
PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 1.76 4.3 
PF13_0117 TBC domain protein, putative 1.18 3.93 
PF07_0121 60S ribosomal subunit export protein, putative 2.12 3.82 
PF10_0081 26S proteasome regulatory subunit 4, putative 1.36 3.72 
PFE0140c mitochondrial inner membrane TIM10 associated protein, putative 1.48 3.66 
PF08_0084 RNA-binding protein (U1 snRNP-like), putative 1.16 3.4 
PF13_0250 G-beta repeat protein, putative 1.32 3.25 
PF14_0493 sortilin, putative 1.38 3.14 
PF10_0221 GcpE protein 1.51 3.12 
PF14_0273 rRNA (adenosine-2'-O-)-methyltransferase, putative 1.19 3.06 
PFC0125w ABC transporter, (TAP family), putative 1.22 3.06 
PFL1285c proliferating cell nuclear antigen 2 1.56 3.02 
Table 3.70.  13 enriched genes down in 7G8 vs. 7G8_CTRL. 





Set Description Size Norm P-val 
No significant sets.     
Table 3.71.  0 enriched sets up in 7G8 vs. 7G8_CTRL in the ring stage. 
No gene sets were significantly up in 7G8 compared to 7G8_CTRL in the ring stage. 
Gene Description Fo ld Norm 
PFL0330c DNA-directed RNA polymerase III subunit, putative 1.33 4.23 
PFI0685w pseudouridylate synthase, putative 1.89 3.82 
PFF1430c amino acid transporter, putative 2.13 3.75 
PFB0420w 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 1.35 3.62 
PF13_0330 ATP-dependent DNA helicase, putative 1.48 3.6 
PF11_0071 RuvB DNA helicase, putative 1.31 3.59 
PFF0915w N-acetylglucosamine transferase 1.68 3.53 
PF08_0065 nucleolar preribosomal assembly protein, putative 1.59 3.47 
MAL13P1.225 thioredoxin 2 1.7 3.28 
PF13_0236 tRNA guanosine-2'-O-methyltransferase, putative 2.48 3.25 
PF11_0067 translocon component PTEX88 1.87 3.23 
PF14_0690 histone deacetylase, putative 1.82 3.14 
PF14_0584 mitochondrial ribosomal protein S4/S9 precursor, putative 1.91 3.13 
PF13_0121 
dihydrolipamide succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex 1.39 3.04 
MAL7P1.150 cysteine desulfurase, putative 1.44 3.01 
PFD0725c arsenical pump-driving ATPase, putative 1.83 3 
Table 3.72.  16 enriched genes up in 7G8 vs. 7G8_CTRL in the ring stage. 
Sixteen genes were significantly up in 7G8 compared to 7G8_CTRL in the ring stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.73.  0 enriched sets down in 7G8 vs. 7G8_CTRL in the ring stage 
No gene sets were significantly down in 7G8 compared to 7G8_CTRL in the ring stage. 
Gene Description Fold Norm 
PF10_0313 mitochondrial preribosomal assembly protein rimM precursor, putative 1.75 4.81 
MAL8P1.101 RNA binding protein, putative 1.52 4.07 





PF10_0221 GcpE protein 2.43 3.21 
PFA0280w asparagine-rich antigen Pfa35-2 2.02 3.18 
PFD1060w u5 small nuclear ribonucleoprotein-specific protein, putative 1.34 3.11 
Table 3.74.  6 enriched genes down in 7G8 vs. 7G8_CTRL in the ring stage. 
Six genes were significantly down in 7G8 compared to 7G8_CTRL in the ring stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.75.  0 enriched sets up in 7G8 vs. 7G8_CTRL in the trophozoite stage. 
No gene sets were significantly up in 7G8 compared to 7G8_CTRL in the tophozoite stage. 
Gene Description Fold Norm 
PF11_0255 ribonucleoprotein, putative 1.71 4.49 
PF14_0398 transcription factor TFIIH complex subunit Tfb5, putative 1.78 3.88 
PF11_0071 RuvB DNA helicase, putative 1.26 3.69 
MAL13P1.165 GPI transamidase subunit PIG-U, putative 1.35 3.56 
PF14_0677 RNA 3'-terminal phosphate cyclase-like protein, putative 1.76 3.39 
PF11_0116 tRNA m5C-methyltransferase, putative 1.27 3.33 
PF11_0066 centrin-4 1.18 3.05 
PF13_0222 phosphatase, putative 1.75 3.02 
Table 3.76.  8 enriched genes up in 7G8 vs. 7G8_CTRL in the trophozoite stage. 
Eight genes were significantly up in 7G8 compared to 7G8_CTRL in the trophozoite stage. 
Set Description Size Norm P-val 
GO:0008234 cysteine-type peptidase activity 21 1.58 4.96 
PF00112 Papain family cysteine protease 14 1.22 6.39 
SM00645 Peptidase C1A, papain C-terminal 14 1.22 6.39 
3.4.22.- Cysteine endopeptidases. 14 1.2 5.05 
GO:0050776 regulation of immune response 8 1.04 7.75 
Table 3.77.  5 enriched sets down in 7G8 vs. 7G8_CTRL in the trophozoite stage. 
Five gene sets were significantly down in 7G8 compared to 7G8_CTRL in the trophozoite stage.  





Gene Description Fold Norm 
PF14_0695 DNA-directed RNA polymerase, alpha subunit, putative 1.59 6.84 
PF07_0121 60S ribosomal subunit export protein, putative 4.52 3.48 
PF14_0430 mitochondrial ribosomal protein S29 precursor, putative 1.73 3.08 
PF13_0131 acetyltransferase, GNAT family, putative 1.45 3.08 
Table 3.78.  4 enriched genes down in 7G8 vs. 7G8_CTRL in the trophozoite stage. 
Four genes were significantly down in 7G8 compared to 7G8_CTRL in the trophozoite stage. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.79.  0 enriched sets up in in 7G8 vs. 7G8_CTRL in the schizont stage. 
No gene sets were significantly up in 7G8 compared to 7G8_CTRL in the schizont stage. 
Gene Description Fold Norm 
PF14_0200 pantothenate kinase, putative 1.74 3.93 
PF13_0208 exoribonuclease, putative 1.29 3.58 
PFE0505w cyclophilin, putative 1.55 3.58 
PF13_0334 polynucleotide kinase, putative 2.04 3.55 
PF14_0373 ubiquinol-cytochrome c reductase iron-sulfur subunit, putative 1.65 3.45 
MAL13P1.165 GPI transamidase subunit PIG-U, putative 1.46 3.29 
PF14_0145 ubiquitin carboxyl-terminal hydrolase, putative 1.32 3.21 
Table 3.80.  7 enriched genes sets up in in 7G8 vs. 7G8_CTRL in the schizont stage. 
Four genes were significantly up in in 7G8 compared to 7G8_CTRL in the schizont stage. 
Set Description Size Norm P-val 
Proteases Peptidases and proteases 92 1.6 6.17 
Hagai Ginsburg 
... Peptidases and proteases 92 1.59 7.16 
GO:0006096 Glycolysis 16 1.56 4.54 
Hagai Ginsburg 
... Redox regulation of proteins 24 1.33 6.46 
3.4.22.- Cysteine endopeptidases. 14 1.27 4.48 
redoxReg Redox regulation of proteins 30 1.26 7.05 
Hagai Ginsburg 
... Proteins with ER retention sequences 10 1.08 4.95 





106/176I-352K parasites with CQ treatment from 
Jiang et al PLOS One 2008 
GO:0000786 Nucleosome 8 1.01 4.17 
PF00125 Core histone H2A/H2B/H3/H4 8 1.01 4.17 
Table 3.81.  10 enriched sets down in 7G8 vs. 7G8_CTRL in the schizont stage. 
Ten gene sets were significantly down in 7G8 compared to 7G8_CTRL in the schizont stage.  As 
before, proteases were significantly down, as well as the redox regulation of proteins.  
Nucleosome and core histone sets were down in 7G8, suggesting that the resistant line is 
involved with less chromatin remodeling.  There was a demonstrable inhibition of glycolysis by 
CQ [319], and there is a reduction in glycolysis gene set expression in the resistant line. 
Gene Description Fold Norm 
PFI0490c Ran-binding protein, putative 1.6 6.41 
PF14_0242 arginine methyltransferase 1 2 4.17 
PF14_0520 6-phosphogluconate dehydrogenase, decarboxylating, putative 1.88 3.6 
PF10_0328 bromodomain protein, putative 1.36 3.35 
PFL1425w T-complex protein 1, gamma subunit, putative 2.34 3.34 
MAL7P1.24 large ribosomal subunit processing protein, putative 1.54 3.24 
PFI0735c type II NADH:quinone oxidoreductase 1.61 3.18 
PF08_0094 cullin-like protein, putative 1.33 3.17 
PFI0570w GTP binding protein, putative 2.55 3.13 
Table 3.82.  9 enriched genes down in 7G8 vs. 7G8_CTRL in the schizont stage. 






7G8_T76K vs. 7G8_CTRL 
The third comparison of the pfcrt set is the CQS 7G8_T76K vs. the low-level CQR 7G8_CTRL 
line.  Each of these lines were engineered to contain a plasmid altering the pfcrt locus, therefore 
ideally the transcriptional effects of adding a plasmid will not be noticeable, and this comparison 
is the most relevant to the effect of the T76K mutation. 
Set Description Size Norm P-val 
3.4.22.- Cysteine endopeptidases. 14 1.3 5.21 
SM00645 Peptidase C1A, papain C-terminal 13 1.14 5.39 
PF00112 Papain family cysteine protease 13 1.14 5.39 
Table 3.83.  3 enriched sets up in 7G8_T76K vs. 7G8_CTRL. 
Three gene sets were significantly up in 7G8_T76K compared to 7G8_CTRL.  The cysteine 
proteases are up in the most sensitive line 7G8_T76K, while compared to 7G8 each line was 
significantly up.  Thus the cysteine protease expression increases as sensitivity increases across 
the three lines. 
Gene Description Fold Norm 
PF11_0177 deubiquinating/deneddylating enzyme 1.34 3.8 
PFC0530w transporter, putative 1.24 3.44 
PFB0260w proteasome 26S regulatory subunit, putative 1.58 3.31 
PFI1585c mitochondrial ribosomal protein S6 precursor, putative 1.2 3.09 
Table 3.84.  4 enriched genes up in 7G8_T76K vs. 7G8_CTRL. 
Four genes were significantly up in 7G8_T76K compared to 7G8_CTRL. 
Set Description Size Norm P-val 
Hagai 
Ginsburg ... Chaperone network of the mitochondrial matrix 7 2.57 4.01 
Chaperone Chaperone network of the mitochondrial matrix 12 2.42 4.92 
SSF52029 GroEL apical domain-like 11 2.15 5.1 





PF00118 TCP-1/cpn60 chaperonin family 10 1.8 5.61 
PR00304 Tailless complex polypeptide 1 (chaperone) signature 10 1.8 5.61 
SSF48592 GroEL equatorial domain-like 10 1.8 5.61 
SSF54849 GroEL-intermediate domain like 10 1.8 5.61 
PR00298 60kDa chaperonin signature 7 1.61 4.57 
PF00227 Proteasome A-type and B-type 13 1.33 4.73 
GO:0051603 
proteolysis involved in cellular protein catabolic 
process 13 1.33 4.73 
GO:0005839 proteasome core complex 13 1.33 4.73 
GO:0004298 threonine-type endopeptidase activity 13 1.33 4.73 
GO:0009116 nucleoside metabolic process 5 1.27 3.92 
GO:0004175 endopeptidase activity 23 1.26 6.05 
GO:0005665 DNA-directed RNA polymerase II, core complex 6 1.13 4.04 
GO:0006094 Gluconeogenesis 5 1.02 4.52 
Table 3.85.  17 enriched sets down in 7G8_T76K vs. 7G8_CTRL. 
17 gene sets were significantly down in 7G8_T76K compared to 7G8_CTRL, including several 
proteasome sets and the cellular metabolic process set.  The most significant gene sets down 
involved the chaperone network of the mitochondrial matrix.  One set that was interesting in 
particular was the TCP-1/cpn60 chaperonin family, which was found to be significantly up-
regulated in proteomic studies of parasites receiving doxycycline treatment [320]. 
Gene Description Fold Norm 
PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 1.88 4.74 
PF14_0273 rRNA (adenosine-2'-O-)-methyltransferase, putative 1.25 4.34 
PF10_0081 26S proteasome regulatory subunit 4, putative 1.37 3.89 
PFE0140c mitochondrial inner membrane TIM10 associated protein, putative 1.45 3.87 
PF14_0381 delta-aminolevulinic acid dehydratase 1.22 3.79 
PF07_0121 60S ribosomal subunit export protein, putative 1.88 3.53 
PFI0660c protease, putative 1.39 3.41 
PFC0125w ABC transporter, (TAP family), putative 1.22 3.16 
PFC0350c TCP-1/cpn60 chaperonin family, putative 1.26 3.16 
PFL1285c proliferating cell nuclear antigen 2 1.64 3.15 
PF13_0117 TBC domain protein, putative 1.14 3.08 
PF13_0118 type I signal peptidase 1.32 3.08 





Twelve genes were significantly down in 7G8_T76K compared to 7G8_CTRL. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.87. 0 enriched sets up in 7G8_T76K vs. 7G8_CTRL in the ring stage. 
No gene sets were significantly up in 7G8_T76K compared to 7G8_CTRL in the ring stage. 
Gene Description Fold Norm 
PF13_0131 acetyltransferase, GNAT family, putative 1.57 4.02 
PF13_0257 glutamate--tRNA ligase, putative 1.83 3.81 
MAL13P1.281 glutamate--tRNA ligase, putative 1.55 3.56 
Table 3.88.  3 enriched genes up in 7G8_T76K vs. 7G8_CTRL in the ring stage. 
Three genes were significantly up in 7G8_T76K compared to 7G8_CTRL in the ring stage.  
PF13_0131, a putative acetyltransferase, was also up stongly in 7G8_T76K compared to 7G8.  
The other two significant genes were both putative glutamate-tRNA ligases, of which there were 
only two measured in the study.  It is striking how similar their fold changes and normalized fold 
changes are. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.89.  0 enriched sets down in 7G8_T76K vs. 7G8_CTRL in the ring stage. 
No gene sets were significantly down in 7G8_T76K compared to 7G8_CTRL in the ring stage. 
Gene Description Fold Norm 
PF10_0313 mitochondrial preribosomal assembly protein rimM precursor, putative 1.78 5.01 
PFD1060w u5 small nuclear ribonucleoprotein-specific protein, putative 1.36 3.82 
PFI0485c SET domain protein, putative 1.59 3.57 
PFD0355c peptidyl-tRNA hydrolase PTH2, putative 1.48 3.28 
PF14_0589 valine-tRNA ligase, putative 1.45 3.19 
PF10_0221 GcpE protein 2.57 3.14 





PFB0875c chromatin-binding protein, putative 1.48 3.1 
MAL13P1.83 exportin 1-like protein, putative 1.32 3.07 
PFF0610c PP-loop family protein, putative 3.17 3.06 
PF11_0088 prefoldin, putative 1.42 3.05 
PFB0415c 3'exoribonuclease, putative 1.88 3.03 
Table 3.90.  12 enriched genes down in 7G8_T76K vs. 7G8_CTRL in the ring stage. 
Twelve genes were significantly down in 7G8_T76K compared to 7G8_CTRL in the ring stage.  
PFI0485c is a putative H3K36 methyltransferase [297, 298].  PF10_0221 (GcpE) was proposed 
to interact with HemH via the heme biosynthesis pathway [321].  PFB0875c is a putative 
chromatin binding protein.   
Set Description Size Norm P-val 
2.3.1.- 
Transferring groups other than amino-acyl 
groups. 5 1.82 4.76 
GO:0016192 vesicle-mediated transport 56 1.33 7.01 
GO:0006886 intracellular protein transport 64 1.31 6.37 
AP2_PFF0200c_DLD_1 Matching set 1 for AP2 - PFF0200c_DLD 270 1.1 6.73 
AP2_PF10_0075_D3_1 Matching set 1 for AP2 - PF10_0075_D3 270 1.1 6.73 
Table 3.91.  5 enriched sets up in 7G8_T76K vs. 7G8_CTRL in the trophozoite stage. 
Five gene sets were significantly up in 7G8_T76K compared to 7G8_CTRL in the trophozoite 
stage.  Vesicle-mediated transport and intracellular protein transport were up significantly in 
7G8_T76K, which has a mutation in the pfcrt gene, which codes for a transporter.  Perhaps the 
changes in transport expression are compensatory transcriptome adjustments to the mutation of 
pfcrt. 
Gene Description Fold Norm 
MAL13P1.167 signal peptidase 21 kDa subunit 3.32 4.33 
PFB0200c aspartate aminotransferase 1.73 3.68 
PFD1175w serine/threonine protein kinase, FIKK family 1.57 3.05 





Three genes were significantly up in 7G8_T76K compared to 7G8_CTRL in the trophozoite 
stage.  MAL13P1.167 is a signal peptidase, whose altered transcription profile in artesunate 
treated cells suggested an alteration in intracellular trafficking [295].  The vaccine potential for 
PFD1175w, a member of the FIKK family, known as the trophozoite protein R45, is a P. 
falciparum antigen that is exported by the parasite to the infected RBC membrane [322]. 
Set Description Size Norm P-val 
No significant sets.     
Table 3.93.  0 enriched sets down in 7G8_T76K vs. 7G8_CTRL in the trophozoite stage. 
No gene sets were significantly down in 7G8_T76K compared to 7G8_CTRL in the trophozoite 
stage. 
Gene Description Fold Norm 
PF14_0695 DNA-directed RNA polymerase, alpha subunit, putative 1.46 6.6 
PF07_0023 minchromosome maintenance (MCM) complex subunit, putative 1.41 4.04 
PFC0865w RNA binding protein, putative 1.85 3.49 
PF07_0121 60S ribosomal subunit export protein, putative 3.65 3.45 
PFE1115c S-adenosylmethionine-dependent methyltransferase, putative 2.01 3.25 
PF08_0094 cullin-like protein, putative 2.02 3.19 
PF13_0118 type I signal peptidase 1.28 3.11 
PFL1475w sun-family protein, putative 1.7 3.05 
Table 3.94.  8 enriched genes down in 7G8 vs. 7G8_T76K in the trophozoite stage. 
Eight genes were significantly down in 7G8_T76K compared to 7G8_CTRL in the trophozoite 
stage. 
Set Description Size Norm P-val 
2.3.1.- Transferring groups other than amino-acyl groups. 5 2.14 4.23 
AP2_PF14_0079_5 Matching set 5 for AP2 - PF14_0079 359 1.5 6.08 
AP2_PF14_0079_4 Matching set 4 for AP2 - PF14_0079 341 1.4 6.5 
EQ:PE45B95 PE45B 95 11 1.35 4.81 
AP2_PF14_0079_3 Matching set 3 for AP2 - PF14_0079 294 1.3 7.52 





Table 3.95.  6 enriched sets up in in 7G8_T76K vs. 7G8_CTRL in the schizont stage. 
Six gene sets were significantly up in 7G8_T76K compared to 7G8_CTRL in the schizont stage.  
The PF14_0079 AP2 binding motif was significantly up in 7G8_T76K, which is hypothesized to 
be involved in zinc ion binding and entry into host [287]. 
Gene Description Fold Norm 
PFD0965w phosphatidylinositol 4-kinase, putative 1.43 8.43 
PFB0480w syntaxin, Qa-SNARE family 2.87 3.16 
Table 3.96.  2 enriched genes up in 7G8_T76K vs. 7G8_CTRL in the schizont stage. 
Two genes were significantly up in 7G8_T76K compared to 7G8_CTRL in the schizont stage.  
PFD0965w, a putative phosphatidylinositol 4-kinase, had the highest normalized fold change, as 
it did for 7G8_T76K compared to 7G8. 
Set Description Size Norm P-val 
GO:0006096 Glycolysis 15 1.71 6.29 
Table 3.97.  1 enriched sets down in 7G8_T76K vs. 7G8_CTRL in the schizont stage. 
One gene set, glycolysis, was significantly down in 7G8_T76K compared to 7G8_CTRL in the 
schizont stage. 
Gene Description Fold Norm 
PF08_0094 cullin-like protein, putative 1.35 4.69 
PF10_0328 bromodomain protein, putative 1.4 4.49 
PF13_0118 type I signal peptidase 1.4 4.12 
PF14_0520 6-phosphogluconate dehydrogenase, decarboxylating, putative 1.78 3.72 
MAL7P1.24 large ribosomal subunit processing protein, putative 1.42 3.28 
PF14_0104 eukaryotic translation initiation factor 2 gamma subunit, putative 1.34 3.23 
PF13_0143 phosphoribosylpyrophosphate synthetase 1.54 3.14 
PF14_0177 minchromosome maintenance (MCM) complex subunit 1.89 3.08 
PF14_0242 arginine methyltransferase 1 1.43 3.07 
MAL13P1.146 AMP deaminase, putative 1.7 3.06 





Table 3.98.  11 enriched genes down in 7G8_T76K vs. 7G8_CTRL in the schizont stage. 
11 genes were significantly down in 7G8_T76K compared to 7G8_CTRL in the schizont stage.  
PF10_0328 is a putative bromodomain and interactions between bromodomains and acetylated 
lysine residuesin histone tails may affect chromatin structural changes and gene regulation [323].  
PF14_0242 is PfPRMT1 and has authentic type 1 PRMT activity to form monomethylarginines 






Combined Analysis of Chloroquine Resistant Parasites 
Though a great deal of information can be garnered through the analysis of paired cell lines, 
commonalities between lines can also be exploited to perform more robust studies that are less 
affected by the noise of individual experiments. 
Of the 11 strains we analyzed, FCB, FCB_3’KD, 7G8, 7G8_CTRL, DD2, and DDR are all 
chloroquine resistance, while 106/1, 7G8_T76K, 3d7, HB3, and 3BR are chloroquine sensitive.  
We gathered all 30 pair-wise comparisons between resistant and sensitive parasites and 
performed a combined analysis. 
We ranked all genes in a comparison A vs. B by their fold change, with a rank score of 1.0 for 
the gene most up in A vs. B, and a rank score of 0.0 for the gene that was most down in A vs. B.  
The ranked values were evenly distributed from 1.0 to 0.0.  For each comparison that had a value 
for a given gene, we created a distribution of rank values and recording the mean and standard 
deviation of that distribution in a summary file.  We also calculated the relative standard 
deviation, which is 100 * standard deviation / mean.  The average normalized fold change for 
each gene and the number of comparisons with measurements for each gene were also recorded.  
Finally, the normalized fold change for each comparison was listed, so that inquiries into any of 
the comparisons could easily be done.  Similar files were produced at the gene set level. 
A similar analysis was performed at the gene set level.  Each comparison that had an enrichment 
score for a gene set was listed and a distribution was created over the rankings of the gene sets, 





Set Description Size Mean StDev 
Hagai Ginsburg ... 
Genes coding for components involved in ribosome 
assembly 93 0.9 0.18 
Ribosomegenes 
Genes coding for components involved in ribosome 
assembly 118 0.85 0.24 
proteinBiosynth Protein biosynthesis 50 0.8 0.29 
ppcpath Pentose Phosphate Cycle 9 0.8 0.25 
2.7.7.6 DNA-directed RNA polymerase 27 0.78 0.31 
GO:0006418 tRNA aminoacylation for protein translation 35 0.78 0.23 
KE:PFA00970 AMINOACYL-TRNA.BIOSYNTHESIS 35 0.78 0.25 
riboMaturation 
Maturation and export of 60S and 40S ribosomal 
subunits 84 0.78 0.3 
KE:PFA00240 PYRIMIDINE.METABOLISM 53 0.77 0.28 
RNApolyStruct The structures of RNA polymerases 21 0.76 0.35 
GO:0005665 DNA-directed RNA polymerase II, core complex 6 0.76 0.31 
GO:0003677 DNA binding 221 0.76 0.24 
GO:0006098 pentose-phosphate shunt 7 0.75 0.28 
Hagai Ginsburg ... The structures of RNA polymerases 17 0.75 0.34 
GO:0004812 aminoacyl-tRNA ligase activity 37 0.75 0.24 
KE:PFA03020 RNA.POLYMERASE 21 0.75 0.34 
Hagai Ginsburg ... Pentose Phosphate Cycle 7 0.75 0.24 
Table 3.99.  17 sets up in CQR vs. CQS. 
We categorized a set as being up in a CQR line vs. a CQS line if it had at least five genes, had an 
enrichment score for at least half of the comparisons (>=15 of 30) and a mean rank of 0.75.  This 
means that on average in each comparison between a CQR line and a CQS line the set in 
question was expressed more highly than 75% of the other gene sets. 
The pentose phosphate cycle generates NADPH, which is required for reduction of reactive 
oxygen species, and is up-regulated in CQR vs. CQS lines, which could assist the resistant lines 
in ameliorating the toxic conditions created by chloroquine [325].  Other gene sets that were up 
included ribosomal gene sets, protein biosynthesis, aminoacyl-tRNA biosynthesis, and 
pyrimidine metabolism. 
Gene Description Mean StDev 





PF10_0373 GDP dissociation inhibitor domain containing protein 0.85 0.12 
PF14_0207 DNA-directed RNA polymerase III subunit C, putative 0.83 0.18 
PFB1040w Rifin 0.82 0.18 
PFE0605c glutathione synthetase 0.81 0.17 
PFE0300c 60S ribosomal subunit protein L24-2, putative 0.81 0.12 
PF10_0269 DNA-directed RNA polymerase II, putative 0.8 0.25 
PFA0755w erythrocyte membrane protein 1 (PfEMP1), pseudogene 0.8 0.18 
PF14_0167 Prefoldin subunit 2, putative 0.8 0.17 
PF14_0730 Plasmodium exported protein (PHISTb), unknown function 0.8 0.36 
Table 3.100.  10 genes up in CQR vs. CQS. 
We categorized a gene as being up in CQR vs. CQS if it was measured in at least half of the 
comparisons (>=15 of 30) and had a mean normalized fold change rank of 0.8.  This means that 
on average in each comparison between a CQR line and a CQS line the gene in question had a 
normalized fold change that was higher than 80% of the other genes. 
PFE0605c, glutathione synthetase, an enzyme responsible for glutathione synthesis is up in CQR 
lines.  Glutathione helps to maintain a proper redox environment in the cell and has been shown 
to degrade non polymerized ferri-protoporphyrin X, playing a role in chloroquine resistance 
[326]. 
PF10_0373, a GDP dissociation inhibitor was up in CQR.  Interestingly, when exposed to 
chloroquine, A. gambiae down-regulated a GDP dissociation inhibitor [327]. 
Set Description Size Mean StDev 
GO:0020003 symbiont-containing vacuole 7 0.85 0.34 
GO:0050776 regulation of immune response 9 0.82 0.31 
PS50011 Protein kinase domain profile 100 0.8 0.26 
SSF56112 Protein kinase-like (PK-like) 113 0.79 0.28 
AP2_MAL8P1.153_1 Matching set for AP2 - MAL8P1.153 549 0.79 0.36 
GO:0006468 protein amino acid phosphorylation 111 0.79 0.27 
GO:0004672 protein kinase activity 104 0.79 0.27 
SM00220 Serine/threonine-protein kinase domain 92 0.78 0.25 





PS50191 CRAL-TRIO lipid binding domain profile 6 0.77 0.13 
AP2_PF14_0633_2 Matching set 2 for AP2 - PF14_0633 343 0.77 0.34 
GO:0002377 immunoglobulin production 8 0.77 0.3 
PS50092 Thrombospondin type-1 (TSP1) repeat profile 7 0.76 0.2 
SM00209 Thrombospondin, type 1 repeat 6 0.76 0.2 
SSF69349 Phage fibre proteins 15 0.76 0.32 
PF00090 Thrombospondin type 1 domain 6 0.76 0.2 
PF00642 Zinc finger C-x8-C-x5-C-x3-H type (and similar) 16 0.76 0.24 
SM00271 Heat shock protein DnaJ, N-terminal 44 0.76 0.22 
AP2_PF13_0267_3 Matching set 3 for AP2 - PF13_0267 751 0.76 0.21 
GO:0004674 protein serine/threonine kinase activity 101 0.76 0.28 
PD968187 
BETA-DEFENSIN ANTIBIOTIC PRECURSOR 
ANTIMICROBIAL DEFENSIN BETA SIGNAL 
DEFENSIN BD-32 DEFB-32 
12 0.76 0.34 
Protein_kinases Protein kinase coding genes 97 0.76 0.28 
SM00181 Epidermal growth factor-like 7 0.76 0.31 
PS50076 dnaJ domain profile 47 0.75 0.21 
GO:0004683 calmodulin-dependent protein kinase activity 7 0.75 0.26 
AP2_PF14_0079_2 Matching set 2 for AP2 - PF14_0079 288 0.75 0.23 
SM00242 Myosin head, motor domain 6 0.75 0.25 
PR00193 Myosin heavy chain signature 6 0.75 0.25 
PF00063 Myosin head (motor domain) 6 0.75 0.25 
GO:0031072 heat shock protein binding 61 0.75 0.23 
AP2_PFF0200c_DLD_1 Matching set 1 for AP2 - PFF0200c_DLD 358 0.75 0.38 
SSF46565 Chaperone J-domain 54 0.75 0.19 
Hagai Ginsburg ... Protein kinase coding genes 94 0.75 0.28 
AP2_PF10_0075_D3_1 Matching set 1 for AP2 - PF10_0075_D3 358 0.75 0.38 
AP2_PFF0200c_DLD_2 Matching set 2 for AP2 - PFF0200c_DLD 438 0.75 0.38 
AP2_PF10_0075_D3_2 Matching set 2 for AP2 - PF10_0075_D3 438 0.75 0.38 
SSF82895 TSP-1 type 1 repeat 10 0.75 0.31 
Table 3.101.  37 sets down in CQR vs. CQS. 
Twice the number of sets were down in CQR vs. CQS, including protein kinases and protein 
amino acid phosphorylation.  The symbiont containing vacuole set was the most down-regulated. 
CRAL-TRIO, a lipid binding domain profile gene set was also down, which differs with the 
general finding that multi-drug resistant parasites up-regulate lipid biosynthesis. 
Gene Description Mean StDev 





PFL2550w DnaJ protein, putative 0.89 0.23 
PFL2520w reticulocyte binding protein homologue 3, pseudogene 0.85 0.27 
PF11_0060 calcium/calmodulin-dependent protein kinase, putative 0.83 0.23 
PFB0340c serine repeat antigen 5 0.82 0.3 
MAL8P1.72 high mobility group protein 0.81 0.26 
PFC0060c serine/threonine protein kinase, FIKK family 0.81 0.21 
PFB0130w octaprenyl pyrophosphate synthase 0.81 0.16 
PFB0480w syntaxin, Qa-SNARE family 0.81 0.25 
PF11_0416 myosin F, putative 0.8 0.16 
Table 3.102.  10 genes down in CQR vs. CQS. 
Along with its down-regulated gene set, the most significantly down-regulated gene in the CQR 
vs. CQS comparison was a putative CRAL-TRIO domain-containing protein.  Two kinases, the 
putative calcium/calmodulin-dependent protein kinase and a member of the FIKK family, a 
serine/threonine protein kinase were both down.  Also, PFB0130w, an octaprenyl pyrophosphate 





Combined Analysis of multi pfmdr1 lines vs. single pfmdr1 lines. 
Of the 11 strains we analyzed, FCB, Dd2, 3BR, and DDR all have multiple copies of pfmdr1, 
while FCB_3’KD, 106/1, 7G8, 7G8_CTRL, 7G8_T76K, 3D7, HB3 have one copy of pmfdr1.  
We gathered all 28 pair-wise comparisons between multiple copy pfmdr1 lines with single copy 
pfmdr1 lines. 
Set Description Size Mean StDev 
thiaminemetpath Thiamine metabolism 17 0.83 0.25 
GO:0065002 intracellular protein transmembrane transport 5 0.81 0.27 
TIGR01492 
CPW_WPC: Plasmodium falciparum CPW-WPC 
domain 9 0.81 0.2 
PF09717 
Plasmodium falciparum domain of unknown function 
(CPW_WPC) 9 0.81 0.2 
SSF52518 Thiamin diphosphate-binding fold (THDP-binding) 8 0.8 0.24 
PF00168 C2 domain 5 0.8 0.24 
4.2.1.70 Pseudouridylate synthase 9 0.8 0.17 
GO:0008173 RNA methyltransferase activity 11 0.8 0.16 
GO:0051301 cell division 12 0.79 0.24 
EQ:C5M2899 C5M28 99 118 0.79 0.24 
PF02779 Transketolase, pyrimidine binding domain 5 0.79 0.2 
KE:PFA00510 N-GLYCAN.BIOSYNTHESIS 7 0.79 0.14 
GO:0006099 tricarboxylic acid cycle 18 0.78 0.24 
GO:0006284 base-excision repair 6 0.78 0.21 
EQ:MD99 MD 99 60 0.78 0.14 
SK3 GPI.ANCHOR.SYNTHESIS 8 0.77 0.18 
SK2 GPI.ANCHOR.SYNTHESIS 8 0.77 0.18 
KE:PFA00530 AMINOSUGARS.METABOLISM 6 0.77 0.14 
selenocysteine Selenocysteine biosynthesis 9 0.76 0.11 
Hagai Ginsburg ... Genes coding for Fe S containing proteins 17 0.76 0.16 
GO:0045261 
proton-transporting ATP synthase complex, catalytic 
core F(1) 9 0.75 0.14 
SSF56815 Sec1/munc18-like (SM) proteins 5 0.75 0.2 
GO:0006904 vesicle docking involved in exocytosis 5 0.75 0.2 
GO:0006512 ubiquitin cycle 19 0.75 0.23 
EQ:C5M2895 C5M28 95 165 0.75 0.26 
SSF52467 DHS-like NAD/FAD-binding domain 5 0.75 0.21 
Hagai Ginsburg ... Selenocysteine biosynthesis 6 0.75 0.18 
SK1 
Santha Kumar's fatty acid related genes - lipid 
recycling and degradation 13 0.75 0.25 





We categorized a set as being up in multi-pfmdr1 vs. single-pfmdr1 if it had at least five genes, 
had an enrichment score for at least half of the comparisons (>=14 of 28) and a mean rank of 
0.75.  This means that on average in each comparison between a multi-pfmdr1 line and a single-
pfmdr1 line the set in question is expressed more highly than 75% of the other gene sets. 
The top set on our list is thiamine metabolism, which was previously discussed in the analysis of 
FCB vs. FCB_3’KD, an example of a multi-pfmdr1 line vs. a single-pfmdr1 line.  This metabolic 
pathway has been proposed as a drug target [301]. 
A lipid recycling and degradation gene set was up as well as GPI anchor synthesis. 
Glycosylphosphatidylinositol (GPI) is a class of glycolipid that anchors proteins to the cell 
surface, and in P. falciparum anchors merozoite surface protein-1 to the surface of parasite cells, 
which contributes to malaria pathogenesis [293].  Iron containing proteins were up, along with 
cell divison and the TCA cycle. 
Gene Description Mean StDev 
MAL8P1.161 Plasmodium exported protein (hyp7), unknown function 0.98 0.04 
PF11_0522 erythrocyte membrane protein 1 (PfEMP1), truncated 0.97 0.05 
MAL8P1.209 var-like protein 0.94 0.09 
PF07_0002 RESA-like protein 0.94 0.11 
PFI1705w phosphatidylinositol N-acetylglucosaminyltransferase subunit P, putative 0.93 0.06 
PFE1090w nucleotide binding protein, putative 0.92 0.05 
PFA0680c Pfmc-2TM Maurer's cleft two transmembrane protein 0.92 0.1 
PF13_0135 vacuolar protein sorting 52 homologue 0.9 0.07 
PF14_0067 LCCL domain-containing protein 0.9 0.2 
MAL13P1.338 U1 small nuclear ribonucleoprotein, putative 0.89 0.16 
PFL2510w chitinase 0.87 0.2 
PFF1105c chorismate synthase 0.85 0.15 
PF14_0738 lysophospholipase, putative 0.85 0.16 
PF14_0183 signal recognition particle, RNP, putative 0.85 0.34 





PF11_0512 ring-infected erythrocyte surface antigen 2 0.84 0.28 
PFE1265w G-protein coupled receptor, putative 0.84 0.13 
PFA0495c selenocysteine-specific elongation factor selB homologue, putative 0.84 0.15 
PFB1045w erythrocyte membrane protein 1 (PfEMP1), truncated 0.83 0.23 
PF13_0061 ATP synthase gamma chain, mitochondrial precursor, putative 0.82 0.11 
PF14_0272 CPW-WPC family protein 0.82 0.2 
PF07_0095 tRNAHis guanylyltransferase, putative 0.82 0.23 
PF08_0045 2-oxoglutarate dehydrogenase E1 component 0.82 0.16 
MAL7P1.186 var-like erythrocyte membrane protein 1 0.81 0.14 
PFD0367w mitochondrial carrier protein, putative 0.81 0.16 
PFE0825w metabolite/drug transporter, putative 0.81 0.17 
PFL2590w Plasmodium exported protein (PHISTa), unknown function 0.81 0.29 
PFF0595c leucine-rich repeat protein 0.81 0.2 
PFE1290w NIMA related kinase 2 0.8 0.29 
Table 3.104.  29 genes up in multi-pmfdr1 vs. single-pfmdr1. 
We categorized a gene as being up in multi-pfmdr1 vs. single-pfmdr1 if it was measured in at 
least half of the comparisons (>=14 of 28) and had a mean normalized fold change rank of 0.8.  
This means that on average in each comparison between a multi-pfmdr1 line and a single-pfmdr1 
line the gene in question had a normalized fold change that was higher than 80% of the other 
genes. 
One very interesting gene was PFE0825w, a metabolite/drug transporter, that apparently is up-
regulated along with pfmdr1, evidence that pmfdr1 has an effect on other members of the drug 
transporter family.  The C5M3 locus of GB4 contributes to increased chloroquine accumulation, 
and PFE0825w was one of two metabolite/drug transporters found on the C5M3 locus [328].  
Co-expression of pfmdr1 and PFE0825w in multi-drug resistant parasite adds more proof that 
PFE0825w is involved in drug resistance. 
PF14_0738, a putative lysophospholipase, and PFI1705w, a putative phosphatidylinositol N-





Set Description Size Mean StDev 
KE:PFA03050 Proteasome  30 0.88 0.2 
EQ:C2M2095 C2M20 95 7 0.87 0.24 
PF00227 Proteasome A-type and B-type 15 0.85 0.19 
GO:0051603 proteolysis involved in cellular protein catabolic process 15 0.85 0.19 
GO:0005839 proteasome core complex 15 0.85 0.19 
GO:0004298 threonine-type endopeptidase activity 15 0.84 0.19 
PF10584 Proteasome subunit A N-terminal signature 7 0.84 0.18 
GO:0005525 GTP binding 127 0.84 0.09 
SSF56235 N-terminal nucleophile aminohydrolases (Ntn hydrolases) 18 0.84 0.18 
GO:0033643 host cell part 5 0.84 0.33 
SM00242 Myosin head, motor domain 6 0.84 0.19 
PR00193 Myosin heavy chain signature 6 0.84 0.19 
PF00063 Myosin head (motor domain) 6 0.84 0.19 
GO:0004175 endopeptidase activity 25 0.83 0.24 
redoxReg Redox regulation of proteins 40 0.82 0.27 
GO:0042540 hemoglobin catabolic process 7 0.82 0.27 
AV:phist phist gene family 73 0.82 0.37 
GO:0003743 translation initiation factor activity 67 0.82 0.14 
SSF57829 Zn-binding ribosomal proteins 5 0.81 0.2 
GO:0022625 cytosolic large ribosomal subunit 30 0.81 0.33 
SSF50630 Acid proteases 14 0.81 0.19 
proteaUbiqpath Proteasome-mediated proteolysis of ubiquinated proteins 74 0.81 0.25 
Hagai Ginsburg ... Peptidases and proteases 113 0.81 0.24 
PR00792 Pepsin (A1) aspartic protease family signature 10 0.8 0.24 
PF00026 Eukaryotic aspartyl protease 10 0.8 0.24 
Hagai Ginsburg ... Redox regulation of proteins 31 0.8 0.3 
GO:0003735 structural constituent of ribosome 164 0.79 0.36 
GO:0020020 food vacuole 12 0.79 0.31 
PF01248 Ribosomal protein L7Ae/L30e/S12e/Gadd45 family 6 0.79 0.22 
GO:0004190 aspartic-type endopeptidase activity 18 0.79 0.2 
GO:0005829 cytosol 23 0.79 0.19 
hemoglobinpolpath Hemoglobin digestion and ferriprotoporphyrin IX polymerization 24 0.79 0.33 
GO:0005840 ribosome 154 0.78 0.36 
GO:0003924 GTPase activity 87 0.78 0.15 
TIGR01639 P_fal_TIGR01639: Plasmodium falciparum uncharacterized domain TIGR01639 48 0.78 0.35 
proteases Peptidases and proteases 111 0.78 0.28 
GO:0006413 translational initiation 62 0.78 0.15 
GO:0009408 response to heat 22 0.78 0.16 





Hagai Ginsburg ... Hemoglobin Digestion amp Ferriprotoporphyrin IX Polymerization 14 0.77 0.34 
intTranslation Initiation of translation 38 0.77 0.26 
EQ:B5M5895 B5M58 95 72 0.77 0.17 
3.4.25.1 Proteasome endopeptidase complex 20 0.77 0.26 
proteasome_new Genes coding for the components of the proteasome degradation machinery and their timed transcription 82 0.76 0.31 
PM from a motif search for the digestive vacuole 148 0.76 0.31 
PR00315 GTP-binding elongation factor signature 13 0.76 0.26 
GO:0006631 fatty acid metabolic process 13 0.76 0.25 
Hagai Ginsburg ... Genes coding for components of the proteasome degradation machinery their timed transcription 80 0.75 0.31 
GO:0006412 translation 267 0.75 0.37 
Hagai Ginsburg ... Established and putative Maurer s clefts proteins 89 0.75 0.42 
SK3 FATTY.ACID.TRANSPORT.STORAGE 18 0.75 0.28 
SSF50104 Translation proteins SH3-like domain 11 0.75 0.21 
GO:0006986 response to unfolded protein 16 0.75 0.2 
SK2 FATTY.ACID.TRANSPORT.STORAGE 18 0.75 0.28 
GO:0015934 large ribosomal subunit 18 0.75 0.32 
Hagai Ginsburg ... Rab and other proteins involved in intracellular traffic 13 0.75 0.14 
KE:PFA03010 Ribosome 72 0.75 0.4 
Table 3.105.  58 enriched sets down in multi-pmfdr1 vs. single-pfmdr1. 
There were twice as many sets enriched down in the multi-pfmdr1 vs. single-pfmdr1 comparison, 
including several proteasome and ribosome sets.  Redox regulation of proteins was down, 
possibly because single-pfmdr1 lines are less equipped to handle oxidative stress, one source 
being the antimalarial drugs that multi-pfmdr1 lines are more resistant too.  Hemoglobin 
catabolism and digestion were also down in the multi-pfmdr1 lines, pathways that are vital to the 
survival of the parasite.  It is possible that the up-regulation of iron containing proteins is linked 
to the down-regulation of hemoglobin catabolism.  Fatty acid metabolism and transport were 
both down, while lipid recycling and degradation and GPI anchor synthesis were up. 
Gene Description Mean StDev 
PFB0105c Plasmodium exported protein (PHISTc), unknown function 0.92 0.17 
PFB0095c erythrocyte membrane protein 3 0.91 0.16 
PFI1750c Plasmodium exported protein (hyp11), unknown function 0.91 0.12 





MAL13P1.470 Plasmodium exported protein (PHISTa), unknown function 0.89 0.19 
PF14_0709 mitochondrial ribosomal protein L20 precursor, putative 0.89 0.1 
PFI0040c erythrocyte membrane protein 1 (PfEMP1), exon2, pseudogene 0.88 0.18 
MAL7P1.218 stevor 0.86 0.09 
MAL13P1.480 histidine-rich protein III 0.86 0.21 
PF11_0260 60S ribosomal protein L35, putative 0.86 0.14 
PFF0155w mitochondrial chaperone BCS1, putative 0.84 0.15 
PFE0175c myosin B 0.84 0.23 
PFC0360w activator of Hsp90 ATPase, putative 0.83 0.19 
PFE0865c splicing factor, putative 0.83 0.15 
PF14_0733 serine/threonine protein kinase, FIKK family 0.83 0.26 
PF14_0076 plasmepsin I 0.83 0.28 
PF07_0126 transcription factor with AP2 domain(s), putative 0.83 0.14 
PF08_0014 apicoplast ribosomal protein L21 precursor, putative 0.83 0.14 
PFI1755c ring-exported protein 3 0.83 0.25 
MAL7P1.158 signal recognition particle SRP9 0.82 0.17 
MAL7P1.320 ribosomal protein, L37e, putative 0.82 0.12 
PFL1270w cof-like hydrolase, had-superfamily, subfamily iib 0.81 0.17 
MAL7P1.12 erythrocyte membrane-associated antigen 0.81 0.14 
MAL8P1.83 eukaryotic translation initiation factor, putative 0.81 0.13 
PF07_0079 60S ribosomal protein L11a, putative 0.81 0.2 
PFE1415w cell cycle regulator with zn-finger domain, putative 0.81 0.11 
PFB0926c Plasmodium exported protein (hyp2), unknown function 0.81 0.18 
PFF0200c transcription factor with AP2 domain(s), putative,SPE2-interacting protein 0.81 0.18 
PFL2100w ubiquitin conjugating enzyme E2, putative 0.81 0.23 
PFE0165w actin-depolymerizing factor 0.8 0.21 
PFL0815w DNA-binding chaperone, putative 0.8 0.19 
 PFD1055w 40S ribosomal protein S19, putative 0.8 0.19 
PFD1170c Plasmodium exported protein (PHISTb), unknown function 0.8 0.29 
PF13_0073 Plasmodium exported protein (hyp12), unknown function 0.8 0.29 
PFB0080c Plasmodium exported protein (PHISTb), unknown function 0.8 0.3 
PF14_0201 surface protein, Pf113 0.8 0.21 
PF13_0280 ER lumen protein retaining receptor 0.8 0.18 
Table 3.106.  37 genes down in multi-pmfdr1 vs. single-pfmdr1. 
Histidine rich protein 3 (hrp3) has been found to be in an unstable genomic region, and therefore 
it being down in a multi-pfmdr1 vs. single-pfmdr1 lines may be just random genomic instability, 





pfmdr1 lines [142].  Plasmepsin I is an aspartic protease involved in hemoglobin catabolism and 
is down along with the hemoglobin catabolism.  The signal recognition particle SRP9 is down, 
which binds 15-30 amino acid peptides, stops translation, and shuttles them to the endoplasmic 











The results of our algorithm can be viewed in three ways.  The first is an analysis at the 
individual time point.  One can focus on any part of the time series and see which genes and gene 
sets are up or down for a given point in time.  Using this method, one can investigate the 
different stages of the IDC and recover gene sets that may be up-regulated in one phase and 
down-regulated in the next.  These sets would be lost a conventional implementation of GSEA, 
which would combine all the time points together for its analysis. 
The second method of analysis for this data is to combine the findings for each time point into a 
single metric, the FDS, which measures the extent to which a gene set is up or down enriched 
across the time series.  The FDS is calculated by multiplying the (1-FDRx) for each time point x.  
Now, we can sort the gene sets by decreasing FDS to get a truer representation of the gene set 
enrichment. 
The third method was to combine the results at each stage using windows for each stage of the 
IDC from Mok et al. [138].  We calculated enrichment by averaging expression across the stage 
and performing GSEA, and then also by performing GSEA on each time point in the stage and 
combining into an FDS for the stage. 
The following useful points emerged from our research: 
Average expression does not offer a full picture. 
Previous analysis of gene expression in P. falciparum has focused on average expression across 





a gene set is under expressed, the results are susceptible to random perturbations in gene 
expression at the low end of the spectrum.  In addition, a focus on average expression overlooks 
gene sets with a small window of peak expression, as well as gene sets that peak at different time 
points in the two lines.  Instead, our analysis focuses on the section of the time series in which a 
given gene set is most expressed, allowing calculation of the maximal enrichment for that gene 
set. 
Eight time points yield sufficient data.  
Comparing our imputed lines to the full transcriptome data from the DeRisi laboratory has 
confirmed that it is possible to recover an accurate representation of the data from the full time 
series by only assaying 8 of the 48 time points.  This finding is important for future experimental 
design. 
Visualization confirms proper alignment. 
Visualization of expression data is a critical component of transcriptomic analysis.  Our PCA 
analysis yielded 3-dimensional plots of all time points in two lines.  These plots helped to 
confirm the proper alignment of the lines and the reproducibility of our experiments.  If any 
experiment had deviated significantly from the rest, it would be immediately evident in the PCA 
plot.  Due to the strong cyclical nature of gene expression in P. falciparum, the time points of 
each line were neatly organized in two principal components.  This enables future researchers to 
spot check new samples for proper alignment by aligning to our data. 
Significant differences between lines drive new hypotheses. 
The computational techniques we introduced helped to identify many genes and gene sets that 





transcriptional impacts of the changes in pfmdr1 and pfcrt in the lines we assayed, which can 
then be tested experimentally.  Our normalization of gene and gene set scores helps to remove 
spurious hits and focus on results that are both significant and rare. 
Our methods can be used for the alignment of any time series data and could facilitate the 
analysis of line-to-line differences in a number of organisms. For example, these techniques 
could be used to align time series from other Plasmodium species, some of which have shorter or 






Chapter 4 Tolerance to dihydroartemisinin is associated with 
increased levels of redox metabolites and expression of histone 
proteins in Plasmodium falciparum 
 
Daniel Scanfelda, Richard Eastmanb,c, Lindsey Altenhofend, Kellen Olszewskid, Michael Muhlee, 
Sophie Adjalleya†, Xin-zhuan Suc, Manuel Llinasd, David Fidockb 
 
a Center for Computational Biology and Bioinformatics, Columbia University College of 
Physicians and Surgeons, New York, NY 10032, USA; bDepartment of Microbiology and 
Immunology and Division of Infectious Diseases, Department of Medicine, Columbia University 
Medical Center, New York, NY 10032, USA; cMalaria Functional Genomics Section, 
Laboratory of Malaria and Vector Research, NIAID, DIR, NIH; dLewis-Sigler Institute for 
Integrative Genomics, Princeton 
University, Princeton, USA; eExxon Mobil Chemical Company, Baytown, TX, USA. 
 
† Current address: Genome Biology Unit, European Molecular Biology Laboratory, 69117, 
Heidelberg, Germany. 
 






Author contributions: RE, ML, and DF designed the experiments.  RE, LA, KO, and SA 
performed experiments.  DS developed analytic tools for microarray data processing.  MM 
performed mathematical modeling.  RE and DS analyzed the microarray data. 
ABSTRACT 
Artemisinin-based combination therapies (ACTs) have become the first-line antimalarial in 
nearly all countries where malaria is endemic, providing relief to areas with chloroquine or 
sulfadoxine-pyrimethamine resistance.  Recent reports of reduced parasite susceptibility have 
spurred investigation into the mechanisms that modulate drug response.  We isolated 
artemisinin-tolerant parasite lines by applying a nearly constant, low drug selection pressure with 
dihydroartemisinin, the primary active metabolite of artemisinin, and increasing it step-wise over 
the course of 200 days.  The resulting tolerant lines were able to survive for extended periods of 
time under previously lethal levels of artemisinin drug pressure.  Compared to the drug-sensitive 
parent, these parasites were able to recrudesce at a higher rate after a four-day exposure to drug, 
and could handle a higher concentration of drug. 
Metabolomic and transcriptional investigation of the drug-tolerant lines compared to the drug-
sensitive line demonstrated an increased abundance of redox metabolites and the transcripts 
involved in redox regulation.  In addition, the dihydroartemisinin-tolerant parasites demonstrated 
a significant reduction in transcription and altered expression of transcripts encoding for core 
histone proteins.  These alterations could potentially work together to lower endogenous redox 
stress in the parasite, which would confer an increased tolerance to drug induced redox 
perturbation.  These studies suggest an additional drug resistance mechanism that may underlie 








In the 1950s, hope for eradication of malaria was at its peak based on two potent weapons, 
chloroquine, the highly effective, fast-acting, and inexpensive 4-aminoquinoline, and the 
insecticide dichlorodiphenyltrichloroethane (DDT), which were very effective in reducing the 
incidence and severity of malaria worldwide [44].  Chloroquine was appealing in that it was easy 
to administer, had few side effects, was highly effective with only a few doses, and only cost ten 
cents per treatment [330].  Initial successes in temperate climates in seasonal malaria 
transmission zones such as the United States and Europe were overshadowed by failures 
throughout Africa as chloroquine resistance spread [331].  Instead of receding, the burden of 
malaria steadily increased in Africa due to many contributing factors, including drug resistance, 
insecticide resistance, war and civil disturbance, environmental changes, climatic changes, 
travel, and population increases [332]. 
New drugs were urgently needed after the two major antimalarials, chloroquine and sulfadoxine-
pyrimethamine fell to resistance, and thankfully the administration of ACTs in recent years has 
had a profound effect [333].  The burden of malaria has decreased substantially over the past 
several years as increases in malaria control efforts, including long-lasting insecticide treated 
bed-nets, residual insecticide spraying, and ACTs have begun to take hold [334].  In Africa, 
Ethiopia and Eritrea have experienced a 70% decline in malaria morbidity, with Kenya, the 






In 2009, disturbing reports from the Thai-Cambodia border indicated that P. falciparum parasites 
had reduced in vivo susceptibility to ACTs compared with northwestern Thailand, exhibiting 
slow parasite clearance times in vivo while maintaining the same in vitro attributes [96, 100].  
Two contributing factors were the availability of substandard artemisinins and the use of 
artemisinin monotherapies at subtherapeutic levels for over 30 years [333].  Recent clinical data 
from Northwestern Thailand also show evidence of decreased parasite clearance rates and the 
potential emergence of resistance [97].  
Artemisinin 
The Chinese wormwood Artemisia annua produces an essential oil that is rich in mono- and 
sesquiterpenes, of which the sesquiterpene lactone artemisinin comprises 0.01-1% of the dry 
weight of the oil [335].  In 1971, the active antimalarial principle was extracted from the 
traditional Chinese medicine qinghaosu (artemisinin) [336] and then synthesized into derivatives 
that displayed much more potent antimalarial characteristics [92].  The derivatives of artemisinin 
in current use are artemether, artesunate, and the major active metabolite dihydroartemsinin, 
which demonstrate improved bioavailability and stability compared to artemisinin [337]. 
Mode of action 
The exact mode of action of the artemisinin derivatives remains unclear, but studies indicate that 
their cytotoxic effects may result from interactions between the heme-iron produced from 
hemoglobin degradation in the digestive vacuole and the endoperoxide bridge [338].  
Deoxyartemisinin lacks the endoperoxide bridge and is consequently devoid of antimalarial 
activity [339].  Several studies suggest that cleavage of the peroxide in artemisinin is promoted 





proteins and lipids within infected red blood cells (RBCs) [340, 341].  The alkylation theory is 
consistent with the finding that the antimalarial activity of artemisinin was enhanced by 
increased oxygen tension, showing synergistic effects with miconazole and doxorubicin, and 
diminished through reducing oxygen tension with catalase, dithiothreitol, and alpha-tocopherol 
[342]. 
A competing theory is that one-electron redox centers may exist in the parasite that can cleave 
artemisinin, and in such a case the S-alkylation could damage the redox center via covalent 
binding to artemisinin, and if the inactivated redox center is in a critical enzyme, the 
modification could be lethal [343]. 
When P. falciparum-infected RBCs were incubated with radiolabeled artemisinin, several 
interacting proteins were labeled, including the P. falciparum translationally controlled tumor 
protein (TCTP) homolog, suggesting that the drug’s lethal effect could in part be mediated by 
alkylation and inactivation of specific parasite proteins [344, 345]. 
An interesting feature of artemisinins, unlike other antimalarials, is that they are effective against 
ring-stage parasites, because parasites in the early ring stage consume minimal amounts of 
hemoglobin and have not yet formed a digestive vacuole, suggesting there is a mode of action 
that does not involve heme [346].  However, recent studies suggest that ring stage parasites can 
degrade hemoglobin and provide a source of iron for artemisinin activation [347]. 
Several proteins have been proposed to be specific targets of artemisinins.  Cysteine proteases 
are possible targets, based on studies that implicate artemisinin in the interference of the 





observations of inhibition of digestive vacuole proteolytic activity, and ex vivo accumulation of 
hemoglobin in parasites treated with artemisinin [348]. 
In the yeast S. cerevisiae, artemisinin disrupts the normal function of mitochondria by 
depolarizing their membrane potential.  Deletion of genes that encode mitochondrial NADH 
dehydrogenases (NDE1 or NDI1) confers resistance to artemisinin, while overexpression 
increases sensitivity, implicating the electron transport chain as a resistance determinant [349].  
In studies with P. berghei, a mouse malaria, the membrane potential of the mitochondria was 
depolarized by artemisinin, and a large amount of reactive oxygen species were produced in both 
malarial and yeast mitochondria, but not in mammalian mitochondria [350]. 
In work with Xenopus laevis oocytes, artemisinin was shown to inhibit PfATP6, a SERCA-type 
Ca2+ATPase, while deoxyartemisinin, lacking the endoperoxide bridge, had no effect on 
PfATP6 [351].  This inhibition was nullified in the presence of the L263E mutation in PfATP6 
[352].  Chelation of iron abrogates the activity of artemisinin and attenuates the inhibition of 
PfATP6, suggesting that artemisinin might act by inhibiting PfATP6 outside the digestive 
vacuole after activation by iron [351].  DNA sequencing of 60 isolates from French Guiana and 
Senegal found an association between the PfATP6 S769N mutation and raised artemether IC50s 
(> 30 nmol/L) [353].  Of note, recent transfection studies show no impact of the L263E mutation 
on IC50 values in transgenic parasites [354]. 
It was also shown that potent artemisinin activity against P. falcipaum was lost upon inhibition 
of hemoglobinase activity via cysteine protease inhibitors, gene deletion of the cysteine protease 






Compared to all other licensed antimalarials, including quinine, artemisinin clears parasites and 
resolves fevers the fastest.  It is also extremely potent against drug-resistant strains, including 
chloroquine-resistant and sulfadoxine-pyrimethamine-resistant P. falciparum [182]. 
In a meta-analysis of ~6,000 patients, it was found that adding a three-day course of artesunate to 
a standard antimalarial treatment resulted in substantial reductions in treatment failure, 
recrudescence, and gametocyte carriage [355].  Artemisinin treatments successfully kill nearly 
all of the intraerythrocytic stages [356] as well as the early stages of gametocyte development 
[357], therefore reducing passage of the disease to others [92, 95]. 
The World Health Organization’s (WHO) guidelines for the treatment of malaria for 2010 places 
ACTs as the recommended treatment for uncomplicated P. falciparum malaria, including 
artemether plus lumefantrine, artesunate plus amodiaquine, dihydroartemisinin plus piperaquine, 
artesunate plus mefloquine, and artesunate plus sulfadoxine-pyrimethamine [358].  The choice of 
ACT in a given country is based on resistance in the area, and neither the artemisinin nor the 
partner drug should be used as a monotherapy [358]. 
Lab isolate categorization 
There is an urgent need for characterization of the mode of action of artemisinin antimalarials 
and mechanisms mediating resistance.  One powerful method toward this end is the isolation and 
characterization of artemisinin-resistant lab isolates.  This provides a controlled laboratory 
condition in which to compare an artemisinin-sensitive parental line with an artemisinin resistant 





to the resistance phenotype than when comparing field isolates, or any two lines that were not 
derived from one another. 
The first genetically stable and transmissible artemisinin- and artesunate-resistant Plasmodium 
parasites were reported in 2006 in parasite lines derived from the rodent malaria P. chabaudi 
[359].  Analysis of four possible modulators of resistance (mdr1, cg10, tctp, atp6) showed no 
mutations or copy number changes [359]. 
Three P. falciparum parasite lines W2, D6, and TM91C235 were exposed to artelinic acid, 
resulting in decreased susceptibility to artelinic acid, artemisinin, mefloquine, quinine, 
halofantrine, and lumefantrine [360].  Accompanying increases in copy number, mRNA 
expression, and protein expression of pfmdr1 occurred in W2 and TM91C235, but not in D6, 
while no expression change occurred in pfatp6 and pftctp [360].  Subsequent analysis of the 
resistant lines found significantly fewer merozoites in the resistant W2 and TM91C235 
compared to the parental lines, while the resistant D6 contained significantly more merozoites 
[242].  It was also determined that W2 and TM91C235 saw increases in pfmdr1 expression 
proportional to the increased drug levels tolerated by those lines [242]. 
Artemisinin-induced dormancy was observed in ring stages from several P. falciparum lines 
exposed to different doses of DHA in the form of a temporary arrest of growth [361].  Also, 
through long-term artemisinin pressure in vitro on the F32-Tanzania strain, an arteminsinin-
tolerant strain was produced that could survive extremely high doses of artemisinin, and drug 
pressure induced a sub-population of rings into a quiescent state [362]. 
Mok et al. profiled three field isolates from Pailin, Cambodia collected from patients that had 





normal parasite clearance.  These authors observed a reduced expression in the ring and 
trophozoite stages of many basic metabolic pathways, suggesting slower growth and maturation 
in the slowly clearing isolates [138]. 
An investigation of the in vitro artemisinin response in the progeny of the HB3 and Dd2 genetic 
cross [284] revealed that reduced artemisinin susceptibility is a multifactorial trait, including 
pfmdr1 and two additional loci on chromosomes 12 and 13 for [363].  This genetic predisposition 
favors the acquisition of stable artemisinin resistance when put under selection pressure. 
Isolating DHA-tolerant lines 
In contrast to past isolation of tolerant lines that used a high, discontinuous drug selection 
pressure, Richard Eastman, a member of the Fidock lab, maintained a nearly constant, low drug-
selection pressure to select for DHA-tolerant parasites over a period of 200 days.  The resulting 
parasite lines demonstrated changes in their recrudescence rate and frequency following short-
term exposure to these drugs, indicating a reduction in drug susceptibility.   
This difference in drug susceptibility was not apparent by standard incorporation assays using 
triturated hypoxanthine or ethanolamine, however the dihydroartemisinin (DHA)-tolerant lines 
demonstrated an increased rate and frequency of recrudescence after exposure to various 
concentrations of DHA.  Moreover, full genomic sequencing of the DHA-sensitive parental line 
and all three DHA-tolerant lines did not reveal any mutations or copy number alterations in 
putative genes that mediate artemisinin susceptibility: pfatp6, pfubp1, or pfmdr1.  However, we 
were able to identify several biological pathways that associated with the drug tolerance 
phenotype using transcriptional studies, including redox regulation and transcription rate.  Our 





essentially measuring the capping of mRNA transcripts.  We found an extremely reproducible set 
of differentially capped genes looking at two parasite lines that warrants further investigation.  
These transcriptional studies are the focus of the remainder of this chapter. 
The results of our study suggest that multiple mechanisms may combine to create an artemisinin 
tolerance phenotype, including increasing the parasite’s ability to respond to redox perturbation, 







I collaborated with Dr. Richard Eastman, a post-doctoral member of the Fidock lab, who 
performed the biological experiments.  His work is described below to provide proper context in 
which to understand my computational analysis. 
Selection of DHA-tolerant parasites 
To examine in vitro the DHA tolerance phenotype and identify the genetic determinants of 
reduced susceptibility as well as the accompanying transcriptional changes, Rich Eastman 
applied increased drug-selection pressure on a clone of the Dd2 P. falciparum strain named Dd2 
1pa.  We followed the method developed by Oduola et al. in 1988 which has since been 
successfully replicated many times, where a clonal population is exposed to gradually increasing 
concentrations of a drug [219].  Figure 4.1 depicts the step-wise selection over 200 days of a 
DHA-tolerant parasite line from the DHA-sensitive parent line Dd2 1pa.  As a reference, the Dd2 
1pa IC50 for DHA was measured to be 16.6 nM.  The initial drug selection was 2.8 nM, with 
gradual step-wise increases to 28 nM for the final 40 days, a drug-pressure level that was ten 






Figure 4.1.  Selection of dihydroartemisinin (DHA)-tolerant parasites. 
A clonal line of Dd2 1pa parasites was challenged with step-wise increased drug-pressure 
(DHA) over the course of 200 days.  The percent parasitemia is plotted on the left y-axis, 
and DHA concentration is plotted on the right y-axis.  The x-axis plots the 200 days of 
the experiment.  The resulting parasites are tolerant to 30 nM DHA. 
Upon thawing of the DHA-tolerant line, the same level of resistance was not retained, therefore 
re-selection of the tolerance phenotype was performed in triplicate.  This suggested a labile 
phenotype, and that the mode of DHA-tolerance was not based on DNA mutation.  The three 
resulting lines (3b1, 3g1, 3b2) were produced in less time than the original selection.  
Interestingly, the three tolerant lines did not have significantly different IC50 values for DHA, 
artesunate, or mefloquine when compared to the sensitive parental line (data not shown). 
Genetic analysis 
Genomic sequencing was carried out on the DHA-sensitive parental line Dd2 1pa, and all three 
DHA-tolerant lines: 3b1, 3g1, and 3b2.  Inspection of putative resistance determinants pfatp6 and 





based quantitative polymerase chain reaction (qPCR) confirmed there was no copy number 
change in pfmdr1, in contrast to a previous study finding an increase in copy number of pfmdr1 
accompanying an artemisinin tolerance phenotype [360].  In our case, copy number variation 
may not make a change as Dd2 already carries three copies of pfmdr1 (data not shown). 
Drug accumulation 
Resistance to some antimalarials, notably chloroquine, has been shown to associate with a 
reduced accumulation or efflux of drug through a P. falciparum chloroquine resistance 
transporter (PfCRT)-dependent mechanism [273, 364, 365].  Biochemical analysis of the DHA-
tolerant lines was performed to evaluate whether drug efflux could be a potential mediator of the 
reduced susceptibility to DHA.  The DHA-tolerant lines did not exhibit any significantly altered 
drug accumulation compared to the DHA-sensitive Dd2 1pa parental line Dd2 (Figure 4.2).  This 
evidence provides support for the hypothesis that the DHA tolerance phenotype we are 
investigating is mediated by a mechanism that ameliorates drug induced toxicity, in contrast to a 






Figure 4.2. Time course of [3H]dihydroartemisinin accumulation in P. falciparum.  
Cell suspensions of either Dd2 (black circles, DHA sensitive) or the DHA-tolerant lines 
(3b1, orange squares; 3g1, green triangles; or 3b2, blue inverted triangles) were incubated 
in 50 nM [3H]dihydroartemisinin and the amounts of internalized dihydroartemisinin 
were determined at the time points indicated, as described in the Methods.  Results 
represent the mean ±SEM of three independent experiments.  Data are from Rich 
Eastman and will be included in a paper on which I will be co-author. 
Recrudescence assays 
An IC50 analysis based on [3H]hypoxanthine or [3H]ethanolamine incorporation did not correlate 
with the ability of the DHA-tolerant and DHA-sensitive parasites to propagate in the presence of 
sustained DHA drug pressure (Figure 4.3 a, d).  Therefore, recrudescence assays were used to 
characterize the DHA-tolerance phenotype.  Analyses were performed using DHA and AS.  The 
first analysis involved a four-day exposure to drug, followed by a 30-day recrudescence assay 
determined by lactate dehydrogenase assay and confirmed by Giemsa stained thin smear.  The 
DHA-tolerant lines demonstrated an increased rate and frequency of recrudescence after 
exposure to 14, 28, 56 and 112 nM DHA, whereas Dd2 1pa did not recover after treatment with 





demonstrated a similar effect but at a decreased rate and frequency compared to DHA with 
significantly altered rates and increased frequency after exposure to 14 and 28 nM artesunate, 
and after 56 nM artesunate for only DHA-tolerant 3b2 (Figure 4.3 E-F). 
 
Figure 4.3.  Drug phenotypic analysis of dihydroartemisinin-tolerant parasites. 
In vitro response to dihydroartemisinin (DHA) were measured by 72-hour 
[3H]hypoxanthine or [3H]ethanolamine incorporation assays.  a.  IC50 values (shown as 
mean ± SEM) were derived by non-linear regression analysis.  The ability of DHA-
tolerant parasites to recrudesce following a four-day exposure to DHA at the indicated 
concentrations was measured over a 30-day recrudescence assay.  b.  The recrudescence 
ratio following exposure to DHA is calculated from the time until a drug-treated was 
positive for growth normalized to the untreated control.  c.  Frequency of recrudescent 
wells, or percentage of positive wells for each condition, following exposure to DHA is 
shown in panel.  d.  Drug response to artesunate (AS), measured by 72-hour 
[3H]hypoxanthine or [3H]ethanolamine is shown.  e.  Drug response to artesunate (AS), 
measured by recrudescence assay (recrudescence ratio) is shown.  f. Drug response to 
artesunate (AS), measured by frequency, was also determined. For statistical 
comparisons, Mann Whitney U tests were performed *P<0.05, **P<0.01, and 
***P<0.001, by pairwise comparison with the Dd2 parental line at the respective 





Analysis of the untreated controls from the recrudescence assays showed that the DHA-tolerant 
lines had a slightly decreased growth rate compared to the parental line, with a fold decrease 
normalized to Dd2 1pa of 1.12 for 3b1, 1.13 for 3g1 and 1.1.3 for 3b2 per 48-hour lifecycle. 
In addition to the recrudescence assays, a modified SYBRGreen/Mitotracker Deep Red assay 
[366] was used to assess the growth phenotype in a five-day flow cytometry-based recrudescence 
assay (Figure 4.4).  Each DHA-tolerant line had higher parasitemia compared to Dd2 1pa, 
measured by the DNA stain SYBRGreen and mitochondria viability stain Mitotracker Deep Red, 
at 2.75, 5.5 and 11 nM at the 72-hour time point, along with the 5.5 and 11 nM time point at 120 
hours. 
 
Figure 4.4.  Exploratory flow cytometry-based recrudescence assay. 
Comparative 72 and 120 hours assay, initial inoculum of 0.5% parasitemia and 2% 
hematocrit with media and drug changed daily.  At 72 and again at 120 hour parasitemia 
was determined by flow-cytometry by co-staining with SYBRGreen (DNA stain) and 





incorporated both SYBRGreen and Mitotracker Deep Red was assessed for both the 72 
hour and 120 hour time points, normalized to the 72 hour no drug control parasitemia.  
Each assay was conducted in duplicate, in at least four independent experiments.  
Statistical analysis was performed by Mann Whitney U test by pairwise comparison to 
the Dd2 1pa values at the respective time points. 
Metabolomic analysis 
Metabolomics, the global analysis of metabolite levels, is an important tool to decipher host-
parasite interactions and discover differences in metabolic pathways between parasite lines 
[367].  The levels of a set of 70 known metabolites were measured at six time points of the 
Intraerythrocytic developmental cycle (IDC) in synchronized Dd2 1pa, and in synchronized 
DHA-tolerant lines either exposed to continuous 28 nM DHA treatment or with drug treatment 
removed. 
Student’s t-test 
The levels of each metabolite at each time point were compared between Dd2 1pa and the three 
DHA-tolerant lines.  The resulting three ratios were evaluated for significance using the 
Student’s t-test.  12 metabolites had significant Student’s t-test scores (P value < 0.001) in at 
least four time points: ADP-D-glucose, CDP-ethanolamine, citraconic acid, D-glucarate, 
glutathione, inosine diphosphate, inosine monophosphate, N-carbamoyl-L-aspartate, S-adenosyl-
L-homocysteine, sn-glycerol-3-phosphate, and thymidine. 
Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) 
Using data generated by Rich Eastman, I collaborated with Michael Muhle to explore which 
metabolites were significantly up or down-regulated between the sensitive and the tolerant lines.  
We utilized OPLS-DA, a method that separates predictive variation from random, non-predictive 





models for the metabolite levels of each parasite line, removed the variation orthogonal to the 
classes, and computed the effect of each metabolite on each model.  Results are summarized in -
Table 4.1. 
3b1 Up-regulated 3b1 Down-regulated 
Glutathione D-glucarate 
glutathione disulfide inosine diphosphate 
citraconic acid ADP-D-glucose 
Malate inosine monophosphate 
N-acetyl-glutamate  
3b2 Up-regulated 3b2 Down-regulated 
Glutathione D-glucarate 
D-sedoheptulose-1/7-phosphate N-acetyl-L-alanine 
 inosine diphosphate 
 ADP-D-glucose 
 inosine monophosphate 
 N-carbamoyl-L-aspartate 
 succinate 
3g1 Up-regulated 3g1 Down-regulated 
Glutathione N-acetyl-L-alanine 
citraconic acid D-glucarate 
 Inosine monophosphate 
 ADP-D-glucose 
Table 4.1.  Common metabolites identified by orthogonal partal least squares discriminant 
analysis (OPLS-DA) with drug treatment removed or under 28 nM DHA pressure. 
Metabolite differences between the DHA-sensitive Dd2 1pa and the DHA-tolerant 3b1, 
3g2, 3b2 with drug treatment removed or under 28 nM DHA pressure.  The table 
summarizes the metabolites that were significantly up or down-regulated. 
The multivariate analysis revealed a consistent up-regulation of glutathione in DHA-tolerant 
lines, and a consistent down-regulation of inosine mono- and di-phosphate as well as di-glucarate 






The 5’ m7G cap is nearly ubiquitously present on eukaryotic mRNAs and helps to stabilize the 
mRNA and aids in binding to the ribosome during translation [368, 369].  There are several 
mechanisms for translation initiation during eukaryotic protein synthesis, including cap-
dependent initiation, re-initiation, and internal initiation, however re-initiation and internal 
initiation are at best only 25% as efficient as cap-dependent initiation, and usually 1-10% as 
efficient [370].  Therefore, an uncapped mRNA is much less efficiently translated and 
consequently produces less protein than a similar mRNA that is capped. 
Nuclear run-on assay 
To investigate whether there was an altered transcriptional rate in the DHA-pressured lines, we 
performed nuclear run-on experiments.  These assays provided direct measure of the density 
elongated RNAs [371].  Nuclear run-on assays were performed on the sensitive line and each of 
the tolerant lines after they were synchronized at the trophozoite stage, and normalized to the 
sensitive line for comparison, summarized in Figure 4.5.  The DHA-sensitive Dd2 1pa had a 
mean ± SEM of 1.0 ± 0.19, while the DHA-tolerant 3b1 measured 0.21 ± 0.1, 3g1 was 0.31 ± 0.1, 






Figure 4.5.  Transcription rate analysis by nuclear run-on assay. 
The relative transcription rates of the Dd2 1pa parental line and each of the DHA-tolerant 
lines were measured by nuclear run-on assay from synchronized, purified trophozoites.  
For statistical comparisons, Mann Whitney U tests were performed. *P<0.05, **P<0.01, 
and ***P<0.001 in comparison with the Dd2 parental line. 
We conducted a microarray analysis of the DHA-sensitive Dd2 and the DHA-tolerant 3b1 to 
search for transcriptional differences that might hint at the DHA-tolerance phenotype.  The 
microarray hybridizations and raw data were generated in the laboratory of Dr. Manuel Llinas 







Figure 4.6. HATS computational pipeline.  
The HATS computational pipeline involves six steps that carry the data from creation to 
final analysis and is the foundation for a large portion of our analyses. 
Below we review the sections of the HATS pipeline most pertinent to our current discussion.  A 
fuller treatment appears in chapter 2.  This computational analysis was my contribution to the 
project. 
Normalization and filtering 
We analyzed a reference pool of 11 lines to create a baseline for gene and gene set enrichment, 
helping us remove spurious hits from our results and identify highly variable gene sets.  This set 
included eight lines analyzed in the Fidock lab and three full time courses analyzed in the DeRisi 
lab with the 3D7, Dd2, and HB3 strains [73, 129].  Each line was aligned and imputed using our 
methods and then pairwise comparisons were made between each possible combination of lines.  













The distribution of fold changes for each gene was determined and then gene rankings were 
normalized to this distribution, reflected in a normalized fold change that represented the number 
of standard deviations a given gene’s rank was above or below the mean.  We also calculated 
similar distributions on each gene set’s ranking and normalized accordingly. 
Interpolation and alignment 
Previous transcriptome analyses of P. falciparum have demonstrated a strikingly nonstochastic 
periodicity characterized by a single maximum and minimum in a 48-hour time period [73, 129].  
We used a fast Fourier transform (FFT) to determine the magnitude and phase at the 48-hour 
frequency of each gene in each parasite line based on six time points collected roughly eight 
hours apart.  This process resulted in a smooth sinusoidal curve allowing the extrapolation of the 
expression level and rank of each gene at any time point in the lifecycle.  Next, each of the 
imputed time points were aligned to 3D7 to ascertain the optimal starting point for each line.  
These transformations were used to alleviate noise inherent in the data caused by differences in 
sampling time, as well as differences in speed through any of the stages for a given line.  For 
each pairwise comparison, the fold-change across all time points was calculated using a hyper-
geometric gene set enrichment analysis method [146].  In addition, the time series was divided 
into subsets focusing on the ring (time points 10-14), trophozoite (time points 22-26), and 
schizont (time points 30-34) stages, based on their window of peak expression as used in Mok et 
al. [138], and fold enrichment was calculated.  
Dimensionality reduction  
Principal Component Analysis (PCA) was used to validate the transcriptional alignment of the 
strains and search for experimental outliers.  The first two principal components accurately 





around the plot with time points from each strain in close proximity, except near the final hours 
of the lifecycle as mentioned above (Figure 4.3a).  The third principal component highlights line-
to-line differences as Dd2-REG and Dd2-EXO are clearly separated from 3B1-REG and 3B1-
EXO. 
 
Figure 4.7.  PCA of 3b1-REG, 3b1-EXO, Dd2-REG, and Dd2-EXO. 
FFT was used to transform the six time point measurements spaced roughly eight hours 
apart, permitting extrapolation of the expression level and rank of each gene along the 
asexual lifecycle of the parasite.  For more information on these techniques see Figure 
3.4.  Compared are the DHA-tolerant 3b1 line (red), the 3b1 line with exonuclease 
treatment (brown), the parental Dd2 1pa line (green), and the Dd2 1pa with exonuclease 
treatment (purple).  a.  The first and second component analysis illustrates the 
progression of the lines along the approximate 48-hour asexual blood stage cycle, with 
the larger circle of the 3b1 line (red) indicates a slightly longer asexual blood stage cycle 
compared to the Dd2 1pa line (green).  b.  The second and third component analysis 
demonstrates a clear delineation between the Dd2 1pa and 3b1 lines, and a slight 






We investigated whether 5’ m7G capping was differentially affected between the tolerant and 
sensitive lines.  Replicates were created for each microarray sample, with one replicate (3b1-
REG, Dd2-REG) profiled normally, and the other replicate (3b1-EXO, Dd2-EXO) treated with 
terminator exonuclease that will degrade any RNA that does not have a 5´-triphosphate, 5´-cap 
or 5´-hydroxyl group.  This allowed for concurrent investigations into altered transcript 
abundance and mRNA processing, via the 3b1-REG vs. Dd2-REG and 3b1-EXO vs. Dd2-EXO 
comparisons respectively. 
To visualize the expression changes, colorimetric heat maps were generated, representing the log 
fold change at each of the imputed time points with log fold changes above 1 in red, log fold 
changes below -1 in blue, log fold changes of 0 in white, and other values represented as shades 
of red or blue (Figure 4.8).  The fold change heat map helps in the determination of which genes 
have consistently higher fold changes across the time series, and at what divisions of the time 






Figure 4.8. Comparative analysis of the transcriptional profile of DHA-tolerant 3b1 and 
Dd2 1pa lines.   
The heat maps represent the log fold change at each of the imputed time points with log 
fold changes above 1 in red, below -1 in blue, no change in white, and intermediate 
values represented as shades of red or blue.  Although the DHA-tolerant line 3b1 
possesses a significant decrease in the overall transcription rate (Figure 4.5), 
transcriptional patterns in both parasites were very similar.  a. untreated, b. exonuclease 
treated. 
Alignment 
To ensure the proper alignment of our samples and to confirm the exonuclease treatment did not 
alter the time-dependent component of the expression signal, each time point from 3b1-REG was 
compared to 3b1-EXO and the Pearson correlation was visualized in Figure 4.9a.  The resulting 
alignment looks much like the alignment between 3b1-REG and Dd2-REG, the non-exonuclease 
treated lines.  There is a strong correlation between matching time points, and anti-correlation 
between time points 24 hours apart.  The analysis was replicated in Figure 4.9b for Dd2-REG vs. 





reproducible, as the gene list ranked by fold change in 3b1-REG vs. 3b1-EXO compared to the 
ranked gene list from the Dd2-REG vs. Dd2-EXO comparison yielded a Spearman correlation of 
0.9.  The striking reproducibility of these results indicates a strong and consistent capping signal. 
 
Figure 4.9.  Alignment of each line to its exonuclease-treated partner. 
a.  Pearson Correlation of 3b1-REG to 3b1-EXO.  The heat map displays the point-to-
point correlation between 3b1-REG and 3b1-EXO, with each cell representing the 
Pearson correlation between two time points.  Regions of correlation are in red and anti-
correlation in blue.  The path of maximal correlation is black.  b.  Pearson Correlation of 
Dd2-REG to Dd2-EXO.  Both these plots demonstrate how well each line correlates to its 
exo-nuclease treated pair.  The exo-nuclease treatment has not removed the very strong 
time dependent signals. 
We also analyzed the time point to time point correlation between 3b1-REG vs. Dd2-REG to the 
time-point-to-time-point correlation between 3b1-EXO vs. Dd2-EXO in Figure 4.10.  There is a 
similar strong correlation down the central diagonal of the plot, while the main difference lies in 
the region of anti-correlation.  In the regular comparison, the anti-correlation signal is strong in 





significantly.  This indicates that all time points are more correlated in the exonuclease-treated 
samples.  Upon inspection of the resulting gene lists, it is clear that the correlation stems from a 
set of genes that do not change between any time points.  The set of unchanging genes most 
likely are uncapped and therefore are always cleaved by the exonuclease treatment, thereby 
producing minimal levels of detectable expression.  This serves as a proof of principle that the 
exonuclease treatment has a reproducible effect on all time points. 
 
Figure 4.10.  Comparison of regular sample alignment vs. exonuclease-treated sample 
alignment.  
a.  Pearson Correlation of 3b1-REG toDd2-REG.  The heat map displays the point-to-
point correlation between 3b1-REG toDd2-REG, with each cell representing the Pearson 
correlation between two time points.  Regions of correlation are in red and anti-
correlation in blue.  The path of maximal correlation is black.  b.  Pearson Correlation of 
3b1-EXO and Dd2-EXO.  The regions of the least correlation is in green, while in the 
regular comparisons it is in blue, demonstrating that the time point to time point 
differences are diminished in the exonuclease treated samples.  This is because the 





Gene set analysis 
Initial analysis focused at the gene set level, which functions to limit the inherent noise of the 
experimental system.  Random fluctuations in gene expression and probes that produce faulty 
measurements are discounted, because the algorithm focuses on the leading edge of a gene set, 
the genes that contribute most to the enrichment score.  Transcriptional differences were 
explored at the gene set level using an algorithm we developed based on the hyper-geometric 
distribution that draws from the popular GSEA method.  GSEA is a computational method that 
identifies sets of genes that display statistically significant, concordant differences between two 
biological states [146].  Our method is Hypergeometric Enrichment Analysis (HEA).  Given a 
gene set and a ranked list of genes, we calculate the probability for each gene in a gene set that 
the subset of the gene set would appear so high or low on the ranked list of genes.  This 
probability is known as the enrichment score, and is normalized over 1000 random permutations 
so that scores can be compared among differing gene set sizes.  In addition, the false discovery 
rate (FDR) is calculated by comparing the distributions of the actual comparison to the random 
permutations.  The FDR helps to quantify the probability that a given finding is actually 
significant.  For analysis of stage variance of transcription hours 10-14 was classified as ring, 







Full transcriptional profiling results for each stage in the lifecycle 
We examined two parasite lines with and without exo-nuclease treatment: 3b1-REG, 3b1-EXO, 
Dd2-REG, and Dd2-EXO.  Here we focus on the 3b1-REG compared to Dd2-REG, which 
compares the DHA-tolerant line to the DHA-sensitive line.  We examine the transcriptional 
changes that occur in the ring stage, the trophozoite stage, the schizont stage, and from the IDC 
as a whole.  The significant changes we find provide hypotheses as to the mechanisms 
modulating DHA tolerance. 
An important feature of our significant results is that they have been compared to a background 
set of parasite lines (listed in chapter 3).  For each of the 55 possible pairwise comparisons of 
parasite lines, each gene and gene set is ranked by up-regulation.  This creates a background 
distribution, which is used to normalize any gene or gene set ranking.  
Significant sets are reported in tables using the following five columns: set, description, size, 
norm, and P-val.  Set is the identifier used for the set.  Description is a text description of the 
genes in the set.  Size is the number of genes in the set that had valid gene expression 
measurements in the two lines being compared.  For each set, we calculate its rank in every 
background pair of lines and use this distribution to produce a norm score that calculates the 
standard deviations above or below the mean for the gene set.  P-val is the original enrichment 
score for the set using the hyper-geometric distribution. 
In each case, the gene sets listed had a false discovery rate (FDR) less than or equal to 0.25, at 





1.0, which indicates the enrichment score for that gene set was at least one standard deviation 
above the average enrichment score for that gene set.  When calculating the standard deviation, 
only line-to-line comparisons not involving the two lines in question were used to form the 
distribution.  For example, if my background pool was lines A, B, C, D, and E, in a comparison 
of A vs. B, I would use C vs. D, C vs. E, and D vs. E as my background distribution.  In our 
experiments there were 11 lines, therefore there were always 9 being compared in the 
background distribution. 
We also examined genes that were enriched in each comparison.  We did not include any genes 
of unknown function in our result tables.  We also included genes that have a normalized fold 
change greater than 3.0, indicating that the fold change for the gene in the comparison was three 
standard deviations above average for that gene. 
Significant genes are reported in tables using the following four columns: gene, description, 
norm, and fold.  “Gene” is the identifier used for the gene.  “Description” is a text description of 
the genes in the set.  For each gene, we calculated its rank in every background pair of lines and 
used this distribution to produce a norm score that calculates how many standard deviations 
above or below the mean the current gene ranking is.  “Fold” is the fold change between the two 






3b1-REG vs Dd2-REG 
The following gene and gene set tables are based on the 3b1-REG vs. Dd2-REG comparison, 
examining a DHA-tolerant line vs. a DHA-sensitive line. 
Set Description Size Norm P-val 
GO:0016740 transferase activity 58 2.15 6.27 
AP2_PFF0670w_D2_8 Matching set 8 for AP2 - PFF0670w_D2 966 2.02 5.97 
AP2_PFF0670w_D2_7 Matching set 7 for AP2 - PFF0670w_D2 641 1.83 6.07 
AP2_PF11_0442_3 Matching set 3 for AP2 - PF11_0442 160 1.77 6.09 
AP2_PF11_0442_2 Matching set 2 for AP2 - PF11_0442 150 1.76 5.57 
GO:0020011 Apicoplast 507 1.7 6.48 
AP2_PF13_0267_3 Matching set 3 for AP2 - PF13_0267 751 1.56 11.97 
EQ:C5M2895 C5M28 95 165 1.53 9.38 
AP2_PF11_0442_1 Matching set 1 for AP2 - PF11_0442 129 1.52 5.7 
EQ:C5M2899 C5M28 99 118 1.48 6.96 
AP2_PF13_0267_2 Matching set 2 for AP2 - PF13_0267 676 1.47 9.98 
molecularMotor Molecular motor prototypes 34 1.46 4.75 
SM00181 Epidermal growth factor-like 7 1.35 5.31 
Protein_kinases Protein kinase coding genes 96 1.29 6.46 
AP2_PFE0840c_D2_7 Matching set 7 for AP2 - PFE0840c_D2 935 1.29 6 
SM00220 Serine/threonine-protein kinase domain 90 1.23 6.81 
Hagai Ginsburg ... Protein kinase coding genes 94 1.22 6.42 
GO:0004674 protein serine/threonine kinase activity 99 1.22 6.76 
PS50011 Protein kinase domain profile 98 1.19 6.98 
GO:0006468 protein amino acid phosphorylation 109 1.18 7.45 
GO:0004672 protein kinase activity 102 1.16 7.55 
PF00063 Myosin head (motor domain) 6 1.16 4.9 
PR00193 Myosin heavy chain signature 6 1.16 4.9 
SM00242 Myosin head, motor domain 6 1.16 4.9 
SSF56112 Protein kinase-like (PK-like) 110 1.09 7.24 
Table 4.2.  25 enriched sets up in 3b1-REG vs. Dd2-REG. 
25 gene sets were significantly up in 3b1-REG compared to Dd2-REG. 
Gene Description Fold Norm 
PF08_0070 RAP protein, putative 1.28 6.08 





PF10_0058 DnaJ protein, putative 1.4 3.72 
Table 4.3.  3 enriched genes up in 3b1-REG vs. Dd2-REG. 
Three genes were significantly up in 3b1-REG compared to Dd2-REG. 
Set Description Size Norm P-val 
EQ:C3M8595 C3M85 95 5 2.72 3.67 
mRNAdeg mRNA degradation 18 1.96 4.29 
GO:0005681 spliceosomal complex 25 1.79 5.13 
SSF47473 EF-hand 165 1.58 8.26 
SSF82704 AlbA-like 6 1.54 3.9 
GO:0000375 RNA splicing, via transesterification reactions 21 1.49 4.54 
AP2_PFF0670w_D1_4 Matching set 4 for AP2 - PFF0670w_D1 954 1.47 9.54 
Hagai Ginsburg ... Pentose Phosphate Cycle 7 1.44 4.78 
PF01423 LSM domain 15 1.35 5.81 
SM00651 
Like-Sm ribonucleoprotein (LSM) domain, 
eukaryotic/archaea-type 15 1.35 5.81 
GO:0006414 translational elongation 23 1.34 4.53 
GO:0006418 tRNA aminoacylation for protein translation 35 1.33 4.53 
KE:PFA00970 Aminoacyl-trna biosynthesis  35 1.22 5.18 
Ppcpath Pentose Phosphate Cycle 9 1.22 6.15 
AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 820 1.22 10.67 
tRNA_mod tRNA modifications 45 1.21 4.76 
SSF50182 Sm-like ribonucleoproteins 18 1.2 4.44 
PS51192 
Superfamilies 1 and 2 helicase ATP-binding type-1 
domain profile 61 1.16 5.26 
GO:0003723 RNA binding 178 1.13 5.91 
GO:0003899 DNA-directed RNA polymerase activity 37 1.12 4.99 
PF09715 
Plasmodium protein of unknown function 
(Plasmod_dom_1) 15 1.1 17.67 
TIGR01519 
plasmod_dom_1: Plasmodium falciparum 
uncharacterized domain 15 1.1 17.67 
Hagai Ginsburg ... 
Genes coding for components involved in ribosome 
assembly 93 1.07 10.15 
6.2.1.3 Long-chain-fatty-acid--CoA ligase 16 1.06 4.27 
Ribosomegenes 
Genes coding for components involved in ribosome 
assembly 118 1.04 13.73 
PF02009 Rifin/stevor family 220 1.03 25.2 
AV:stevor stevor gene family 36 1.01 6.6 
KE:PFA00030 Pentose phosphate pathway 13 1.01 4.65 
Table 4.4.  28 enriched sets down in 3b1-REG vs. Dd2-REG. 





Gene Description Fold Norm 
PF10_0149 cysteinyl-tRNA synthetase, putative 1.14 4.33 
PFB0875c chromatin-binding protein, putative 1.07 4.03 
PF10_0299 glycoprotease, putative 1.16 3.73 
PF13_0158 nonsense-mediated mRNA decay protein Upf3, putative 1.13 3.69 
PFI1085w ubiquitin-like protein, putative 1.14 3.53 
PFC0780w CPSF (cleavage and polyadenylation specific factor), subunit A, putative 1.14 3.43 
PFL0460w lsm7 homologue, putative 1.15 3.17 
PF07_0051 erythrocyte membrane protein 1, PfEMP1 1.2 3.14 
PFI0740c ubiquitin conjugating enzyme, putative 1.18 3.09 
PFI0490c Ran-binding protein, putative 1.12 3.07 
PFB0200c aspartate aminotransferase 1.24 3.05 
PF08_0123 U2 snRNA/tRNA pseudouridine synthase, putative 1.13 3.02 
PF07_0049 erythrocyte membrane protein 1, PfEMP1 1.1 3.02 
Table 4.5.  13 enriched genes down in 3b1-REG vs. Dd2-REG. 
Thirteen genes were significantly down in 3b1-REG compared to Dd2-REG. 
Set Description Size Norm P-val 
SSF47473 EF-hand 165 1.51 11.36 
GO:0016020 Membrane 1020 1.13 9.24 
GO:0003676 nucleic acid binding 221 1 7.27 
Table 4.6.  3 enriched sets up in 3b1-REG vs. Dd2-REG in the ring stage. 
Three gene sets were significantly up in 3b1-REG compared to Dd2-REG in the ring stage. 
Gene Description Fold Norm 
PF11_0049 NOT family protein, putative 1.52 5.05 
MAL13P1.269 tryptophan-rich antigen 1.67 4.08 
PF14_0723 LCCL domain-containing protein 1.74 3.82 
PF11_0481 tubulin-tyrosine ligase, putative 2.66 3.04 
PFE0795c protein phosphatase, putative 1.33 3.04 
Table 4.7.  5 enriched genes up in 3b1-REG vs. Dd2-REG in the ring stage. 
Five genes were significantly up in 3b1-REG compared to Dd2-REG in the ring stage.  





(PArt) has been shown to be an artesunate-tolerance determinant in transgenic parasites 
overexpressing PArt [372].  PF14_0723 (PfCCp1) is expressed inside the gametocyte 
parasitophorous vacuole and released during gamete emergence, where it relocates 
extracellularly surrounding exflagellation complexes [373].   
Set Description Size Norm P-val 
AP2_PFF0670w_D1_4 Matching set 4 for AP2 - PFF0670w_D1 954 1.83 12.91 
AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 820 1.62 14.04 
AV:hyp hyp gene family 51 1.05 29.28 
Table 4.8.  3 enriched sets down in 3b1-REG vs. Dd2-REG in the ring stage. 
Three gene sets were significantly down in 3b1-REG compared to Dd2-REG in the ring stage. 
Gene Description Fold Norm 
PFA0725w surface-associated interspersed protein 1.3 (SURFIN 1.3) 1.93 3.44 
PF14_0451 mitochondrial ribosomal protein S14 precursor, putative 1.28 3.34 
Table 4.9.  2 enriched genes down in 3b1-REG vs. Dd2-REG in the ring stage. 
Two genes were significantly up in 3b1-REG compared to Dd2-REG in the ring stage. 
Set Description Size Norm P-val 
Chromatin Structure and organization of centromeric chromatin 11 1.92 4.41 
SSF54928 RNA-binding domain, RBD 81 1.56 6.29 
SSF46785 Winged helix DNA-binding domain 34 1.54 5.75 
Histone Histone acetylation 24 1.51 7.89 
NucleoAssembly Nucleosome assembly and regulation 35 1.43 5.34 
Arginine Protein arginine methylation 14 1.42 5.63 
PF00012 Hsp70 protein 6 1.38 3.96 
PR00301 70kDa heat shock protein signature 6 1.38 3.96 
SSF100934 Heat shock protein 70kD (HSP70), C-terminal subdomain 6 1.38 3.96 
GO:0051276 chromosome organization 10 1.31 8.39 
SSF47113 Histone-fold 17 1.23 7.02 
GO:0005737 Cytoplasm 908 1.14 10.71 
GO:0003723 RNA binding 178 1.13 7.42 





Thirteen gene sets were significantly up in 3b1-REG compared to Dd2-REG in the trophozoite 
stage. 
Gene Description Fold Norm 
PF14_0286 glutamate dehydrogenase, putative 1.28 3.81 
PF13_0052 ribosomal RNA methyltransferase, putative 1.19 3.22 
PF14_0088 aldo-keto reductase, putative 1.46 3.2 
PFL0805w perforin like protein 2 1.46 3.07 
Table 4.11.  4 enriched genes up in 3b1-REG vs. Dd2-REG in the trophozoite stage. 
Four genes were significantly up in 3b1-REG compared to Dd2-REG in the trophozoite stage. 
Set Description Size Norm P-val 
gen_phosph Generation of polyphosphates 18 2.27 5.66 
GO:0006631 fatty acid metabolic process 13 1.98 4.97 
SK1:FATTY.ACID Santha Kumar's fatty acid related genes 52 1.84 5.8 
Hagai Ginsburg ... 
Transporters of the mitochondrial and apicoplast 
membranes 8 1.84 4.12 
Facidsynthesispath Fatty acid synthesis in the apicoplast 38 1.77 5.03 
AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 820 1.76 6.81 
Hagai Ginsburg ... 
Phosphatidylethanolamine and phosphatidylserine 
metabolism 14 1.75 4.74 
SK2:FATTY.ACID - 124 1.67 7.3 
Gen_apic_genome Genes of the apicoplast genome 40 1.55 8.47 
SSF56801 Acetyl-CoA synthetase-like 15 1.52 4.39 
SK1: 
Santha Kumar's fatty acid related genes - transport 
and storage 16 1.52 5.77 
SK1: Santha Kumar's fatty acid related genes - elongation 5 1.43 4.02 
SK2: VLC fatty acid elongation ER 5 1.43 4.02 
SK3: VLC fatty acid elongation 5 1.43 4.02 
6.2.1.3 Long-chain-fatty-acid--CoA ligase 16 1.41 5.99 
PF00501 AMP-binding enzyme 14 1.38 5.1 
KE:PFA00240 Pyrimidine metabolism  53 1.38 5 
PR00154 AMP-binding signature 12 1.31 4.23 
SSF47473 EF-hand 165 1.28 23.42 
AP2_PF14_0079_5 Matching set 5 for AP2 - PF14_0079 538 1.21 7.41 
AP2_PF14_0079_4 Matching set 4 for AP2 - PF14_0079 514 1.2 8.16 
AV:stevor stevor gene family 36 1.18 7.73 
AP2_PF14_0079_6 Matching set 6 for AP2 - PF14_0079 563 1.14 6.66 
Phserine 
Phosphatidylethanolamine and phosphatidylserine 





KE:PFA00071 Fatty acid metabolism 13 1.13 4.67 
TIGR01478 STEVOR: variant surface antigen, stevor family 36 1.1 7.73 
GO:0020036 Maurer's cleft 49 1.08 6.03 
AP2_PF14_0079_3 Matching set 3 for AP2 - PF14_0079 451 1.03 6.81 
AV:rifin rifin gene family 162 1.02 35.35 
Table 4.12.  29 enriched sets down in 3b1-REG vs. Dd2-REG in the trophozoite stage. 
Twenty-nine gene sets were significantly down in 3b1-REG compared to Dd2-REG in the 
trophozoite stage.  Several fatty acid related gene sets were enriched down in 3b1-REG, which 
suggests that 3b1 trophozoites synthesize less endogenous fatty acids or require less fatty acids. 
Gene Description Fold Norm 
PFC0581w co-chaperone p23 1.35 3.43 
PFL0120c cyclophilin, putative 1.32 3.16 
Table 4.13.  2 enriched genes down in 3b1-REG vs. Dd2-REG in the trophozoite stage. 
Two genes were significantly down in 3b1-REG compared to Dd2-REG in the trophozoite stage.   
Set Description Size Norm P-val 
GO:0006334 nucleosome assembly 12 1.72 5.39 
GO:0000786 Nucleosome 8 1.33 6.51 
PF00125 Core histone H2A/H2B/H3/H4 8 1.33 6.51 
GO:0051276 chromosome organization 10 1.02 5.93 
Table 4.14.  4 enriched sets up in 3b1-REG vs. Dd2-REG in the schizont stage. 
Four gene sets were significantly up in 3b1-REG compared to Dd2-REG in the schizont stage. 
Gene Description Fold Norm 
PF11_0210 metal ion channel - Mg2 , Co2  and Ni2  1.27 3.15 
PF10_0281 merozoite TRAP-like protein 1.58 3.04 
Table 4.15.  2 enriched genes up in 3b1-REG vs. Dd2-REG in the schizont stage. 
Two genes were significantly up in 3b1-REG compared to Dd2-REG in the schizont stage.   
Set Description Size Norm P-val 





AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 820 1.37 6.88 
prenylation 
N-myristoylation, S-acylation and prenylation of 
proteins 23 1.29 5.04 
SSF47473 EF-hand 165 1.21 23.94 
Gen_apic_genome Genes of the apicoplast genome 40 1.18 6.47 
Hagai Ginsburg ... Protein biosynthesis 16 1.16 4.89 
PF09715 
Plasmodium protein of unknown function 
(Plasmod_dom_1) 15 1.08 12.76 
TIGR01519 
plasmod_dom_1: Plasmodium falciparum 
uncharacterized domain 15 1.08 12.76 
TIGR01478 STEVOR: variant surface antigen, stevor family 36 1.03 7.44 
proteinBiosynth Protein biosynthesis 50 1 5.55 
Table 4.16.  9 enriched sets down in 3b1-REG vs. Dd2-REG in the schizont stage. 
Nine gene sets were significantly down in 3b1-REG compared to Dd2-REG in the schizont 
stage. 
Gene Description Fold Norm 
PF10_0004 Rifin 2.2 3.93 
PF10_0149 cysteinyl-tRNA synthetase, putative 1.35 3.67 
MAL13P1.221 aspartate carbamoyltransferase 1.35 3.52 
PFD0780w glutamyl-tRNA(Gln) amidotransferase subunit A, putative 1.22 3.13 
PFB0050c stevor, pseudogene 2.13 3.09 
PF13_0052 ribosomal RNA methyltransferase, putative 1.16 3.02 
Table 4.17.  6 enriched genes down in 3b1-REG vs. Dd2-REG in the schizont stage. 






3b1-EXO vs Dd2-EXO 
The following gene and gene set tables are based on the 3b1-EXO vs. Dd2-EXO comparison, 
examining a DHA-tolerant line after exonuclease-treatment vs. a DHA-sensitive line after 
exonuclease-treatment. 
Set Description Size Norm P-val 
AP2_PFF0670w_D2_8 Matching set 8 for AP2 - PFF0670w_D2 966 1.98 8.74 
AP2_PFF0670w_D2_7 Matching set 7 for AP2 - PFF0670w_D2 641 1.81 8.36 
AP2_PF13_0267_1 Matching set 1 for AP2 - PF13_0267 161 1.81 6.43 
GO:0015629 actin cytoskeleton 7 1.7 3.63 
AP2_PF11_0442_2 Matching set 2 for AP2 - PF11_0442 150 1.67 4.91 
AP2_PFF0670w_D2_6 Matching set 6 for AP2 - PFF0670w_D2 557 1.66 5.54 
GO:0020011 Apicoplast 507 1.57 7.07 
SSF47113 Histone-fold 17 1.56 7.09 
AP2_PF13_0267_3 Matching set 3 for AP2 - PF13_0267 751 1.51 11.57 
NucleoAssembly Nucleosome assembly and regulation 35 1.47 4.65 
AP2_PFE0840c_D2_6 Matching set 6 for AP2 - PFE0840c_D2 842 1.45 6.57 
AP2_PF13_0267_2 Matching set 2 for AP2 - PF13_0267 676 1.43 9.13 
AP2_PFE0840c_D2_3 Matching set 3 for AP2 - PFE0840c_D2 584 1.42 5.75 
AP2_PFE0840c_D2_5 Matching set 5 for AP2 - PFE0840c_D2 741 1.41 5.31 
arginine Protein arginine methylation 14 1.41 4.42 
Histone Histone acetylation 24 1.4 5.32 
AP2_PFE0840c_D2_4 Matching set 4 for AP2 - PFE0840c_D2 617 1.27 5.91 
SSF54001 Cysteine proteinases 35 1.26 5.07 
Hagai Ginsburg ... Actin and filaments 14 1.24 3.8 
GO:0006333 chromatin assembly or disassembly 9 1.22 3.76 
PF03815 LCCL domain 5 1.2 4.29 
PS50820 LCCL domain profile 5 1.2 4.29 
SM00603 LCCL 5 1.2 4.29 
SSF69848 LCCL domain 5 1.2 4.29 
GO:0006508 Proteolysis 93 1.18 5.52 
AP2_PFE0840c_D2_7 Matching set 7 for AP2 - PFE0840c_D2 935 1.15 5.38 
PF00069 Protein kinase domain 71 1.14 5.32 
GO:0006334 nucleosome assembly 12 1.14 7.28 
SM00181 Epidermal growth factor-like 7 1.14 5.55 
EQ:C5M2895 C5M28 95 165 1.13 7.15 
GO:0051276 chromosome organization 10 1.12 6.13 





PR00193 Myosin heavy chain signature 6 1.08 4.37 
SM00242 Myosin head, motor domain 6 1.08 4.37 
PS50011 Protein kinase domain profile 98 1.07 5.87 
GO:0008234 cysteine-type peptidase activity 24 1.06 4.56 
SM00220 Serine/threonine-protein kinase domain 90 1.05 5.36 
actin Actin and filaments 27 1.04 4.54 
Table 4.18.  39 enriched sets up in 3b1-EXO vs. Dd2-EXO. 
39 gene sets were significantly up in 3b1-EXO compared to Dd2-EXO. 
Gene Description Fold Norm 
PFL0630w iron-sulfur subunit of succinate dehydrogenase 1.23 3.78 
PFD0780w glutamyl-tRNA(Gln) amidotransferase subunit A, putative 1.21 3.42 
Table 4.19.  2 enriched genes up in 3b1-EXO vs. Dd2-EXO. 
Two genes were significantly up in 3b1-REG compared to Dd2-EXO.  
Set Description Size Norm P-val 
Hagai Ginsburg ... Asparagine and Aspartate Metabolism 5 1.91 3.71 
GO:0005732 small nucleolar ribonucleoprotein complex 12 1.84 4.5 
GO:0016272 prefoldin complex 8 1.64 4.33 
GO:0004812 aminoacyl-tRNA ligase activity 37 1.49 6.26 
GO:0006418 tRNA aminoacylation for protein translation 35 1.49 7.57 
apicoplastgenes Nuclear genes with apicoplast signal sequences 142 1.47 5.51 
PF01423 LSM domain 15 1.44 8.69 
SM00651 
Like-Sm ribonucleoprotein (LSM) domain, 
eukaryotic/archaea-type 15 1.44 8.69 
SSF47473 EF-hand 165 1.39 11.59 
SSF50182 Sm-like ribonucleoproteins 18 1.36 7.67 
Hagai Ginsburg ... tRNA modifications 11 1.35 5.72 
KE:PFA00970 AMINOACYL-TRNA.BIOSYNTHESIS 35 1.31 7.57 
AP2_PFF0670w_D1_4 Matching set 4 for AP2 - PFF0670w_D1 954 1.26 6.67 
tRNA_mod tRNA modifications 45 1.19 7.31 
GO:0000175 3'-5'-exoribonuclease activity 7 1.14 4.3 
KE:PFA00240 PYRIMIDINE.METABOLISM 53 1.1 5.36 
AP2_PFF0670w_D1_3 Matching set 3 for AP2 - PFF0670w_D1 820 1.09 7.72 
nuclearGenes Nuclear genes with mitochondrial signal sequences 238 1.09 6.68 
Hagai Ginsburg ... Nuclear genes with mitochondrial signal sequences 235 1.05 6.55 
Hagai Ginsburg ... 
Genes coding for components involved in ribosome 
assembly 93 1.04 10.44 






Table 4.20.  21 enriched sets down in 3b1-EXO vs. Dd2-EXO. 
21 sets were significantly down in 3b1-EXO compared to Dd2-EXO. 
Gene Description Fold Norm 
PF10_0293 transcription factor, putative 1.19 4.92 
PF10_0149 cysteinyl-tRNA synthetase, putative 1.24 4.54 
PF13_0318 RNA binding protein, putative 1.27 4.12 
PF11_0225 ABC transporter GCN20 1.18 3.7 
MAL13P1.253 small nuclear ribonucleoprotein, putative 1.29 3.68 
MAL13P1.242 step II splicing factor, putative 1.27 3.67 
PF13_0158 nonsense-mediated mRNA decay protein Upf3, putative 1.23 3.53 
PFL2295w nucleolar rRNA processing protein, putative 1.2 3.46 
PFL2400w rRNA processing protein, putative 1.21 3.44 
PF14_0661 small subunit rRNA processing KH domain protein, putative 1.11 3.06 
PF11_0336 pre-mRNA splicing factor, putative 1.2 3.03 
PFL0460w lsm7 homologue, putative 1.22 3.03 
Table 4.21.  12 enriched genes down in 3b1-EXO vs. Dd2-EXO. 
12 genes were significantly down in 3b1-EXO compared to Dd2-EXO. 
Set Description Size Norm P-val 
GO:0005737 cytoplasm 908 1.73 8.35 
PF03815 LCCL domain 5 1.61 5.32 
PS50820 LCCL domain profile 5 1.61 5.32 
SM00603 LCCL 5 1.61 5.32 
SSF69848 LCCL domain 5 1.61 5.32 
Table 4.22.  5 enriched sets up in 3b1-EXO vs. Dd2-EXO in the ring stage. 
Five gene sets were significantly up in 3b1-EXO compared to Dd2-EXO in the ring stage. 
Gene Description Fold Norm 
PF07_0071 queuine tRNA-ribosyltransferase, putative 1.35 3.97 
PFI1135c OTU-like cysteine protease, putative 1.29 3.34 
PFL2095w translation initiation factor SUI1, putative 1.35 3.03 





Three genes were significantly up in 3b1-EXO compared to Dd2-EXO in the ring stage.  
Set Description Size Norm P-val 
Gen_apic_genome Genes of the apicoplast genome 40 1.3 11.82 
AV:hyp hyp gene family 51 1 16.62 
Table 4.24.  2 enriched sets down in 3b1-EXO vs. Dd2-EXO in the ring stage. 
Two gene sets were significantly down in 3b1-EXO compared to Dd2-EXO in the ring stage.  
Gene Description Fold Norm 
MAL13P1.253 small nuclear ribonucleoprotein, putative 1.32 3.58 
PF14_0451 mitochondrial ribosomal protein S14 precursor, putative 1.56 3.56 
PFL0460w lsm7 homologue, putative 1.22 3.34 
PF14_0489 transcriptional regulatory protein sir2b 1.24 3.23 
PF11_0240 dynein heavy chain, putative 1.29 3.03 
PFI1745c early transcribed membrane protein 1.56 3.03 
Table 4.25.  6 enriched genes down in 3b1-EXO vs. Dd2-EXO in the ring stage. 
Six genes were significantly up in 3b1-EXO compared to Dd2-EXO in the ring stage.  
Set Description Size Norm P-val 
Gen_apic_genome Genes of the apicoplast genome 40 1.35 13.88 
GO:0051276 chromosome organization 10 1.21 5.07 
SSF47113 Histone-fold 17 1.18 4.95 
SSF49899 Concanavalin A-like lectins/glucanases 42 1.09 6.37 
PF10584 Proteasome subunit A N-terminal signature 7 1.08 4.91 
Table 4.26.  5 enriched sets up in 3b1-EXO vs. Dd2-EXO in the trophozoite stage. 
Five gene sets were significantly up in 3b1-EXO compared to Dd2-EXO in the trophozoite stage.  
Gene Description Fold Norm 
PFL1200c splicing factor 3b subunit, putative 1.31 3.58 
MAL13P1.415 hypothetical protein, pseudogene 2.5 3.53 
MAL8P1.113 peptidase family C50, putative 1.31 3.24 
PFE0750c RNA recognition motif, putative 1.39 3.09 
PF11_0524 lsm4 homologue, putative 1.23 3.01 





Five genes were significantly up in 3b1-EXO compared to Dd2-EXO in the trophozoite stage.  
Set Description Size Norm P-val 
AP2_PFE0840c_D2_7 Matching set 7 for AP2 - PFE0840c_D2 935 1.4 6.91 
AP2_PFE0840c_D2_6 Matching set 6 for AP2 - PFE0840c_D2 842 1.32 6.98 
AP2_PF14_0079_2 Matching set 2 for AP2 - PF14_0079 288 1.23 6.56 
AP2_PF14_0079_5 Matching set 5 for AP2 - PF14_0079 538 1.14 9.91 
AP2_PF14_0079_6 Matching set 6 for AP2 - PF14_0079 563 1.1 9.46 
AP2_PF14_0079_4 Matching set 4 for AP2 - PF14_0079 514 1.09 10.12 
SSF47473 EF-hand 165 1.09 20.29 
PF00063 Myosin head (motor domain) 6 1.03 4.9 
PR00193 Myosin heavy chain signature 6 1.03 4.9 
SM00242 Myosin head, motor domain 6 1.03 4.9 
Table 4.28.  10 enriched sets down in 3b1-EXO vs. Dd2-EXO in the trophozoite stage. 
10 gene sets were significantly down in 3b1-EXO compared to Dd2-EXO in the trophozoite 
stage.  
Gene Description Fold Norm 
PFE0560c MORN repeat protein, putative 1.27 4.34 
PF13_0087 1-methyladenosine tRNA methyltransferase subunit, putative 1.18 3.86 
PF10_0221 GcpE protein 1.33 3.43 
MAL8P1.203 serine/threonine protein kinase, FIKK family 1.37 3.34 
PFL1315w potassium channel protein 1.33 3.33 
Table 4.29.  5 enriched genes down in 3b1-EXO vs. Dd2-EXO in the trophozoite stage. 
Five genes were significantly down in 3b1-EXO compared to Dd2-EXO in the trophozoite stage.  
Set Description Size Norm P-val 
Hagai Ginsburg … Glycolysis 12 1.74 4.22 
Histone Histone acetylation 24 1.74 5.68 
GO:0006333 chromatin assembly or disassembly 9 1.65 4.51 
NucleoAssembly Nucleosome assembly and regulation 35 1.64 5.85 
SSF47113 Histone-fold 17 1.55 6.68 
SSF48726 Immunoglobulin 9 1.5 5.39 
GO:0006334 nucleosome assembly 12 1.48 7.77 
AP2_PF10_0075_D3_3 Matching set 3 for AP2 - PF10_0075_D3 524 1.42 6.07 






Components of the linear motor responsible for 
merozoite motility in invasion 22 1.3 6.56 
AP2_PF10_0075_D3_1 Matching set 1 for AP2 - PF10_0075_D3 358 1.22 7.65 
AP2_PFF0200c_DLD_1 Matching set 1 for AP2 - PFF0200c_DLD 358 1.22 7.65 
GO:0000786 Nucleosome 8 1.17 9.27 
PF00125 Core histone H2A/H2B/H3/H4 8 1.17 9.27 
GO:0016209 antioxidant activity 11 1.15 4.25 
AP2_PF10_0075_D3_2 Matching set 2 for AP2 - PF10_0075_D3 438 1.13 6.86 
AP2_PFF0200c_DLD_2 Matching set 2 for AP2 - PFF0200c_DLD 438 1.13 6.86 
Hagai Ginsburg ... Redox regulation of proteins 31 1.13 5.57 
EQ:C5M2895 C5M28 95 165 1.12 5.93 
Hagai Ginsburg ... Proteins with ER retention sequences 11 1.12 5.19 
Gen_apic_genome Genes of the apicoplast genome 40 1.11 20.91 
EQ:C5M2899 C5M28 99 118 1.08 7.19 
AP2_PFF0200c_DLD_4 Matching set 4 for AP2 - PFF0200c_DLD 711 1.06 6.98 
redoxReg Redox regulation of proteins 40 1.01 5.05 
Table 4.30.  24 enriched sets up in 3b1-EXO vs. Dd2-EXO in the schizont stage. 
24 gene sets were significantly up in 3b1-EXO compared to Dd2-EXO in the schizont stage.  
Gene Description Fold Norm 
PF07_0049 erythrocyte membrane protein 1, PfEMP1 1.38 4.86 
PFE1420w f-actin capping protein alpha subunit, putative 1.67 4.13 
PFI1325w CS domain protein, putative 1.46 3.37 
MAL13P1.281 glutamate--tRNA ligase, putative 1.4 3.23 
PF10_0203 ADP-ribosylation factor 1.49 3.09 
PFI1145w perforin like protein 3 1.97 3.07 
PFE0165w actin-depolymerizing factor 2.41 3.06 
PF11_0524 lsm4 homologue, putative 1.3 3.04 
PFL2215w actin I 3.18 3.02 
Table 4.31.  9 enriched genes up in 3b1-EXO vs. Dd2-EXO in the schizont stage. 
Nine genes were significantly up in 3b1-EXO compared to Dd2-EXO in the schizont stage. .   
Set Description Size Norm P-val 
SSF47473 EF-hand 165 1.17 16.97 
PF09715 Plasmodium protein of unknown function (Plasmod_dom_1) 15 1.09 12.55 
TIGR01519 plasmod_dom_1: Plasmodium falciparum uncharacterized domain 15 1.09 12.55 
tRNA_mod tRNA modifications 45 1.01 6.89 





Four gene sets were significantly down in 3b1-EXO compared to Dd2-EXO in the schizont 
stage.  
Gene Description Fold Norm 
PF14_0145 ubiquitin carboxyl-terminal hydrolase, putative 1.42 4.03 
PF11_0036 flavoprotein, putative 1.49 3.37 
PF13_0142 lsm6 homologue, putative 1.43 3.34 
PFL0835w GTP binding protein, putative 1.2 3.32 
PFL0310c eukaryotic translation initiation factor 3 subunit 8, putative 1.35 3.15 
PFI1085w ubiquitin-like protein, putative 1.65 3.08 
PFE0560c MORN repeat protein, putative 1.22 3.03 
Table 4.33.  7 enriched genes down in 3b1-EXO vs. Dd2-EXO in the schizont stage. 






A summary of the comparative analysis of tolerant and sensitive lines. 
For comparative analysis of the transcriptional changes in the 3b1 DHA-tolerant line and the 
parental Dd2 1pa sensitive line we used Gene Set Enrichment Analysis (GSEA), a computational 
method that determines whether an a priori defined set of genes shows statistically significant, 
concordant differences between two biological phenotypes [146].  Annotated gene ontology 
categories were used as the defined gene sets.  This analysis across all time points identified a 
significant up-regulation of genes encoding proteins exported to the host red blood cell.  Most of 
these gene sets contain antigenic variant gene families, including rifin, stevor, phist, hyp and 
erythrocyte membrane protein members, expected to transcriptionally vary between lines [249, 
374].  However, there are members that have increased abundance that are not known to be 
variant genes: the early transcribed membrane protein 10.3 (Pf10_0164) increased 3.13-fold; 
CSP/TRAP-related protein (PFC0640w) increased 2.25-fold; and the secreted ookinete protein 
(PFE0680w) increased 2.15-fold.  In addition, transcripts that encode for proteins that function in 
the invasion process were also found to be increased in the DHA-tolerant line, including: 
reticulocyte binding protein 2b (MAL13P1.176) increased 2.01-fold; reticulocyte binding protein 
2a (Pf13_0198) increased 1.98-fold; erythrocyte binding antigen-181 (PFA0125c) increased 
2.05-fold; and erythrocyte binding antigen-140 (MAL13P1.60) increased 1.81-fold [375]. 
In addition, transcription of the gene set encompassing genes encoding for proteins involved in 
redox regulation was significantly up-regulated in the DHA-tolerant 3b1 line compared to Dd2 
1pa during the trophozoite stage (P= 6.0e-9, FDR of 0.007).  Leading edge genes that increased 
during the trophozoite stage include: glyceraldehyde-3-phosphate dehydrogenase (Pf14_0598, 





(Pf07_0029; 1.85-fold increase) and HSP70 (Pf08_0054; 1.76-fold increase), thioredoxin 
peroxidase (Pf14_0368, 2.76-fold increase), and thioredoxin (PFI0945w; 2.35-fold increase). 
Fold-change analysis also revealed altered expression of genes encoding for core histone proteins 
in the DHA-tolerant line.  During the trophozoite stage, the core histone gene set was 
significantly increased in the DHA-tolerant 3b1 line compared to the parental Dd2 1pa line, 
P=9.1e-10, FDR 0 (Figure 4.11). 
 
Figure 4.11.  Gene expression of the core histone set 3b1-REG vs. Dd2-REG. 
Gene set enrichment analysis identified the core histone set as significantly enriched in 
the 3b1 DHA-tolerant parasite with greater abundance during the trophozoite stage.  The 
following genes had a higher abundance compared to parental Dd2 1pa, of core histone 
transcripts: Histone H2A (PFF0860c, 2.81-fold); Histone H3 (PFF0510w, 2.69-fold); 





H2B variant (Pf07_0054, 2.38-fold); Histone H2B (Pf11_0062, 2.15-fold); Histone H2A 
variant (PFC0920w, 1.75-fold) and Histone H3 variant (Pf13_0185), 1.47-fold. 
Up-regulation of the core histone transcripts during the trophozoite stage was verified by qPCR 
(Table 4.14).  qPCR replicates were done in triplicate and clearly indicate up-regulation at time 
point 24 (hours post-invasion). 
Time H2A H2B H3 H3.3 H4 


































Figure 4.12.  Histone gene expression of 3b1 vs Dd2 
Shown here are the average 2-ΔΔCt values and the ranges based on the standard 
deviations, using a previously described method [376], calculated from at least three 
qPCR replicates for each gene.  ΔCt values were determined by subtracting the average 
of the histone Ct from the average C341, a constitutively expressed reference gene [125], 
Ct (ΔCt = Ct(histone) − Ct(C341)).  Standard deviations were calculated using the 
formula S = (S1^2 + S2^2)1 / 2.  Similarly, ΔΔCt values were calculated by using the 
ΔCt value of the parental Dd2 1pa line as the calibrator using ΔΔCt = ΔCt(3b1) − 
ΔCt(Dd2 1pa).  The values denote fold-change in expression relative to the Dd2 1pa line, 
assayed using untreated, purified total RNA collected at the indicated time points during 
the erythrocytic cycle. 
To identify genes and gene sets that were differentially affected by exonuclease treatment in 3b1 
and Dd2 and to further confirm our initial results, we compared the 3b1 and Dd2 exonuclease-
treated samples.   The core histone gene set was the highest scoring set that did not comprise 





4.13).  Therefore, the core histone gene set is high in both comparisons between 3b1 and Dd2, 
regular and exonuclease treated. 
 
Figure 4.13.  Gene expression of the core histone set 3b1-EXO vs. Dd2-EXO. 
The core histone gene set was significantly enriched up in the 3b1-EXO vs. Dd2-EXO 
comparison.  The set was also enriched up in the 3b1-REG vs. Dd2-REG comparison, 
however not as strongly across all time points. 
We also analyzed gene sets for each of the ApiAP2 protein binding genes, which encompasses 
all genes that contain the sequence motif experimentally determined to match that ApiAP2 gene, 
and therefore are predicted to be transcriptionally regulated by that factor [287].  Interestingly, 
Histone 2A and 2B were in the leading edge for the ApiAP2 Pf10_0075 and PFF0200c gene sets 
(P=2.1e-14, FDR 0 for both), along with a newly described chromatin-associated nuclear 





These findings suggest that the histone transcripts expressed more in the DHA-tolerant 3b1 line 
compared to the DHA sensitive Dd2, and that a greater portion of the histone transcripts might 







Comparisons to field 
We also compared the transcriptional differences to those previously described upon treatment 
with artemisinins or in resistant lines and found only modest concordance.  Mok et al. examined 
gene expression differences between eight sensitive and three resistant clinical isolates (Table 
4.15) [138].  Though a time series of measurements were performed on each sample, we could 
not make a reliable comparison using our methods since many of the samples arrested during 
sampling, leaving gaps of up to 20 hours.  Consequently, there was not data for the entire 
lifecycle for most samples, and instead of imputing a curve, we aligned each time point to 3D7, 
and then compared resistant to sensitive samples that were at most eight hours apart.  From these 
127 comparisons, we calculated a fold change for each gene and averaged across all time points 
and specifically during the ring, trophozoite, and schizont stages and calculated gene set 
enrichment.  There was a Spearman correlation between our data and the ex vivo clinical isolates 
of 0.05 at the gene level and 0.19 at the gene set level.  Comparison at the level of individual 
asexual stage gave an even lower correlation; however, there were genes and gene sets that were 
shared by both analyses.  The apicoplast gene set had a rank of 50 in our results and seven in the 
ex vivo samples when looking at sets up in resistant samples, while the ribosome gene set ranked 






Figure 4.14.  Alignment of ex-vivo clinical isolates. 
a. Alignment of three artemisinin resistant clinical isolates to 3D7 reveals differences in 
speed of each line.  Only the parasite in blue aligns with 3D7 across the full asexual 
blood stage cycle.  The other two lines have no time points that align in the 0-13 hour 
window of 3D7.  The alignment is poor because these two strains arrested during the 
transcriptional profiling effort.  b. Alignment of eight artemisinin-sensitive clinical 
isolates.  Several isolates cover the entire time series, while many experience a growth 
arrest in the first half of their sampling. 
Our transcriptional analysis was also compared to that of Natalang et al.  [295] who examined 
transcriptional changes in the P. falciparum strain FCR3 following a short term exposure to 780 
nM.  Samples were collected following 90 min and three-hour drug exposures on synchronized 
cultures between 20 and 30 hours post invasion.  The average Spearman correlation to our data 
was 0.05 at the gene level and 0.09 at the gene set level.  The similarity was primarily derived 
from the ribosomal gene sets that were up in the sensitive lines. 
Finally, we compared our results to the study by Witkowski et al., which described nine genes 





[378].  A majority of the non-antigenic variant genes displayed correlation in our data set to that 
observed by Witkowski et al. with expression levels above the mean in the resistant line of 2.75 
vs 1.51 for PFC0085c, a hypoxanthine phosphoribosyltransferase, 2.19 vs. 0.99 for PFC0045w, a 
70-kDa heat shock protein, and 1.33 vs. 0.83 for PF08_0054, a Plasmodium exported protein of 








In light of the recent reports of reduced in vivo susceptibility to ACTs in western Cambodia and 
more recently northwestern Thailand [96, 97], we undertook a comparative study of in vitro 
selected DHA-tolerant lines and the isogenic DHA-sensitive parental line in order to understand 
the potential mechanisms mediating the reduced susceptibility to artemisinin.  The DHA-tolerant 
parasites demonstrated a significantly higher rate and frequency of growth and recrudescence 
after four-day exposures to DHA and artemisinin.  The tolerant parasites displayed a dose-
dependent response, where at higher treatment concentrations (112 nM) DHA, growth was 
detected later and at a reduced frequency compared to lower treatment concentrations (14 and 28 
M) DHA, where the delay in growth was very slight.  The parasites recovered 15 days after 
exposure to 100 nM DHA or artemisinin, which is comparable to the delay measured in previous 
lab-selected lines [362].  The tolerant lines were maintained in culture under a constant 14 nM 
DHA selection pressure for six days out of every week for 300 days, demonstrating their 
tolerance to low drug concentration.  Interestingly, with the same concentration at seven days out 
of every week, the selection pressure was eventually lethal, suggesting that the parasites have 
acquired a mechanism that reduces the lethal effects of artemisinin, but under constant pressure 
this mechanism is eventually overpowered. 
Quiescence 
Previous studies using laboratory-selected parasites have suggested a model for in vitro 
artemisinin resistance whereby the parasite enters a quiescent/dormant stage that allows the 





trials involving artesunate monotherapy may suggest a similar mechanism of resistance [380, 
381].  However, this model is not completely concordant with the reports by Dondorp et al. of 
delayed in vivo parasite clearance times on the Thai-Cambodian border [96].  While the model 
properly describes the decreased treatment efficacy in both the in vivo and in vitro parasite lines, 
the model also suggests an increase in treatment failures or recrudescence of parasites will follow 
cessation of drug therapy, which happens in the in vitro lines, but fails to materialize in the in 
vivo infections. 
The DHA tolerance phenotype we witness in our study is more closely associated with 
observations from the Thai-Cambodian border.  Since the parasites grew under constant drug 
pressure and retained their ability to continuously replicate, there is no evidence of any parasites 
entering a quiescent or dormant stage.  There may be a connection between the two models, as 
DHA tolerant parasites that are exposed to supraphysiologic DHA concentrations, (micromolar) 
do enter a quiescent state [362].  Additional studies investigating this phenomenon are ongoing. 
Resistance determinants 
Our DHA-tolerant parasites do not exhibit any genomic alterations in candidate genes of interest 
to the field.  One putative resistance determinant is PfATP6, a P. falciparum SERCA-type 
calcium-dependent ATPase in the endoplasmic reticulum, which has been shown to be inhibited 
by artemisinin in work with transfected Xenopus laevis oocytes [22].  The endoperoxide bridge 
of artemisinin was shown to be important to this inhibition, because deoxyartemisinin, lacking 
the endoperoxide bridge, had no effect on PfATP6 [351].  Similarly, researchers utilizing a P.  
chabaudi model identified a single-nucleotide polymorphism (SNP) in artesunate-resistant lines 
in the gene that encodes a putative deubiquitinating protease termed UBP-1 [359, 382].  





revealed no polymorphisms.  An increase in the copy number of pfmdr1 had been implicated in 
artemisinin resistance in previous studies [360, 383], however qPCR of all three DHA-tolerant 
lines revealed three copies of pfmdr1 and qPCR of the parental DHA-sensitive line also found 
three copies of pfmdr1.  These findings imply that the DHA tolerance is not mediated by 
polymorphisms or copy number changes in any of the putative resistance determinants of 
artemisinin. 
Drug accumulation 
Resistance to chloroquine has been shown to be mediated by a drug flux mechanism through a 
PfCRT-dependent mechanism [364, 365].  To assess whether altered drug accumulation played a 
role in the DHA tolerance phenotype, biochemical analysis was performed on the tolerant lines 
and the sensitive line.  While similar studies with chloroquine demonstrated an efflux of drug in 
resistant lines, there was no significant alteration in drug accumulation between the DHA-
tolerant and DHA-sensitive lines.  This suggests that the DHA tolerance phenotype is driven by a 
different means than a conventional drug efflux mechanism, possibly a mechanism that attempts 
to reduce or respond better to drug-induced toxicity. 
Reduction of redox stress 
Although there is no decisive evidence for the handful of proposed mechanisms by which 
artemisinins exert their antimalarial activity [384], a popular hypothesis backed by several 
studies is that reductive scission of the peroxide bridge in artemisinin is promoted by the heme-
iron produced from hemoglobin degradation in the digestive vacuole.  This leads to the 
formation of free radicals that alkylate several membrane-associated proteins and lipids within 
infected RBCs [338, 340, 341].  As substantiating evidence to the alkylation theory, in vitro 





agents [342].  When a membrane-permeant probe was used to monitor intracellular oxidative 
stress, a dose-dependent increase in fluorescent signal accompanied artemisinin treatment, 
supporting that artemisinins act, at least in part, by perturbation of the parasite redox state [347]. 
Interestingly, there were signatures of a reaction to redox stress in both the metabolomic and 
transcriptional studies of the DHA-tolerant parasites.  Redox metabolite levels were increased in 
the DHA-tolerant lines compared to the DHA-sensitive parental line, specifically glutathione and 
reduced glutathione.  In addition, altered transcription of the gene set encompassing transcripts 
encoding proteins involved in redox regulation were up-regulated in 3b1 compared to Dd2 
during the trophozoite stage (P= 6.0e-9, FDR 0.007).  Leading edge genes driving this gene set 
up-regulated during the trophozoite stage include: glyceraldehyde-3-phosphate dehydrogenase 
(Pf14_0598, 2.92-fold increase), heat shock proteins PFI0875w (HSP70; 2.6-fold increase, 
Pf07_0029 (HSP90; 1.85-fold increase and Pf08_0054 (HSP70; 1.76-fold increase) and 
thioredoxin peroxidase (Pf14_0368, 2.76-fold increase).  The increased activities of these 
pathways potentially contribute to the decreased toxicity in the DHA-tolerant parasites mediated 
through reduction of redox stress. 
Reduced transcription 
A nuclear run-on assay of synchronized trophozoite stage parasites revealed a significant 
decrease in the transcription rate of DHA-tolerant parasites compared to the isogenic drug-
sensitive parent (Figure 4.5).  Transcriptional analysis demonstrated that this reduction in 
transcription rate did not accompany a large transcriptional deviation; the traditional 
transcription cascade usually seen in P. falciparum was largely the same, indicating well-





Further analysis of the transcriptional profile of the DHA-tolerant 3b1 line suggested a possible 
mechanism underlying the reduced transcription rate in these parasites, specifically the increased 
expression of transcripts encoding for core histone proteins.  As shown in Figure 4.11, there is a 
significant increase during the trophozoite stage in the core histone gene set, P=9.1e-10, FDR 0, 
with histone H2B, histone H4, histone H3, histone H3 variant (putative) and histone H2A up-
regulated over 2-fold compared to Dd2 1pa.  These expression levels suggest that increased 
chromatin occupancy may be responsible for the observed decreased transcription rate in the 
DHA-tolerant parasites.  Consistent with this hypothesis, previous studies have demonstrated 
that the rate of transcription by eukaryotic RNA polymerases is reduced 2- to 10-fold on 
nucleosomal templates [385-387], arising primarily from nucleosome-induced pausing [388]. 
Analysis of copy number variations in parasites that demonstrate a delayed clearance time after 
treatment with ACTs from patients in Cambodia also found an increase in the histone 4 gene 
[138], providing an in vivo correlate to the in vitro increase in histone 4 gene expression 
witnessed in our study.  In addition, citraconic acid, the distillation product of citric acid, is 
significantly increased in the two DHA-tolerant lines 3b1 and 3g1, while almost reaching 
significance in the third DHA-tolerant line 3b2, which may also suggest a reduction of histone 
acylation, leading to a higher proportion of heterochromatin and transcriptional silencing.  As 
earlier work has demonstrated, this branch of the bifurcated citric acid cycle in P. falciparum 
synthesizes the acyl group for the modification of histones and an increased abundance of 
citraconic acid may result from decreased flux through this pathway [155]. 
Proposed mechanism of resistance 
Our studies of a set of DHA-tolerant parasite lines have uncovered two additional putative 





altered mRNA processing could have produced the reduced transcription rate measured in the 
DHA-tolerant lines.  Decreased cellular activity resulting from an altered transcription rate may 
contribute to decreased oxidative stress arising from normal cellular respiration [389].  Elevated 
glutathione abundance and up-regulation of redox enzyme transcripts also decrease oxidative 
stress.  These two mechanisms may act cooperatively to reduce the endogenously generated 
redox stress and increase the parasites antioxidant capacity permitting the parasites to better 
ameliorate the reactive oxidative species generated by DHA, thereby leading to an increased 
tolerance to DHA pressure.  Further studies are required to evaluate this mechanism in clinical 






Chapter 5 Conclusions and future directions 
OVERVIEW 
Malaria eradication and the race against resistance 
The goal of malaria eradication was abandoned in 1969 after the Global Malaria Eradication 
Program (GMEP) encountered a range of roadblocks, from insufficient funding to widespread 
resistance to available treatments.  For the next 50 years, the global public health community 
largely focused on malaria control, attempting to limit its damage rather than eliminate it.  
Today, malaria is the focus of unprecedented levels of political and financial capital, which has 
helped to spark a renewed interest in eradication [42]. 
Global guidelines for malaria interventions include vector control, intermittent treatment for 
vulnerable populations, rapid diagnosis, and proper treatment for malaria patients.  Our work 
focuses on proper treatment, a vital tool in reducing morbidity and mortality, reducing 
transmission, and retaining the integrity of current first-line antimalarials.  During the last 
century, we saw every first-line treatment fall to resistance, beginning with quinine in 1910 [88], 
chloroquine in 1957 [84], sulfadoxine-pyrimethamine in 1967 [391], amodiaquine in 1971 [91], 
mefloquine in 1982 [392], and halofantrine in 1990 [393] 
The current first line antimalarial in most malaria endemic countries, artemisinin-based 
combination therapy (ACT) has been highly effective in reducing malaria mortality (Figure 5.1).  
Unfortunately, increased clearance times have begun to emerge in Southeast Asia [96, 97, 101], 






Figure 5.1. Artemisinin-based combination therapies (ACTs) reduce malaria across Africa. 
ACTs have contributed to substantial reductions in malaria incidence and mortality.  
There are currently no suitable alternatives.  Reproduced from the World Malaria Report 
2008 [394]. 
In this context, the public health community must protect current treatments with careful 
monitoring and compliance, while the scientific community works to identify new drug targets.  
Our work is in pursuit of the latter, as we seek to better understand the mode of action of 





Scientific and computational advances set the stage for a new level of analysis 
The opportunities for computational analysis are greater than ever.  Given advances in the speed 
and size of assays, the amount of data available for analysis has increased exponentially over the 
last decade.  In recent years, we also have witnessed a proliferation of biological databases, 
experienced advances in computational speed, and seen the cost of storing data drop 
dramatically.  These tandem biological and computational developments have set the stage for 
fruitful explorations into rich datasets. 
KEY QUESTIONS CONCERNING RESISTANCE 
Chapter 3: How do the alterations in the expression levels and sequence of pfmdr1 and pfcrt 
impact the transcriptional profiles of other genes? 
In chapter 3, we introduced a transcriptional profiling study conducted by Dr. Sophie Adjallay, 
who sought to better understand the function of the P. falciparum chloroquine resistance 
transporter (PfCRT) and the multidrug resistance-1 (PfMDR1) transporter, which have been 
identified as determinants of decreased in vitro susceptibility to several antimalarial drugs [259, 
260]. 
To study the effect of changes in copy number of pfmdr1, we measured the gene expression 
levels at eight time points of a parasite line that expressed two copies of pfmdr1, FCB, and two 
parasite lines that expressed one copy of pfmdr1, FCB_3’KD and 106/1 [225].  To investigate 
genetic alterations in pfcrt, transcriptional profiling was performed on an unaltered drug resistant 





sensitive to drug, and a control line 7G8_CTRL that had a plasmid integrate in pfcrt with no 
alterations to sequence [228]. 
Chapter 4: What genetic and biochemical alterations are associated with decreased 
susceptibility to dihydroartemisinin (DHA)? 
The focus of chapter 4 was an experiment conducted by Dr. Richard Eastman, which sought to 
explore mechanisms of resistance for DHA, one of three artemisinin-derivatives used in current 
ACTs.  Artemisinin derivatives, such as DHA, are responsible for the majority of the 
combination’s efficiency and provide a curative treatment even in areas where parasites are 
resistant to the combination partner drug [94].  By comparing expression levels between drug-
sensitive and drug-resistant lines, we hoped to discover potential genes and gene sets involved in 
developing resistance. 
Which genes and gene sets are significantly differentially expressed between parasite lines? 
Though the experiments described above seek to answer distinct biological questions, the 
computational question is essentially the same.  Fundamentally, we sought to identify significant 
differences between the sensitive and resistant strains in hopes of better understanding modes of 
resistance.   
COMPUTATIONAL PIPELINE 






• Aligning data from two time series experiments that proceed at different speeds to enable 
comparison. 
• Visualizing high dimensional time series data to facilitate comparison. 
• Calculating the enrichment of a set of genes from their fold changes. 
• Ensuring that the high scoring genes and gene sets that resulted were in fact significant 
and would not score highly on any comparison. 
In chapter 2, we introduced our computational pipeline, which facilitates these analyses and 
overcomes the basic challenges inherent in comparing noisy data from different experiments.  It 
incorporates six key steps summarized briefly below: 
• Data creation.  Data for these analyses are gathered via time series measurements of the 
transcriptome of a parasite line. 
• Normalization and filtering.  Results from the microarray experiment are normalized 
relative to the foreground and background intensity of probes.  We then filter out the 
probes with low signal intensity or inadequate coverage. 
• Interpolation and alignment.  In order to extrapolate expression levels across the 48-
hour lifecycle with readings from just six or eight time points, we use fast Fourier 
transforms (FFT), which automatically aligns different strains by creating a smooth sine 
curve, removing much of the noise, and reducing variations in speed.   
• Dimensionality reduction.  We use principal component analysis (PCA) to reduce 
~3,000 dimensions into the “principal components” that account for the greatest 
variability in the data.  
• Individual gene analysis.  We use two methods (area under the curve (AUC) and 





the fold change and rank individual genes.  We use pair-wise analyses between a 
background pool of 11 lines to create distributions for each gene.  For our individual gene 
analysis we define genes as having significant differences between lines if expression 
levels were are at least three standard deviations above the mean of the background pool 
measurements. 
• Gene set analysis.  Based on the ranked list of genes from our individual gene analysis, 
we calculate the enrichment of sets of genes toward the top of the list.  Similar to the 
individual gene analysis, we create an enrichment distribution for each set, and we focus 
only on gene sets that were significantly enriched, defined as being at least one standard 
deviation over the mean enrichment for the set. 
Two particularly novel contributions of this approach merit further discussion.  First, our use of 
fast Fourier transforms (FFTs) ensures that the gene expression differences that we measure 
between two parasite lines at a given time point are real and not simply discrepancies in timing.  
FFT is an algorithm that decomposes a sequence of values by frequency, and we use it to 
interrogate the main 48-hour frequency of the gene to extrapolate all time points based on its 
phase and amplitude.  This critical step helps to (1) remove differences in the timing of sampling 
between two parasite lines, (2) reduce the effect of variations in speed of each stage of the life 
cycle, (3) reduce the impact of noisy probes.  We believe this is an improvement to current 
alignment approaches, which do not sufficiently handle contraction and expansion of individual 
stages and therefore risk improper analysis. 
Our FFT method forces all genes to a sinusoidal path through the 48-hour lifecycle, which helps 
to remove difference in timing.  By creating a curve that is the best fit to all the points, we also 





sample by aligning all lines to the 3D7 time series, shifting each parasite line the requisite 
amount of time forward or backward.  
Second, we present a novel normalization procedure for evaluating all gene and gene set 
enrichment results via a background pool of 11 parasite lines.  A common concern when 
analyzing microarray data is whether the genes and gene sets are actually significant or just 
experimental noise.  Our normalization procedure addresses this by calculating the gene and 
gene set enrichment of 55 different pairs of parasite lines to create background distributions for 
all genes and gene sets.  We then normalize the gene fold change and the gene set enrichment to 
their respective distributions in the background pool. 
As an example, there are several antigenic variant gene sets, such as the var genes, which will 
always have a high enrichment in any line-to-line comparison, because their constituent genes 
are stochastically expressed.  Without prior knowledge of the gene set, one would interpret their 
high enrichment score as meaningful.  Against the background pool distributions, the normalized 
score for the comparison would be quite low, and the variant sets would be filtered from the 
results.  Without such an approach, the list of results is littered with irrelevant genes and gene 
sets that must then be hand-curated – a process that is dependent on expert knowledge and risks 
reinforcing a researcher’s existing biases. 
RESULTS AND NEXT STEPS 
A focused list of significant genes and gene sets 
By creating ranked lists of genes and gene sets that are differentially expressed between lines and 
against our background pool, we are able to offer new insights into genes and gene sets that 





assigned to over 6,400 gene sets in 11 lines – a quantity of data unfeasible to review.  By culling 
just the potentially relevant genes and gene sets, we create a list that is short enough for human 
analysis.  This unbiased approach enables data-driven research design and will hopefully 
uncover previously unconsidered avenues for research. 
Our analysis simultaneously culls a massive dataset into a manageable list, while significantly 
expanding potential avenues for new scientific exploration.  In chapter 4, for example, we 
identified a gene (MAL13P1.269) from a tryptophan-rich family that was up-regulated in the 
DHA-tolerant 3b1-REG vs. the DHA-sensitive Dd2-REG.  In a recent study on artesunate 
tolerance, another member of the tryptophan-rich family, Pf10_0026 (PArt), was shown to be an 
artesunate-tolerance determinant in transgenic parasites overexpressing Part.  This was 
particularly interesting, with two separate lines of inquiry – one a transgenic parasite and the 
other a drug-pressure-selected parasite – pointing to the same tryptophan-rich gene family as 
connected to an increase in drug-tolerance.  We hope our research serves to inspire future study 
of the tryptophan-rich gene family, along with many other promising genes and gene sets that 
scored highly in our analyses. 
Outcomes and future directions 
I hope three core outcomes emerge from this research:  
• that biologists will continue to review our rich set of results to drive future experiments 
that will help to understand mechanisms of resistance and ultimately guide drug 
discovery;  
• that bioinformaticists will draw on our methods as they develop new computational 





• that biologists and bioinformaticists working with time-series data will continue to utilize 
our computational pipeline for future analyses.   
The tools we have created for this work could be used to analyze time series gene expression 
data from a range of sources.  We would like to create a stand-alone software tool that would 
allow researchers to input their data, use our algorithms, and easily share the results with 
colleagues.  The GASER project discussed in Chapter 2 could serve as the foundation for this 
tool. 
This public-facing software tool could expand our computational pipeline to include several 
possible components at each step and enable members of the community to incorporate their own 
methodologies.  We finalized our current pipeline through a series of iterations, and some of the 
components we abandoned might be of interest to others, depending on their use case. 
The interface between computational biology and parasitology is still being defined, and we are 
excited for the future as the connection between dry lab and wet lab becomes more fluid, with 








1. Cox FE: History of the discovery of the malaria parasites and their vectors. Parasit 
Vectors 2010, 3:5. 
2. Gunn SW: Understanding the global dimensions of health. New York: Springer; 2005. 
3. Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, 
Suh E, et al: Early origin and recent expansion of Plasmodium falciparum. Science 
2003, 300:318-321. 
4. Selendy JM: Water and sanitation related diseases and the environment : challenges, 
interventions, and preventive measures. Hoboken, N.J.: Wiley-Blackwell; 2011. 
5. Cunha CB, Cunha BA: Brief history of the clinical diagnosis of malaria: from 
Hippocrates to Osler. J Vector Borne Dis 2008, 45:194-199. 
6. Dobson M: Marsh fever: the geography of malaria in England. J Hist Geogr 1980, 
6:357-389. 
7. Guillemin J: Choosing scientific patrimony: Sir Ronald Ross, Alphonse Laveran, 
and the mosquito-vector hypothesis for malaria. J Hist Med Allied Sci 2002, 57:385-
409. 
8. Lawrence C: Laveran remembered: malaria haemozoin in leucocytes. Lancet 1999, 
353:1852. 
9. Faerstein E, Winkelstein W, Jr.: Carlos Juan Finlay: rejected, respected, and right. 
Epidemiology 2010, 21:158. 
10. Garcia CR, Markus RP, Madeira L: Tertian and quartan fevers: temporal regulation 
in malarial infection. J Biol Rhythms 2001, 16:436-443. 
11. Haldar K: Intracellular trafficking in Plasmodium-infected erythrocytes. Curr Opin 
Microbiol 1998, 1:466-471. 
12. Bockarie MJ, Gbakima AA, Barnish G: It all began with Ronald Ross: 100 years of 
malaria research and control in Sierra Leone (1899-1999). Ann Trop Med Parasitol 
1999, 93:213-224. 
13. Ross R: PIGMENTED CELLS in MOSQUITOS. Br Med J 1898, 1:550-551. 
14. Ross R: On some Peculiar Pigmented Cells Found in Two Mosquitos Fed on 
Malarial Blood. Br Med J 1897, 2:1786-1788. 
15. Manson P: SURGEON-MAJOR RONALD ROSS'S RECENT INVESTIGATIONS on the 
MOSQUITO-MALARIA THEORY. Br Med J 1898, 1:1575-1577. 
16. Ross R: The prevention of malaria. New York,: E.P. Dutton & company.; 1910. 
17. Chernin E: Sir Ronald Ross, malaria, and the rewards of research. Med Hist 1988, 
32:119-141. 
18. Ferroni E, Jefferson T, Gachelin G: Angelo Celli and research on the prevention of 
malaria in Italy a century ago. J R Soc Med 2012, 105:35-40. 
19. Rathore D, McCutchan TF, Sullivan M, Kumar S: Antimalarial drugs: current status 
and new developments. Expert Opin Investig Drugs 2005, 14:871-883. 
20. Carter R, Mendis KN: Evolutionary and historical aspects of the burden of malaria. 
Clin Microbiol Rev 2002, 15:564-594. 
21. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay 
SI: A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 
2011, 10:378. 
22. World Malaria Report 2011. 
23. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, 
Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a 





24. Craig MH, Snow RW, le Sueur D: A climate-based distribution model of malaria 
transmission in sub-Saharan Africa. Parasitol Today 1999, 15:105-111. 
25. Drakeley C, Sutherland C, Bousema JT, Sauerwein RW, Targett GA: The epidemiology 
of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends 
Parasitol 2006, 22:424-430. 
26. Sachs J, Malaney P: The economic and social burden of malaria. Nature 2002, 
415:680-685. 
27. Trampuz A, Jereb M, Muzlovic I, Prabhu RM: Clinical review: Severe malaria. Crit 
Care 2003, 7:315-323. 
28. Malaria: Fact Sheet [http://www.who.int/mediacentre/factsheets/fs094/en/] 
29. Bloom DE, Canning D: Policy forum: public health. The health and wealth of 
nations. Science 2000, 287:1207, 1209. 
30. Fernando D, de Silva D, Carter R, Mendis KN, Wickremasinghe R: A randomized, 
double-blind, placebo-controlled, clinical trial of the impact of malaria prevention 
on the educational attainment of school children. Am J Trop Med Hyg 2006, 74:386-
393. 
31. Gallup JL, Sachs JD: The economic burden of malaria. Am J Trop Med Hyg 2001, 
64:85-96. 
32. Andrews JM: Perspective on malaria today. JAMA 1963, 184:873-875. 
33. Andrews JM, Quinby GE, Langmuir AD: Malaria eradication in the United States. Am 
J Public Health Nations Health 1950, 40:1405-1411. 
34. Faust EC: The American Academy of Tropical Medicine. Science 1945, 102:583. 
35. Barrionuevo A: Goodbye Malaria, Hello Condos. In The New York Times; 2012. 
36. Helpern M: Malaria among drug addicts in New York City (March 30, 1934): An 
epidemic of aestivo-autumnal and quartan malaria among drug addicts in New 
York City transmitted by the use of contaminated hypodermic syringes. Public 
Health Rep 1976, 91:477-479. 
37. Leprince JA: Malaria Control in the Environment of the Cantonments. 1918. 
38. The History of Malaria, an Ancient Disease [http://www.cdc.gov/malaria/about/history/] 
39. Langmuir AD: The surveillance of communicable diseases of national importance. 
N Engl J Med 1963, 268:182-192. 
40. Elimination of Malaria in the United States (1947-1951) 
[http://www.cdc.gov/malaria/about/history/elimination_us.html] 
41. Hundley JM: Diet and health. Public Health Rep 1962, 77:277-280. 
42. Najera JA, Gonzalez-Silva M, Alonso PL: Some lessons for the future from the 
Global Malaria Eradication Programme (1955-1969). PLoS Med 2011, 8:e1000412. 
43. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE: 
Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 
118:1266-1276. 
44. Eastman RT, Fidock DA: Artemisinin-based combination therapies: a vital tool in 
efforts to eliminate malaria. Nat Rev Microbiol 2009, 7:864-874. 
45. Nabarro DN, Tayler EM: The "roll back malaria" campaign. Science 1998, 280:2067-
2068. 
46. RBM Mandate [http://www.rbm.who.int/rbmmandate.html] 
47. GMAP - The Global Malaria Action Plan [http://www.rbm.who.int/rbmgmap.html] 
48. Kerr T, Kaplan K, Suwannawong P, Jurgens R, Wood E: The Global Fund to Fight 
AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes. 
Lancet 2004, 364:11-12. 





50. Katz I, Komatsu R, Low-Beer D, Atun R: Scaling up towards international targets for 
AIDS, tuberculosis, and malaria: contribution of global fund-supported programs 
in 2011-2015. PLoS One 2011, 6:e17166. 
51. Beatrice Bernescut IG, Ralf Jürgens and Paula Hacopian: The Global Fund Annual 
Report 2010. The Global Fund to Fight AIDS, Tuberculosis, and Malaria; 2011. 
52. Snow RW, Guerra CA, Mutheu JJ, Hay SI: International funding for malaria control in 
relation to populations at risk of stable Plasmodium falciparum transmission. 
PLoS Med 2008, 5:e142. 
53. President's Malaria Intiative (PMI) 
[http://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/pmi.html] 
54. Funding [http://www.fightingmalaria.gov/funding/index.html] 
55. Organization WH: World Malaria Report 2011. World Health Organization; 2011. 
56. Ng'ang'a PN, Jayasinghe G, Kimani V, Shililu J, Kabutha C, Kabuage L, Githure J, 
Mutero C: Bed net use and associated factors in a rice farming community in 
Central Kenya. Malar J 2009, 8:64. 
57. Ranson H, N'Guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V: Pyrethroid resistance 
in African anopheline mosquitoes: what are the implications for malaria control? 
Trends Parasitol 2011, 27:91-98. 
58. Simpson DC, Kabyemela E, Muehlenbachs A, Ogata Y, Mutabingwa TK, Duffy PE, Fried 
M: Plasma levels of apolipoprotein A1 in malaria-exposed primigravidae are 
associated with severe anemia. PLoS One 2010, 5:e8822. 
59. Organization WH: A Strategic Framework for Malaria Prevention and Control During 
Pregnancy in the African Region. World Health Organization; 2004. 
60. Klausner R, Alonso P: An attack on all fronts. Nature 2004, 430:930-931. 
61. Report of the Technical consultation on Seasonal Malaria Chemoprevention 
(SMC). World Health Organization; 2011. 
62. Chandramohan D, Jaffar S, Greenwood B: Use of clinical algorithms for diagnosing 
malaria. Trop Med Int Health 2002, 7:45-52. 
63. Mwangi TW, Mohammed M, Dayo H, Snow RW, Marsh K: Clinical algorithms for 
malaria diagnosis lack utility among people of different age groups. Trop Med Int 
Health 2005, 10:530-536. 
64. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH: A review of 
malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am J Trop 
Med Hyg 2007, 77:119-127. 
65. Hawkes M, Katsuva JP, Masumbuko CK: Use and limitations of malaria rapid 
diagnostic testing by community health workers in war-torn Democratic Republic 
of Congo. Malar J 2009, 8:308. 
66. Krafts KP, Hempelmann E, Oleksyn BJ: The color purple: from royalty to laboratory, 
with apologies to Malachowski. Biotech Histochem 2011, 86:7-35. 
67. Drakeley C, Reyburn H: Out with the old, in with the new: the utility of rapid 
diagnostic tests for malaria diagnosis in Africa. Trans R Soc Trop Med Hyg 2009, 
103:333-337. 
68. Murray CK, Gasser RA, Jr., Magill AJ, Miller RS: Update on rapid diagnostic testing 
for malaria. Clin Microbiol Rev 2008, 21:97-110. 
69. Perkins SL, Schall JJ: A molecular phylogeny of malarial parasites recovered from 
cytochrome b gene sequences. J Parasitol 2002, 88:972-978. 
70. Martinsen ES, Perkins SL, Schall JJ: A three-genome phylogeny of malaria parasites 
(Plasmodium and closely related genera): evolution of life-history traits and host 
switches. Mol Phylogenet Evol 2008, 47:261-273. 
71. Baron JM, Higgins JM, Dzik WH: A Revised Timeline for the Origin of Plasmodium 





72. Jongwutiwes S, Putaporntip C, Iwasaki T, Sata T, Kanbara H: Naturally acquired 
Plasmodium knowlesi malaria in human, Thailand. Emerg Infect Dis 2004, 10:2211-
2213. 
73. Llinas M, Bozdech Z, Wong ED, Adai AT, DeRisi JL: Comparative whole genome 
transcriptome analysis of three Plasmodium falciparum strains. Nucleic Acids Res 
2006, 34:1166-1173. 
74. Aravind L, Iyer LM, Wellems TE, Miller LH: Plasmodium biology: genomic gleanings. 
Cell 2003, 115:771-785. 
75. General Pscyhopathology. Cambridge: Cambridge University Press; 1983. 
76. DePalma RG, Hayes VW, Zacharski LR: Bloodletting: past and present. J Am Coll 
Surg 2007, 205:132-144. 
77. Duffin C: Fish otoliths and folklore: a survey. 
78. Wallace DJ: The history of antimalarials. Lupus 1996, 5 Suppl 1:S2-3. 
79. Butler AR, Khan S, Ferguson E: A brief history of malaria chemotherapy. J R Coll 
Physicians Edinb 2010, 40:172-177. 
80. Klayman DL: In reply: antimalarial etymology. Science 1985, 229:706-708. 
81. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, 
D'Alessandro U: Quinine, an old anti-malarial drug in a modern world: role in the 
treatment of malaria. Malar J 2011, 10:144. 
82. Covell G, Coatney GR, Field JW, Singh J: Chemotherapy of malaria. Monogr Ser 
World Health Organ 1955, 27:1-123. 
83. Harinasuta T, Suntharasamai P, Viravan C: Chloroquine-resistant falciparum malaria 
in Thailand. Lancet 1965, 2:657-660. 
84. Payne D: Spread of chloroquine resistance in Plasmodium falciparum. Parasitol 
Today 1987, 3:241-246. 
85. Kean BH: Chloroquine-resistant falciparum malaria from Africa. JAMA 1979, 
241:395. 
86. Talisuna AO, Bloland P, D'Alessandro U: History, dynamics, and public health 
importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17:235-254. 
87. Wernsdorfer WH: The development and spread of drug-resistant malaria. Parasitol 
Today 1991, 7:297-303. 
88. Wernsdorfer WH: Epidemiology of drug resistance in malaria. Acta Trop 1994, 
56:143-156. 
89. Marsh K: Malaria disaster in Africa. Lancet 1998, 352:924. 
90. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, 
Lagarde E, Molez JF, Simondon F: Impact of chloroquine resistance on malaria 
mortality. C R Acad Sci III 1998, 321:689-697. 
91. Ekland EH, Fidock DA: In vitro evaluations of antimalarial drugs and their relevance 
to clinical outcomes. Int J Parasitol 2008, 38:743-747. 
92. White NJ: Qinghaosu (artemisinin): the price of success. Science 2008, 320:330-
334. 
93. Price RN: Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 
2000, 9:1815-1827. 
94. Eastman RT, Dharia NV, Winzeler EA, Fidock DA: Piperaquine resistance is 
associated with a copy number variation on chromosome 5 in drug-pressured 
Plasmodium falciparum parasites. Antimicrob Agents Chemother 2011, 55:3908-
3916. 
95. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG, Richman A, Sim 
BK, Lee MC, Hoffman SL, Fidock DA: Quantitative assessment of Plasmodium 
falciparum sexual development reveals potent transmission-blocking activity by 





96. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, 
Hanpithakpong W, Lee SJ, et al: Artemisinin resistance in Plasmodium falciparum 
malaria. N Engl J Med 2009, 361:455-467. 
97. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-
Saai S, Dondorp AM, Lwin KM, et al: Emergence of artemisinin-resistant malaria on 
the western border of Thailand: a longitudinal study. Lancet 2012. 
98. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Phyo AP, Moo 
CL, Lwin KM, et al: A major genome region underlying artemisinin resistance in 
malaria. Science 2012, 336:79-82. 
99. O'Brien C, Henrich PP, Passi N, Fidock DA: Recent clinical and molecular insights 
into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect 
Dis 2011, 24:570-577. 
100. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM: Evidence of 
artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008, 359:2619-
2620. 
101. Uhlemann AC, Fidock DA: Loss of malarial susceptibility to artemisinin in Thailand. 
Lancet 2012. 
102. Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, Camargo N, Daly TM, Bergman 
LW, Kappe SH: A combined transcriptome and proteome survey of malaria 
parasite liver stages. Proc Natl Acad Sci U S A 2008, 105:305-310. 
103. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci U S A 1977, 74:5463-5467. 
104. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, 
Slocombe PM, Smith M: Nucleotide sequence of bacteriophage phi X174 DNA. 
Nature 1977, 265:687-695. 
105. Sanger F, Coulson AR, Friedmann T, Air GM, Barrell BG, Brown NL, Fiddes JC, 
Hutchison CA, 3rd, Slocombe PM, Smith M: The nucleotide sequence of 
bacteriophage phiX174. J Mol Biol 1978, 125:225-246. 
106. Shendure J, Ji H: Next-generation DNA sequencing. Nat Biotechnol 2008, 26:1135-
1145. 
107. Venter JC, Adams MD, Sutton GG, Kerlavage AR, Smith HO, Hunkapiller M: Shotgun 
sequencing of the human genome. Science 1998, 280:1540-1542. 
108. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N: Enzymatic 
amplification of beta-globin genomic sequences and restriction site analysis for 
diagnosis of sickle cell anemia. Science 1985, 230:1350-1354. 
109. Innis MA, Myambo KB, Gelfand DH, Brow MA: DNA sequencing with Thermus 
aquaticus DNA polymerase and direct sequencing of polymerase chain reaction-
amplified DNA. Proc Natl Acad Sci U S A 1988, 85:9436-9440. 
110. Hunkapiller T, Kaiser RJ, Koop BF, Hood L: Large-scale and automated DNA 
sequence determination. Science 1991, 254:59-67. 
111. Griffin HG, Griffin AM: DNA sequencing. Recent innovations and future trends. Appl 
Biochem Biotechnol 1993, 38:147-159. 
112. Kleparnik K, Foret F, Berka J, Goetzinger W, Miller AW, Karger BL: The use of elevated 
column temperature to extend DNA sequencing read lengths in capillary 
electrophoresis with replaceable polymer matrices. Electrophoresis 1996, 17:1860-
1866. 
113. Ewing B, Green P: Base-calling of automated sequencer traces using phred. II. 
Error probabilities. Genome Res 1998, 8:186-194. 
114. Ewing B, Hillier L, Wendl MC, Green P: Base-calling of automated sequencer traces 





115. Turcatti G, Romieu A, Fedurco M, Tairi AP: A new class of cleavable fluorescent 
nucleotides: synthesis and optimization as reversible terminators for DNA 
sequencing by synthesis. Nucleic Acids Res 2008, 36:e25. 
116. Fedurco M, Romieu A, Williams S, Lawrence I, Turcatti G: BTA, a novel reagent for 
DNA attachment on glass and efficient generation of solid-phase amplified DNA 
colonies. Nucleic Acids Res 2006, 34:e22. 
117. Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, Rosenbaum AM, Wang 
MD, Zhang K, Mitra RD, Church GM: Accurate multiplex polony sequencing of an 
evolved bacterial genome. Science 2005, 309:1728-1732. 
118. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, 
Nelson KE, Bowman S, et al: Genome sequence of the human malaria parasite 
Plasmodium falciparum. Nature 2002, 419:498-511. 
119. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene 
expression patterns with a complementary DNA microarray. Science 1995, 
270:467-470. 
120. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent 
JM: Use of a cDNA microarray to analyse gene expression patterns in human 
cancer. Nat Genet 1996, 14:457-460. 
121. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW: Parallel human genome 
analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad 
Sci U S A 1996, 93:10614-10619. 
122. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, Brown PO, Botstein 
D, Futcher B: Comprehensive identification of cell cycle-regulated genes of the 
yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell 1998, 
9:3273-3297. 
123. Cho RJ, Campbell MJ, Winzeler EA, Steinmetz L, Conway A, Wodicka L, Wolfsberg TG, 
Gabrielian AE, Landsman D, Lockhart DJ, Davis RW: A genome-wide transcriptional 
analysis of the mitotic cell cycle. Mol Cell 1998, 2:65-73. 
124. Hayward RE, Derisi JL, Alfadhli S, Kaslow DC, Brown PO, Rathod PK: Shotgun DNA 
microarrays and stage-specific gene expression in Plasmodium falciparum 
malaria. Mol Microbiol 2000, 35:6-14. 
125. Ben Mamoun C, Gluzman IY, Hott C, MacMillan SK, Amarakone AS, Anderson DL, 
Carlton JM, Dame JB, Chakrabarti D, Martin RK, et al: Co-ordinated programme of 
gene expression during asexual intraerythrocytic development of the human 
malaria parasite Plasmodium falciparum revealed by microarray analysis. Mol 
Microbiol 2001, 39:26-36. 
126. Le Roch KG, Zhou Y, Batalov S, Winzeler EA: Monitoring the chromosome 2 
intraerythrocytic transcriptome of Plasmodium falciparum using oligonucleotide 
arrays. Am J Trop Med Hyg 2002, 67:233-243. 
127. Bozdech Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, DeRisi JL: Expression 
profiling of the schizont and trophozoite stages of Plasmodium falciparum with a 
long-oligonucleotide microarray. Genome Biol 2003, 4:R9. 
128. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder 
AA, Batalov S, Carucci DJ, Winzeler EA: Discovery of gene function by expression 
profiling of the malaria parasite life cycle. Science 2003, 301:1503-1508. 
129. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL: The transcriptome of 
the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 
2003, 1:E5. 
130. Silvestrini F, Bozdech Z, Lanfrancotti A, Di Giulio E, Bultrini E, Picci L, Derisi JL, Pizzi E, 





gametocytogenesis in Plasmodium falciparum. Mol Biochem Parasitol 2005, 
143:100-110. 
131. Ganesan K, Ponmee N, Jiang L, Fowble JW, White J, Kamchonwongpaisan S, 
Yuthavong Y, Wilairat P, Rathod PK: A genetically hard-wired metabolic 
transcriptome in Plasmodium falciparum fails to mount protective responses to 
lethal antifolates. PLoS Pathog 2008, 4:e1000214. 
132. Baruch DI, Pasloske BL, Singh HB, Bi X, Ma XC, Feldman M, Taraschi TF, Howard RJ: 
Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and 
adherence receptor on the surface of parasitized human erythrocytes. Cell 1995, 
82:77-87. 
133. Ralph SA, Bischoff E, Mattei D, Sismeiro O, Dillies MA, Guigon G, Coppee JY, David 
PH, Scherf A: Transcriptome analysis of antigenic variation in Plasmodium 
falciparum--var silencing is not dependent on antisense RNA. Genome Biol 2005, 
6:R93. 
134. Andrews KT, Tran TN, Wheatley NC, Fairlie DP: Targeting histone deacetylase 
inhibitors for anti-malarial therapy. Curr Top Med Chem 2009, 9:292-308. 
135. Hu G, Cabrera A, Kono M, Mok S, Chaal BK, Haase S, Engelberg K, Cheemadan S, 
Spielmann T, Preiser PR, et al: Transcriptional profiling of growth perturbations of 
the human malaria parasite Plasmodium falciparum. Nat Biotechnol 2010, 28:91-98. 
136. Andrews KT, Gupta AP, Tran TN, Fairlie DP, Gobert GN, Bozdech Z: Comparative 
gene expression profiling of P. falciparum malaria parasites exposed to three 
different histone deacetylase inhibitors. PLoS One 2012, 7:e31847. 
137. Mackinnon MJ, Li J, Mok S, Kortok MM, Marsh K, Preiser PR, Bozdech Z: Comparative 
transcriptional and genomic analysis of Plasmodium falciparum field isolates. 
PLoS Pathog 2009, 5:e1000644. 
138. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, Mayxay M, Chotivanich K, 
Liong KY, Russell B, et al: Artemisinin resistance in Plasmodium falciparum is 
associated with an altered temporal pattern of transcription. BMC Genomics 2011, 
12:391. 
139. Foth BJ, Zhang N, Chaal BK, Sze SK, Preiser PR, Bozdech Z: Quantitative Time-
course Profiling of Parasite and Host Cell Proteins in the Human Malaria Parasite 
Plasmodium falciparum. Mol Cell Proteomics 2011, 10:M110 006411. 
140. Gresham D, Ruderfer DM, Pratt SC, Schacherer J, Dunham MJ, Botstein D, Kruglyak L: 
Genome-wide detection of polymorphisms at nucleotide resolution with a single 
DNA microarray. Science 2006, 311:1932-1936. 
141. Dharia NV, Sidhu AB, Cassera MB, Westenberger SJ, Bopp SE, Eastman RT, Plouffe D, 
Batalov S, Park DJ, Volkman SK, et al: Use of high-density tiling microarrays to 
identify mutations globally and elucidate mechanisms of drug resistance in 
Plasmodium falciparum. Genome Biol 2009, 10:R21. 
142. Dharia NV, Plouffe D, Bopp SE, Gonzalez-Paez GE, Lucas C, Salas C, Soberon V, 
Bursulaya B, Kochel TJ, Bacon DJ, Winzeler EA: Genome scanning of Amazonian 
Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant 
parasites. Genome Res 2010, 20:1534-1544. 
143. Westenberger SJ, Cui L, Dharia N, Winzeler E: Genome-wide nucleosome mapping 
of Plasmodium falciparum reveals histone-rich coding and histone-poor 
intergenic regions and chromatin remodeling of core and subtelomeric genes. 
BMC Genomics 2009, 10:610. 
144. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH: Issues in cDNA microarray 
analysis: quality filtering, channel normalization, models of variations and 





145. Tu Y, Stolovitzky G, Klein U: Quantitative noise analysis for gene expression 
microarray experiments. Proc Natl Acad Sci U S A 2002, 99:14031-14036. 
146. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich 
A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide expression profiles. 
Proc Natl Acad Sci U S A 2005, 102:15545-15550. 
147. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP: GSEA-P: a desktop 
application for Gene Set Enrichment Analysis. Bioinformatics 2007, 23:3251-3253. 
148. Holden M, Deng S, Wojnowski L, Kulle B: GSEA-SNP: applying gene set enrichment 
analysis to SNP data from genome-wide association studies. Bioinformatics 2008, 
24:2784-2785. 
149. Tamayo P, Scanfeld D, Ebert BL, Gillette MA, Roberts CW, Mesirov JP: Metagene 
projection for cross-platform, cross-species characterization of global 
transcriptional states. Proc Natl Acad Sci U S A 2007, 104:5959-5964. 
150. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, Croce 
CM, Nakamura T, Canaani E, Young RA: Aberrant chromatin at genes encoding 
stem cell regulators in human mixed-lineage leukemia. Genes Dev 2008, 22:3403-
3408. 
151. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, 
Shaikh AY, Roach P, Kreike B, et al: An interferon-related gene signature for DNA 
damage resistance is a predictive marker for chemotherapy and radiation for 
breast cancer. Proc Natl Acad Sci U S A 2008, 105:18490-18495. 
152. Lakshmanan V, Rhee KY, Daily JP: Metabolomics and malaria biology. Mol Biochem 
Parasitol 2011, 175:104-111. 
153. Teng R, Junankar PR, Bubb WA, Rae C, Mercier P, Kirk K: Metabolite profiling of the 
intraerythrocytic malaria parasite Plasmodium falciparum by (1)H NMR 
spectroscopy. NMR Biomed 2009, 22:292-302. 
154. Olszewski KL, Morrisey JM, Wilinski D, Burns JM, Vaidya AB, Rabinowitz JD, Llinas M: 
Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell 
Host Microbe 2009, 5:191-199. 
155. Olszewski KL, Mather MW, Morrisey JM, Garcia BA, Vaidya AB, Rabinowitz JD, Llinas 
M: Branched tricarboxylic acid metabolism in Plasmodium falciparum. Nature 
2010, 466:774-778. 
156. Plata G, Hsiao TL, Olszewski KL, Llinas M, Vitkup D: Reconstruction and flux-balance 
analysis of the Plasmodium falciparum metabolic network. Mol Syst Biol 2010, 
6:408. 
157. White NJ: Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 
1992, 30:571-585. 
158. Wells TN, Alonso PL, Gutteridge WE: New medicines to improve control and 
contribute to the eradication of malaria. Nat Rev Drug Discov 2009, 8:879-891. 
159. Magarinos MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, Shanmugam D, Van 
Voorhis WC, Aguero F: TDR Targets: a chemogenomics resource for neglected 
diseases. Nucleic Acids Res 2012, 40:D1118-1127. 
160. Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, Berriman M, 
Nwaka S, Ralph SA, Roos DS, Van Voorhis WC, Aguero F: Identification of attractive 
drug targets in neglected-disease pathogens using an in silico approach. PLoS 
Negl Trop Dis 2010, 4:e804. 
161. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, 
Carruthers IM, Chan AW, Chen F, et al: Genomic-scale prioritization of drug targets: 





162. Pennisi E: Human genome 10th anniversary. Will computers crash genomics? 
Science 2011, 331:666-668. 
163. Treatment and prevention of malaria. New York: Springer; 2011. 
164. Kanz C, Aldebert P, Althorpe N, Baker W, Baldwin A, Bates K, Browne P, van den Broek 
A, Castro M, Cochrane G, et al: The EMBL Nucleotide Sequence Database. Nucleic 
Acids Res 2005, 33:D29-33. 
165. Bairoch A, Apweiler R: The SWISS-PROT protein sequence database and its 
supplement TrEMBL in 2000. Nucleic Acids Res 2000, 28:45-48. 
166. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, 
Ceric G, Clements J, et al: The Pfam protein families database. Nucleic Acids Res 
2012, 40:D290-301. 
167. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic 
Acids Res 2000, 28:27-30. 
168. Caspi R, Foerster H, Fulcher CA, Hopkinson R, Ingraham J, Kaipa P, Krummenacker M, 
Paley S, Pick J, Rhee SY, et al: MetaCyc: a multiorganism database of metabolic 
pathways and enzymes. Nucleic Acids Res 2006, 34:D511-516. 
169. Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N, 
Holloway E, Kapushesky M, Kemmeren P, Lara GG, et al: ArrayExpress--a public 
repository for microarray gene expression data at the EBI. Nucleic Acids Res 2003, 
31:68-71. 
170. Barrett T, Edgar R: Mining microarray data at NCBI's Gene Expression Omnibus 
(GEO)*. Methods Mol Biol 2006, 338:175-190. 
171. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene 
expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-
210. 
172. Bahl A, Brunk B, Coppel RL, Crabtree J, Diskin SJ, Fraunholz MJ, Grant GR, Gupta D, 
Huestis RL, Kissinger JC, et al: PlasmoDB: the Plasmodium genome resource. An 
integrated database providing tools for accessing, analyzing and mapping 
expression and sequence data (both finished and unfinished). Nucleic Acids Res 
2002, 30:87-90. 
173. Foth BJ, Ralph SA, Tonkin CJ, Struck NS, Fraunholz M, Roos DS, Cowman AF, 
McFadden GI: Dissecting apicoplast targeting in the malaria parasite Plasmodium 
falciparum. Science 2003, 299:705-708. 
174. Krogh A, Larsson B, von Heijne G, Sonnhammer EL: Predicting transmembrane 
protein topology with a hidden Markov model: application to complete genomes. J 
Mol Biol 2001, 305:567-580. 
175. Hajduk PJ, Huth JR, Tse C: Predicting protein druggability. Drug Discov Today 2005, 
10:1675-1682. 
176. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, 
Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification of biology. The 
Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 
177. Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, Bernard T, Binns D, 
Bork P, Burge S, et al: InterPro in 2011: new developments in the family and domain 
prediction database. Nucleic Acids Res 2012, 40:D306-312. 
178. Ginsburg H: Progress in in silico functional genomics: the malaria Metabolic 
Pathways database. Trends Parasitol 2006, 22:238-240. 
179. Ginsburg H, Tilley L: Plasmodium falciparum metabolic pathways (MPMP) project 
upgraded with a database of subcellular locations of gene products. Trends 
Parasitol 2011, 27:285-286. 
180. Becker K: Apicomplexan parasites : molecular approaches toward targeted drug 





181. Wells TN: Natural products as starting points for future anti-malarial therapies: 
going back to our roots? Malar J 2011, 10 Suppl 1:S3. 
182. White NJ: The role of anti-malarial drugs in eliminating malaria. Malar J 2008, 7 
Suppl 1:S8. 
183. Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH: Target assessment for antiparasitic 
drug discovery. Trends Parasitol 2007, 23:589-595. 
184. Jensen K, Plichta D, Panagiotou G, Kouskoumvekaki I: Mapping the genome of 
Plasmodium falciparum on the drug-like chemical space reveals novel anti-
malarial targets and potential drug leads. Mol Biosyst 2012. 
185. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, 
Connelly M, Clark J, Zhu F, et al: Chemical genetics of Plasmodium falciparum. 
Nature 2010, 465:311-315. 
186. Stein L: Genome annotation: from sequence to biology. Nat Rev Genet 2001, 2:493-
503. 
187. Benson DA, Karsch-Mizrachi I, Clark K, Lipman DJ, Ostell J, Sayers EW: GenBank. 
Nucleic Acids Res 2012, 40:D48-53. 
188. Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou A, Mooney P, Tivey A, 
Berriman M, Hall N, Rutherford K, et al: GeneDB: a resource for prokaryotic and 
eukaryotic organisms. Nucleic Acids Res 2004, 32:D339-343. 
189. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002, 1:727-
730. 
190. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland 
GL, Iype L, Jain S, et al: The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 
2002, 58:899-907. 
191. Dzikowski R, Templeton TJ, Deitsch K: Variant antigen gene expression in malaria. 
Cell Microbiol 2006, 8:1371-1381. 
192. Kolaskar AS, Tongaonkar PC: A semi-empirical method for prediction of antigenic 
determinants on protein antigens. FEBS Lett 1990, 276:172-174. 
193. Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, Berriman M, Florens L, Janssen CS, 
Pain A, Christophides GK, et al: A comprehensive survey of the Plasmodium life 
cycle by genomic, transcriptomic, and proteomic analyses. Science 2005, 307:82-
86. 
194. Li L, Stoeckert CJ, Jr., Roos DS: OrthoMCL: identification of ortholog groups for 
eukaryotic genomes. Genome Res 2003, 13:2178-2189. 
195. Cherry JM, Adler C, Ball C, Chervitz SA, Dwight SS, Hester ET, Jia Y, Juvik G, Roe T, 
Schroeder M, et al: SGD: Saccharomyces Genome Database. Nucleic Acids Res 
1998, 26:73-79. 
196. Yamazaki Y, Niki H, Kato J: Profiling of Escherichia coli Chromosome database. 
Methods Mol Biol 2008, 416:385-389. 
197. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, 
Wanner BL, Mori H: Construction of Escherichia coli K-12 in-frame, single-gene 
knockout mutants: the Keio collection. Mol Syst Biol 2006, 2:2006 0008. 
198. McNeil LK, Reich C, Aziz RK, Bartels D, Cohoon M, Disz T, Edwards RA, Gerdes S, 
Hwang K, Kubal M, et al: The National Microbial Pathogen Database Resource 
(NMPDR): a genomics platform based on subsystem annotation. Nucleic Acids Res 
2007, 35:D347-353. 
199. Harris TW, Lee R, Schwarz E, Bradnam K, Lawson D, Chen W, Blasier D, Kenny E, 
Cunningham F, Kishore R, et al: WormBase: a cross-species database for 





200. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey 
S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity 
database for drug discovery. Nucleic Acids Res 2012, 40:D1100-1107. 
201. Schomburg I, Chang A, Schomburg D: BRENDA, enzyme data and metabolic 
information. Nucleic Acids Res 2002, 30:47-49. 
202. Bahl A, Brunk B, Crabtree J, Fraunholz MJ, Gajria B, Grant GR, Ginsburg H, Gupta D, 
Kissinger JC, Labo P, et al: PlasmoDB: the Plasmodium genome resource. A 
database integrating experimental and computational data. Nucleic Acids Res 2003, 
31:212-215. 
203. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, Gao X, Gingle A, 
Grant G, Harb OS, et al: PlasmoDB: a functional genomic database for malaria 
parasites. Nucleic Acids Res 2009, 37:D539-543. 
204. Attwood TK, Bradley P, Flower DR, Gaulton A, Maudling N, Mitchell AL, Moulton G, 
Nordle A, Paine K, Taylor P, et al: PRINTS and its automatic supplement, 
prePRINTS. Nucleic Acids Res 2003, 31:400-402. 
205. Sigrist CJ, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A, Hulo 
N: PROSITE, a protein domain database for functional characterization and 
annotation. Nucleic Acids Res 2010, 38:D161-166. 
206. Letunic I, Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, Ponting CP, Bork P: 
SMART 4.0: towards genomic data integration. Nucleic Acids Res 2004, 32:D142-
144. 
207. Bru C, Courcelle E, Carrere S, Beausse Y, Dalmar S, Kahn D: The ProDom database 
of protein domain families: more emphasis on 3D. Nucleic Acids Res 2005, 
33:D212-215. 
208. Nikolskaya AN, Arighi CN, Huang H, Barker WC, Wu CH: PIRSF family classification 
system for protein functional and evolutionary analysis. Evol Bioinform Online 2006, 
2:197-209. 
209. Wilson D, Pethica R, Zhou Y, Talbot C, Vogel C, Madera M, Chothia C, Gough J: 
SUPERFAMILY--sophisticated comparative genomics, data mining, visualization 
and phylogeny. Nucleic Acids Res 2009, 37:D380-386. 
210. Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, 
Muruganujan A, Doremieux O, Campbell MJ, et al: The PANTHER database of protein 
families, subfamilies, functions and pathways. Nucleic Acids Res 2005, 33:D284-
288. 
211. Yeats C, Lees J, Carter P, Sillitoe I, Orengo C: The Gene3D Web Services: a platform 
for identifying, annotating and comparing structural domains in protein 
sequences. Nucleic Acids Res 2011, 39:W546-550. 
212. Haft DH, Selengut JD, White O: The TIGRFAMs database of protein families. Nucleic 
Acids Res 2003, 31:371-373. 
213. Gattiker A, Michoud K, Rivoire C, Auchincloss AH, Coudert E, Lima T, Kersey P, Pagni 
M, Sigrist CJ, Lachaize C, et al: Automated annotation of microbial proteomes in 
SWISS-PROT. Comput Biol Chem 2003, 27:49-58. 
214. Kotera M, Hirakawa M, Tokimatsu T, Goto S, Kanehisa M: The KEGG databases and 
tools facilitating omics analysis: latest developments involving human diseases 
and pharmaceuticals. Methods Mol Biol 2012, 802:19-39. 
215. Wellems TE, Panton LJ, Gluzman IY, do Rosario VE, Gwadz RW, Walker-Jonah A, 
Krogstad DJ: Chloroquine resistance not linked to mdr-like genes in a Plasmodium 
falciparum cross. Nature 1990, 345:253-255. 
216. Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in 
dihydrofolate reductase-thymidylate synthase confers resistance to 





217. Nguyen-Dinh P, Payne D: Pyrimethamine sensitivity in Plasmodium falciparum: 
determination in vitro by a modified 48-hour test. Bull World Health Organ 1980, 
58:909-912. 
218. Bhasin VK, Trager W: Gametocyte-forming and non-gametocyte-forming clones of 
Plasmodium falciparum. Am J Trop Med Hyg 1984, 33:534-537. 
219. Oduola AM, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE: Plasmodium 
falciparum: induction of resistance to mefloquine in cloned strains by continuous 
drug exposure in vitro. Exp Parasitol 1988, 67:354-360. 
220. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT, Corcoran 
LM, Burkot TR, Carter R: Genetic analysis of the human malaria parasite 
Plasmodium falciparum. Science 1987, 236:1661-1666. 
221. Ponnudurai T, Leeuwenberg AD, Meuwissen JH: Chloroquine sensitivity of isolates 
of Plasmodium falciparum adapted to in vitro culture. Trop Geogr Med 1981, 33:50-
54. 
222. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, 
Cooper RA, Wootton JC, et al: Multiple transporters associated with malaria 
parasite responses to chloroquine and quinine. Mol Microbiol 2003, 49:977-989. 
223. Su X, Kirkman LA, Fujioka H, Wellems TE: Complex polymorphisms in an 
approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in 
Southeast Asia and Africa. Cell 1997, 91:593-603. 
224. Triglia T, Foote SJ, Kemp DJ, Cowman AF: Amplification of the multidrug resistance 
gene pfmdr1 in Plasmodium falciparum has arisen as multiple independent 
events. Mol Cell Biol 1991, 11:5244-5250. 
225. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA: 
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens 
susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J 
Infect Dis 2006, 194:528-535. 
226. Bayoumi RA, Creasey AM, Babiker HA, Carlton JM, Sultan AA, Satti G, Sohal AK, 
Walliker D, Jensen JB, Arnot DE: Drug response and genetic characterization of 
Plasmodium falciparum clones recently isolated from a Sudanese village. Trans R 
Soc Trop Med Hyg 1993, 87:454-458. 
227. Burkot TR, Williams JL, Schneider I: Infectivity to mosquitoes of Plasmodium 
falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 
1984, 78:339-341. 
228. Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, Alakpa 
GE, Hughes RH, Ward SA, Krogstad DJ, et al: A critical role for PfCRT K76T in 
Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 
2005, 24:2294-2305. 
229. Eisen MB, Brown PO: DNA arrays for analysis of gene expression. Methods Enzymol 
1999, 303:179-205. 
230. Anamika K, Srinivasan N: Comparative kinomics of Plasmodium organisms: unity in 
diversity. Protein Pept Lett 2007, 14:509-517. 
231. Kruggel S, Lemcke T: Generation and evaluation of a homology model of PfGSK-3. 
Arch Pharm (Weinheim) 2009, 342:327-332. 
232. Zhang VM, Chavchich M, Waters NC: Targeting protein kinases in the malaria 
parasite: update of an antimalarial drug target. Curr Top Med Chem 2012, 12:456-
472. 
233. Becker JV, Mtwisha L, Crampton BG, Stoychev S, van Brummelen AC, Reeksting S, 
Louw AI, Birkholtz LM, Mancama DT: Plasmodium falciparum spermidine synthase 
inhibition results in unique perturbation-specific effects observed on transcript, 





234. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ: Amino acid changes linked to 
pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase 
gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 1988, 85:9109-9113. 
235. Foote SJ, Galatis D, Cowman AF: Amino acids in the dihydrofolate reductase-
thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil 
resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad 
Sci U S A 1990, 87:3014-3017. 
236. Trenholme KR, Brown CL, Skinner-Adams TS, Stack C, Lowther J, To J, Robinson MW, 
Donnelly SM, Dalton JP, Gardiner DL: Aminopeptidases of malaria parasites: new 
targets for chemotherapy. Infect Disord Drug Targets 2010, 10:217-225. 
237. Skinner-Adams TS, Stack CM, Trenholme KR, Brown CL, Grembecka J, Lowther J, 
Mucha A, Drag M, Kafarski P, McGowan S, et al: Plasmodium falciparum neutral 
aminopeptidases: new targets for anti-malarials. Trends Biochem Sci 2010, 35:53-
61. 
238. Chen X, Chong CR, Shi L, Yoshimoto T, Sullivan DJ, Jr., Liu JO: Inhibitors of 
Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial 
activity. Proc Natl Acad Sci U S A 2006, 103:14548-14553. 
239. Becker K, Gromer S, Schirmer RH, Muller S: Thioredoxin reductase as a 
pathophysiological factor and drug target. Eur J Biochem 2000, 267:6118-6125. 
240. Andricopulo AD, Akoachere MB, Krogh R, Nickel C, McLeish MJ, Kenyon GL, Arscott 
LD, Williams CH, Jr., Davioud-Charvet E, Becker K: Specific inhibitors of Plasmodium 
falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med 
Chem Lett 2006, 16:2283-2292. 
241. Creedon KA, Rathod PK, Wellems TE: Plasmodium falciparum S-
adenosylhomocysteine hydrolase. cDNA identification, predicted protein 
sequence, and expression in Escherichia coli. J Biol Chem 1994, 269:16364-16370. 
242. Tucker MS, Mutka T, Sparks K, Patel J, Kyle DE: Phenotypic and genotypic analysis 
of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. 
Antimicrob Agents Chemother 2012, 56:302-314. 
243. Makanga M, Bray PG, Horrocks P, Ward SA: Towards a proteomic definition of 
CoArtem action in Plasmodium falciparum malaria. Proteomics 2005, 5:1849-1858. 
244. Bowyer PW, Gunaratne RS, Grainger M, Withers-Martinez C, Wickramsinghe SR, Tate 
EW, Leatherbarrow RJ, Brown KA, Holder AA, Smith DF: Molecules incorporating a 
benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium 
falciparum. Biochem J 2007, 408:173-180. 
245. Francis SE, Sullivan DJ, Jr., Goldberg DE: Hemoglobin metabolism in the malaria 
parasite Plasmodium falciparum. Annu Rev Microbiol 1997, 51:97-123. 
246. Green JL, Martin SR, Fielden J, Ksagoni A, Grainger M, Yim Lim BY, Molloy JE, Holder 
AA: The MTIP-myosin A complex in blood stage malaria parasites. J Mol Biol 2006, 
355:933-941. 
247. Kyes S, Horrocks P, Newbold C: Antigenic variation at the infected red cell surface 
in malaria. Annu Rev Microbiol 2001, 55:673-707. 
248. Barry JD, Ginger ML, Burton P, McCulloch R: Why are parasite contingency genes 
often associated with telomeres? Int J Parasitol 2003, 33:29-45. 
249. Templeton TJ: The varieties of gene amplification, diversification and 
hypervariability in the human malaria parasite, Plasmodium falciparum. Mol 
Biochem Parasitol 2009, 166:109-116. 
250. Kats LM, Black CG, Proellocks NI, Coppel RL: Plasmodium rhoptries: how things 
went pear-shaped. Trends Parasitol 2006, 22:269-276. 
251. Kaneko O, Tsuboi T, Ling IT, Howell S, Shirano M, Tachibana M, Cao YM, Holder AA, 





members of the clag multigene family in Plasmodium falciparum and Plasmodium 
yoelii. Mol Biochem Parasitol 2001, 118:223-231. 
252. Sam-Yellowe TY: The role of the Maurer's clefts in protein transport in Plasmodium 
falciparum. Trends Parasitol 2009, 25:277-284. 
253. Olszewski KL, Llinas M: Central carbon metabolism of Plasmodium parasites. Mol 
Biochem Parasitol 2011, 175:95-103. 
254. Sato S, Wilson RJ: The genome of Plasmodium falciparum encodes an active delta-
aminolevulinic acid dehydratase. Curr Genet 2002, 40:391-398. 
255. Zheng M, Wang X, Templeton LJ, Smulski DR, LaRossa RA, Storz G: DNA microarray-
mediated transcriptional profiling of the Escherichia coli response to hydrogen 
peroxide. J Bacteriol 2001, 183:4562-4570. 
256. Natarajan K, Meyer MR, Jackson BM, Slade D, Roberts C, Hinnebusch AG, Marton MJ: 
Transcriptional profiling shows that Gcn4p is a master regulator of gene 
expression during amino acid starvation in yeast. Mol Cell Biol 2001, 21:4347-4368. 
257. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: Pgh1 modulates sensitivity 
and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000, 
403:906-909. 
258. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, 
Sidhu AB, Naude B, Deitsch KW, et al: Mutations in the P. falciparum digestive 
vacuole transmembrane protein PfCRT and evidence for their role in chloroquine 
resistance. Mol Cell 2000, 6:861-871. 
259. Duraisingh MT, Cowman AF: Contribution of the pfmdr1 gene to antimalarial drug-
resistance. Acta Trop 2005, 94:181-190. 
260. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA: Defining the role of PfCRT 
in Plasmodium falciparum chloroquine resistance. Mol Microbiol 2005, 56:323-333. 
261. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, 
Nomura T, Fidock DA, et al: A molecular marker for chloroquine-resistant 
falciparum malaria. N Engl J Med 2001, 344:257-263. 
262. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, 
Laing K, Looareesuwan S, White NJ, et al: Mefloquine resistance in Plasmodium 
falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447. 
263. Goldberg DE: Hemoglobin degradation. Curr Top Microbiol Immunol 2005, 295:275-
291. 
264. Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchell GH: A brief illustrated guide 
to the ultrastructure of Plasmodium falciparum asexual blood stages. Parasitol 
Today 2000, 16:427-433. 
265. Sullivan DJ: Theories on malarial pigment formation and quinoline action. Int J 
Parasitol 2002, 32:1645-1653. 
266. Muller S: Redox and antioxidant systems of the malaria parasite Plasmodium 
falciparum. Mol Microbiol 2004, 53:1291-1305. 
267. Abu Bakar N, Klonis N, Hanssen E, Chan C, Tilley L: Digestive-vacuole genesis and 
endocytic processes in the early intraerythrocytic stages of Plasmodium 
falciparum. J Cell Sci 2010, 123:441-450. 
268. Fidock DA, Nomura T, Cooper RA, Su X, Talley AK, Wellems TE: Allelic modifications 
of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant 
Plasmodium falciparum. Mol Biochem Parasitol 2000, 110:1-10. 
269. Martin RE, Kirk K: The malaria parasite's chloroquine resistance transporter is a 
member of the drug/metabolite transporter superfamily. Mol Biol Evol 2004, 
21:1938-1949. 
270. Valderramos SG, Fidock DA: Transporters involved in resistance to antimalarial 





271. Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquine resistance in Plasmodium 
falciparum malaria parasites conferred by pfcrt mutations. Science 2002, 298:210-
213. 
272. Waller KL, Muhle RA, Ursos LM, Horrocks P, Verdier-Pinard D, Sidhu AB, Fujioka H, 
Roepe PD, Fidock DA: Chloroquine resistance modulated in vitro by expression 
levels of the Plasmodium falciparum chloroquine resistance transporter. J Biol 
Chem 2003, 278:33593-33601. 
273. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K: Chloroquine transport 
via the malaria parasite's chloroquine resistance transporter. Science 2009, 
325:1680-1682. 
274. Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, Shankar AH, Wirth DF: 
Amplification of a gene related to mammalian mdr genes in drug-resistant 
Plasmodium falciparum. Science 1989, 244:1184-1186. 
275. Foote SJ, Thompson JK, Cowman AF, Kemp DJ: Amplification of the multidrug 
resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989, 
57:921-930. 
276. Peel SA, Bright P, Yount B, Handy J, Baric RS: A strong association between 
mefloquine and halofantrine resistance and amplification, overexpression, and 
mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum 
in vitro. Am J Trop Med Hyg 1994, 51:648-658. 
277. Volkman SK, Cowman AF, Wirth DF: Functional complementation of the ste6 gene 
of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum. 
Proc Natl Acad Sci U S A 1995, 92:8921-8925. 
278. Cowman AF, Galatis D, Thompson JK: Selection for mefloquine resistance in 
Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-
resistance to halofantrine and quinine. Proc Natl Acad Sci U S A 1994, 91:1143-
1147. 
279. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, 
Krishna S: The pfmdr1 gene is associated with a multidrug-resistant phenotype in 
Plasmodium falciparum from the western border of Thailand. Antimicrob Agents 
Chemother 1999, 43:2943-2949. 
280. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, Milhous WK, Wirth DF: 
Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance 
in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 1993, 57:151-160. 
281. Sidhu AB, Valderramos SG, Fidock DA: pfmdr1 mutations contribute to quinine 
resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium 
falciparum. Mol Microbiol 2005, 57:913-926. 
282. Young JA, Fivelman QL, Blair PL, de la Vega P, Le Roch KG, Zhou Y, Carucci DJ, 
Baker DA, Winzeler EA: The Plasmodium falciparum sexual development 
transcriptome: a microarray analysis using ontology-based pattern identification. 
Mol Biochem Parasitol 2005, 143:67-79. 
283. Aach J, Church GM: Aligning gene expression time series with time warping 
algorithms. Bioinformatics 2001, 17:495-508. 
284. Su X, Ferdig MT, Huang Y, Huynh CQ, Liu A, You J, Wootton JC, Wellems TE: A 
genetic map and recombination parameters of the human malaria parasite 
Plasmodium falciparum. Science 1999, 286:1351-1353. 
285. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J: OPLS 
discriminant analysis: combining the strengths of PLS-DA and SIMCA 
classification. Journal of Chemometrics 2006, 20:341-351. 
286. Painter HJ, Campbell TL, Llinas M: The Apicomplexan AP2 family: integral factors 





287. Campbell TL, De Silva EK, Olszewski KL, Elemento O, Llinas M: Identification and 
genome-wide prediction of DNA binding specificities for the ApiAP2 family of 
regulators from the malaria parasite. PLoS Pathog 2010, 6:e1001165. 
288. De Silva EK, Gehrke AR, Olszewski K, Leon I, Chahal JS, Bulyk ML, Llinas M: Specific 
DNA-binding by apicomplexan AP2 transcription factors. Proc Natl Acad Sci U S A 
2008, 105:8393-8398. 
289. Besteiro S, Vo Duy S, Perigaud C, Lefebvre-Tournier I, Vial HJ: Exploring 
metabolomic approaches to analyse phospholipid biosynthetic pathways in 
Plasmodium. Parasitology 2010, 137:1343-1356. 
290. Bethke LL, Zilversmit M, Nielsen K, Daily J, Volkman SK, Ndiaye D, Lozovsky ER, Hartl 
DL, Wirth DF: Duplication, gene conversion, and genetic diversity in the species-
specific acyl-CoA synthetase gene family of Plasmodium falciparum. Mol Biochem 
Parasitol 2006, 150:10-24. 
291. Lopez-Rubio JJ, Mancio-Silva L, Scherf A: Genome-wide analysis of heterochromatin 
associates clonally variant gene regulation with perinuclear repressive centers in 
malaria parasites. Cell Host Microbe 2009, 5:179-190. 
292. Nagaraj VA, Arumugam R, Prasad D, Rangarajan PN, Padmanaban G: 
Protoporphyrinogen IX oxidase from Plasmodium falciparum is anaerobic and is 
localized to the mitochondrion. Mol Biochem Parasitol 2010, 174:44-52. 
293. Mitamura T, Palacpac NM: Lipid metabolism in Plasmodium falciparum-infected 
erythrocytes: possible new targets for malaria chemotherapy. Microbes Infect 2003, 
5:545-552. 
294. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P, Felgner PL, 
Doolan DL: Sterile protective immunity to malaria is associated with a panel of 
novel P. falciparum antigens. Mol Cell Proteomics 2011, 10:M111 007948. 
295. Natalang O, Bischoff E, Deplaine G, Proux C, Dillies MA, Sismeiro O, Guigon G, 
Bonnefoy S, Patarapotikul J, Mercereau-Puijalon O, et al: Dynamic RNA profiling in 
Plasmodium falciparum synchronized blood stages exposed to lethal doses of 
artesunate. BMC Genomics 2008, 9:388. 
296. Silvestrini F, Lasonder E, Olivieri A, Camarda G, van Schaijk B, Sanchez M, Younis 
Younis S, Sauerwein R, Alano P: Protein export marks the early phase of 
gametocytogenesis of the human malaria parasite Plasmodium falciparum. Mol 
Cell Proteomics 2010, 9:1437-1448. 
297. Volz J, Carvalho TG, Ralph SA, Gilson P, Thompson J, Tonkin CJ, Langer C, Crabb BS, 
Cowman AF: Potential epigenetic regulatory proteins localise to distinct nuclear 
sub-compartments in Plasmodium falciparum. Int J Parasitol 2010, 40:109-121. 
298. Cui L, Fan Q, Miao J: Histone lysine methyltransferases and demethylases in 
Plasmodium falciparum. Int J Parasitol 2008, 38:1083-1097. 
299. Le Bras J, Durand R: The mechanisms of resistance to antimalarial drugs in 
Plasmodium falciparum. Fundam Clin Pharmacol 2003, 17:147-153. 
300. Alenquer M, Tenreiro S, Sa-Correia I: Adaptive response to the antimalarial drug 
artesunate in yeast involves Pdr1p/Pdr3p-mediated transcriptional activation of 
the resistance determinants TPO1 and PDR5. FEMS Yeast Res 2006, 6:1130-1139. 
301. Du Q, Wang H, Xie J: Thiamin (vitamin B1) biosynthesis and regulation: a rich 
source of antimicrobial drug targets? Int J Biol Sci 2011, 7:41-52. 
302. Thompson J, Fernandez-Reyes D, Sharling L, Moore SG, Eling WM, Kyes SA, Newbold 
CI, Kafatos FC, Janse CJ, Waters AP: Plasmodium cysteine repeat modular proteins 
1-4: complex proteins with roles throughout the malaria parasite life cycle. Cell 
Microbiol 2007, 9:1466-1480. 
303. Douradinha B, Augustijn KD, Moore SG, Ramesar J, Mota MM, Waters AP, Janse CJ, 





for malaria parasite transmission from the mosquito to the host. Malar J 2011, 
10:71. 
304. Tonkin CJ, Carret CK, Duraisingh MT, Voss TS, Ralph SA, Hommel M, Duffy MF, Silva 
LM, Scherf A, Ivens A, et al: Sir2 paralogues cooperate to regulate virulence genes 
and antigenic variation in Plasmodium falciparum. PLoS Biol 2009, 7:e84. 
305. Artavanis-Tsakonas K, Misaghi S, Comeaux CA, Catic A, Spooner E, Duraisingh MT, 
Ploegh HL: Identification by functional proteomics of a 
deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol Microbiol 
2006, 61:1187-1195. 
306. Isokpehi RD, Hide WA: Integrative analysis of intraerythrocytic differentially 
expressed transcripts yields novel insights into the biology of Plasmodium 
falciparum. Malar J 2003, 2:38. 
307. Mwai L, Diriye A, Masseno V, Muriithi S, Feltwell T, Musyoki J, Lemieux J, Feller A, Mair 
GR, Marsh K, et al: Genome wide adaptations of Plasmodium falciparum in 
response to lumefantrine selective drug pressure. PLoS One 2012, 7:e31623. 
308. Joubert F, Harrison CM, Koegelenberg RJ, Odendaal CJ, de Beer TA: Discovery: an 
interactive resource for the rational selection and comparison of putative drug 
target proteins in malaria. Malar J 2009, 8:178. 
309. Suraveratum N, Krungkrai SR, Leangaramgul P, Prapunwattana P, Krungkrai J: 
Purification and characterization of Plasmodium falciparum succinate 
dehydrogenase. Mol Biochem Parasitol 2000, 105:215-222. 
310. Ch'ng JH, Kotturi SR, Chong AG, Lear MJ, Tan KS: A programmed cell death 
pathway in the malaria parasite Plasmodium falciparum has general features of 
mammalian apoptosis but is mediated by clan CA cysteine proteases. Cell Death 
Dis 2010, 1:e26. 
311. Aucan C, Traore Y, Tall F, Nacro B, Traore-Leroux T, Fumoux F, Rihet P: High 
immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human 
resistance to Plasmodium falciparum malaria. Infect Immun 2000, 68:1252-1258. 
312. de Koning-Ward TF, Gilson PR, Boddey JA, Rug M, Smith BJ, Papenfuss AT, Sanders 
PR, Lundie RJ, Maier AG, Cowman AF, Crabb BS: A newly discovered protein export 
machine in malaria parasites. Nature 2009, 459:945-949. 
313. Modrzynska KK, Creasey A, Loewe L, Cezard T, Borges ST, Martinelli A, Rodrigues L, 
Cravo P, Blaxter M, Carter R, Hunt P: Quantitative genome re-sequencing defines 
multiple mutations conferring chloroquine resistance in rodent malaria. BMC 
Genomics 2012, 13:106. 
314. Flueck C, Bartfai R, Niederwieser I, Witmer K, Alako BT, Moes S, Bozdech Z, Jenoe P, 
Stunnenberg HG, Voss TS: A major role for the Plasmodium falciparum ApiAP2 
protein PfSIP2 in chromosome end biology. PLoS Pathog 2010, 6:e1000784. 
315. Jiang H, Patel JJ, Yi M, Mu J, Ding J, Stephens R, Cooper RA, Ferdig MT, Su XZ: 
Genome-wide compensatory changes accompany drug- selected mutations in the 
Plasmodium falciparum crt gene. PLoS One 2008, 3:e2484. 
316. Vazquez de Aldana CR, Marton MJ, Hinnebusch AG: GCN20, a novel ATP binding 
cassette protein, and GCN1 reside in a complex that mediates activation of the 
eIF-2 alpha kinase GCN2 in amino acid-starved cells. EMBO J 1995, 14:3184-3199. 
317. Maughan SC, Pasternak M, Cairns N, Kiddle G, Brach T, Jarvis R, Haas F, Nieuwland J, 
Lim B, Muller C, et al: Plant homologs of the Plasmodium falciparum chloroquine-
resistance transporter, PfCRT, are required for glutathione homeostasis and 
stress responses. Proc Natl Acad Sci U S A 2010, 107:2331-2336. 
318. Kruger T, Sanchez CP, Lanzer M: Complementation of Saccharomyces 
cerevisiaepik1ts by a phosphatidylinositol 4-kinase from Plasmodium falciparum. 





319. Famin O, Ginsburg H: The treatment of Plasmodium falciparum-infected 
erythrocytes with chloroquine leads to accumulation of ferriprotoporphyrin IX 
bound to particular parasite proteins and to the inhibition of the parasite's 6-
phosphogluconate dehydrogenase. Parasite 2003, 10:39-50. 
320. Briolant S, Almeras L, Belghazi M, Boucomont-Chapeaublanc E, Wurtz N, Fontaine A, 
Granjeaud S, Fusai T, Rogier C, Pradines B: Plasmodium falciparum proteome 
changes in response to doxycycline treatment. Malar J 2010, 9:141. 
321. Rao A, Yeleswarapu SJ, Raghavendra G, Srinivasan R, Bulusu G: PlasmoID: A P. 
falciparum protein information discovery tool. In Silico Biol 2009, 9:195-202. 
322. Schneider AG, Mercereau-Puijalon O: A new Apicomplexa-specific protein kinase 
family: multiple members in Plasmodium falciparum, all with an export signature. 
BMC Genomics 2005, 6:30. 
323. Marmorstein R, Berger SL: Structure and function of bromodomains in chromatin-
regulating complexes. Gene 2001, 272:1-9. 
324. Fan Q, Miao J, Cui L: Characterization of PRMT1 from Plasmodium falciparum. 
Biochem J 2009, 421:107-118. 
325. Shaw PJ, Ponmee N, Karoonuthaisiri N, Kamchonwongpaisan S, Yuthavong Y: 
Characterization of human malaria parasite Plasmodium falciparum eIF4E 
homologue and mRNA 5' cap status. Mol Biochem Parasitol 2007, 155:146-155. 
326. Meierjohann S, Walter RD, Muller S: Regulation of intracellular glutathione levels in 
erythrocytes infected with chloroquine-sensitive and chloroquine-resistant 
Plasmodium falciparum. Biochem J 2002, 368:761-768. 
327. Abrantes P, Dimopoulos G, Grosso AR, do Rosario VE, Silveira H: Chloroquine 
mediated modulation of Anopheles gambiae gene expression. PLoS One 2008, 
3:e2587. 
328. Sanchez CP, Mayer S, Nurhasanah A, Stein WD, Lanzer M: Genetic linkage analyses 
redefine the roles of PfCRT and PfMDR1 in drug accumulation and susceptibility 
in Plasmodium falciparum. Mol Microbiol 2011, 82:865-878. 
329. Keenan RJ, Freymann DM, Stroud RM, Walter P: The signal recognition particle. 
Annu Rev Biochem 2001, 70:755-775. 
330. Wellems TE, Plowe CV: Chloroquine-resistant malaria. J Infect Dis 2001, 184:770-
776. 
331. Snow RW, Trape JF, Marsh K: The past, present and future of childhood malaria 
mortality in Africa. Trends Parasitol 2001, 17:593-597. 
332. Greenwood B, Mutabingwa T: Malaria in 2002. Nature 2002, 415:670-672. 
333. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L: 
Artemisinin resistance: current status and scenarios for containment. Nat Rev 
Microbiol 2010, 8:272-280. 
334. O'Meara WP, Mangeni JN, Steketee R, Greenwood B: Changes in the burden of 
malaria in sub-Saharan Africa. Lancet Infect Dis 2010, 10:545-555. 
335. Teoh KH, Polichuk DR, Reed DW, Nowak G, Covello PS: Artemisia annua L. 
(Asteraceae) trichome-specific cDNAs reveal CYP71AV1, a cytochrome P450 with 
a key role in the biosynthesis of the antimalarial sesquiterpene lactone 
artemisinin. FEBS Lett 2006, 580:1411-1416. 
336. Liu J-M, Ni, M.-Y., Fan, J.-F., Tu, Y.-Y., Wu, Z.-H., Wu, Y.-L. and Chou, W.-S.: 
Structure and reaction of arteannuin. Acta Chimica Sinica 1979, 37:129-143. 
337. Gordi T, Lepist EI: Artemisinin derivatives: toxic for laboratory animals, safe for 
humans? Toxicol Lett 2004, 147:99-107. 
338. Fidock DA, Eastman RT, Ward SA, Meshnick SR: Recent highlights in antimalarial 





339. Klayman DL: Qinghaosu (artemisinin): an antimalarial drug from China. Science 
1985, 228:1049-1055. 
340. Asawamahasakda W, Ittarat I, Pu YM, Ziffer H, Meshnick SR: Reaction of antimalarial 
endoperoxides with specific parasite proteins. Antimicrob Agents Chemother 1994, 
38:1854-1858. 
341. Kannan R, Kumar K, Sahal D, Kukreti S, Chauhan VS: Reaction of artemisinin with 
haemoglobin: implications for antimalarial activity. Biochem J 2005, 385:409-418. 
342. Krungkrai SR, Yuthavong Y: The antimalarial action on Plasmodium falciparum of 
qinghaosu and artesunate in combination with agents which modulate oxidant 
stress. Trans R Soc Trop Med Hyg 1987, 81:710-714. 
343. Wu Y: How might qinghaosu (artemisinin) and related compounds kill the 
intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res 2002, 35:255-
259. 
344. Bhisutthibhan J, Meshnick SR: Immunoprecipitation of [(3)H]dihydroartemisinin 
translationally controlled tumor protein (TCTP) adducts from Plasmodium 
falciparum-infected erythrocytes by using anti-TCTP antibodies. Antimicrob Agents 
Chemother 2001, 45:2397-2399. 
345. Bhisutthibhan J, Pan XQ, Hossler PA, Walker DJ, Yowell CA, Carlton J, Dame JB, 
Meshnick SR: The Plasmodium falciparum translationally controlled tumor protein 
homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem 1998, 
273:16192-16198. 
346. Haynes RK, Krishna S: Artemisinins: activities and actions. Microbes Infect 2004, 
6:1339-1346. 
347. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L: 
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake 
and digestion. Proc Natl Acad Sci U S A 2011, 108:11405-11410. 
348. Pandey AV, Tekwani BL, Singh RL, Chauhan VS: Artemisinin, an endoperoxide 
antimalarial, disrupts the hemoglobin catabolism and heme detoxification 
systems in malarial parasite. J Biol Chem 1999, 274:19383-19388. 
349. Li W, Mo W, Shen D, Sun L, Wang J, Lu S, Gitschier JM, Zhou B: Yeast model 
uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 2005, 
1:e36. 
350. Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, Zhou B: Artemisinin directly targets 
malarial mitochondria through its specific mitochondrial activation. PLoS One 
2010, 5:e9582. 
351. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill 
PM, Bray PG, Ward SA, Krishna S: Artemisinins target the SERCA of Plasmodium 
falciparum. Nature 2003, 424:957-961. 
352. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, 
East M, Lee A, Brady L, Haynes RK, Krishna S: A single amino acid residue can 
determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005, 
12:628-629. 
353. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, 
Esterre P, Fandeur T, Mercereau-Puijalon O: Resistance of Plasmodium falciparum 
field isolates to in-vitro artemether and point mutations of the SERCA-type 
PfATPase6. Lancet 2005, 366:1960-1963. 
354. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S: Investigations into 
the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in 






355. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N: Artesunate combinations 
for treatment of malaria: meta-analysis. Lancet 2004, 363:9-17. 
356. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S: Plasmodium falciparum: in 
vitro studies of the pharmacodynamic properties of drugs used for the treatment 
of severe malaria. Exp Parasitol 1993, 76:85-95. 
357. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ: The infectivity of 
gametocytes of Plasmodium falciparum from patients treated with artemisinin. 
Chin Med J (Engl) 1994, 107:709-711. 
358. WHO: Guidelines for the treatment of malaria: second edition. 2010. 
359. Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, Cravo P: Malaria 
parasites can develop stable resistance to artemisinin but lack mutations in 
candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum 
Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother 2006, 50:480-
489. 
360. Chavchich M, Gerena L, Peters J, Chen N, Cheng Q, Kyle DE: Role of pfmdr1 
amplification and expression in induction of resistance to artemisinin derivatives 
in Plasmodium falciparum. Antimicrob Agents Chemother 2010, 54:2455-2464. 
361. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q: Artemisinin-induced 
dormancy in plasmodium falciparum: duration, recovery rates, and implications in 
treatment failure. J Infect Dis 2010, 202:1362-1368. 
362. Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, Berry A, Benoit-Vical F: 
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a 
quiescence mechanism. Antimicrob Agents Chemother 2010, 54:1872-1877. 
363. Beez D, Sanchez CP, Stein WD, Lanzer M: Genetic predisposition favors the 
acquisition of stable artemisinin resistance in malaria parasites. Antimicrob Agents 
Chemother 2011, 55:50-55. 
364. Sanchez CP, Rohrbach P, McLean JE, Fidock DA, Stein WD, Lanzer M: Differences in 
trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium 
falciparum. Mol Microbiol 2007, 64:407-420. 
365. Sanchez CP, McLean JE, Stein W, Lanzer M: Evidence for a substrate specific and 
inhibitable drug efflux system in chloroquine resistant Plasmodium falciparum 
strains. Biochemistry 2004, 43:16365-16373. 
366. Ekland EH, Schneider J, Fidock DA: Identifying apicoplast-targeting antimalarials 
using high-throughput compatible approaches. FASEB J 2011. 
367. Kafsack BF, Llinas M: Eating at the table of another: metabolomics of host-parasite 
interactions. Cell Host Microbe 2010, 7:90-99. 
368. Muthukrishnan S, Both GW, Furuichi Y, Shatkin AJ: 5'-Terminal 7-methylguanosine in 
eukaryotic mRNA is required for translation. Nature 1975, 255:33-37. 
369. Shatkin AJ: Capping of eucaryotic mRNAs. Cell 1976, 9:645-653. 
370. Merrick WC: Cap-dependent and cap-independent translation in eukaryotic 
systems. Gene 2004, 332:1-11. 
371. Hirayoshi K, Lis JT: Nuclear run-on assays: assessing transcription by measuring 
density of engaged RNA polymerases. Methods Enzymol 1999, 304:351-362. 
372. Deplaine G, Lavazec C, Bischoff E, Natalang O, Perrot S, Guillotte-Blisnick M, Coppee 
JY, Pradines B, Mercereau-Puijalon O, David PH: Artesunate tolerance in transgenic 
Plasmodium falciparum parasites overexpressing a tryptophan-rich protein. 
Antimicrob Agents Chemother 2011, 55:2576-2584. 
373. Pradel G, Wagner C, Mejia C, Templeton TJ: Plasmodium falciparum: Co-dependent 
expression and co-localization of the PfCCp multi-adhesion domain proteins. Exp 





374. Flueck C, Bartfai R, Volz J, Niederwieser I, Salcedo-Amaya AM, Alako BT, Ehlgen F, 
Ralph SA, Cowman AF, Bozdech Z, et al: Plasmodium falciparum heterochromatin 
protein 1 marks genomic loci linked to phenotypic variation of exported virulence 
factors. PLoS Pathog 2009, 5:e1000569. 
375. Lopaticki S, Maier AG, Thompson J, Wilson DW, Tham WH, Triglia T, Gout A, Speed 
TP, Beeson JG, Healer J, Cowman AF: Reticulocyte and erythrocyte binding-like 
proteins function cooperatively in invasion of human erythrocytes by malaria 
parasites. Infect Immun 2011, 79:1107-1117. 
376. Miao J, Fan Q, Cui L, Li J: The malaria parasite Plasmodium falciparum histones: 
organization, expression, and acetylation. Gene 2006, 369:53-65. 
377. Richard D, Bartfai R, Volz J, Ralph SA, Muller S, Stunnenberg HG, Cowman AF: A 
genome-wide chromatin-associated nuclear peroxiredoxin from the malaria 
parasite Plasmodium falciparum. J Biol Chem 2011, 286:11746-11755. 
378. Witkowski B, Iriart X, Soh PN, Menard S, Alvarez M, Naneix-Laroche V, Marchou B, 
Magnaval JF, Benoit-Vical F, Berry A: pfmdr1 amplification associated with clinical 
resistance to mefloquine in West Africa: implications for efficacy of artemisinin 
combination therapies. J Clin Microbiol 2010, 48:3797-3799. 
379. Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML: Artemisinin-induced parasite 
dormancy: a plausible mechanism for treatment failure. Malar J 2011, 10:56. 
380. Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, Schindler A, Matsiegui 
PB, Kun JF, Krishna S, Lell B, Kremsner PG: Short-course artesunate treatment of 
uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents 
Chemother 2003, 47:901-904. 
381. Ittarat W, Pickard AL, Rattanasinganchan P, Wilairatana P, Looareesuwan S, Emery K, 
Low J, Udomsangpetch R, Meshnick SR: Recrudescence in artesunate-treated 
patients with falciparum malaria is dependent on parasite burden not on parasite 
factors. Am J Trop Med Hyg 2003, 68:147-152. 
382. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos SG, McNae 
I, Cheesman S, do Rosario V, et al: Gene encoding a deubiquitinating enzyme is 
mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol 
Microbiol 2007, 65:27-40. 
383. Chen N, Chavchich M, Peters JM, Kyle DE, Gatton ML, Cheng Q: Deamplification of 
pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is 
associated with reduced resistance to artelinic acid in vitro. Antimicrob Agents 
Chemother 2010, 54:3395-3401. 
384. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE: Current perspectives on the 
mechanism of action of artemisinins. Int J Parasitol 2006, 36:1427-1441. 
385. Izban MG, Luse DS: Transcription on nucleosomal templates by RNA polymerase II 
in vitro: inhibition of elongation with enhancement of sequence-specific pausing. 
Genes Dev 1991, 5:683-696. 
386. Morse RH: Nucleosomes inhibit both transcriptional initiation and elongation by 
RNA polymerase III in vitro. EMBO J 1989, 8:2343-2351. 
387. Wasylyk B, Chambon P: Transcription by eukaryotic RNA polymerases A and B of 
chromatin assembled in vitro. Eur J Biochem 1979, 98:317-327. 
388. Studitsky VM, Clark DJ, Felsenfeld G: Overcoming a nucleosomal barrier to 
transcription. Cell 1995, 83:19-27. 
389. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE: Mitochondria and 
reactive oxygen species. Free Radic Biol Med 2009, 47:333-343. 
390. Anderson TJ, Nair S, Nkhoma S, Williams JT, Imwong M, Yi P, Socheat D, Das D, 





indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect 
Dis 2010, 201:1326-1330. 
391. Hurwitz ES, Johnson D, Campbell CC: Resistance of Plasmodium falciparum malaria 
to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand. Lancet 
1981, 1:1068-1070. 
392. Boudreau EF, Webster HK, Pavanand K, Thosingha L: Type II mefloquine resistance 
in Thailand. Lancet 1982, 2:1335. 
393. Gay F, Bustos DG, Diquet B, Rojas Rivero L, Litaudon M, Pichet C, Danis M, Gentilini M: 
Cross-resistance between mefloquine and halofantrine. Lancet 1990, 336:1262. 
394. World Malaria Report 2008. 
 
 
